WO2008121670A1 - Pyrimidine hydrazide compounds as pgds inhibitors - Google Patents

Pyrimidine hydrazide compounds as pgds inhibitors Download PDF

Info

Publication number
WO2008121670A1
WO2008121670A1 PCT/US2008/058347 US2008058347W WO2008121670A1 WO 2008121670 A1 WO2008121670 A1 WO 2008121670A1 US 2008058347 W US2008058347 W US 2008058347W WO 2008121670 A1 WO2008121670 A1 WO 2008121670A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carboxylic acid
pyrimidine
amide
pyridin
Prior art date
Application number
PCT/US2008/058347
Other languages
French (fr)
Inventor
Suzanne C. Aldous
Michael W. Fennie
John Z. Jiang
Stanly John
Lan Mu
Brian Pedgrift
James R. Pribish
Barbara Rauckman
Jeffrey S. Sabol
Grzegorz T. Stoklosa
Sukanthini Thurairatnam
Christopher L. Vandeusen
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2008800100835A priority Critical patent/CN101646656B/en
Priority to DK08744426.1T priority patent/DK2142516T3/en
Priority to JP2010501206A priority patent/JP5427769B2/en
Priority to ES08744426T priority patent/ES2400622T3/en
Priority to BRPI0809974-0A2A priority patent/BRPI0809974A2/en
Priority to CA2682629A priority patent/CA2682629C/en
Priority to AU2008232771A priority patent/AU2008232771B2/en
Priority to MX2009009443A priority patent/MX2009009443A/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to EP08744426A priority patent/EP2142516B1/en
Priority to NZ579892A priority patent/NZ579892A/en
Publication of WO2008121670A1 publication Critical patent/WO2008121670A1/en
Priority to IL200898A priority patent/IL200898A/en
Priority to US12/570,355 priority patent/US8258130B2/en
Priority to MA32299A priority patent/MA31326B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention is directed to pyrimidine hydrazide compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the prostaglandin D synthase.
  • Allergic rhinitis the most common atopic disease, has an estimated prevalence ranging from about 5 to about 22 percent of the general human population and is characterized by the symptoms of sneezing, nasal discharge, and nasal congestion. These symptoms are believed to be triggered by multiple mediators released from mast cells and other inflammatory cells.
  • PGD2 prostaglandin D2
  • PGD2 is the major cyclooxygenase product of arachidonic acid produced from mast cells on immunological challenge [Lewis, RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ II, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE, J. Immunol. 129, 1627-1631, 1982].
  • Activated mast cells are one of the key players in driving the allergic response in conditions such as asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis and other diseases [Brightling CE, Bradding P, Pavord ID, Wardlaw AJ, New Insights into the role of the mast cell in asthma, Clin. Exp. Allergy 33, 550-556, 2003].
  • PGD2 is formed by the isomerization of PGH2, a common precursor of prostanoids, by catalytic action of prostaglandin D synthase "(PGDS)".
  • PGDS prostaglandin D synthase
  • L-PGDS L-PGDS
  • H-PGDS is a cytosolic enzyme, which is distributed in the peripheral tissues, and which is localized in the antigen- presenting cells, mast cells, megakaryocytes, and Th2 lymphocytes.
  • the action of the product PGD2 is mediated by G-protein coupled receptors: D prostaglandin "(DP)" and crTH2. See (1) Prostaglandin D Synthase: Structure and Function. T. Urade and O.
  • PGDS inhibitors have been reported.
  • the compound, HQL-79 is reported to be a weak PGDS inhibitor, and is antiasthmatic in guinea pig and rat models (Matsusshita, et al., Jpn. J. Pharamcol. 78: 11, 1998).
  • the compound Tranilast is described as a PGDS inhibitor. (Inhibitory Effect of Tranilast on Prostaglandin D Synthesase. K. Ikai, M. Jihara, K. Fujii, and Y. Urade. Biochemical Pharmacology, 1989, 28, 2773-2676).
  • the present invention is directed to a compound of formula (I):
  • R 1 is (Ci-Ce)-alkyl optionally substituted one or more times independently by halo, hydroxy,
  • R 2 is hydrogen or (Ci-C 4 )-alkyl optionally substituted one or more times by halo;
  • R 3 is hydrogen, alkyl, aryl or heteroaryl,
  • Y 1 and Y 2 together with the nitrogen atom to which they are attached form heterocyclyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to formula (I), or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier.
  • Another aspect of the present invention is directed to a method of treating allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD) in a patient in need thereof by administering to the patient a compound according to formula (I), or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • allergic and/or inflammatory disorders particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • acyl means H-CO- or (aliphatic or cyclyl)-CO-. Particular acyl includes lower alkanoyl that contains a lower alkyl. Exemplary acyl includes formyl, acetyl, propanoyl, 2- methylpropanoyl, butanoyl, palmitoyl, acryloyl, propynoyl, and cyclohexylcarbonyl.
  • Alkenyl means a straight or branched aliphatic hydrocarbon group containing a carbon- carbon double bond and having 2 to about 15 carbon atoms. Particular alkenyl has 2 to about 12 carbon atoms. More particular alkenyl has 2 to about 4 carbon atoms. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkenyl chain. "Lower alkenyl” means about 2 to about 4 carbon atoms in the chain that may be straight or branched.
  • Exemplary alkenyl includes ethenyl, propenyl, n-butenyl, z-butenyl, 3- methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, and decenyl.
  • Alkoxy means alkyl-O-. Exemplary alkoxy includes methoxy, ethoxy, n-propoxy, i- propoxy, n-butoxy, and heptoxy.
  • Alkoxycarbonyl means alkyl-O-CO-.
  • exemplary alkoxycarbonyl includes methoxycarbonyl, ethoxycarbonyl, and t-butyloxycarbonyl.
  • Alkyl means straight or branched aliphatic hydrocarbon having 1 to about 20 carbon atoms. Particular alkyl has 1 to about 12 carbon atoms. More particular alkyl is lower alkyl. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl” means 1 to about 4 carbon atoms in a linear alkyl chain that may be straight or branched.
  • Alkylamino means alkyl-NH-. Particular alkylamino is (Ci-C 6 )-alkylamino. Exemplary alkylamino includes methylamino and ethylamino.
  • Alkylsulfmyl means alkyl-SO-. Particular alkylsulfonyl is (Ci-C 6 )-alkylsulfmyl. Exemplary alkylsulfmyl includes CH 3 -SO-, and CH 3 CH 2 -SO-.
  • Alkylsulfonyl means alkyl-S02-. Particular alkylsulfonyl is (Ci-C6)-alkylsulfonyl. Exemplary alkylsulfonyl includes CH 3 -SO 2 -, and CH 3 CH 2 -SO 2 -.
  • Alkylthio means an alkyl-S-.
  • Exemplary alkylthio includes CH 3 -S-.
  • Alkynyl means straight or branched aliphatic hydrocarbon containing a carbon-carbon triple bond and having 2 to about 15 carbon atoms. Particular alkynyl has 2 to about 12 carbon atoms. More particular alkynyl has 2 to about 6 carbon atoms. Branched means that one or more lower alkyl such as methyl, ethyl or propyl are attached to a linear alkynyl chain. "Lower alkynyl” means 2 to about 4 carbon atoms in a linear alkynyl chain that may be straight or branched.
  • Exemplary alkynyl includes ethynyl, propynyl, n-butynyl, 2-butynyl, 3- methylbutynyl, n-pentynyl, heptynyl, octynyl, and decynyl.
  • Aroyl means aryl-CO-.
  • Exemplary aroyl includes benzoyl, and 1-and 2-naphthoyl.
  • Aryl means an aromatic monocyclic or multicyclic ring system of about 6 to about 14 carbon atoms. Particular aryl include about 6 to about 10 carbon atoms. Exemplary aryl include phenyl and naphthyl.
  • Arylcycloalkenyl means a fused aryl and cycloalkenyl. Particular arylcycloalkenyl is one wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to about 7 ring atoms. An arylcycloalkenyl is bonded through any atom of the cycloalkenyl moiety thereof capable of such bonding. Exemplary arylcycloalkenyl includes 1 ,2-dihydronaphthylene and indene. "Arylcycloalkyl” means a fused aryl and cycloalkyl.
  • Particular arylcycloalkyl is one wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to about 6 ring atoms.
  • An arylcycloalkyl is bonded through any atom of the cycloalkyl moiety thereof capable of such bonding.
  • Exemplary arylcycloalkyl includes 1,2,3,4-tetrahydro-naphthylene.
  • Arylheterocyclenyl means a fused aryl and heterocyclenyl. Particular arylheterocyclenyl is one wherein the aryl thereof is phenyl and the heterocyclenyl consists of about 5 to about 6 ring atoms. An arylheterocyclenyl is bonded through any atom of the heterocyclenyl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before the heterocyclenyl portion of the arylheterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of an arylheterocyclenyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heterocyclenyl portion of the arylheterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • Exemplary arylheterocyclenyl includes 3H- indolinyl, lH-2-oxoquinolyl, 2H-l-oxoisoquinolyl, 1 ,2-di-hydroquinolinyl, 3,4- dihydroquinolinyl, 1 ,2-dihydroisoquinolinyl, and 3,4-dihydroisoquinolinyl.
  • Arylheterocyclyl means a fused aryl and heterocyclyl.
  • Particular heterocyclylaryl is one wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms.
  • An arylheterocyclyl is bonded through any atom of the heterocyclyl moiety thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heterocyclyl portion of the arylheterocyclyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of an arylheterocyclyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heterocyclyl portion of the arylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • exemplary arylheterocyclyl includes indolinyl, 1, 2,3, 4-tetrahydroisoquino line, 1, 2,3, 4-tetrahydroquino line, lH-2,3-dihydroisoindol-2-yl, 2,3-dihydrobenz[f]isoindol- 2-yl, and 1,2,3,4- tetrahydrobenz[g]-isoquinolin-2-yl.
  • Aryloxy means an aryl-O-. Exemplary aryloxy includes phenoxy and naphthoxy.
  • Compounds of the present invention are meant to embrace compounds of Formula (I) as hereinbefore described, the hydrates, solvates and N-oxides thereof, and the pharmaceutically acceptable salts thereof, where the context so permits.
  • reference to intermediates, whether or not they themselves are claimed is meant to embrace their salts, N-oxides and solvates, where the context so permits.
  • Cycloalkenyl means a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms, particularly of about 5 to about 10 carbon atoms, and which contains at least one carbon-carbon double bond. Particular rings of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower”.
  • Exemplary monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, and cycloheptenyl.
  • An exemplary multicyclic cycloalkenyl is norbornylenyl.
  • Cycloalkenylaryl means a fused aryl and cycloalkenyl. Particular cycloalkenylaryl is one wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to about 6 ring atoms. A cycloalkenylaryl is bonded through any atom of the aryl moiety thereof capable of such bonding. Exemplary cycloalkenylaryl includes 1 ,2-dihydronaphthylene and indene.
  • Cycloalkenylheteroaryl means a fused heteroaryl and cycloalkenyl. Particular cycloalkenylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkenyl consists of about 5 to about 6 ring atoms. A cycloalkenylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heteroaryl portion of the cycloalkenylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a cycloalkenylheteroaryl may be a basic nitrogen atom.
  • the nitrogen atom of the heteroaryl portion of the cycloalkenylheteroaryl may also be optionally oxidized to the corresponding N-oxide.
  • Exemplary cycloalkenylheteroaryl includes 5,6- dihydroquinolyl, 5,6-dihydroisoquinolyl, 5,6-dihydroquinoxalinyl, 5,6- dihydroquinazolinyl, 4,5- dihydro-lH -benzimidazolyl, and 4,5-di-hydrobenzoxazolyl.
  • Cycloalkyl means a non-aromatic mono- or multicyclic saturated ring system of about 3 to about 10 carbon atoms, particularly of about 5 to about 10 carbon atoms. Particular ring systems include about 5 to about 7 ring atoms; and such particular ring systems are also referred to as "lower”.
  • Exemplary monocyclic cycloalkyl includes cyclopentyl, cyclohexyl, and cycloheptyl.
  • Exemplary multicyclic cycloalkyl includes 1-decalin, norbornyl, and adamant-(l- or 2-)yl.
  • Cycloalkylaryl means a fused aryl and cycloalkyl. Particular cycloalkylaryl is one wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to about 6 ring atoms. A cycloalkylaryl is bonded through any atom of the cycloalkyl moiety thereof capable of such bonding. Exemplary cycloalkylaryl includes 1,2,3,4-tetrahydro-naphthylene.
  • Cycloalkylheteroaryl means a fused heteroaryl and cycloalkyl.
  • Particular cycloalkylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkyl consists of about 5 to about 6 ring atoms.
  • a cycloalkylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heteroaryl portion of the fused cycloalkylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a cycloalkylheteroaryl may be a basic nitrogen atom.
  • the nitrogen atom of the heteroaryl portion of the cycloalkylheteroaryl may also be optionally oxidized to the corresponding N-oxide.
  • Exemplary cycloalkylheteroaryl includes 5,6,7,8- tetrahydroquinolinyl, 5,6,7,8-tetra-hydroisoquinolyl, 5,6,7,8-tetrahydroquinoxalinyl, 5,6,7,8- tetrahydroquinazolyl, 4,5 ,6,7-tetrahydro- 1 H-benzimidazolyl, and 4,5,6,7- tetrahydrobenzoxazolyl.
  • Cyclyl means cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl.
  • Dialkylamino means (alkyl) 2 -N-. Particular dialkylamino is (Ci-C 6 alkyl) 2 -N-. Exemplary dialkylamino groups include dimethylamino, diethylamino and methylethylamino.
  • Halo or halogen means fluoro, chloro, bromo, or iodo. Particular halo or halogen is fluoro or chloro.
  • Haloalkoxy means alkoxy substituted by one to three halo groups. Particular haloalkoxy are loweralkoxy substituted by one to three halogens. Most particular haloalkoxy are loweralkoxy substituted by one halogen.
  • Haloalkyl means alkyl substituted by one to three halo groups. Particular haloalkyl are loweralkyl substituted by one to three halogens. Most particular haloalkyl are loweralkyl substituted by one halogen.
  • Heteroaroyl means heteroaryl-CO-.
  • exemplary heteroaroyl includes thiophenoyl, nicotinoyl, pyrrol-2-ylcarbonyl, and pyridinoyl.
  • Heteroaryl means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur.
  • Particular aromatic ring systems include about 5 to about 10 carbon atoms, and include 1 to 3 heteroatoms. More particular ring sizes of rings of the ring system include about 5 to about 6 ring atoms.
  • the designation of the aza, oxa or thio as a prefix before heteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • a nitrogen atom of a heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N- oxide.
  • a heteroaryl When a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer.
  • Exemplary heteroaryl includes pyrazinyl, thienyl, isothiazolyl, oxazolyl, pyrazolyl, furanyl, pyrrolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[l,2- ajpyridine, imidazo[2,l-b]thiazolyl, benzofuranyl, azaindolyl, benzimidazolyl, benzothienyl, thienopyridyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, benzoazaindo
  • Heteroarylalkyl means heteroaryl-alkyl-. Particular heteroarylalkyl contains a (Ci-C 4 )-alkyl moiety. Exemplary heteroarylalkyl includes tetrazol-5-ylmethyl.
  • Heteroarylcycloalkenyl means a fused heteroaryl and cycloalkenyl.
  • Particular heteroarylcycloalkenyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkenyl consists of about 5 to about 6 ring atoms.
  • a heteroarylcycloalkenyl is bonded through any atom of the cycloalkenyl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heteroaryl portion of the heteroarylcycloalkenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heteroarylcycloalkenyl may be a basic nitrogen atom.
  • the nitrogen atom of the heteroaryl portion of the heteroarylcycloalkenyl may also be optionally oxidized to the corresponding N-oxide.
  • Exemplary heteroarylcycloalkenyl includes 5,6- dihydroquinolyl, 5,6-dihydroisoquinolyl, 5,6-dihydroquinoxalinyI, 5,6- dihydroquinazolinyl, 4,5- dihydro-lH-benzimidazolyl, and 4,5-di-hydrobenzoxazolyl.
  • Heteroarylcycloalkyl means a fused heteroaryl and cycloalkyl.
  • Particular heteroarylcycloalkyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkyl consists of about 5 to about 6 ring atoms.
  • a heteroarylcycloalkyl is bonded through any atom of the cycloalkyl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heteroaryl portion of the fused heteroarylcycloalkyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heteroarylcycloalkyl may be a basic nitrogen atom.
  • the nitrogen atom of the heteroaryl portion of the heteroarylcycloalkyl may also be optionally oxidized to the corresponding N-oxide.
  • Exemplary heteroarylcycloalkyl includes 5,6,7,8- tetrahydroquinolinyl, 5,6,7,8-tetra-hydroisoquinolyl, 5,6,7,8-tetrahydroquinoxalinyl, 5,6,7,8- tetrahydroquinazolyl, 4,5,6,7-tetrahydro-lH-benzimidazolyl, and 4,5,6,7- tetrahydrobenzoxazolyl
  • Heteroarylheterocyclenyl means a fused heteroaryl and heterocyclenyl.
  • Particular heteroarylheterocyclenyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclenyl consists of about 5 to about 6 ring atoms.
  • a heteroarylheterocyclenyl is bonded through any atom of the heterocyclenyl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclenyl portion of the heteroarylheterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heteroarylazaheterocyclenyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heteroaryl or heterocyclenyl portion of the heteroarylheterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S- oxide or S,S-dioxide.
  • Exemplary heteroarylheterocyclenyl includes 7,8-dihydro[l,7]naphthyridinyl, l,2-dihydro[2,7]- naphthyridinyl, 6,7-dihydro-3H -imidazo [4,5-c]pyridyl, l,2-dihydro-l,5-naphthyridinyl, 1 ,2- dihydro-l,6-naphthyridinyl, l,2-dihydro-l,7 -naphthyridinyl, 1,2-dihydro-l ,8-naphthyridinyl, and 1 ,2-dihydro-2,6-naphthyridinyl.
  • Heteroarylheterocyclyl means a fused heteroaryl and heterocyclyl.
  • Particular heteroarylheterocyclyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclyl consists of about 5 to about 6 ring atoms.
  • a heteroarylheterocyclyl is bonded through any atom of the heterocyclyl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a fused heteroarylheterocyclyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the heteroarylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • heteroarylheterocyclyl includes 2,3-dihydro-lH-pyrrol[3,4-b]quinolin-2-yl, 1,2,3,4- tetrahydrobenz [b][l,7]naphthyridin-2-yl, l,2,3,4-tetrahydrobenz[b][l,6]naphthyridin-2-yl, 1 ,2,3,4-tetra-hydro-9H-pyrido[3,4-b]indol-2yl, 1 ,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-2yl, 2,3-dihydro-lH-pyrrolo[3,4-b ]indol-2-yl, lH-2,3,4,5-tetrahydroazepino[3,4-b]indol-2-yl, IH- 2,3,4,5-tetra-hydroazepino[4,3
  • Heteroaryloxy means heteroaryl-O- .
  • exemplary heteroaryloxy includes pyridyloxy.
  • Heterocyclenyl means a non-aromatic monocyclic or multicyclic hydrocarbon ring system of about 3 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur atoms, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond.
  • a particular non-aromatic ring system includes about 5 to about 10 carbon atoms, and 1 to 3 heteroatoms. More particular ring sizes of rings of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower”.
  • heterocyclenyl The designation of the aza, oxa or thio as a prefix before heterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heterocyclenyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S, S- dioxide.
  • Exemplary monocyclic azaheterocyclenyl includes 1,2,3,4-tetrahydrohydropyridyl, 1 ,2-dihydropyridyl, 1 ,4-dihydropyridyl, 1,2,3,6-tetra-hydropyridyl, 1,4,5,6-tetrahydro- pyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, and 2-pyrazolinyl.
  • Exemplary oxaheterocyclenyl includes 3,4-dihydro-2H-pyran, dihydrofuranyl, and fluorodihydro-furanyl.
  • An exemplary multicyclic oxaheterocyclenyl is 7-oxabicyclo[2.2.1]heptenyl.
  • Exemplary monocyclic thioheterocyclenyl includes dihydrothiophenyl and dihydrothiopyranyl.
  • Heterocyclenylaryl means a fused aryl and heterocyclenyl. Particular heterocyclenylaryl is one wherein the aryl thereof is phenyl and the heterocyclenyl consists of about 5 to about 6 ring atoms. A heterocyclenylaryl is bonded through any atom of the aryl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heterocyclenyl portion of the fused heterocyclenylaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heterocyclenylaryl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heterocyclenyl portion of the heterocyclenylaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • exemplary heterocyclenylaryl include 3H-indolinyl, IH-2-oxoquinolyl, 2H-1- oxoisoquinolyl, 1 ,2-di-hydroquinolinyl, 3,4-dihydroquinolinyl, 1 ,2-dihydroisoquinolinyl, and 3 ,4-dihydroisoquinolinyl.
  • Heterocyclenylheteroaryl means a fused heteroaryl and heterocyclenyl.
  • Particular heterocyclenylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclenyl consists of about 5 to about 6 ring atoms.
  • a heterocyclenylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclenyl portion of the heterocyclenylheteroaryl define that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of an azaheterocyclenylheteroaryl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heteroaryl or heterocyclenyl portion of the heterocyclenylheteroaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • Exemplary heterocyclenylheteroaryl includes 7,8-dihydro[l,7]naphthyridinyl, l,2-dihydro[2,7]- naphthyridinyl, 6,7-dihydro-3H-imidazo[4,5-c]pyridyl, l,2-dihydro-l,5-naphthyridinyl, 1 ,2- dihydro-l,6-naphthyridinyl, 1 ,2-dihydro-l,7-naphthyridinyl, 1 ,2-dihydro-l,8-naphthyridinyl and l,2-dihydro-2,6-naphthyridinyl.
  • Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system of about 3 to about 10 carbon atoms, in which one or more of the atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur.
  • a particular ring system contains about 5 to about 10 carbon atoms, and from 1 to 3 heteroatoms.
  • Particular ring sizes of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower”.
  • the designation of the aza, oxa or thio as a prefix before heterocyclyl define that at least a nitrogen, oxygen or sulfur atom is present respectively as a ring atom.
  • the nitrogen atom of a heterocyclyl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heterocyclyl may also be optionally oxidized to the corresponding N- oxide, S-oxide or S,S-dioxide.
  • Exemplary monocyclic heterocyclyl includes piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4- dioxanyl, THFyI, tetrahydrothiophenyl, and tetrahydrothiopyranyl.
  • Heterocyclylaryl means a fused aryl and heterocyclyl. Particular heterocyclylaryl is one wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms. A heterocyclylaryl is bonded through any atom of the aryl moiety thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before heterocyclyl portion of the heterocyclylaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heterocyclylaryl may be a basic nitrogen atom.
  • heterocyclylaryl includes indolinyl, 1, 2,3, 4-tetrahydroisoquino line, 1,2,3,4- tetrahydroquinoline, lH-2,3-dihydroisoindol-2-yl, and 2,3-dihydrobenz[f]isoindol-2-yl, and 1,2,3,4- tetrahydrobenz[g]-isoquinolin-2-yl.
  • Heterocyclylheteroaryl means a fused heteroaryl and heterocyclyl.
  • Particular heterocyclylheteroaryl is one wherein the heteoraryl thereof consists of about 5 to about 6 ring atoms and the heterocyclyl consists of about 5 to about 6 ring atoms.
  • a heterocyclylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding.
  • the designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclyl portion of the heterocyclylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
  • the nitrogen atom of a heterocyclylheteroaryl may be a basic nitrogen atom.
  • the nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the heterocyclylheteroaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • heterocyclylheteroaryl includes 2,3-dihydro-lH-pyrrol[3,4-b]quinolin-2-yl, 1,2,3,4- tetrahydrobenz [b][l,7]naphthyridin-2-yl, l,2,3,4-tetrahydrobenz[b][l,6]naphthyridin-2-yl, 1 ,2,3,4-tetra-hydro-9H-pyrido[3,4-b]indol-2yl, 1 ,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-2yl, 2,3-dihydro-lH-pyrrolo[3,4-b ]indol-2-yl, lH-2,3,4,5-tetrahydroazepino[3,4-b]indol-2-yl, IH- 2,3,4,5-tetra-hydroazepino[4,3
  • Multicyclic alkaryl means a multicyclic ring system including at least one aromatic ring fused to at least one non-aromatic ring that may be saturated or unsaturated, and may also contain in the ring system one or more heteroatoms, such as nitrogen, oxygen or sulfur.
  • Exemplary multicyclic alkaryl includes arylcycloalkenyl, arylcycloalkyl, arylheterocyclenyl, arylheterocyclyl, cycloalkenylaryl, cycloalkylaryl, cycloalkenylheteroaryl, cycloalkylheteroaryl, heteroarylcycloalkenyl, heteroarylcycloalkyl, heteroarylheterocyclenyl, heteroarylheterocyclyl, heterocyclenylaryl, heterocyclenylheteroaryl, heterocyclylaryl, and heterocyclylheteroaryl.
  • Particular multicyclic alkaryl groups are bicyclic rings that include one aromatic ring fused to one non-aromatic ring and that also may contain in the ring system one or more heteroatoms, such as nitrogen, oxygen or sulfur.
  • “Patient” includes human and other mammals.
  • “Pharmaceutically acceptable salts” refers to the non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts may be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. In some cases, the compounds themselves are capable of self-pro tonating basic sites on the molecule and forming an internal amphoteric salt.
  • Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, sulfamates, malonates, salicylates, propionates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p- toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and lauryls
  • Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed.
  • Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts.
  • a particular base addition salt is sodium salt or potassium salt.
  • Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, and zinc hydroxide.
  • Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and particularly include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use.
  • Exemplary amin includes ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N 5 N'- dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N- benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, and dicyclohexylamine.
  • Solvate means a physical association of a compound of the present invention with one or more solvent molecules. This physical association includes hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and insoluble solvates. Particular solvates include hydrates, ethanolates, and methanolates.
  • Substituted one or more times independently means substituted one or more times by same or different substituent groups, particularly substituted one, two or three times by same or different substituent groups.
  • One particular embodiment of the invention is a compound of formula (I) wherein R 1 is aryl or heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-C 6 )-alkyl, hydroxy, (Ci-C 6 )-alkoxy, (Ci-C 4 )-haloalkyl or (Ci-C 4 )-haloalkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 1 is phenyl or five or six membered heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 1 is phenyl, pyridyl, pyrimidinyl, thiazolyl, or oxodiazolyl, each of which is optionally substituted one or more times independently by halo, (Ci-C 6 )-alkyl, hydroxy, or (d-C 6 )-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • R 1 is phenyl, pyridyl or pyrimidinyl, each of which is optionally substituted independently at the ortho or meta position by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 1 is phenyl optionally substituted independently at the ortho or meta position by halo, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 1 is pyridyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 2 is hydrogen, methyl or trifluoromethyl, or a hydrate solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 2 is hydrogen, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein R 2 is methyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein L 1 is a bond, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein: R 3 and R 4 together with the nitrogen atom to which they are attached form heterocyclyl, heterocyclenyl, arylheterocyclyl, or heteroaryl, each of which is optionally substituted one or more times independently by R ;
  • Y 1 and Y 2 are each independently hydrogen, alkylsulfonyl, aroyl, or alkyl optionally substituted by morpholinyl, or
  • Y 1 and Y 2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein: R 3 and R 4 together with the nitrogen atom to which they are attached form [l,2,4]triazolyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[3,2-b]pyridyl, or pyrrolo[2,3- c]pyridyl, each of which is optionally substituted one or more times independently by R 6 ;
  • Y 1 and Y 2 are each independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y 1 and Y 2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I) wherein: R 3 and R 4 together with the nitrogen atom to which they are attached form imidazolidinyl,
  • R 6 is oxo, alkoxy, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y 1 Y 2 N-SO 2 -, alkyl optionally substituted one or more times independently by hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, heterocyclyl, cycloalkyl, alkylsulf
  • Another particular embodiment of the invention is a compound of formula (I) wherein:
  • R 3 and R 4 together with the nitrogen atom to which they are attached form indolyl, optionally substituted one or more times independently by R 6 ;
  • R 6 is Y 1 Y 2 N-SO 2 -, alkoxycarbonyl, carboxyalkyl, cyano, halo, alkylsulfonyl, alkoxy, or acyl optionally substituted one or more times independently by halo; and
  • Y 1 and Y 2 are each independently independently hydrogen, or alkyl optionally substituted by morpholinyl, or
  • Y 1 and Y 2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • R 5 is phenyl, pyridyl, or benzo[l,3]dioxolyl, each of which is optionally substituted one or more times independently by R 6 ;
  • R 6 is Y 1 Y 2 N-SO 2 -, hydroxy, alkoxy, halo, alkyl, or haloalkyl; and Y 1 and Y 2 are each independently hydrogen or alkyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
  • Another particular embodiment of the invention is a compound of formula (I), which is 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 - yl)amide,
  • 2-Phenyl-pyrimidine-5-carboxylic acid (3-isopropyl-5-oxo- 1 ,5-dihydro-[ 1 ,2,4]triazol-4-yl)- amide
  • 2-Phenyl-pyrimidine-5 -carboxylic acid (5-morpholin-4-ylmethyl-2-oxo-oxazolidin-3-yl)- amide
  • 2-Phenyl-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid (2-oxo-oxazolidin-3-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl]-amide,
  • 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2,2,2-trifluoro-acetyl)-piperazin- 1 -yl]-amide
  • 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-methoxy-ethyl)-piperazin- 1 -yl]-amide
  • 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazin-l-yl]- amide
  • 2-Phenyl-pyrimidine-5-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid pyrrolidin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-piperadin-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin-l-yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihydro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5
  • Another particular embodiment of the invention is a compound of formula (I), which is: 2-Phenyl-pyrimidine-5-carboxylic acid (4-benzyl-piperazin-l-yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-methanesulfonyl-piperazin- 1 -yl)-amide, 2-(2-Methyl-thiazol-4-yl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-2-carbonyl)-piperazin- 1 - yl] -amide,
  • the present invention also includes within its scope a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the invention, in admixture with a pharmaceutically acceptable carrier.
  • Compounds of the present invention are PGDS inhibitors and thus, are useful for treating allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
  • another invention herein is directed to a method of treating a patient suffering from allergic rhinitis, asthma, and/or chronic obstructive pulmonary disease (COPD) comprising administering to the patient a pharmaceutically effective amount of compound of formula (I), or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
  • References herein directed to treating should be understood to include prophylactic therapy to inhibit PGDS, as well as to treat an established acute or chronic or physiological conditions associated with PGDS to essentially cure a patient suffering therefrom, or ameliorate the physiological conditions associated therewith.
  • Physiological conditions discussed herein include some, but not all, of the possible clinical situations where an anti- allergic rhinitis and/or asthma treatment is warranted. Those experienced in this field are well aware of the circumstances requiring treatment.
  • the compound of the present invention may be administered in pharmaceutically acceptable dosage form to humans and other mammals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, colonic, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the particular route may vary with for example the physiological condition of the recipient.
  • “Pharmaceutically acceptable dosage forms” refers to dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.
  • a particular aspect of the invention provides for the compound of the invention to be administered in the form of a pharmaceutical composition.
  • Pharmaceutically acceptable carriers include at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, coatings, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, emulsion stabilizing agents, suspending agents, isotonic agents, sweetening agents, flavoring agents, perfuming agents, coloring agents, antibacterial agents, antifungal agents, other therapeutic agents, lubricating agents, adsorption delaying or promoting agents, and dispensing agents, depending on the nature of the mode of administration and dosage forms.
  • pharmaceutically acceptable carriers such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, emulsion stabilizing agents, suspending agents, isotonic agents, sweetening agents, flavoring agents, perfuming agents, coloring agents, antibacterial agents, antifungal agents, other therapeutic agents, lubricating agents, adsorption delaying or promoting agents, and dispensing agents,
  • suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances.
  • antibacterial and antifungal agents for the prevention of the action of microorganisms include parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Exemplary isotonic agents include sugars, sodium chloride, and the like.
  • Exemplary adsorption delaying agents to prolong absorption include aluminum monostearate and gelatin.
  • Exemplary adsorption promoting agents to enhance absorption include dimethyl sulfoxide and related analogs.
  • Exemplary diluents, solvents, vehicles, solubilizing agents, emulsifiers and emulsion stabilizers include water, chloroform, sucrose, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, tetrahydrofurfuryl alcohol, benzyl benzoate, polyols, propylene glycol, 1,3-butylene glycol, glycerol, polyethylene glycols, dimethylformamide, Tween® 60, Span® 60, cetostearyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate, fatty acid esters of sorbitan, vegetable oils (such as cottonseed oil, groundnut oil, olive oil, castor oil and sesame oil) and injectable organic esters such as ethyl oleate, and the like, or suitable mixtures of these substances.
  • vegetable oils such as cotton
  • Exemplary excipients include lactose, milk sugar, sodium citrate, calcium carbonate and dicalcium phosphate.
  • Exemplary disintegrating agents include starch, alginic acids and certain complex silicates.
  • Exemplary lubricants include magnesium stearate, sodium lauryl sulfate, talc, as well as high molecular weight polyethylene glycols.
  • the choice of pharmaceutical acceptable carrier is generally determined in accordance with the chemical properties of the active compound such as solubility, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as a solid dosage form, such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, or as a powder or granules; as a liquid dosage form such as a solution or a suspension in an aqueous liquid or a non- aqueous liquid, or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Solid dosage form means the dosage form of the compound of the invention is solid form, for example capsules, tablets, pills, powders, dragees or granules.
  • the compound of the invention is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or: (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used.
  • a mixture of the powdered compounds moistened with an inert liquid diluent may be molded in a suitable machine to make molded tablets.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Solid compositions may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
  • the compound can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as a biocompatible, biodegradable polymer matrices (e.g., poly(d,l-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer.
  • a biocompatible, biodegradable polymer matrices e.g., poly(d,l-lactide co-glycolide)
  • liposomes e.g., liposomes
  • microspheres subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer.
  • the compounds may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of
  • Liquid dosage form means the dose of the active compound to be administered to the patient is in liquid form, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such solvents, solubilizing agents and emulsif ⁇ ers.
  • aqueous suspensions When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.
  • compositions suitable for topical administration mean formulations that are in a form suitable to be administered topically to a patient.
  • the formulation may be presented as a topical ointment, salves, powders, sprays and inhalants, gels (water or alcohol based), creams, as is generally known in the art, or incorporated into a matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.
  • the active ingredients may be employed with either a paraff ⁇ nic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • Formulations suitable for topical administration in the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the oily phase of the emulsion pharmaceutical composition may be constituted from known ingredients, in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. In a particular embodiment, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. Together, the emulsifier(s) with, or without, stabilizer(s) make up the emulsifying wax, and together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • an emulsifier also known as an emulgent
  • a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer.
  • the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as, propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • a polyhydric alcohol i.e. an alcohol having two or more hydroxyl groups such as, propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound that enhances absorption, or penetration of the active ingredient through the skin, or other affected areas.
  • a cream should particularly be a non-greasy, non- staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • compositions suitable for rectal or vaginal administrations mean formulations that are in a form suitable to be administered rectally or vaginally to a patient and containing at least one compound of the invention.
  • Suppositories are a particular form for such formulations that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • composition administered by injection may be by transmuscular, intravenous, intraperitoneal, and/or subcutaneous injection.
  • the compositions of the present invention are formulated in liquid solutions, in particular in physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • the compositions may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
  • the formulations are sterile and include emulsions, suspensions, aqueous and nonaqueous injection solutions, which may contain suspending agents and thickening agents and anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic, and have a suitably adjusted pH, with the blood of the intended recipient.
  • compositions suitable for nasal or inhalational administration means compositions that are in a form suitable to be administered nasally or by inhalation to a patient.
  • the composition may contain a carrier, in a powder form, having a particle size for example in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.).
  • Suitable compositions wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops include aqueous or oily solutions of the active ingredient.
  • Compositions suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents.
  • Inhalational therapy is readily administered by metered dose inhalers or any suitable dry powder inhaler, such as the Eclipse, Spinhaler®, or Ultrahaler® as described in patent application WO2004/026380, and US Patent No. 5,176,132.
  • Actual dosage levels of active ingredient(s) in the compositions of the invention may be varied so as to obtain an amount of active ingredient(s) that is (are) effective to obtain a desired therapeutic response for a particular composition and method of administration for a patient.
  • a selected dosage level for any particular patient therefore depends upon a variety of factors including the desired therapeutic effect, on the route of administration, on the desired duration of treatment, the etiology and severity of the disease, the patient's condition, weight, sex, diet and age, the type and potency of each active ingredient, rates of absorption, metabolism and/or excretion and other factors.
  • Total daily dose of the compound of this invention administered to a patient in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body weight daily and particularly 0.01 to 10 mg/kg/day.
  • the doses are generally from about 0.01 to about 100, particularly about 0.01 to about 10, mg/kg body weight per day by inhalation, from about 0.01 to about 100, particularly 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.01 to about 50, particularly 0.01 to 10, mg/kg body weight per day by intravenous administration.
  • the percentage of active ingredient in a composition may be varied, though it should constitute a proportion such that a suitable dosage shall be obtained.
  • Dosage unit compositions may contain such amounts or such submultiples thereof as may be used to make up the daily dose.
  • several unit dosage forms may be administered at about the same time.
  • a dosage may be administered as frequently as necessary in order to obtain the desired therapeutic effect.
  • Some patients may respond rapidly to a higher or lower dose and may find much lower maintenance doses adequate.
  • it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
  • the formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the pharmaceutically active ingredient with the carrier that constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • the first step reaction may conveniently be carried out, for example, at a temperature about 10O 0 C, in an inert solvent, such as DMF.
  • the second step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 10O 0 C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et 3 N, in an inert solvent, such as DMF.
  • a coupling agent such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt
  • a base such as DIPEA or Et 3 N
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, by first reacting the compound of formula (4) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et 3 N, K 2 CO 3 or Na 2 CO 3 , in an inert solvent, such as DCM or DMF.
  • a base such as DIPEA, Et 3 N, K 2 CO 3 or Na 2 CO 3
  • R 2 (C r C 4 )-alkyl optionally substituted one or more times by halo
  • L 1 is a bond, -NH-C(O)- or (C r C 2 )-alkylene optionally substituted one or more times by halo
  • the first step reaction may conveniently be carried out, for example, at a temperature about 10O 0 C, in the presence of sodium metal, in a solvent, such as EtOH.
  • the second step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 10O 0 C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et 3 N, in an inert solvent, such as DMF.
  • a coupling agent such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt
  • a base such as DIPEA or Et 3 N
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, by first reacting the compound of formula (8) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et 3 N, K 2 CO 3 or Na 2 CO 3 , in an inert solvent, such as DCM or DMF.
  • a base such as DIPEA, Et 3 N, K 2 CO 3 or Na 2 CO 3
  • the first step reaction may conveniently be carried out, for example, at a temperature about room temperature to 5O 0 C, in an inert solvent, such as Et 2 O.
  • the second step reaction may conveniently be carried out, for example, at a temperature about 15O 0 C, in the presence of potassium hexacyanoferrate(II) trihydrate, palladium (II) acetate and a base such as Na 2 CO 3 or K 2 CO 3 , in an inert solvent, such as dimethylacetamide or DMF.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, in the presence of an inorganic base such as KOH, NaOH or LiOH, in a solvent, such as MeOH, or a mixture of MeOH and water.
  • the fourth step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof.
  • the fifth step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 100 0 C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et 3 N, in an inert solvent, such as DMF.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, by first reacting the compound of formula (4) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et 3 N, K 2 CO 3 or Na 2 CO 3 , in an inert solvent, such as DCM or DMF.
  • a compound of formula (I), wherein L 1 is -O-, and R 1 , R 2 , R 3 and R 4 are as defined herein, may be prepared, as shown in Scheme IV below, by (i) oxidizing a compound of formula (14) to provide a compound of formula (15), (ii) reacting the compound of formula (15) with a corresponding compound having formula R 1 ONa to provide a compound of fomrmula (16), (iii) hydro lyzing the compound of formula (16) to provide a compound of formula (17), and (iv) coupling the compound of formula (17) with a corresponding compound of formula (5).
  • L 1 is -O- (17)
  • the first step oxidation reaction may conveniently be carried out, for example, at room temperature, in the presence of MCPBA and Na 2 S 2 O 3 , in an inert solvent, such as DCM.
  • the second step reaction may conveniently be carried out, for example, in a microwave heated at a temperature about 100 0 C, in an inert solvent, such as NMP.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, in the presence of an inorganic base such as KOH, NaOH or LiOH, in a solvent, such as THF, MeOH, or a mixture thereof.
  • the fourth step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 100 0 C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et 3 N, in an inert solvent, such as DMF.
  • the third step reaction may conveniently be carried out, for example, at about a temperature about O 0 C to room temperature, by first reacting the compound of formula (17) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et 3 N, K2CO3 or Na 2 CO 3 , in an inert solvent, such as DCM or DMF.
  • Compounds of the invention may also be prepared by interconversion of other compounds of the invention.
  • compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of Formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallization techniques, or they are separately prepared from the appropriate isomers of their intermediates.
  • Mass Spectra are recorded using a Micromass LCT mass spectrometer. The method is positive electrospray ionization, scanning mass m/z from 100 to 1000.
  • Step 1 A solution of potassium tert-butoxidc (1.84 g, 16.43 mmol) and 5-fluoro-2- methylindole (1.21 g, 8.09 mmol) in DMF (20 mL) is stirred under N 2 at rt for 60 min. A solution of monochloroamine in ether (65 mL, 9.75 mmol) is added via an addition funnel over 10 min. The resulting mixture is stirred at 23°C for 2 hours, and then concentrated in vacuo. The residue is partitioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO 3 , water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 2 A 250 mL, three-neck, round-bottom flask equipped with a magnetic stirrer and a reflux condenser is purged with N 2 .
  • the flask is charged sequentially with methyl 3,3- dimethoxypropionate (5.22 g, 35.3 mmol), anhydrous 1 ,2-dimethoxyethane (25 mL), anhydrous methyl formate (5 mL), 60% sodium hydride (1.7 g, 42.5 mmol), and the mixture warmed to 40 - 5O 0 C until evolution of hydrogen gas stops.
  • the reaction mixture is cooled in an ice/water bath and slowly allowed to reach room temperature overnight with stirring.
  • Step 3 To a solution of nicotinamidine hydrochloride (1 g, 6.35 mmol) in anhydrous DMF (12 mL) is added sodium salt of 2-dimethoxymethyl-3-hydroxy-acrylicacid methyl ester (1.46 g, 7.36 mmol) and the reaction mixture is heated at 100 0 C under N 2 for 3 hours. After this time the reaction is cooled to room temperature and water (48 mL) is added. The precipitate is collected by filtration, washed with water and vacuum dried to afford 2-pyridin-3-yl- pyrimidine-5-carboxylic acid methyl ester (0.7 g, 51%). MS: 216 (M+H).
  • Step 4 A solution of 2-pyridin-3-yl-pyrimidine-5-carboxylic acid methyl ester (0.73 g, 3.32 mmol) and IM aqueous LiOH (3.32 mL) in MeOH (5 mL) is stirred at rt overnight. The MeOH is removed in vacuo, and the aqueous solution is treated with 3 N aqueous HCl to adjust the pH ⁇ 2-3. The solid is filtered off and washed with water and dried in vacuum to yield 2-pyridin-3 -yl-pyrimidine-5 -carboxy lie acid (0.2 g, 30%) as a solid. MS: 202 (M+H).
  • Step 5 A solution of 2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (506 mg, 2.13 mmol), HCTU (970 mg, 2.34 mmol), and DIPEA (1 mL, 5.72 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. 5-Fluoro-2-methyl-indol-l-ylamine (311 mg, 1.89 mmol) is added. The resulting mixture is stirred at 75°C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO 3 , water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 1 Na 0 (0.66 g, 28.6 mmol) is added to anhydrous EtOH (100 rnL) and stirred at rt for 15 min. 3-Fluorobenzamidine hydrochloride (4.87 g, 27.8 mmol) is added and the solution is stirred for 15 min. 2-Dimethylaminomethylene-3-oxo-butyric acid ethyl ester (5.3 g, 28.6 mmol,) is added and the reaction mixture is heated at reflux under N 2 for 1 hours. The reaction is cooled to rt and concentrated in vacuo.
  • Step 2 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid ethyl ester (6.7 g, 27.2 mmol) and NaOH (2.1 g, 54.4 mmol) in a 1 :1 :1 solution of THF, MeOH and water (300 mL) is heated at reflux for 45 min. The THF/MeOH is evaporated, and the aqueous solution is treated with 3 N HCl to adjust the pH to between 2 and 3. The solid is filtered off, washed with water and dried in vacuo to yield 2-(3-fluoro-phenyl)-4-methyl- pyrimidine-5-carboxylic acid (5.4 g, 91%) as a solid.
  • Step 3 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (340 mg, 1.46 mmol, prepared according to the general procedure described in Example 1, steps 3 and 4), HOAt (248 mg, 1.82 mmol), and HATU (645 mg, 1.70 mmol) in DMF (15 mL) is stirred at rt under N 2 for 20 min. 5-Fluoro-2-methyl-indol-l-ylamine (237 mg, 1.44 mmol) and DIPEA (380 ⁇ L, 2.18 mmol) are added. The resulting mixture is stirred at 80 0 C overnight. The mixture is cooled and portioned between EtOAc and water.
  • Step 1 A suspension of NaH (2.01 g, 50.3 mmol, 60% in mineral oil) in DMF (45 mL) at 0 0 C is treated with 5-fluoro-3-methyl-lH-indole (500 mg, 3.55 mmol), and the mixture is stirred at 0 0 C for 1 h.
  • NH 2 OSO 3 H (1.9 g, 16.75 mmol) is added portion wise, and the mixture is then warmed to rt and stirred for 2 h. The mixture is quenched with MeOH, diluted with water, extracted with EtOAc, dried (Na 2 SO 4 ), filtered and concentrated to afford 5 -fluoro-3 -methyl- indol-1-ylamine.
  • Step 2 Na 0 (31.7 mmol) is added to anhydrous EtOH (100 mL) and stirred at rt for 15 min. Pyridine -2-carboxamidine hydrochloride (31.7 mmol) is added and the solution is stirred for 15 min. 2-Dimethylaminomethylene-3-oxo-butyric acid ethyl ester (31.7mmol) is added and the reaction mixture is heated at reflux under N 2 for 1 h. The reaction is cooled to rt and concentrated in vacuo.
  • Step 3 A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid ethyl ester (26.7 mmol) and LiOH (53.4 mmol) in a 1 :1 :1 solution of THF, MeOH and water (200 mL) is stirre at rt overnight.
  • the THF/MeOH is evaporated, and the aqueous solution is treated with 10% aqueous HCl to adjust the pH to between 1.5 and 2.5.
  • the solid is filtered off, washed with water and dried in vacuo to yield 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5.50 g, 96%) as a solid.
  • Step 4 A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (335 mg, 1.56 mmol), HOTT (638 mg, 1.72 mmol), and DIPEA) (700 ⁇ L, 4.01 mmol in DMF (6 mL) is stirred stirred at rt under N 2 for 20 min. 5-Fluoro-3-methyl-indol-l-ylamine (241 mg, 1.47 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water.
  • Step 1 Following the procedures similar to those of Example 1, step 3, but substituting pyridine-2-carboxamidine hydrochloride nicotinamidine hydrochloride, there is prepared I 1 pyridin-2-yl-pyrimidine-5-carboxylic acid methyl ester.
  • Step 2 Following the procedures similar to those of Example 2, step 1, but substituting 2- pyridin-2-yl-pyrimidine-5-carboxylic acid methyl ester for 2-pyridin-3-yl-pyrimidine-5- carboxylic acid methyl ester, there is prepared 2-pyridin-2-yl-pyrimidine-5-carboxylic acid.
  • Step 3 A solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (209 mg, 0.88 mmol),
  • Step 2 Following the procedures similar to those of Example 2, step 1, but substituting 2- pyridin-3-yl-4-methyl-pyrimidine-5-carboxylic acid ethyl ester for 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid ethyl ester, there is prepared 4-methyl-2-pyridin-3-yl- pyrimidine-5-carboxylic acid.
  • Step 3 A solution of 4-methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (502 mg, 2.33 mmol), HCTU (1.054 g, 2.55 mmol), and DIPEA (1.10 mL, 6.30 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. 5-Fluoro-3-methyl-indol-l-ylamine (341 mg, 2.08 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHC ⁇ 3, water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 1 To a solution of 3-fluoro-benzamidine hydrochloride (4 g, 22.6mmol) in anhydrous DMF (35 mL) is added sodium 3,3-dimethoxy-2-carbomethoxyprop-l -en- 1 -oxide (4.99g, 25.2mmol). The reaction mixture is heated at 100 0 C under N 2 for 3 h and then cooled to rt. Water (150 mL) is added and the mixture is extracted with EtOAc. The organic layer is washed with brine, dried (MgSO 4 ) filtered and concentrated in vacuo to afford 2-(3-fluoro- phenvD-pyrimidine-5-carboxylic acid methyl ester (1.76 g, 34%). MS: 233 (M+H).
  • Step 2 To a solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid methyl ester (1.76 g, 7.58 mmol) in anhydrous MeOH (35 mL) is added LiOH (0.38g, 15.9mmol) and the reaction mixture is stirred at rt overnight. The mixture is concentrated in vacuo and the residue is partitionned between EtOAc and 3 N aqueous HCl (7.6 mL).
  • Step 3 A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (372 mg, 1.7 mmol), HCTU (757 mg, 1.83 mmol), and DIPEA (780 ⁇ L, 4.47 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. 5-Fluoro-3-methyl-indol-l-ylamine (250 mg, 1.52 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO 3 , water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 1 Isoamyl nitrite (3.4 mL, 25.42 mmol) is added to a solution of 5-fluoro-3,3-dimethyl- 2,3-dihydro-lH-indole (3.75 g, 22.69 mmol) in DCM. The mixture is refluxed overnight. The mixture is cooled and portioned between DCM and water. The organic phase is separated, washed with saturated aqueous NaHCO 3 , water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo to afford 5-fluoro-3,3-dimethyl-l-nitroso-2,3-dihydro-lH-indole (4.23 g, 96%) as a solid. MS: 195 (M+H). 1 H NMR (300MHz, CD 3 Cl)): ⁇ 7.77 (dd, IH), 7.08- 6.98 (m, 2H), 3.94 (s, 2H), 1.39 (s, 6H).
  • Step 2 To a solution of 5-fluoro-3,3-dimethyl-l-nitroso-2,3-dihydro-lH-indole (4.03 g, 20.75 mmol) in THF (70 mL) at 0 0 C is added a solution OfLiAlH 4 (40 mL, 40 mmol) in THF dropwise. The mixture is allowed to warm to rt and stirred overnight. The mixture is quenched with a saturated aqueous solution of Rochelle's Salt. The resulting mixture is stirred until a slurry is obtained.
  • Step 3 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (348 mg, 1.5 mmol), HOTT (618 mg, 1.66 mmol), and DIPEA (700 ⁇ L, 4.01 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. 5-Fluoro-3,3-dimethyl-2,3-dihydro-indol-l-ylamine (239 mg, 1.33 mmol) is added. The resulting mixture is stirred at 80 0 C overnight. The mixture is cooled and portioned between EtOAc and water.
  • Step 1 Following procedures similar to those of Example 1, step 1, but substituting 3-(2,2,2- trifluoro-acetyl)indole for 5-fluoro-2-methylindole, l-(l-amino-lH-indol-3-yl)-2,2,2- trifluoro-ethanone is prepared.
  • Step 2 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (360 mg, 1.55 mmol), HOTT (628 mg, 1.69 mmol), and DIPEA (740 ⁇ L, 4.24 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. l-(l-Amino-lH-indol-3-yl)-2,2,2-trifluoro-ethanone (322 mg, 1.4 mmol) is added. The resulting mixture is stirred at 80 0 C overnight. The mixture is cooled and portioned between EtOAc and water.
  • Step 1 Following procedures similar to those of Example 1, step 1, but substituting 2,3- dimethylindole for 5-fluoro-2-methylindole, there is prepared 2,3-dimethyl-indol- 1 -ylamine as a solid. MS: 161 (M+H). 1 H NMR (300MHz, CDCl 3 ): ⁇ 7.48-7.45 (m, IH), 7.33-7.30 (m, IH), 7.19-7.13 (m, IH), 7.10-7.05 (m, 1 H), 4.40 (br s, 2H), 2.37 (s, 3H), 2.23 (s, 3H).
  • Step 2 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (764 mg, 3.29 mmol), HOTT (1.33 g, 3.58 mmol), and DIPEA (1.65 mL, 9.45 mmol) in DMF (15 mL) is stirred at rt under N 2 for 10 min. 2,3-Dimethyl-indol-l-ylamine (497 mg, 3.1 mmol) is added. The resulting mixture is stirred at 80 0 C overnight. The mixture is cooled and portioned between EtOAc and water.
  • Step 1 Following procedures similar to those of Example 1, step 1, but substituting 5-chloro- 2-methylindole for 5-fluoro-2-methylindole, there is prepared 5-chloro-2-methyl-indol-l- ylamine as a solid. MS: 181 (M+H). 1 H NMR (300MHz, CDCl 3 ): ⁇ 7.46-7.43 (m, IH), 7.27- 7.24 (m, IH), 7.12-7.09 (m, IH), 6.10 (s, 1 H), 4.44 (br s, 2H), 2.44-2.43 (m, 3H).
  • Step 2 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (379 mg, 1.63 mmol), HOTT (662 mg, 1.78 mmol), and DIPEA (800 ⁇ L, 4.58 mmol) in DMF (10 mL) is stirred at rt under N 2 for 10 min. 5-Chloro-2-methyl-indol-l-ylamine (274 mg, 1.52 mmol) is added. The resulting mixture is stirred at 80 0 C overnight. The mixture is cooled and portioned between EtOAc and water.
  • Step 1 Following procedures similar to those of Example 1, step 1, but substituting 5- bromoindole for 5-fluoro-2-methylindole, there is prepared 5 -bromoindol- 1 -ylamine as a solid. MS: 211 (M+H). 1 H NMR (300MHz, CDCl 3 ): ⁇ 7.71-7.70 (m, IH), 7.29-7.28 (m, 2H), 7.13 (d, IH), 6.32-6.31 (m, 1 H), 4.73 (br s, 2H).
  • Step 2 A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (596 mg, 2.57 mmol), PyAOP (2.63 mmol), and DIPEA (830 ⁇ L, 4.75 mmol) in DCM (20 niL) is stirred at rt under N 2 for 10 min. 5-Bromoindol-l-ylamine (500 mg, 2.37 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO 3 , water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 2 Following the procedures described in P. Shenbagamurthi, H. A. Smith, J. M. Becker, F. Naider J. Med Chem. 1986, 29 (5), 802-809; R. K. Olsen J. Org. Chem.
  • Step 3 To a O 0 C solution of AD-mix- ⁇ (2.54 g) in a mixture of t-butanol (10 rnL) and water (12 rnL) is added a solution of (allyl-benzyloxycarbonyl-amino)-acetic acid ethyl ester (0.52 g, 1.91 mmol) in t-butanol (2.00 rnL). The reaction mixture is allowed to gradually warm to ambient temperature over 2 h, and stirred at rt for 20 h. Excess oxidant is quenched by the addition OfNa 2 SOs (2.58 g, 20.44 mmol) and the mixture is stirred vigorously for 4 h.
  • OfNa 2 SOs (2.58 g, 20.44 mmol
  • Step 4 To a solution of [benzyloxycarbonyl-(2,3-dihydroxy-propyl)-amino]-acetic acid ethyl ester (1.98 g, 6.37 mmol) in DCM (30 mL) is added NaIO 4 -impregnated silica (13.04 g). The slurry is stirred rapidly for 4.5 h, and then filtered through a coarse porosity sintered glass funnel. The filtrate is concentrated to afford [benzyloxycarbonyl-(2-oxo-ethyl)-amino "
  • Step 5 N-Aminophthalimide (0.55 g, 3.4 mmol) is added to a solution of benzyloxycarbonyl- (2 -oxo-ethyl)-amino] -acetic acid ethyl ester (0.72, 2.6 mmol) in 1,4-dioxane (10 mL), and the mixture is heated to reflux under N 2 for 15 h. The reaction mixture is cooled to rt and filtered through diatomaceous earth. The filtrate is concentrated. The residue is re-dissolved in CHCl 3 (30 mL) and filtered again through diatomaceous earth.
  • Step 6 A solution of (benzyloxycarbonyl- ⁇ 2-[(E)-l,3-dioxo-l,3-dihydro-isoindol-2- ylimino]ethyl ⁇ -amino)-acetic acid ethyl ester (7.7 mmol) in CH3CN (65 rnL) is treated with sodium cyanoborohydride (1.92 g, 30.5 mmol), and acetic acid (6.8 mL, 118.8 mmol) is added with stirring under N 2 .
  • reaction solution is diluted with EtOAc (150 mL) and washed with saturated aqueous KHCO3 (3 x 50 mL) and saturated aqueous NaCl (50 mL).
  • the organic phase is dried (MgS ⁇ 4), filtered, and concentrated in vacuo.
  • Step 7 A solution of (benzyloxycarbonyl-[2-(l,3-dioxo-l,3-dihydro-isoindol-2-ylamino)- ethyl] -amino ⁇ -acetic acid ethyl ester (0.22 g, 0.52 mmol) in diphenyl ether (3 mL) is heated to reflux for 2 h.
  • Diphenyl ether is removed by vacuum distillation and the residue is purified by flash silica gel chromatography (2:1 :1 to 1 :1 :1 heptane:DCM:EtOAc gradient elution) to afford 4-(l ,3-dioxo- 1 ,3-dihydro-isoindol-2-yl)-3-oxo-piperazine- 1 -carboxylic acid benzyl ester as a solid (0.126 g, 64%).
  • Step 8 To a solution of benzamidine hydrochloride hydrate (2 mmol) in anhydrous DMF (4 mL) is added sodium salt of 2-dimethoxymethyl-3-hydroxy-acrylicacid methyl ester (0.46 g, 2.32 mmol) and the reaction mixture heated at 100 0 C under N2 for 1 hour. The reaction is cooled to rt and water (15 mL) is added. After addition of water, immediate precipitation of the product is observed. The solids are collected by filtration, washed with water (2.5 mL) and vacuum dried to yield 2 -phenyl-pyrimidine-5 -carboxylic acid methyl ester (0.32 g, 74%). (see: P. Zhichkin, D.J. Fairfax, S.A. Eisenbeis, Synthesis, 2002, 720-722.)
  • Step 9 A solution of 2-phenyl-pyrimidine-5 -carboxylic acid methyl ester (3.15 g) and LiOH (0.71 g) in a mixture of MeOH, THF and water (1 :1 :1 in volume, 120 mL) is stirred at rt overnight. MeOH and THF are evaporated off to give an aqueous solution. The aqueous solution is acidified with 5% hydrochloric acid to adjust pH to between 2.5 and 3. The precipitate is filtered off and washed with water, dried in vacuo to yield 2.94 g (-100%) of 2z phenyl-pyrimidine-5 -carboxylic acid as a solid. MS: 201 (M+H).
  • Step 10 A solution of 4-(l,3-dioxo-l,3-dihydro-isoindol-2-yl)-3-oxo-piperazine-l-carboxylic acid benzyl ester (53 mg, 0.14 mmol) in MeOH (10 rnL) is treated with anhydrous hydrazine (0.3 mL, 9.56 mmol). The reaction mixture is stirred at reflux under N 2 for 3.5 h. The reaction mixture is concentrated. The residue is dissolved in a mixture of DMF (2 mL) and DCM (2 mL), and treated with 2-phenyl-pyrimidine-5-carbonyl chloride (32 mg, 0.15 mmol).
  • Step 1 A solution of 5-fluoroindole (5.4 g) and toluene-4sulponyl chloride (9.12 g) in toluene (300 mL) is treated with a cooled solution of sodium hydroxide pellets (23.2 g) in water (200 mL) followed by the tetrabutylammonium hydrogen sulfate catalyst (400 mg). The mixture is stirred at rt for 24 h. The organic phase is separated, washed with water and brine, dried (MgSO 4 ) and concentrated in vacuo to afford 5 -fluoro- 1 -(toluene-4-sulfonvD- 1 H-indole (10.7 g, 78%).
  • Step 2 A solution of 5-fluoro-l-(toluene-4-sulfonyl)indole (5.2 g) in dry CH 3 CN (80 niL) is cooled in an ice-bath and treated drop wise with chlorosulfonic acid (12 mL). The reaction mixture is allowed to warm to rt and stirred for 24 h. The reaction mixture is carefully poured onto ice/water (300 mL).
  • Step 3 A solution of 5-fluoro-3-chlorosulfonyl-l-(toluene-4-sulfonyl)indole (2.52 g) in DCM (75 mL) is added to an aqueous solution of dimethylamine (40%, 20 mL) in water (50 mL) and stirred at rt for 20 h. The organic phase is separated, washed with water, brine, dried (MgSO 4 ), filtered and concentrated in vacuo to afford 5 -fluoro- 1 -(toluene-4-sulfonvD- 1 H- indole-3-sulpfonic acid dimethylamide (2.55 g, 99%) as a solid. MS: 397 (M+H).
  • Step 4 A mixture of 5 -fluoro- l-(touene-4-sulfonyl)indole-3 -sulfonic acid dimethylamide (2.55 g) in MeOH (100 mL) and 5 N KOH (15mL) is heated to reflux for 1.5 hours. The reaction mixture is concentrated in vacuo. The residue is diluted with water (50 mL) and acidified to pH ⁇ 3 with IO N aqueous HCl. The mixture is extracted with EtOAc.
  • Step 5 A solution of 5 -fluoro- lH-indole-3 -sulfonic acid dimethylamide (1.24 g) in dry DMF (50 mL) is cooled to 0 0 C and treated portion wise with 60% MaH oil dispersion (3.07 g). The mixtire is stirred at 0 0 C for 30 min. Hydroxylamine-O-sulfonic acid (2.9 g) is added portion wise and the mixture is warmed to rt and stirred for 5 h. The reaction mixture is poured onto ice/water and extracted with EtOAc. The organic layer is separated, washed water and brine, dried (MgSO 4 ) filtered and concentrated in vacuo. The residue is triturated with ether. The solid is collected by filteration to afford l-amino-5 -fluoro- lH-indole-3 -sulfonic acid dimethylamide (0.53 g, 41%). MS: 258 (M+H).
  • Step 6 A suspension of 2-(3-fluorophenyl)-pyrimidine-5-carboxylic acid (76 mg) in dry DCM (25mL)/dry DMF (2 drops) is treated with oxalyl chloride (0.15mL) and stirred at rt for 3.5 hours. The reaction mixture is concentrated in vacuo. The residue is dissolved in toluene (15 niL) and then concentrated in vacuo. The residue is dried on high vacuum pump, and then dissolved in EtOAc (7 mL).
  • Step 1 A solution of 5-fluoro-3-chlorosulfonyl-l-(toluene-4-sulfonyl)-lH-indole (1 g) in DCM is added to a solution of morpholine (2.26 niL) in water (50 mL) and stirred at rt for 5 h. The organic phase is separated and washed water, brine and dried (MgSO 4 ), filtered and concentrated in vacuo to afford 5-fluoro-3-(morpholine-4-sulfonyl)-l-(toluene-4-sulfonyl)- lH-indole q.3 g, ⁇ 100%). MS: 439 (M+H).
  • Step 2 A solution of 5-fluoro-3-(morpholine-4-sulfonyl)-l-(toluene-4-sulfonyl)-lH-indole (1.3 g) in MeOH (50 mL)/5 N KOH (3mL) is heated to reflux for 1 h. The reaction mixture is concentrated in vacuo. The residue is diluted with water (30 mL) and acidified with IO N aqueous HCl to pH ⁇ 4. The mixture is extracted with EtOAc.
  • Step 3 Following procedures similar to those of Example 21, step 5, but substituting 5-fluoro- 3 -(morpholine-4-sulfonyl)-l H-indole for 5 -fluoro-lH-indole-3 -sulfonic acid dimethylamide, and the product is purified by silica gel chromatography eluting with 20% EtOAc, there is prepared l-amino-5-fluoro-3-(morpholine-4-sulfonyl)-l H-indole (16%) as a solid. MS: 300 (M+H).
  • Step 4 Following procedures similar to those of Example 21, step 6, but substituting 1-amino- 5 -fluoro-3-(morpholine-4-sulfonyl)-l H-indole for l-amino-5-fluoro-lH-indole-3 -sulfonic acid dimethylamide, there is prepared 2-(3-fluorophenyl)pyrimidine-5-carboxylicacid-r5-fluoro-3- (morpholine-4-sulfonvnindol- 1 -yll amide (27%) as a solid. MS: 500 (M+H).
  • Step 1 A solution of 2-(3-fluorophenyl)pyrimidine-5 -carboxylic acid-(5-fluoroindol-l- yl)amide (0.35 g,) in dry CH3CN (20 mL) is treated with chlorosulfonic acid (0.5 mL) and stirred at rt for 24 h. Thereaction mixture is poured onto ice/water (150 mL) and extracted with EtOAc.
  • Step 2 A solution of 5-fluoro-l- ⁇ [2-(3-fluorophenyl)pyrimidine-5-carbonyl]amino ⁇ -lH- indole-3 -sulfonyl chloride (0.14 g) in DCM (20 mL) is treated with a solution of aqueous ammonia solution (28%-5 mL) in water (15 mL) and stirred at rt for 24 h. The reaction mixture is acidified with IO N aqueous HCl to pH ⁇ 3 and extracted with DCM. The organic layer is washed with water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 1 A solution 2-(3-fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-(5-fluoroindol-l- yl)amide (1 g, 2.75 mmol) in dry CH3CN is cooled to 0 0 C and treated drop wise with chlorosulfonic acid (0.55 mL) and stirred for 2hours. The precipitated solid is filtered off and washed with ether to afford 5 -fluoro- 1 - ⁇ [2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carbonyll amino 1-1 H-indole-3 -sulfonic acid (1.06 g, 87%) as an off-white solid. MS: 443 (MH-).
  • Step 2 To a suspension of 5 -fluoro- 1- ⁇ [2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carbonyl]amino ⁇ -lH-indole-3-sulfonic acid (1.06 g) in DCM (60 mL) at 0 0 C is added dry DMF (10 drops). Oxalyl chloride (1.05 mL) is added drop wise and the mixture is stirred at 0 0 C for 3 h.
  • Step 3 Following procedures similar to those of Example 25, step 2, but substituting 40% aqueous methylamine for the aqueous ammonia solution, and substituting 5 -fluoro- 1- ⁇ [2-(3- fluorophenyl)-4-methylpyrimidine-5 -carbonyl] amino ⁇ -1 H-indole-3 -sulfonyl chloride for 5- fluoro- 1 - ⁇ [2-(3 -fluorophenyl)pyrimidine-5 -carbonyl] amino ⁇ - 1 H-indole-3 -sulfonyl chloride, there is prepared 2-(3-fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-[5-fluoro-3- methylsulfamovOindol- 1 -vQamide (40 mg, 35%) as a solid.
  • Step 1 The crude product of l-amino-4-fluoroindole is prepared according to the procedures described in J.Hymes et al., J.O.C., (2004), 69, 1368-1371. The crude product is then purified by silica gel chromatography eluting with 30% DCM in heptane to afford l-amino-4- fluoroindole (43%). MS: 151 (M+H).
  • Step 2 A solution of 2-(3-fluorophenyl)-pyrimidine-5-carboxylic acid (0.33 g), HATU (0.67 g) and hydroxy azabenzotriazole (0.26 g) in dry DMF (15 rnL) is stirred at rt for 30 min under N 2 .
  • a solution of l-amino-4-fluoroindole (0.24 g) in dry DMF (5 mL) is added followed by the addition of DIPEA (0.39 mL). The mixture is stirred at 80 0 C for 24 h, cooled to rt, and then concentrated in vacuo.
  • Step 1 Following procedures described in F. Chau, J.-C. Malanda, and R. Milcent J. Heterocyclic Chem. 1997, 34, 1603-1606, there is prepared 5-methyl-3H-l,3,4-oxadiazol-2- one (24%). MS: 101 (M+H); 1 H NMR (300 MHz, CDCl 3 ) ⁇ 9.76 (br s, IH), 2.28 (s, 3H).
  • Step 2 To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (2.77 g, 27.7 mmol) in MeOH (25 mL) is added 25 wt % NaOMe solution in methanol (6.4 mL, 27.9 mmol) and the mixture is stirred at rt for 10 min. The mixture is concentrated in vacuo and the residue is added to a solution of 2-chloro-4'-fluoroacetophenone (4.71 g, 27.3 mmol) and tetrabutylammonium bromide (0.174 g, 0.54 mmol) in CHCl 3 (16 mL). The mixture is heated to reflux for 2.5 h under N 2 .
  • Step 3 To a solution of 3-[2-(4-fluoro-phenyl)-2-oxo-ethyl]-5-methyl-3H-l,3,4-oxadiazol-2- one (2.3 g, 9.7 mmol) in a mixture of 2-propanol (12 mL) and water (0.3 rnL) is added hydrzazine monohydrate (0.71 mL, 14.6 mmol).
  • Step 4 To a slurry of N-[6-(4-fiuoro-phenyl)-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl]- acetamide (0.48 g, 1.9 mmol) in MeOH (5 mL) is added 37% aqueous HCl. The mixture is heated to reflux for 3 h, and then cooled to rt. The mixture is basif ⁇ ed with 1 M aqueous NaOH to pH ⁇ 12.
  • Step 5 To a slurry of 4-amino-6-(4-fluoro-phenyl)-4,5-dihydro-2H-l,2,4-triazin-3-one (0.26 g, 1.23 mmol), 2-phenyl-pyrimidine-5-carboxylic acid (0.25 g, 1.23 mmol), and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.37 g, 1.94 mmol) in DMF (12 mL) is added Et 3 N (0.2 mL, 1.435 mmol) under N 2 and the reaction mixture is stirred at rt for 49 h.
  • Step 1 A solution of (5-fluoro-lH-indol-3-yl)-acetic acid (1 g, 5.2 mmol) in MeOH (20 mL) is treated with sulfuric acid (20 ⁇ L) and stirred at rt for 1 h. This mixture is treated with 10% aqueous NaHCO 3 (200 ⁇ L) and then concentrated in vacuo to afford (5-fluoro-lH-indol-3-yl)- acetic acid methyl ester, which is used in the next step without further purification.
  • Step 2 The above (5-fluoro-lH-indol-3-yl)-acetic acid methyl ester is dissolved in THF (40 mL), cooled to 0 0 C, and treated with MeMgBr (18.5 mL, 26 mmol, 1.4 M in PhMe/THF
  • Step 3 A solution of l-(5-fluoro-lH-indol-3-yl)-2-methyl-propan-2-ol (207 mg, 1 mmol) in DMF (10 mL) is cooled to 0 0 C, treated with NaH (600 mg, 15 mmol, 60% in mineral oil) and stirred for 30 min. H 2 NOSO 3 H (565 mg, 5 mmol) is added portion wise, and the mixture is warmed to rt over 2 h.
  • Step 4 A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (175 mg, 0.8 mmol) in DCM (5 mL) is treated with DMF (20 ⁇ L) and ClCOCOCl (348 ⁇ L, 4 mmol), and stirred at rt for 3 h. Toluene (10 mL) is added and the mixture is concentrated in vacuo. The residue is added to a solution of the above l-(l-amino-5-fluoroindol-3-yl)-2-methyl-propan-2-ol and Na 2 CO 3 (1 g) in EtOAc/H 2 O (20 mL, 1 :1). The mixture is stirred at rt for 12 h.
  • Method A To a solution of 2-phenyl-pyrimidine-5-carboxylic acid (150 mg, 075 mmol) in DCM (10 mL) is added l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (158 mg, 0.83 mmol) and N-hydroxybenzotriazole (112 mg, 0.83 mmol) at rt and the mixture is stirred for 10 min.
  • 1-Aminopiperidine 150 mg, 1.5 mmol is added. The mixture is stirred at rt overnight.
  • Step 1 To a solution of 2-methylsulfanyl-pyrimidine-5-carboxylic acid methyl ester 1 (1 g, 5.43 mmol) in DCM (60 mL) is added MCPBA (2.81 g, 16.29 mmol) portion wise at rt. The resulting solution is stirred at rt overnight. A solution OfNa 2 S 2 O 3 (1.6 g) in water (60 mL) is added. The mixture is stirred at rt for 20 min. The layer is separated, and the water layer is extracted with DCM (2x20 mL).
  • Step 2 To a solution of 2-methanesulfonyl-pyrimidine-5-carboxylic acid methyl ester 2 (2.5 g, 11.56 mmol) in DCM (30 mL) is added a solution of tetrabutylammonium cyanide (3.1 g, 11.56 mmol) in water (30 mL) slowly at rt. The mixture is stirred for 80 min. The mixture is washed with water (2x20mL), dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
  • Step 3 To a solution of 2-cyano-pyrimidine-5-carboxylic acid methyl ester 3 (1 g, 6.13 mmol) in MeOH (20 mL) at rt is added hydroxylamine hydrochloride (0.64g, 9.2mmol) and sodium acetate (0.76 g, 9.2 mmol). The resulting mixture is heated to reflux for 2 hours. The mixture is cooled to rt and concentrated in vacuo. Water (30 mL) is added to the residue, and the solid is filtered, and washed with water twice.
  • Step 4 To a solution of 2-(N-hydroxycarbamimidoyl)-pyrimidine-5-carboxylic acid methyl ester (900 mg, 4.59 mmol) in pyridine (15 mL) is added acetyl chloride (432 mg, 5.5 mmol) dropwise. The resulting solution is stirred at rt for 1 hour, and heated to reflux for 3h. The solution is cooled to rt and concentrated in vacuo. Water (30 mL) is added to the residue, and the mixture is extracted with EtOAc (3x20 mL).
  • Step 5 To a solution of 2-(5-methyl-[l,2,3]oxadiazo-3-yl)-pyrimidine-5-carboxylic acid methyl ester (900 mg) in MeOH (20 mL) is added a solution of LiOH (100 mg) in water (20 mL) at O 0 C. The ice-bath is removed, and the mixture is stirred for another 10 min. The solvent is evaporated, and water (20 mL) is added. The water solution is washed with ether (2x20mL), and acidified with 2 N HCl to pH ⁇ 3.
  • Step 1 5-Bromo-2-chloropyrimidine (7.51 g, 38.83 mmol) is dissolved in DMSO (20 niL) is added to a mixture of NaCN (1.9 g, 38.83 mmol) and l,4-diazabicyclo[2,2,2]octane (0.87 g, 7.77 mmol) in DMSO (10 mL) and water (20 mL). The mixture is stirred at rt overnight, and then water (100 mL) is added. The mixture is extracted with ether (3x100 mL). The combined organic layer is dried (Na 2 SO 4 ), filtered and concentrated in vacuo to afford 5_; bromo-pyrimidine-2-carbonitrile (6.28 g, 88%) as a solid. MS: 184 (M+H).
  • Step 2 5-Bromo-pyrimidine-2-carbonitrile(2.5 g, 13.59 mmol) is dissolved ether (30 mL), and PhMgBr (3 ether solution, 13.59 mmol, 4.53 mL) is added dropwise at rt. The mixture is heated to reflux for 3 h under N 2 , and then cooled to rt. THF (30 mL) is added followed by the addition of 2 N aqueous HCl (10 mL). The resulting solution is stirred at rt for 30 min, and water (30 mL) is added. The aqueous layer is extracted with EtOAc (3x20 mL).
  • Step 3 (5-Bromo-pyrimidine-2-yl)-phenyl-methanone (1.6 g, 6.08 mmol) is dissolved in dimethylacetamide (20 mL), and potassium hexacyanoferrate(II) trihydrate (0.57 g, 1.34 mmol) is added, followed by Na 2 CO 3 (0.64 g, 6.08 mmol), and palladium (II) acetate (68 mg, 0.3 mmol). The mixture is heated to 150 0 C under N 2 for 3 h, and then cooled to rt. EtOAc (30 mL) is added and the mixture is filtered.
  • Step 5 2-Benzoyl-pyrimidine-5-carboxylic acid methyl ester (420 mg, 1.73 mmol) is dissolved in THF (5 mL), and a solution of LiOH (46 mg, 1.91 mmol) in water (5 mL) is added in one portion at 0 0 C. The mixture is stirred at 0 0 C for 60 min. THF is evaporated in vacuo, and the residue is diluted with water (5 mL) and washed with ether (10 mL). The aqueous layer is acidified with 2 N aqueous HCl to pH ⁇ 3.
  • Step 6 2-Benzoyl-pyrimidine-5-carboxylic acid (50 mg, 0.22 mmol) is dissolved in anhydrous DCM (5 mL), and a 2 M oxalyl chloride (0.26 mmol, 0.13 mL) solution in DCM is added at rt followed by one drop of DMF. The mixture is stirred at rt for 2 h, and then concentrated in vacuo. The residue is dissolved in DCM (5 mL), and morpholine-4-ylamine (0.24 mmol, 25 mg) is added, followed by DIPEA (0.44 mmol, 57 mg). The reaction mixture is stirred at rt overnight, and then concentrated in vacuo.
  • Step 1 A mixture of Methyl-5-bromovalerate(3 g, 15.4 mmol) and hydrazine hydrate (55%, 15.4 mmol) in MeOH (50 mL) is stirred at rt for 18 h. A solution of NaOMe (15.4 mmol) in MeOH (10 mL) is added and the reaction mixture is stirred at rt for 18 h. The reaction mixture is concentrated in vacuo. The residue is triturated with cold MeOH and then filtered. The filtrate is concentrated in vacuo. The residue is placed on a SCX column (10 g) and the column is washed with MeOH (3x20 mL. The product is eluted with 7 M ammonia in MeOH to afford 1 -amino-piperidin-2-one as an oil. MS: 137 (M+Na).
  • Step 2 To a solution of 2-phenyl-pyrimidine-5-carboxylic acid (100 mg, 0.52 mmol), 1- hydroxybenzotriazole (77 mg, 0.57 mmol), l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (111 mg, 0.57 mmol) and DIPEA (0.57 mmol) in DCM (5 mL) is added l-amino-piperidin-2- one (64 mg, 0.57 mmol), and the mixture is stirred at rt for 18 h.
  • Step 1 To a solution of 2-methylsulfanyl-pyrimidine-5-carboxylic acid methyl ester (I g, 5.43 mmol) in DCM (60 mL) is added MCPBA (2.81 g, 16.29 mmol) portion wise at rt. The resulting solution is stirred at rt overnight. A solution OfNa 2 S 2 O 3 (1.6 g) in water (60 mL) is added. The mixture is stirred at rt for 20 min. The organic layer and aqueous layer are separated, and the aqueous layer is extracted with DCM (2x20 mL).
  • Step 2 To a solution of 2-methanesulfonyl-pyrimidine-5-carboxylic acid methyl ester (0.8 g, 3.7 mmol) in NMP (3 mL) is added sodium phenoxide trihydrate (0.68 g, 4 mmol). The mixture is heated at 100 0 C in Biotage Microwave for 60 sec. The reaction is poured into water and the precipitate is collted by filtration and dried to afford 2-phenoxy-pyrimidine-5 - carboxylic acid methyl ester (0.56g, 66%) as a solid.
  • Step 3 To a solution of 2-phenoxy-pyrimidine-5-carboxylic acid methyl ester (0.5 g, 2.17 mmol) in THF (10 mL) and water (5 mL) is added LiOH (105 mg, 4.35 mmol). The reaction is stirred at O 0 C for 1 h. The THF is evaporated and the aqueous reissue is washed with ether, acidified with 2 M aqueous HCl. The resulting precipitate is filtered and dried to afford I 1 phenoxy-pyrimidine-5 -carboxylic acid (0.34g, 73%) as a solid.
  • Step 4 To a solution of 2-phenoxy-pyrimidine-5-carboxylic acid (60 mg, 0.28 mmol) in DCM (5 niL) is added oxalyl chloride (2M in DCM, 0.15 rnL, 0.29 mmol) and 1 drop of DMF. The reaction is stirred at rt for 1 h and concentrated in vacuo.
  • Step 1 2-Methylsulfanyl-pyrimidine-5-carboxylicacid methyl ester (323 mg, 1.75 mmol), Copper(I)thiophene-2-carboxylate (501 mg, 2.63 mmol), tetrakis(triphenylphosphine) palladium(O) (202 mg, 0.175 mmol) and 3-methoxyphenylboronic acid (400 mg, 2.63 mmol) are taken in a glass tube, evacuated, refilled with N 2 , added anhydrous THF (6 mL) and is heated overnight at 85°C after closing with a cap. The reaction is cooled to rt, diluted with EtOAc and ammonium hydroxide is added.
  • Step 2 A mixture of 2-(3-methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester (145 mg, 0.59 mmol), lithium hydroxide monohydrate (49.5 mg, 1.18 mmol), MeOH (1.5 mL), water (1.5 mL) and THF (1.5 ml) is stirred at rt for 3.5 hrs. Ther eaction mixture is concentrated, and water (1 rnL) and 1 N aqueous HCl (1.2 rnL) are added. The precipitated product is filtered and dried to afford 2-(3 -methoxy-phenyl)-pyrimidine-5 -carboxylic acid (140 mg).
  • Step 3 A mixture of 2-(3-methoxy-phenyl)-pyrimidine-5 -carboxylic acid (135 mg, 0.58 mmol), 4-amino-6-methyl-4,5-dihydro-2H-[l,2,4]triazin-3-one (76 mg, 0.58 mmol), DMTMM (171 mg, 0.6 mmol) and DMF (3 mL) is stirred at rt for 2 days.
  • Step 1 To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (5.509 g, 55.0 mmol) in MeOH (40 mL) is added 25wt % NaOMe solution in methanol (12.7 mL, 58.8 mmol). The mixture is stirred at rt for 15 min and then concentrated in vacuo. The residue is added to a solution of tetrabutylammonium bromide (0.358 g, 1.08 mmol) and chloro-acetone (4.6 ml, 54.9 mmol) in CHCI3 (33 mL), and the mixture is heated to reflux for 5 h under N 2 . The mixture is cooled to rt and stirred overnight.
  • Step 2 To a solution of 5-methyl-3-(2-oxo-propyl)-3H-l,3,4-oxadiazol-2-one (1.518 g, 9.72 mmol) in a mixture of 2-propanol (8.8 rnL) and water (0.22 rnL) is added methyl hydrazine (0.79 mL, 14.6 mmol). The reaction mixture is heated to reflux under N 2 for 4 h, and then a solution of oxalic acid (0.273 g, 2.92 mmol) in 2-propanol (4 mL) is added. The resulting precipitate is removed by filtration. The filtrate is concentrated in vacuo and the residue dissolved in 2-propanol (25 mL).
  • Step 3 To a slurry of N-(2,6-dimethyl-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl)-acetamide (0.34 g, 1.846 mmol) in MeOH (3 mL) is added concentrated HCl (0.25 mL, 2.9 mmol). The mixture is heated to reflux for 3 h. The mixture is then chilled to O 0 C, adjusted to pH ⁇ 12 with 1 M aqueous NaOH (2.9 mL) and concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered.
  • Step 4 To a solution of 4-amino-2,6-dimethyl-4,5-dihydro-2H-l,2,4-triazin-3-one (0.219g, 1.58 mmol) and 2-phenyl-pyrimidine-5-carboxylic acid (0.317 g, 1.58 mmol) in dry DMF (10 mL) under N 2 is added DMTMM (0.46 g, 1.66 mmol). The mixture is stirred at rt for 22 h, then diluted with EtOAc (70 mL), and washed successively with saturated aqueous NaHC ⁇ 3 solution (2x10 mL) and brine (10 mL). The organic phase is dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step 1 To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (1.01 g, 10.09 mmol) in MeOH (8 niL) is added 25 wt % NaOMe solution in methanol (2.32 niL, 10.8 mmol). The mixture is stirred at rt forl5 min and then concentrated in vacuo. The residue is added to a solution of tetrabutylammonium bromide (0.07 g, 0.22 mmol) and 1-chloropinacolone (1.35 mL, 10.07 mmol). in CHCI3 (7 mL), and the mixture is heated to reflux for 5 h under N 2 .
  • Step 2 To a solution of 3-(3,3-dimethyl-2-oxo-butyl)-3H-l,3,4-oxadiazol-2-one (0.91 g, 4.59 mmol) in a mixture of 2-propanol (4 mL) and water (0.1 mL) is added hydrazine monohydrate (0.34 mL, 6.89 mmol). The reaction mixture is heated to reflux under nitrogen for 5 h, then a solution of oxalic acid (0.13 g, 1.38 mmol) in 2-propanol (5 mL) is added to the hot solution. The resulting precipitate is removed hot by filtration.
  • Step 3 To a slurry of N-(6-tert-butyl-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl)-acetamide (0.51 g, 2.40 mmol) in MeOH (5 mL) is added concentrated HCl (0.33 mL, 3.84 mmol). The mixture is heated to reflux for 3 h. The mixture is then chilled to O 0 C and basified with 1 M aqueous NaOH (2.9 mL) to pH ⁇ 12, and concentrated in vacuo. EtOH is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered.
  • Step 4 Following the procedure similar to those of Example 60, step 4, but substituting A- amino-6-tert-butyl-4,5-dihydro-2H-l ,2,4-triazin-3-one for 4-amino-2,6-dimethyl-4,5-dihydro- 2H- 1 ,2,4-triazin-3-one, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (6-tert-butyl- 3-oxo-2.5-dihvdro-3H-1.2.4-triazin-4-yl)-amide (74%) as a solid.
  • Step 1 To a solution of 5-methyl-3-(2-oxo-propyl)-3H-l,3,4-oxadiazol-2-one (2.052 g, 13.14 mmol) in a mixture of 2-propanol (12 mL) and water (0.3 mL) is added hydrazine monohydrate (0.96 mL, 19.8 mmol). The mixture is stirred at rt under N 2 for 15 h, and then heated to reflux for 7 h. A solution of oxalic acid (0.363 g, 4.032 mmol) in 2-propanol (6 mL) is added to the warm reaction solution.
  • Step 2 Following the procedure similar to those of Example 35, step 4, but substituting N-(6- methyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazin-4-yl)-acetamide for N-[6-(4-fluoro-phenyl)-3-oxo- 2,5-dihydro-3H-l,2,4-triazin-4-yl]-acetamide, there is prepared 4-amino-6-methyl-4,5- dihvdro-2H- 1.2.4-triazin-3-one (92%) as a solid.
  • Step 3 To a solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (0.152 g, 0.75 mmol), in dry DCM (3 mL) and DMF (0.9 ⁇ L) in a dry flask under N 2 is added oxalyl chloride (74 ⁇ L, 0.86 mmol). The reaction mixture is stirred at rt for 1 h. The solvent is evaporated and toluene is added and evaporated three times.
  • step 3 substituting 2-(3-Fluoro- phenyl)-pyrimidine-5-carbonyl chloride for 2-pyridin-2-yl-pyrimidine-5-carbonyl chloride, substituting 4-amino-6-tert-butyl-4,5-dihydro-2H-l,2,4-triazin-3-one for 4-amino-6-methyl- 4,5-dihydro-2H-l,2,4-triazin-3-one, and substituting Et 3 N for DIPEA, there is prepared 2-(3- fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazine-4-vn-amide (0.067 g, 61%).
  • Et 3 N (13.15 mmol) is added to a stirred solution of 2-phenyl-pyrimidine-5 -carboxylic acid chloride (5.26 mmol) and hydrazine-acetic acid ethyl ester hydrochloride (5 mmol) in DCM (30 mL) at rt, and the mixture is stirred at rt for 5 h. The mixture is quenched with water and extracted with EtOAc (60 mL). The organic layer is washed with water (20 mL) and brine(15 mL), dried, filtered and concentrated in vacuo.
  • Oxalyl chloride in DCM (2 M, 1.5 mL) is added to a solution of 2-phenyl-pyrimidine-5- carboxylic acid (200 mg, 2 mmol) in DCM (20 mL) and stirred at rt for 2 h.
  • the reaction solution is concentrated in vacuo.
  • the residue is dissolved in DCM (20 rnL).
  • N-amino- indoline (268 mg, 2 mmol) and triethylamine (404 mg, 4 mmol) are added and stirred at rt overnight.
  • Step 1 Following procedures similar to those of Example 64 but substituting piperazin-1- ylamine for 3- ⁇ 3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid piperazin-1-yl-amide.
  • Step 2 Phenyl-pyrimidine-5-carboxylic acid piperazin-1-yl-amide is dissolved in HCl methanol solution and evaporated methanol to dryness to afford 2-phenyl-pyrimidine-5 - carboxylic acid piperazin-1-vD-amide dihydrochloride as a solid.
  • Step 3 A suspended solution of 2-phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide dihydrochloride (0.5 mmol), methyl bromoacetate (0.5 mmol) and Na 2 CO 3 (2.5 mmol) in wet THF (20 mL) is stirred at rt for 20 h. The mixture is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 1-5% methanol in DCM to afford (4-[2- phenyl-pyrimidine-5-carbonyl)-amino "
  • Step 1 To a suspended solution of 2-phenyl-pyrimidine-5-carboxylic acid [4-(2-hydroxy- ethyl)-piperazin-l-yl]-amide (0.83 mmol) in DCM (8 mL) under N 2 are added a solution of Et 3 N (2.67 mmol) in DCM (1 mL), a solution of N,N-dimethyl-4-aminopyridine (0.2 mmol) in DCM (1 mL) and a solution of di-tert-butyl dicarbonate (1.48 mmol) in DCM (1 mL) at rt. The resulting mixture is stirred at rt for 3 h, and then concentrated in vacuo.
  • Step 2 A solution of [4-(2-methoxy-ethyl)-piperazin-l-yl]-(2-phenyl-pyrimidine-5-carbonyl)- carbamic acid tert-butyl ester (0.21 mmol), NaH (60%, 0.66 mmol) and iodomethane (0.63 mmol) in DMF (8 rnL) is stirred under N 2 at rt overnight. The reaction mixture is quenched with water, and extracted with EtOAc. The organic layer is separated, dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
  • Step 1 Following the procedures similar to those of Example 59, step 1, but substituting 4- methoxyphenylboronic acid for 3-methoxyphenylboronic acid, there is prepared 2-(4- methoxy-phenvD-pyrimidine-5-carboxylic acid methyl ester.
  • Step 2 Following the procedures similar to those of Example 59, step 2, but substituting 2-(4- methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester for 2-(3-methoxy-phenyl)- pyrimidine-5-carboxylic acid methyl ester, there is prepared 2-(4-methoxy-phenvD- pyrimidine-5-carboxylic acid.
  • Step 3 Following the procedures similar to those of Example 59, step 3, but substituting 2-(4- methoxy-phenyl)-pyrimidine-5-carboxylic acid for 2-(3-methoxy-phenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(4-methoxy-phenyl)-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H- ⁇ .2.41triazin-4-yl)-amide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Description

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS
FIELD OF THE INVENTION
The present invention is directed to pyrimidine hydrazide compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the prostaglandin D synthase.
BACKGROUND OF THE INVENTION
Allergic rhinitis, the most common atopic disease, has an estimated prevalence ranging from about 5 to about 22 percent of the general human population and is characterized by the symptoms of sneezing, nasal discharge, and nasal congestion. These symptoms are believed to be triggered by multiple mediators released from mast cells and other inflammatory cells. Current therapies, such as antihistamines, deal effectively with the sneezing and nasal discharge, but have little effect on congestion, which is a key symptom affecting the quality of life of patients.
Local allergen challenge in patients with allergic rhinitis, bronchial asthma, allergic conjunctivitis and atopic dermatitis has been shown to result in rapid elevation of prostaglandin D2 "(PGD2)" levels in nasal and bronchial lavage fluids, tears and skin chamber fluids. PGD2 has many inflammatory actions, such as increasing vascular permeability in the conjunctiva and skin, increasing nasal airway resistance, airway narrowing and eosinophil infiltration into the conjunctiva and trachea. PGD2 is the major cyclooxygenase product of arachidonic acid produced from mast cells on immunological challenge [Lewis, RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ II, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE, J. Immunol. 129, 1627-1631, 1982]. Activated mast cells, a major source of PGD2, are one of the key players in driving the allergic response in conditions such as asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis and other diseases [Brightling CE, Bradding P, Pavord ID, Wardlaw AJ, New Insights into the role of the mast cell in asthma, Clin. Exp. Allergy 33, 550-556, 2003].
In the presence of sulfhydryl compounds, PGD2 is formed by the isomerization of PGH2, a common precursor of prostanoids, by catalytic action of prostaglandin D synthase "(PGDS)". There are two isoforms of the PGDS enzyme: L-PGDS; and H-PGDS. H-PGDS is a cytosolic enzyme, which is distributed in the peripheral tissues, and which is localized in the antigen- presenting cells, mast cells, megakaryocytes, and Th2 lymphocytes. The action of the product PGD2 is mediated by G-protein coupled receptors: D prostaglandin "(DP)" and crTH2. See (1) Prostaglandin D Synthase: Structure and Function. T. Urade and O. Hayaishi, Vitamin and Hormones, 2000, 58, 89-120, (2) J. J. Murray, N. Engl. J. Med., 1986 Sept. 25; 315(13):800, and (3) Urade et. al,, J. Immunology 168: 443-449, 2002.
We believe that inhibiting the formation of PGD2 should have an effect on nasal congestion and, therefore, be of therapeutic benefit in allergic rhinitis. In addition, we believe that a PGDS inhibitor should be of therapeutic benefit in a number of other indications such as bronchial asthma.
PGDS inhibitors have been reported. The compound, HQL-79, is reported to be a weak PGDS inhibitor, and is antiasthmatic in guinea pig and rat models (Matsusshita, et al., Jpn. J. Pharamcol. 78: 11, 1998). The compound Tranilast is described as a PGDS inhibitor. (Inhibitory Effect of Tranilast on Prostaglandin D Synthesase. K. Ikai, M. Jihara, K. Fujii, and Y. Urade. Biochemical Pharmacology, 1989, 28, 2773-2676). SUMMARY OF THE INVENTION
The present invention is directed to a compound of formula (I):
Figure imgf000004_0001
(I)
wherein:
R1 is (Ci-Ce)-alkyl optionally substituted one or more times independently by halo, hydroxy,
(Ci-Ce)-alkoxy, or (Ci-C4)-haloalkoxy, or
(C3-Ce)-cycloalkyl, aryl or heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, (Ci-Ce)-alkoxy,
(Ci-C4)-haloalkyl or (Ci-C4)-haloalkoxy;
R2 is hydrogen or (Ci-C4)-alkyl optionally substituted one or more times by halo; R3 is hydrogen, alkyl, aryl or heteroaryl,
R4 is hydrogen, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylsulfonyl, heteroarylsulfonyl, -CC=O)-NY1Y2, -Q=S)-NY1Y2, R5, -C(=O)-R5 or -C(=S)-R5, wherein the aryl, heteroaryl or heterocyclyl moiety is optionally substituted one or more times independently by R6, or R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl, heterocyclenyl, heteroaryl, arylheterocyclyl, arylheterocylenyl, heteroarylheterocyclyl, heteroarylhetercyclenyl, heterocyclylheteroaryl or heterocyclenylheteroaryl, each of which is optionally substituted one or more times independently by R6; R5 is cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, heterocyclenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by R6; L1 is a bond, -O-, -C(=O)-, -NH-C(=O)-, or (Ci-C2)-alkylene optionally substituted one or more times by halo;
R6 is cyano, nitro, halo, hydroxy, carboxy, Y1Y2N-, Y1Y2N-Q=O)-, Y1Y2N-SO2-, acyl, acyloxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfϊnyl, or alkylsulfonyl, each of which is optionally substituted one or more times independently by: acyloxy, halo, alkoxy, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, Y1Y2N-, Y1Y2N-Q=O)-, Y1Y2N-SO2-, aryl, aryloxy, aroyl, heteroaryl, heteroaryloxy, heteroaroyl, heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, amino, alkylamino, dialkylamino, carboxy, or alkoxycarbonyl, or aryl, heteroaryl, aroyl, heteroaroyl, aryloxy, heteroaryloxy, heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by alkyl, haloalkyl, halo, alkoxy, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, Y1Y2N-, or Y1Y2N-SO2-, wherein the heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl moiety of R6 is also optionally substituted one or more times independently by oxo; Y1 and Y2 are each independently: hydrogen, alkylsulfonyl, aroyl, heteroaroyl, or alkyl optionally substituted one or more times independently by hydroxy, carboxy, halo, amino, alkylamino, dialkylamino, alkoxy, heterocyclyl, aryl or heteroaryl, or
Y1 and Y2 together with the nitrogen atom to which they are attached form heterocyclyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another aspect of the present invention is a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to formula (I), or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier.
Another aspect of the present invention is directed to a method of treating allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD) in a patient in need thereof by administering to the patient a compound according to formula (I), or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
Definition of Terms
As used above, and throughout the description of the invention, the following terms unless otherwise indicated, shall be understood to have the following meanings:
"Acyl" means H-CO- or (aliphatic or cyclyl)-CO-. Particular acyl includes lower alkanoyl that contains a lower alkyl. Exemplary acyl includes formyl, acetyl, propanoyl, 2- methylpropanoyl, butanoyl, palmitoyl, acryloyl, propynoyl, and cyclohexylcarbonyl.
"Acyloxy" means acyl-O-.
"Alkenyl" means a straight or branched aliphatic hydrocarbon group containing a carbon- carbon double bond and having 2 to about 15 carbon atoms. Particular alkenyl has 2 to about 12 carbon atoms. More particular alkenyl has 2 to about 4 carbon atoms. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain that may be straight or branched. Exemplary alkenyl includes ethenyl, propenyl, n-butenyl, z-butenyl, 3- methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, and decenyl.
"Alkoxy" means alkyl-O-. Exemplary alkoxy includes methoxy, ethoxy, n-propoxy, i- propoxy, n-butoxy, and heptoxy.
"Alkoxycarbonyl" means alkyl-O-CO-. Exemplary alkoxycarbonyl includes methoxycarbonyl, ethoxycarbonyl, and t-butyloxycarbonyl.
"Alkyl" means straight or branched aliphatic hydrocarbon having 1 to about 20 carbon atoms. Particular alkyl has 1 to about 12 carbon atoms. More particular alkyl is lower alkyl. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl" means 1 to about 4 carbon atoms in a linear alkyl chain that may be straight or branched.
"Alkylamino" means alkyl-NH-. Particular alkylamino is (Ci-C6)-alkylamino. Exemplary alkylamino includes methylamino and ethylamino.
"Alkylsulfmyl" means alkyl-SO-. Particular alkylsulfonyl is (Ci-C6)-alkylsulfmyl. Exemplary alkylsulfmyl includes CH3-SO-, and CH3CH2-SO-.
"Alkylsulfonyl" means alkyl-S02-. Particular alkylsulfonyl is (Ci-C6)-alkylsulfonyl. Exemplary alkylsulfonyl includes CH3-SO2-, and CH3CH2-SO2-.
"Alkylthio" means an alkyl-S-. Exemplary alkylthio includes CH3-S-.
"Alkynyl" means straight or branched aliphatic hydrocarbon containing a carbon-carbon triple bond and having 2 to about 15 carbon atoms. Particular alkynyl has 2 to about 12 carbon atoms. More particular alkynyl has 2 to about 6 carbon atoms. Branched means that one or more lower alkyl such as methyl, ethyl or propyl are attached to a linear alkynyl chain. "Lower alkynyl" means 2 to about 4 carbon atoms in a linear alkynyl chain that may be straight or branched. Exemplary alkynyl includes ethynyl, propynyl, n-butynyl, 2-butynyl, 3- methylbutynyl, n-pentynyl, heptynyl, octynyl, and decynyl.
"Aroyl" means aryl-CO-. Exemplary aroyl includes benzoyl, and 1-and 2-naphthoyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system of about 6 to about 14 carbon atoms. Particular aryl include about 6 to about 10 carbon atoms. Exemplary aryl include phenyl and naphthyl.
"Arylcycloalkenyl" means a fused aryl and cycloalkenyl. Particular arylcycloalkenyl is one wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to about 7 ring atoms. An arylcycloalkenyl is bonded through any atom of the cycloalkenyl moiety thereof capable of such bonding. Exemplary arylcycloalkenyl includes 1 ,2-dihydronaphthylene and indene. "Arylcycloalkyl" means a fused aryl and cycloalkyl. Particular arylcycloalkyl is one wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to about 6 ring atoms. An arylcycloalkyl is bonded through any atom of the cycloalkyl moiety thereof capable of such bonding. Exemplary arylcycloalkyl includes 1,2,3,4-tetrahydro-naphthylene.
"Arylheterocyclenyl" means a fused aryl and heterocyclenyl. Particular arylheterocyclenyl is one wherein the aryl thereof is phenyl and the heterocyclenyl consists of about 5 to about 6 ring atoms. An arylheterocyclenyl is bonded through any atom of the heterocyclenyl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before the heterocyclenyl portion of the arylheterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of an arylheterocyclenyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclenyl portion of the arylheterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary arylheterocyclenyl includes 3H- indolinyl, lH-2-oxoquinolyl, 2H-l-oxoisoquinolyl, 1 ,2-di-hydroquinolinyl, 3,4- dihydroquinolinyl, 1 ,2-dihydroisoquinolinyl, and 3,4-dihydroisoquinolinyl.
"Arylheterocyclyl" means a fused aryl and heterocyclyl. Particular heterocyclylaryl is one wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms. An arylheterocyclyl is bonded through any atom of the heterocyclyl moiety thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heterocyclyl portion of the arylheterocyclyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of an arylheterocyclyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclyl portion of the arylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary arylheterocyclyl includes indolinyl, 1, 2,3, 4-tetrahydroisoquino line, 1, 2,3, 4-tetrahydroquino line, lH-2,3-dihydroisoindol-2-yl, 2,3-dihydrobenz[f]isoindol- 2-yl, and 1,2,3,4- tetrahydrobenz[g]-isoquinolin-2-yl.
"Aryloxy" means an aryl-O-. Exemplary aryloxy includes phenoxy and naphthoxy. "Compounds of the present invention", and equivalent expressions, are meant to embrace compounds of Formula (I) as hereinbefore described, the hydrates, solvates and N-oxides thereof, and the pharmaceutically acceptable salts thereof, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, N-oxides and solvates, where the context so permits.
"Cycloalkenyl" means a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms, particularly of about 5 to about 10 carbon atoms, and which contains at least one carbon-carbon double bond. Particular rings of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower". Exemplary monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, and cycloheptenyl. An exemplary multicyclic cycloalkenyl is norbornylenyl.
"Cycloalkenylaryl" means a fused aryl and cycloalkenyl. Particular cycloalkenylaryl is one wherein the aryl thereof is phenyl and the cycloalkenyl consists of about 5 to about 6 ring atoms. A cycloalkenylaryl is bonded through any atom of the aryl moiety thereof capable of such bonding. Exemplary cycloalkenylaryl includes 1 ,2-dihydronaphthylene and indene.
"Cycloalkenylheteroaryl" means a fused heteroaryl and cycloalkenyl. Particular cycloalkenylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkenyl consists of about 5 to about 6 ring atoms. A cycloalkenylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heteroaryl portion of the cycloalkenylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a cycloalkenylheteroaryl may be a basic nitrogen atom. The nitrogen atom of the heteroaryl portion of the cycloalkenylheteroaryl may also be optionally oxidized to the corresponding N-oxide. Exemplary cycloalkenylheteroaryl includes 5,6- dihydroquinolyl, 5,6-dihydroisoquinolyl, 5,6-dihydroquinoxalinyl, 5,6- dihydroquinazolinyl, 4,5- dihydro-lH -benzimidazolyl, and 4,5-di-hydrobenzoxazolyl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic saturated ring system of about 3 to about 10 carbon atoms, particularly of about 5 to about 10 carbon atoms. Particular ring systems include about 5 to about 7 ring atoms; and such particular ring systems are also referred to as "lower". Exemplary monocyclic cycloalkyl includes cyclopentyl, cyclohexyl, and cycloheptyl. Exemplary multicyclic cycloalkyl includes 1-decalin, norbornyl, and adamant-(l- or 2-)yl.
"Cycloalkylaryl" means a fused aryl and cycloalkyl. Particular cycloalkylaryl is one wherein the aryl thereof is phenyl and the cycloalkyl consists of about 5 to about 6 ring atoms. A cycloalkylaryl is bonded through any atom of the cycloalkyl moiety thereof capable of such bonding. Exemplary cycloalkylaryl includes 1,2,3,4-tetrahydro-naphthylene.
"Cycloalkylheteroaryl" means a fused heteroaryl and cycloalkyl. Particular cycloalkylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkyl consists of about 5 to about 6 ring atoms. A cycloalkylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heteroaryl portion of the fused cycloalkylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a cycloalkylheteroaryl may be a basic nitrogen atom. The nitrogen atom of the heteroaryl portion of the cycloalkylheteroaryl may also be optionally oxidized to the corresponding N-oxide. Exemplary cycloalkylheteroaryl includes 5,6,7,8- tetrahydroquinolinyl, 5,6,7,8-tetra-hydroisoquinolyl, 5,6,7,8-tetrahydroquinoxalinyl, 5,6,7,8- tetrahydroquinazolyl, 4,5 ,6,7-tetrahydro- 1 H-benzimidazolyl, and 4,5,6,7- tetrahydrobenzoxazolyl.
"Cyclyl" means cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl.
"Dialkylamino" means (alkyl)2-N-. Particular dialkylamino is (Ci-C6alkyl)2-N-. Exemplary dialkylamino groups include dimethylamino, diethylamino and methylethylamino.
"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Particular halo or halogen is fluoro or chloro.
"Haloalkoxy" means alkoxy substituted by one to three halo groups. Particular haloalkoxy are loweralkoxy substituted by one to three halogens. Most particular haloalkoxy are loweralkoxy substituted by one halogen. "Haloalkyl" means alkyl substituted by one to three halo groups. Particular haloalkyl are loweralkyl substituted by one to three halogens. Most particular haloalkyl are loweralkyl substituted by one halogen.
"Heteroaroyl" means heteroaryl-CO-. Exemplary heteroaroyl includes thiophenoyl, nicotinoyl, pyrrol-2-ylcarbonyl, and pyridinoyl.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur. Particular aromatic ring systems include about 5 to about 10 carbon atoms, and include 1 to 3 heteroatoms. More particular ring sizes of rings of the ring system include about 5 to about 6 ring atoms. The designation of the aza, oxa or thio as a prefix before heteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. A nitrogen atom of a heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N- oxide. When a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer. Exemplary heteroaryl includes pyrazinyl, thienyl, isothiazolyl, oxazolyl, pyrazolyl, furanyl, pyrrolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[l,2- ajpyridine, imidazo[2,l-b]thiazolyl, benzofuranyl, azaindolyl, benzimidazolyl, benzothienyl, thienopyridyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, benzoazaindolyl, 1,2,4- triazinyl, benzothiazolyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, and triazolyl.
"Heteroarylalkyl" means heteroaryl-alkyl-. Particular heteroarylalkyl contains a (Ci-C4)-alkyl moiety. Exemplary heteroarylalkyl includes tetrazol-5-ylmethyl.
"Heteroarylcycloalkenyl" means a fused heteroaryl and cycloalkenyl. Particular heteroarylcycloalkenyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkenyl consists of about 5 to about 6 ring atoms. A heteroarylcycloalkenyl is bonded through any atom of the cycloalkenyl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heteroaryl portion of the heteroarylcycloalkenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heteroarylcycloalkenyl may be a basic nitrogen atom. The nitrogen atom of the heteroaryl portion of the heteroarylcycloalkenyl may also be optionally oxidized to the corresponding N-oxide. Exemplary heteroarylcycloalkenyl includes 5,6- dihydroquinolyl, 5,6-dihydroisoquinolyl, 5,6-dihydroquinoxalinyI, 5,6- dihydroquinazolinyl, 4,5- dihydro-lH-benzimidazolyl, and 4,5-di-hydrobenzoxazolyl.
"Heteroarylcycloalkyl" means a fused heteroaryl and cycloalkyl. Particular heteroarylcycloalkyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the cycloalkyl consists of about 5 to about 6 ring atoms. A heteroarylcycloalkyl is bonded through any atom of the cycloalkyl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heteroaryl portion of the fused heteroarylcycloalkyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heteroarylcycloalkyl may be a basic nitrogen atom. The nitrogen atom of the heteroaryl portion of the heteroarylcycloalkyl may also be optionally oxidized to the corresponding N-oxide. Exemplary heteroarylcycloalkyl includes 5,6,7,8- tetrahydroquinolinyl, 5,6,7,8-tetra-hydroisoquinolyl, 5,6,7,8-tetrahydroquinoxalinyl, 5,6,7,8- tetrahydroquinazolyl, 4,5,6,7-tetrahydro-lH-benzimidazolyl, and 4,5,6,7- tetrahydrobenzoxazolyl
"Heteroarylheterocyclenyl" means a fused heteroaryl and heterocyclenyl. Particular heteroarylheterocyclenyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclenyl consists of about 5 to about 6 ring atoms. A heteroarylheterocyclenyl is bonded through any atom of the heterocyclenyl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclenyl portion of the heteroarylheterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heteroarylazaheterocyclenyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heteroaryl or heterocyclenyl portion of the heteroarylheterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S- oxide or S,S-dioxide. Exemplary heteroarylheterocyclenyl includes 7,8-dihydro[l,7]naphthyridinyl, l,2-dihydro[2,7]- naphthyridinyl, 6,7-dihydro-3H -imidazo [4,5-c]pyridyl, l,2-dihydro-l,5-naphthyridinyl, 1 ,2- dihydro-l,6-naphthyridinyl, l,2-dihydro-l,7 -naphthyridinyl, 1,2-dihydro-l ,8-naphthyridinyl, and 1 ,2-dihydro-2,6-naphthyridinyl.
"Heteroarylheterocyclyl" means a fused heteroaryl and heterocyclyl. Particular heteroarylheterocyclyl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclyl consists of about 5 to about 6 ring atoms. A heteroarylheterocyclyl is bonded through any atom of the heterocyclyl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a fused heteroarylheterocyclyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the heteroarylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary heteroarylheterocyclyl includes 2,3-dihydro-lH-pyrrol[3,4-b]quinolin-2-yl, 1,2,3,4- tetrahydrobenz [b][l,7]naphthyridin-2-yl, l,2,3,4-tetrahydrobenz[b][l,6]naphthyridin-2-yl, 1 ,2,3,4-tetra-hydro-9H-pyrido[3,4-b]indol-2yl, 1 ,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-2yl, 2,3-dihydro-lH-pyrrolo[3,4-b ]indol-2-yl, lH-2,3,4,5-tetrahydroazepino[3,4-b]indol-2-yl, IH- 2,3,4,5-tetra-hydroazepino[4,3-b]indol-3-yl, lH-2,3,4,5-tetrahydroazepino[4,5-b]indol-2 yl, 5,6,7,8-tetra-hydro[l,7]naphthyridyl, l,2,3,4-tetrhydro[2,7]naphthyridyl, 2,3- dihydro[l,4]dioxino[2,3-b]pyridyl, 2,3-dihydro-[l,4]dioxino[2,3-b]pyridyl, 3,4-dihydro-2H-l- oxa[4,6]diazanaphthalenyl, 4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridyl, 6,7- dihydro[5,8]diazanaphthalenyl, 1 ,2,3,4-tetrahydro[l ,5]-naphthyridinyl, 1 ,2,3,4- tetrahydro[l ,6]naphthyridinyl, 1 ,2,3,4-tetrahydro[l ,7]naphthyridinyl, 1 ,2,3,4- tetrahydro[l ,8]naphthyridinyl, and 1 ,2,3,4-tetra-hydro[2,6]naphthyridinyl.
"Heteroaryloxy" means heteroaryl-O- . Exemplary heteroaryloxy includes pyridyloxy.
"Heterocyclenyl" means a non-aromatic monocyclic or multicyclic hydrocarbon ring system of about 3 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur atoms, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. A particular non-aromatic ring system includes about 5 to about 10 carbon atoms, and 1 to 3 heteroatoms. More particular ring sizes of rings of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower". The designation of the aza, oxa or thio as a prefix before heterocyclenyl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heterocyclenyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S, S- dioxide. Exemplary monocyclic azaheterocyclenyl includes 1,2,3,4-tetrahydrohydropyridyl, 1 ,2-dihydropyridyl, 1 ,4-dihydropyridyl, 1,2,3,6-tetra-hydropyridyl, 1,4,5,6-tetrahydro- pyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, and 2-pyrazolinyl. Exemplary oxaheterocyclenyl includes 3,4-dihydro-2H-pyran, dihydrofuranyl, and fluorodihydro-furanyl. An exemplary multicyclic oxaheterocyclenyl is 7-oxabicyclo[2.2.1]heptenyl. Exemplary monocyclic thioheterocyclenyl includes dihydrothiophenyl and dihydrothiopyranyl.
"Heterocyclenylaryl" means a fused aryl and heterocyclenyl. Particular heterocyclenylaryl is one wherein the aryl thereof is phenyl and the heterocyclenyl consists of about 5 to about 6 ring atoms. A heterocyclenylaryl is bonded through any atom of the aryl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heterocyclenyl portion of the fused heterocyclenylaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heterocyclenylaryl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclenyl portion of the heterocyclenylaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary heterocyclenylaryl include 3H-indolinyl, IH-2-oxoquinolyl, 2H-1- oxoisoquinolyl, 1 ,2-di-hydroquinolinyl, 3,4-dihydroquinolinyl, 1 ,2-dihydroisoquinolinyl, and 3 ,4-dihydroisoquinolinyl.
"Heterocyclenylheteroaryl" means a fused heteroaryl and heterocyclenyl. Particular heterocyclenylheteroaryl is one wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclenyl consists of about 5 to about 6 ring atoms. A heterocyclenylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclenyl portion of the heterocyclenylheteroaryl define that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of an azaheterocyclenylheteroaryl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heteroaryl or heterocyclenyl portion of the heterocyclenylheteroaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary heterocyclenylheteroaryl includes 7,8-dihydro[l,7]naphthyridinyl, l,2-dihydro[2,7]- naphthyridinyl, 6,7-dihydro-3H-imidazo[4,5-c]pyridyl, l,2-dihydro-l,5-naphthyridinyl, 1 ,2- dihydro-l,6-naphthyridinyl, 1 ,2-dihydro-l,7-naphthyridinyl, 1 ,2-dihydro-l,8-naphthyridinyl and l,2-dihydro-2,6-naphthyridinyl.
"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system of about 3 to about 10 carbon atoms, in which one or more of the atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur. A particular ring system contains about 5 to about 10 carbon atoms, and from 1 to 3 heteroatoms. Particular ring sizes of the ring system include about 5 to about 6 ring atoms; and such particular ring sizes are also referred to as "lower". The designation of the aza, oxa or thio as a prefix before heterocyclyl define that at least a nitrogen, oxygen or sulfur atom is present respectively as a ring atom. The nitrogen atom of a heterocyclyl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclyl may also be optionally oxidized to the corresponding N- oxide, S-oxide or S,S-dioxide. Exemplary monocyclic heterocyclyl includes piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4- dioxanyl, THFyI, tetrahydrothiophenyl, and tetrahydrothiopyranyl.
"Heterocyclylaryl" means a fused aryl and heterocyclyl. Particular heterocyclylaryl is one wherein the aryl thereof is phenyl and the heterocyclyl consists of about 5 to about 6 ring atoms. A heterocyclylaryl is bonded through any atom of the aryl moiety thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before heterocyclyl portion of the heterocyclylaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heterocyclylaryl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heterocyclyl portion of the heterocyclylaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary heterocyclylaryl includes indolinyl, 1, 2,3, 4-tetrahydroisoquino line, 1,2,3,4- tetrahydroquinoline, lH-2,3-dihydroisoindol-2-yl, and 2,3-dihydrobenz[f]isoindol-2-yl, and 1,2,3,4- tetrahydrobenz[g]-isoquinolin-2-yl.
"Heterocyclylheteroaryl" means a fused heteroaryl and heterocyclyl. Particular heterocyclylheteroaryl is one wherein the heteoraryl thereof consists of about 5 to about 6 ring atoms and the heterocyclyl consists of about 5 to about 6 ring atoms. A heterocyclylheteroaryl is bonded through any atom of the heteroaryl thereof capable of such bonding. The designation of the aza, oxa or thio as a prefix before the heteroaryl or heterocyclyl portion of the heterocyclylheteroaryl defines that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom. The nitrogen atom of a heterocyclylheteroaryl may be a basic nitrogen atom. The nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the heterocyclylheteroaryl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Exemplary heterocyclylheteroaryl includes 2,3-dihydro-lH-pyrrol[3,4-b]quinolin-2-yl, 1,2,3,4- tetrahydrobenz [b][l,7]naphthyridin-2-yl, l,2,3,4-tetrahydrobenz[b][l,6]naphthyridin-2-yl, 1 ,2,3,4-tetra-hydro-9H-pyrido[3,4-b]indol-2yl, 1 ,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-2yl, 2,3-dihydro-lH-pyrrolo[3,4-b ]indol-2-yl, lH-2,3,4,5-tetrahydroazepino[3,4-b]indol-2-yl, IH- 2,3,4,5-tetra-hydroazepino[4,3-b]indol-3-yl, lH-2,3,4,5-tetrahydroazepino[4,5-b]indol-2-yl, 5,6,7,8-tetra-hydro[l,7]naphthyridyl, l,2,3,4-tetrhydro[2,7]naphthyridyl, 2,3- dihydro[l,4]dioxino[2,3-b]pyridyl, 2,3-dihydro-[l,4]dioxino[2,3-b]pyridyl, 3,4-dihydro-2H-l- oxa[4,6]diazanaphthalenyl, 4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridyl, 6,7- dihydro[5,8]diazanaphthalenyl, 1 ,2,3,4-tetrahydro[l ,5]-naphthyridinyl, 1 ,2,3,4- tetrahydro[l ,6]naphthyridinyl, 1 ,2,3,4-tetrahydro[l ,7]naphthyridinyl, 1 ,2,3,4- tetrahydro[l ,8]naphthyridinyl, and 1 ,2,3,4-tetra-hydro[2,6]naphthyridinyl.
"Multicyclic alkaryl" means a multicyclic ring system including at least one aromatic ring fused to at least one non-aromatic ring that may be saturated or unsaturated, and may also contain in the ring system one or more heteroatoms, such as nitrogen, oxygen or sulfur. Exemplary multicyclic alkaryl includes arylcycloalkenyl, arylcycloalkyl, arylheterocyclenyl, arylheterocyclyl, cycloalkenylaryl, cycloalkylaryl, cycloalkenylheteroaryl, cycloalkylheteroaryl, heteroarylcycloalkenyl, heteroarylcycloalkyl, heteroarylheterocyclenyl, heteroarylheterocyclyl, heterocyclenylaryl, heterocyclenylheteroaryl, heterocyclylaryl, and heterocyclylheteroaryl. Particular multicyclic alkaryl groups are bicyclic rings that include one aromatic ring fused to one non-aromatic ring and that also may contain in the ring system one or more heteroatoms, such as nitrogen, oxygen or sulfur.
"Patient" includes human and other mammals. "Pharmaceutically acceptable salts" refers to the non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts may be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. In some cases, the compounds themselves are capable of self-pro tonating basic sites on the molecule and forming an internal amphoteric salt.
Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, sulfamates, malonates, salicylates, propionates, methylene-bis-β-hydroxynaphthoates, gentisates, isethionates, di-p- toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and laurylsulfonate salts. See, for example S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 66, 1-19 (1977) that is incorporated herein by reference. Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. A particular base addition salt is sodium salt or potassium salt. Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, and zinc hydroxide. Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and particularly include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. Exemplary amin includes ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N5N'- dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N- benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, and dicyclohexylamine.
"Solvate" means a physical association of a compound of the present invention with one or more solvent molecules. This physical association includes hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and insoluble solvates. Particular solvates include hydrates, ethanolates, and methanolates.
"Substituted one or more times independently" means substituted one or more times by same or different substituent groups, particularly substituted one, two or three times by same or different substituent groups.
Particular Embodiments of the Invention
One particular embodiment of the invention is a compound of formula (I) wherein R1 is aryl or heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-C6)-alkyl, hydroxy, (Ci-C6)-alkoxy, (Ci-C4)-haloalkyl or (Ci-C4)-haloalkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R1 is phenyl or five or six membered heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R1 is phenyl, pyridyl, pyrimidinyl, thiazolyl, or oxodiazolyl, each of which is optionally substituted one or more times independently by halo, (Ci-C6)-alkyl, hydroxy, or (d-C6)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R1 is phenyl, pyridyl or pyrimidinyl, each of which is optionally substituted independently at the ortho or meta position by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R1 is phenyl optionally substituted independently at the ortho or meta position by halo, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R1 is pyridyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R2 is hydrogen, methyl or trifluoromethyl, or a hydrate solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R2 is hydrogen, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein R2 is methyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein L1 is a bond, -O-, -C(=O)-, or -NH-C(=O)-, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein L1 is a bond, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein: R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl, heterocyclenyl, arylheterocyclyl, or heteroaryl, each of which is optionally substituted one or more times independently by R ;
R > 6 is alkoxy, hydroxyl, cycloalkyl, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by acyloxy, hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, alkylsulfonyl, cyano, Y1Y2N-, or Y1Y2N-CC=O)-, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and
Y1 and Y2 are each independently hydrogen, alkylsulfonyl, aroyl, or alkyl optionally substituted by morpholinyl, or
Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein: R3 and R4 together with the nitrogen atom to which they are attached form [l,2,4]triazolyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[3,2-b]pyridyl, or pyrrolo[2,3- c]pyridyl, each of which is optionally substituted one or more times independently by R6;
R6 is alkoxy, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by Y1Y2N-Q=O)-, hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, heterocyclyl, cycloalkyl, alkylsulfonyl, cyano, heterocyclylcarbonyl, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and
Y1 and Y2 are each independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof. Another particular embodiment of the invention is a compound of formula (I) wherein: R3 and R4 together with the nitrogen atom to which they are attached form imidazolidinyl,
[l,2,4]triazinanyl, piperazinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydro- pyrimidinyl, piperidinyl, oxazolidinyl, 2,3-dihydro-indolyl, octahydro- cyclopenta[c]pyrrolyl, or 3,4-dihydro-benzo[l,4]oxazine, each of which optionally substituted one or more times independently by R6; R6 is oxo, alkoxy, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, heterocyclyl, cycloalkyl, alkylsulfonyl, cyano, heterocyclylcarbonyl, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and Y1 and Y2 are each independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein:
R3 and R4 together with the nitrogen atom to which they are attached form indolyl, optionally substituted one or more times independently by R6; R6 is Y1Y2N-SO2-, alkoxycarbonyl, carboxyalkyl, cyano, halo, alkylsulfonyl, alkoxy, or acyl optionally substituted one or more times independently by halo; and Y1 and Y2 are each independently independently hydrogen, or alkyl optionally substituted by morpholinyl, or
Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I) wherein: R5 is phenyl, pyridyl, or benzo[l,3]dioxolyl, each of which is optionally substituted one or more times independently by R6;
R6 is Y1Y2N-SO2-, hydroxy, alkoxy, halo, alkyl, or haloalkyl; and Y1 and Y2 are each independently hydrogen or alkyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I), which is 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 - yl)amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)- amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3- dihydro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-acetyl)-indol- l-yl]-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihydro- indol- 1 -yl)-amide,
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihydro- indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3-dimethyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-chloro-2-methyl-indol- 1 -yl)- amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-bromo-indol- 1 -yl)-amide, 3-0x0-4- [(2 -phenyl-pyrimidine-5-carbonyl)-amino]-piperazine- 1 -carboxylic acid benzyl ester,
2-(3 -Fluorophenyl)pyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 -fluoro-indol- 1 - yl)amide, 2-(3 -Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 - fluoroindol- 1 -yl)amide,
2-(3-Fluorophenyl)pyrimidine-5-carboxylicacid-[5-fluoro-3-(morpholine-4-sulfonyl)indol-l- yl] amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3- (morpholine-4- sulfonyl) indol-1-yl] amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-sulfamoylindol-l-yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-methylsulfamoyl)indol- 1 - yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-(2-morpholin-4- ylethylsulfamoyl)indol- 1 -yl)amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3- methylsulfamoyl)indol- 1 -yl)amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-{5-fluoro-[(3-tetrahydropyran-4- ylmethyl)sulfamoyl]indol- 1 -yl} amide, 2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3-(2-morpholin-4- ylethylsulfamoyl)indol- 1 -yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-(4-fluoroindol-l-yl)amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(4-fluoroindol- 1 -yl)amide,
2-(Pyridin-2-yl)-pyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -yl)amide, 2-(Pyridin-2-yl)-4-methylpyrimidine-5 -carboxylic acid-(4-fluoroindol- 1 -yl)amide,
2-Phenyl-pyrimidine-5-carboxylic acid [6-(4-fluoro-phenyl)-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazin-4-yl]-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid-[4-(2-hydroxy-ethyl)-piperazin- 1 -yl]- amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid[5-fluoro-3-(2-hydroxy-2-methyl-propyl)- indol-1-yl] -amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3-(2-hydroxy-2-methyl- propyl)-indol- 1 -yl] -amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5-fluoro-3-(2-hydroxy-2-methyl- propyl)-indol-l yl]-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyano-5-fluoro-indol-l-yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3-(lH-tetrazol-5-yl)- indol-1-yl] -amide,
2- Phenyl-pyrimidine-5-carboxylic acid [1,2,4] triazol-4-ylamide, 2-phenyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid N'-(2-fluoro-phenyl)-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -ethyl-N ' -tolyl-hydrazide,
2-Phenyl-pyrimidine-5-carboxylic acid (3-oxo-morpholin-4-yl)-amide,
2-(5 -Methyl- [ 1 ,2,4]oxadiazol-3-yl)-pyrimidine-5-carboxylic acid morpholin-4-ylamide, 2-Benzoyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide,
2-Benzoyl-pyrimidine-5 -carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yl] -amide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - [5 -trifluoromethyl-pyridin-2-yl]- hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - [4-trifluoromethyl-pyridin-2-yl]- hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N'-pyridin-2-yl-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N'-(2-chloro-phenyl)-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N'-(2-oxo-piperidin- 1 -yl)-amide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -cyclohexyl-N ' -methyl-hydrazide, 2-Phenyoxy-pyrimidine-5 -carboxylic acid N'-morpholin-4-yl-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-3-oxo-2,5-dihydro-3H-l ,2,4-triazine-4- yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazine-4- yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-l,2,4-triazine-
4-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazine-4-yl)-amide, 3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-amino]-l,2,3,4-tetrahydro-pyrimidin-5-yl}- propionic acid methyl ester,
3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-amino]-l,2,3,4-tetrahydro-pyrimidin-5-yl}- propionic acid, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-methyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yl] -amide, 2-Phenyl-pyrimidine-5 -carboxylic acid ((s)-2-methoxymethyl)-pyrrolidin- 1 -yl] -amide, 2-Phenyl-pyrimidine-5 -carboxylic acid ((R)-2-methoxymethyl)-pyrrolidin- 1 -yl] -amide, 2-Phenyl-pyrimidine-5-carboxylic acid (5-bromo-2, 4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid (3-isopropyl-5-oxo- 1 ,5-dihydro-[ 1 ,2,4]triazol-4-yl)- amide, 2-Phenyl-pyrimidine-5 -carboxylic acid pyrrol- 1-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid (5-morpholin-4-ylmethyl-2-oxo-oxazolidin-3-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid (2-oxo-oxazolidin-3-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl]-amide,
[N'-(2-Phenyl-pyrimidine-5-carbonyl)-hydrazino]-acetic acid ethyl ester, 2- [N ' -(2-Phenyl-pyrimidine-5 -carbonyl)-hydrazino] -acetamide, 4-[3-(4-Morpholino)propyl]-l-(2-phenyl-pyrimidine-5-carbonyl)-3-thiosemicarbazide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, {4-[2-Phenyl-pyrimidine-5-carbonyl)-amino]-piperazin-l-yl}-acetic acid methyl ester, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-cyanomethyl-piperazin- 1 -yl)-amide, Acetic acid 2-{4-[(2-phenyl-pyrimidine-5-carbonyl)-amino]-piperazin-l-yl}-ethyl ester, 2-Phenyl-pyrimidine-5-carboxylic acid (4-acetyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-(2-oxo-tetrahydro-furan-3 -yl)-piperazin- 1 -yl] - amide,
2-Phenyl-pyrimidine-5-carboxylic acid [4-(2,2,2-trifluoro-acetyl)-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-methoxy-ethyl)-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazin-l-yl]- amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid piperadin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid piperadin-1-yl-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid pyrrolidin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-piperadin-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin-l-yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihydro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihydro-indol-l-yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -pyridin-2-yl-hydrazide, 2-Phenyl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- l-yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid indol-1-yl-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid indol- 1 -yl-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2-methyl-2,3-dihydro-indol- 1 - yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (2-methyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid indol- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid indol- 1 -ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (5-methanesulfonyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-methanesulfonyl-indol-l-yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide, 2-Pyridin-3-yl-pyrimidine-5 -carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-methanesulfonyl-indol-l-yl)- amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid pyrrolo[2,3-b]pyridin-l -ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid pyrro Io [3, 2-b]pyridin-l -ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-indol-l-yl)-amide, 2-(3-Fluoro-phenyl-4-methyl)-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[3,2-b]pyridin-l-ylamide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l-ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- l-yl)-amide,
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridine- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrro Io [3, 2-b]pyridin-l -ylamide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid pyrro Io [3, 2-b]pyridin-l -ylamide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-cyano-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (4-cyano-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [4-(lH-tetrazol-5-yl)-indol-l -ylamide, l-{[2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl] -amino }-lH-indol-4-carboxylic acid methyl ester, l-{[2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl] -amino }-lH-indol-4-carboxylic acid,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyanomethyl-indol- 1 -yl)- amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(lH-tetrazol-5-ylmethyl)- indol-1-yl] -amide,
2-(2-Phenyl-pyrimidine-5-carbonyl)- 1 -hydrazinecarboxamide, 2-(2-Phenyl-pyrimidine-5 -carbonyl)- 1 -hydrazine- 1 -carbothioamide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,4-dioxo-imidazolidin-l-yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-[l ,2,4]triazin-4-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid N'-phenyl-hydrazide, Pyridine-2-carboxylic acid N ' -(2-phenyl-pyrimidine-5 -carbonyl)-hydrazide,
4- [N ' -(2-Phenyl-pyrimidine-5 -carbonyl)-hydrazino] -benzenesulfonamide,
3 -Hydroxy-benzoic acid N ' -(2-phenyl-pyrimidine-5 -carbonyl)-hydrazide,
Benzo[l,3]dioxo-5-carboxylic acid N'-(phenyl-pyrimidine-5-carbonyl)-hydrazide, 3 ,4-Dimethoxy-benzoic acid N ' -(phenyl-pyrimidine-5 -carbonyl)-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -phenyl-hydrazide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-indol- 1 -yl)- amide,
2-(3-Methoxy-phenyl)-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl)-amide,
2-(2-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide,
2-(4-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide, 2-(3 -Hy droxy-phenyl)-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide,
2-(2-Hydroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide,
2-(4-Hydroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide,
2-Thiazol-2-yl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide,
[2,2']Bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylicacid(3chloro-5-fluoro-indol- 1 -yl)- amide,
5 -Fluoro- 1 - { [2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyl] -amino } - 1 H-indole-3 - carboxylic acid amide,
2-{5-Fluoro-l-[(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-amino]-lH-indol-3-yl}-2- methyl-propionic acid,
2-(5-Fluoro-l-{[2-(3-fluoro-phenyl) -4-methyl-pyrimidine-5-carbonyl]-amino}-lH-indol-3- yl)-2 -methyl-propionic acid, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3- (3 -hydroxy-3 - methyl-butyl)-indol- 1 -yl]-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl- butyl)-indol- 1 -yl] -amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3- (2-pyridin-3-yl- ethyl)-indol-l-yl]- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5 -fluoro-3 -formyl-indol- 1 -yl)-amide,
5 -Fluoro- 1 -[(4-methyl-2-pyridin-2-yl-pyrimidine-5 -carbonyl)-amino] - 1 H-indole-3 -carboxylic acid, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -hydroxymethyl-indol- 1 -yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl-butyl)-indol- l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl- butyl)-indol-l-yl] -amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- 1 -yl)- amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- 1-yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy- indol- 1 -yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1 - yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1-yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1 - yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (6-trifluoromethyl-indol- 1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol-l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3, 2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3 ,2- b]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3,2- b]pyridin-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-methoxy-2-methyl-indol- 1 -yl)- amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid TV, Λf'-diphenyl-hydrazide
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (7-fluoro-3-methyl-indol-l-yl)- amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-3 -methyl- indol- 1 -yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo[2,3-b]pyridin- 1 -yl)- amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-ethyl-pyrrolo[2,3-b]pyridin-l- yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-ethyl-pyrrolo[2,3c] pyridin-1- yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo[2,3-c]pyridin- 1 -yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin- l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-5-trifluoromethyl-indol- 1 - yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin-l-yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[2,3c]pyridin- 1 - yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-c]pyridin- 1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin-l-yl)- amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin- l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-nitro-indol- 1 -yl)-amide,
2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-amino-indol-l-yl)-amide,
2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -(dimethanesulfonyl)-amino- indol-1-yl] -amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-benzoylamino-indol- 1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5-fluoro-3-(l ,2,3,6-tetrahydro-pyridin-
4-yl)-indol-l-yl] -amide, 2-Pyridin-2-yl-4-trifluoromethyl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol- 1 -yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2 -methyl-indol- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4- yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-l,4-benzoxazin-4-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3-b]pyridin- l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-pyrrolo[2,3-b]pyridin- l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-pyrrolo[2,3-b]pyridin- 1 -yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (2-cyclopropyl-5-fluoro-indol- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (2-cyclopropyl-5-fluoro-indol-l-yl)- amide,
2-Pyrimidin-2-yl-4-methyl-pyrimidine-5 -carboxylic acid (5-methoxyl-indol-l-yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2-b]pyridin-l- yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methoxy-3 -methyl- pyrrolo [3 ,2-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(l-oxy-pyridin-2-yl)-pyrimidin-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)- amide,
2-(3-Difluoromethyl-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)- amide, or 2-(3-Trifluoromethyl-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)- amide, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
Another particular embodiment of the invention is a compound of formula (I), which is: 2-Phenyl-pyrimidine-5-carboxylic acid (4-benzyl-piperazin-l-yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-methanesulfonyl-piperazin- 1 -yl)-amide, 2-(2-Methyl-thiazol-4-yl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-2-carbonyl)-piperazin- 1 - yl] -amide,
2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-4-carbonyl)-piperazin- 1 - yl] -amide,
4- [(2-Phenyl-pyrimidine-5-carbonyl)-amino]-piperazine-l -carboxylic acid tert-butyl ester, 2-Phenyl-pyrimidine-5-carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- 1 -yl]-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- l-yl]-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide, 2-Phenyl-pyrimidine-5-carboxylic acid indol-1-ylamide, 2-Phenyl-pyrimidine-5-carboxylic acid (4-methoxy-piperidin- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-indol- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-benzo[l ,4]oxazin-4- yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-benzo[l,4]oxazin-4-yl)-amide,
1 - { [2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyl] -amino } -3 -(2-morpholin-4-yl- ethyl)- lH-indole-6-carboxylic acid methyl ester,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahydro-pyran-4- yl)-indol- 1 -yl]-amide, N-methyl-N-(5 -fluoro)-indol-3 -ylsulfonyl N ' - [2-(3 -fluoro)-phenyl-pyrimidine-5 -carbonyl] - hydrazide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahy dro-pyran-4-yl)- indol-1-yl] -amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol-l-yl)-amide, 4-Methyl-2-(l-oxy)-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol-1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin-l-yl)- amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l- ylamide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l -ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-b]pyridin- 1 -ylamide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-b]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [2,3 - b]pyridin-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-c]pyridin- 1 -ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-c]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethy l-pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin-l-yl)- amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid pyrrolo[3,2-c]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-isopropyl-pyrrolo[3,2-c]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-trifluoromethyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin-l-yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethy 1- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin- 1 - ylamide,
4-Methyl-2-(4-chloro -thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethy 1- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l- yl)-amide,
2-(4-Methyl-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 - yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2-methyl-3-oxo-2,3-dihydro- indazol- 1 -yl)amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid(5-fluoro-indol-l- yl)amide)amide,
6-(4-Chloro-thiazol-2-yl)-2-methyl-N-pyrrolo[2,3-c]pyridin-l-yl-nicotinamide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid(5-methyl-4-oxo-4,5-dihydro- pyrrolo[3,2-c]pyridin-l-yl)amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (5-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difiuoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifiuoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difiuoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifiuoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difiuoro-ethyl)- pyrrolo[2,3-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (5 -trifluoromethyl-pyrrolo [3 ,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (5-difluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo[3,2- b]pyridin-l-yl] -amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[3,2-c]pyridin-l-yl]-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo [3 ,2-c]pyridin- 1 -yl] -amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[2,3-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo [3 ,2-c]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo [3 ,2-c]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-difluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-c] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro
Io [3 ,2-c]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo [3 ,2-c]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-2,2-diuoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-c] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro lo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo [2,3-c]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[2,3-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[2,3-b]pyridin- 1 -yl] -amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -trifluoro methyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -difluorom ethyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo [3 ,2-b]pyridin- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo [3 ,2-c]pyridin- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[2,3-c]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [2,3 - b]pyridin- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl)
-pyrrolo[3,2-b]pyridin-l-yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-indol-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-indol- 1 - yl)-amide, or
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-indol- 1 -yl)-amide, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
It is to be understood that this invention covers all appropriate combinations of the particular embodiments referred thereto.
The present invention also includes within its scope a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the invention, in admixture with a pharmaceutically acceptable carrier.
Compounds of the present invention are PGDS inhibitors and thus, are useful for treating allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD). Accordingly, another invention herein is directed to a method of treating a patient suffering from allergic rhinitis, asthma, and/or chronic obstructive pulmonary disease (COPD) comprising administering to the patient a pharmaceutically effective amount of compound of formula (I), or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
References herein directed to treating should be understood to include prophylactic therapy to inhibit PGDS, as well as to treat an established acute or chronic or physiological conditions associated with PGDS to essentially cure a patient suffering therefrom, or ameliorate the physiological conditions associated therewith. Physiological conditions discussed herein include some, but not all, of the possible clinical situations where an anti- allergic rhinitis and/or asthma treatment is warranted. Those experienced in this field are well aware of the circumstances requiring treatment.
In practice, the compound of the present invention may be administered in pharmaceutically acceptable dosage form to humans and other mammals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, colonic, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the particular route may vary with for example the physiological condition of the recipient.
"Pharmaceutically acceptable dosage forms" refers to dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.
A particular aspect of the invention provides for the compound of the invention to be administered in the form of a pharmaceutical composition.
Pharmaceutically acceptable carriers include at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, coatings, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, emulsion stabilizing agents, suspending agents, isotonic agents, sweetening agents, flavoring agents, perfuming agents, coloring agents, antibacterial agents, antifungal agents, other therapeutic agents, lubricating agents, adsorption delaying or promoting agents, and dispensing agents, depending on the nature of the mode of administration and dosage forms.
Exemplary suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances.
Exemplary antibacterial and antifungal agents for the prevention of the action of microorganisms include parabens, chlorobutanol, phenol, sorbic acid, and the like.
Exemplary isotonic agents include sugars, sodium chloride, and the like.
Exemplary adsorption delaying agents to prolong absorption include aluminum monostearate and gelatin.
Exemplary adsorption promoting agents to enhance absorption include dimethyl sulfoxide and related analogs.
Exemplary diluents, solvents, vehicles, solubilizing agents, emulsifiers and emulsion stabilizers, include water, chloroform, sucrose, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, tetrahydrofurfuryl alcohol, benzyl benzoate, polyols, propylene glycol, 1,3-butylene glycol, glycerol, polyethylene glycols, dimethylformamide, Tween® 60, Span® 60, cetostearyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate, fatty acid esters of sorbitan, vegetable oils (such as cottonseed oil, groundnut oil, olive oil, castor oil and sesame oil) and injectable organic esters such as ethyl oleate, and the like, or suitable mixtures of these substances.
Exemplary excipients include lactose, milk sugar, sodium citrate, calcium carbonate and dicalcium phosphate.
Exemplary disintegrating agents include starch, alginic acids and certain complex silicates. Exemplary lubricants include magnesium stearate, sodium lauryl sulfate, talc, as well as high molecular weight polyethylene glycols. The choice of pharmaceutical acceptable carrier is generally determined in accordance with the chemical properties of the active compound such as solubility, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as a solid dosage form, such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, or as a powder or granules; as a liquid dosage form such as a solution or a suspension in an aqueous liquid or a non- aqueous liquid, or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
"Solid dosage form" means the dosage form of the compound of the invention is solid form, for example capsules, tablets, pills, powders, dragees or granules. In such solid dosage forms, the compound of the invention is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or: (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, (j) opacifying agents, (k) buffering agents, and agents which release the compound of the invention in a certain part of the intestinal tract in a delayed manner.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used. A mixture of the powdered compounds moistened with an inert liquid diluent may be molded in a suitable machine to make molded tablets. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Solid compositions may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
If desired, and for more effective distribution, the compound can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as a biocompatible, biodegradable polymer matrices (e.g., poly(d,l-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer. The compounds may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
"Liquid dosage form" means the dose of the active compound to be administered to the patient is in liquid form, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art, such solvents, solubilizing agents and emulsifϊers.
When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.
Pharmaceutical compositions suitable for topical administration mean formulations that are in a form suitable to be administered topically to a patient. The formulation may be presented as a topical ointment, salves, powders, sprays and inhalants, gels (water or alcohol based), creams, as is generally known in the art, or incorporated into a matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier. When formulated in an ointment, the active ingredients may be employed with either a paraffϊnic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. Formulations suitable for topical administration in the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The oily phase of the emulsion pharmaceutical composition may be constituted from known ingredients, in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. In a particular embodiment, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. Together, the emulsifier(s) with, or without, stabilizer(s) make up the emulsifying wax, and together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
If desired, the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as, propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound that enhances absorption, or penetration of the active ingredient through the skin, or other affected areas.
The choice of suitable oils or fats for a composition is based on achieving the desired properties. Thus a cream should particularly be a non-greasy, non- staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Pharmaceutical compositions suitable for rectal or vaginal administrations mean formulations that are in a form suitable to be administered rectally or vaginally to a patient and containing at least one compound of the invention. Suppositories are a particular form for such formulations that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
Pharmaceutical composition administered by injection may be by transmuscular, intravenous, intraperitoneal, and/or subcutaneous injection. The compositions of the present invention are formulated in liquid solutions, in particular in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compositions may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. The formulations are sterile and include emulsions, suspensions, aqueous and nonaqueous injection solutions, which may contain suspending agents and thickening agents and anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic, and have a suitably adjusted pH, with the blood of the intended recipient.
Pharmaceutical composition of the present invention suitable for nasal or inhalational administration means compositions that are in a form suitable to be administered nasally or by inhalation to a patient. The composition may contain a carrier, in a powder form, having a particle size for example in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.). Suitable compositions wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Compositions suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Inhalational therapy is readily administered by metered dose inhalers or any suitable dry powder inhaler, such as the Eclipse, Spinhaler®, or Ultrahaler® as described in patent application WO2004/026380, and US Patent No. 5,176,132. Actual dosage levels of active ingredient(s) in the compositions of the invention may be varied so as to obtain an amount of active ingredient(s) that is (are) effective to obtain a desired therapeutic response for a particular composition and method of administration for a patient. A selected dosage level for any particular patient therefore depends upon a variety of factors including the desired therapeutic effect, on the route of administration, on the desired duration of treatment, the etiology and severity of the disease, the patient's condition, weight, sex, diet and age, the type and potency of each active ingredient, rates of absorption, metabolism and/or excretion and other factors.
Total daily dose of the compound of this invention administered to a patient in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body weight daily and particularly 0.01 to 10 mg/kg/day. For example, in an adult, the doses are generally from about 0.01 to about 100, particularly about 0.01 to about 10, mg/kg body weight per day by inhalation, from about 0.01 to about 100, particularly 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.01 to about 50, particularly 0.01 to 10, mg/kg body weight per day by intravenous administration. The percentage of active ingredient in a composition may be varied, though it should constitute a proportion such that a suitable dosage shall be obtained. Dosage unit compositions may contain such amounts or such submultiples thereof as may be used to make up the daily dose. Obviously, several unit dosage forms may be administered at about the same time. A dosage may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much lower maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
The formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the pharmaceutically active ingredient with the carrier that constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Compounds of the invention may be prepared by the application or adaptation of known methods, by which is a meant method used heretofore or described in the literature, for example those described by R. C. Larock in Comprehensive Organic Transformations, VCH publishers, 1989.
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc., 1999.
A compound of formula (I), wherein R2 is hydrogen, L1 is a bond, -NH-C(=O)- or (Ci-C2)- alkylene optionally substituted one or more times by halo, and R1, R3 and R4 are as defined herein, may be prepared, as shown in Scheme I below, by (i) reacting a corresponding amidine compound of formula (1), with a reagent of formula (2) to provide a compound of formula (3), (ii) hydrolyzing the compound offormula (3) to provide a compound of formula (4), and (iii) coupling the compound of (4) with a corresponding compound of formula (5). Scheme I
Figure imgf000049_0001
(1) (2)
(3)
optionally substituted one or more times by halo
The first step reaction may conveniently be carried out, for example, at a temperature about 10O0C, in an inert solvent, such as DMF. The second step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof. The third step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 10O0C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et3N, in an inert solvent, such as DMF. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, by first reacting the compound of formula (4) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et3N, K2CO3 or Na2CO3, in an inert solvent, such as DCM or DMF.
A compound of formula (I), wherein R2 is (Ci-C4)-alkyl optionally substituted one or more times by halo, L1 is a bond, -NH-C(=0)- or (d-C2)-alkylene optionally substituted one or more times by halo, and R1, R3 and R4 are as defined herein,may also be prepared, as shown in Scheme II below, by (i) reacting a corresponding amidine compound of formula (1), with a reagent of formula (6) to provide a compound of formula (7), (ii) hydrolyzing the compound of formula (7) to provide a compound of fomrmula (8), and (iii) coupling the compound of formula (8) with a corresponding compound of formula (5). Scheme II
Figure imgf000050_0001
R2 = (CrC4)-alkyl optionally substituted one or more times by halo, and L1 is a bond, -NH-C(O)- or (CrC2)-alkylene optionally substituted one or more times by halo
The first step reaction may conveniently be carried out, for example, at a temperature about 10O0C, in the presence of sodium metal, in a solvent, such as EtOH. The second step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof. The third step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 10O0C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et3N, in an inert solvent, such as DMF. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, by first reacting the compound of formula (8) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et3N, K2CO3 or Na2CO3, in an inert solvent, such as DCM or DMF.
A compound of formula (I), wherein L1 is -C(=0)-, and R1, R2, R3 and R4 are as defined herein,may be prepared, as shown in Scheme III below, by (1) reacting a corresponding compound of formula (9), with a Grignard reagent of formula R1MgBr to provide a compound of formula (10), (2) converting the compound of formula (10) into a compound of fomrmula (11), and (3) hydro lyzing the compound of formula (11) to provide a compound of formula (12), (4) hydrokyzing the compound of formula (12) to provide a compound of formula (13) and (5) coupling the compound of formula (13) with a corresponding compound of formula
(5).
Scheme III
Figure imgf000051_0001
(12)
LMs -CC=O)- (13)
The first step reaction may conveniently be carried out, for example, at a temperature about room temperature to 5O0C, in an inert solvent, such as Et2O. The second step reaction may conveniently be carried out, for example, at a temperature about 15O0C, in the presence of potassium hexacyanoferrate(II) trihydrate, palladium (II) acetate and a base such as Na2CO3 or K2CO3, in an inert solvent, such as dimethylacetamide or DMF. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, in the presence of an inorganic base such as KOH, NaOH or LiOH, in a solvent, such as MeOH, or a mixture of MeOH and water. The fourth step reaction may conveniently be carried out, for example, at room temperature, in the presence of an inorganic base, such as LiOH, KOH or NaOH, in a solvent, such as THF, MeOH, water, or a mixture thereof. The fifth step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 1000C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et3N, in an inert solvent, such as DMF. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, by first reacting the compound of formula (4) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et3N, K2CO3 or Na2CO3, in an inert solvent, such as DCM or DMF.
A compound of formula (I), wherein L1 is -O-, and R1, R2, R3 and R4 are as defined herein,may be prepared, as shown in Scheme IV below, by (i) oxidizing a compound of formula (14) to provide a compound of formula (15), (ii) reacting the compound of formula (15) with a corresponding compound having formula R1ONa to provide a compound of fomrmula (16), (iii) hydro lyzing the compound of formula (16) to provide a compound of formula (17), and (iv) coupling the compound of formula (17) with a corresponding compound of formula (5).
Scheme IV
Figure imgf000052_0001
L1 is -O- (17)
The first step oxidation reaction may conveniently be carried out, for example, at room temperature, in the presence of MCPBA and Na2S2O3, in an inert solvent, such as DCM. The second step reaction may conveniently be carried out, for example, in a microwave heated at a temperature about 1000C, in an inert solvent, such as NMP. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, in the presence of an inorganic base such as KOH, NaOH or LiOH, in a solvent, such as THF, MeOH, or a mixture thereof. The fourth step reaction may conveniently be carried out, for example, at about a temperature about room temperature to 1000C, in the presence of a coupling agent, such as HCTU, HOTT, PyBrOP, DMTMM, or HATU with HOAt, and a base, such as DIPEA or Et3N, in an inert solvent, such as DMF. The third step reaction may conveniently be carried out, for example, at about a temperature about O0C to room temperature, by first reacting the compound of formula (17) with oxalyl chloride, and then adding the compound of formula (5) and a base such as DIPEA, Et3N, K2CO3 or Na2CO3, in an inert solvent, such as DCM or DMF.
Compounds of the invention may also be prepared by interconversion of other compounds of the invention.
It will be appreciated that compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of Formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallization techniques, or they are separately prepared from the appropriate isomers of their intermediates.
The compounds of the invention, their methods or preparation and their biological activity will appear more clearly from the examination of the following examples that are presented as an illustration only and are not to be considered as limiting the invention in its scope. Compounds of the invention are identified, for example, by the following analytical methods.
Mass Spectra (MS) are recorded using a Micromass LCT mass spectrometer. The method is positive electrospray ionization, scanning mass m/z from 100 to 1000.
300MHz 1H nuclear magnetic resonance spectra (1H NMR) are recorded at ambient temperature using a Varian Mercury (300 MHz) spectrometer with an ASW 5 mm probe. In the 1H NMR chemical shifts (δ) are indicated in parts per million (ppm) with reference to tetramethylsilane (TMS) as the internal standard. As used in the examples and preparations that follow, as well as the rest of the application, the terms used therein shall have the meanings indicated: "kg" = kilograms, "g" = grams, "mg" = milligrams, "μg" = micrograms, "mol" = moles, "mmol" = millimoles, "M" = molar, "mM" = millimolar, "μM" = micromolar, "nM" = nanomolar, "L" = liters, "mL" or "ml" = milliliters, "μL" = microliters, "0C" = degrees Celsius, "mp" or "m.p." = melting point, "bp" or "b.p." = boiling point, "mm of Hg" = pressure in millimeters of mercury, "cm" = centimeters, "nm" = nanometers, "abs." = absolute, "cone." = concentrated, "c" = concentration in g/mL, "rt" = room temperature, "TLC" = thin layer chromatography, "HPLC" = high performance liquid chromatography, "i.p." = intraperitoneally, "i.v." = intravenously, "s" = singlet, "d" = doublet; "t" = triplet; "q" = quartet; "m" = multiplet, "dd" = doublet of doublets; "br" = broad, "LC" = liquid chromatograph, "MS" = mass spectrograph, "ESI/MS" = electrospray ionization/mass spectrograph, "RT" = retention time, "M" = molecular ion, "PSI" = pounds per square inch, "DMSO" = dimethyl sulfoxide, "DMF" = N,N-dimethylformamide, "DCM" = dichloromethane, "HCl" = hydrochloric acid, "SPA" = Scintillation Proximity Assay, "EtOAc" = ethyl acetate, "PBS"= Phosphate Buffered Saline, "IUPAC" = International Union of Pure and Applied Chemistry, "MHz" = megahertz, "MeOH " = methanol, "N" = normality, "THF" = tetrahydrofuran, "min" = minute(s), "N2" = nitrogen gas, "MeCN" or "CH3CN" = acetonitrile, "Et2O" = ethyl ether, "TFA" = trifluoroacetic acid, "~" = approximately, "MgSO4" = magnesium sulfate, "Na2SO4" = sodium sulfate, "NaHCO3" = sodium bicarbonate, "Na2CO3" = sodium carbonate, "MCPBA" = 3-Chloroperoxybenzoic acid, "NMP" = N-methylpyrrolidone, "PS-DCC" = polymer supported- dicyclohexylcarbodiimde, "LiOH" = Lithium hydroxide, "PS-trisamine" = polymer supported-trisamine, "PGH2" = prostaglandin H2, "PGD2" = prostaglandin D2; "PGE2" = prostaglandin E2, "hPGDS" = Hematopoietic PGD2 Synthase, "GSH" = glutathione (reduced), "EIA" = Enzyme immunoassay, "KH2PO4" = potassium phosphate, monobasic, "K2HPO4" = potassium phosphate, dibasic, "FeCl2" = ferrous chloride, "MOX" = methoxylamine; "EtOH" = ethanol, "DMSO" = dimethylsulfoxide, "Ag2O" = silver(I) oxide, "HATU" = O-(7-azabenzotriazole-l-yl)-N,N,Λr,N'-tetramethyluronium hexafluorophosphate, "HOAt" = l-hydroxy-7-azabenzotriazole, "DIPEA" = JV,JV-diisopropylethylamine, "HOTT" = 5f-(l-Oxido-2-pyridyl)-N,N,Λ/',Λ/'-tetramethylthiuronium hexafluorophosphate, "HCTU" = Λ/,Λ/,Λ/',Λ/r'-tetramethyl-O-(6-chloro-lH-benzotriazol-l-yl)uronium hexafluorophosphate., "PyBrOP" = bromo-trø-pyrrolidinophosphonium hexafluorophosphate, "LiAlH4" = lithium aluminum hydride, "PyAOP" = (7-azabenzotriazol-l-yloxy)-tripyrrolidinophosphonium hexafluorophosphate, "TBTU" = O-benzotriazol-l-yl-N,N,N,N,-tetramethyluronium tetrafluoroborate, "NaHMDS" = sodium bis(trimethylsilyl)amide, "NMP" = N-methyl-2- pyrrolidinone, "HOSA" = hydroxylamine-O-sulfonic acid, "DMTMM" = 4-(4,6-dimethoxy- l,3,5-triazin-2-yl)-4-methylmorpholinium chloride, "TMSN3" = trimethylsily azide, "TBAF" = tetrabutylammonium fluoride, "TFAA" = trifluoro acetic anhydride.
EXAMPLES
Example 1 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide
Figure imgf000055_0001
Step 1 : A solution of potassium tert-butoxidc (1.84 g, 16.43 mmol) and 5-fluoro-2- methylindole (1.21 g, 8.09 mmol) in DMF (20 mL) is stirred under N2 at rt for 60 min. A solution of monochloroamine in ether (65 mL, 9.75 mmol) is added via an addition funnel over 10 min. The resulting mixture is stirred at 23°C for 2 hours, and then concentrated in vacuo. The residue is partitioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% EtOAc in heptane to afford 5 -fluoro-2-methyl-indol- 1 -ylamine (290 mg, 22%) as a solid. MS: 165 (M+H); 1H NMR (300MHz, CDCl3): δ 7.24-7.19 (m, IH), 7.12 (dd, IH), 6.92 (dt, IH), 6.12 (s, IH), 4.23 (br s, 2 H), 2.39 (s, 3H).
Step 2: A 250 mL, three-neck, round-bottom flask equipped with a magnetic stirrer and a reflux condenser is purged with N2. The flask is charged sequentially with methyl 3,3- dimethoxypropionate (5.22 g, 35.3 mmol), anhydrous 1 ,2-dimethoxyethane (25 mL), anhydrous methyl formate (5 mL), 60% sodium hydride (1.7 g, 42.5 mmol), and the mixture warmed to 40 - 5O0C until evolution of hydrogen gas stops. The reaction mixture is cooled in an ice/water bath and slowly allowed to reach room temperature overnight with stirring. Anhydrous ether (25 mL) is added, and the resulting suspension is filtered under N2, washed with anhydrous ether (10 mL), and vacuum dried for 2 hours to yield sodium salt of 2- dimethoxymethyl-3-hydroxy-acrylicacid methyl ester (3.51 g, 50%) as a powder. 1H NMR (CD3OD): δ 3.33 (s, 6H), 3.60 (s, 3H), 5.31 (s, IH), 8.89 (s, IH). (see: P. Zhichkin, D.J. Fairfax, S.A. Eisenbeis, Synthesis, 2002, 720-722.)
Step 3: To a solution of nicotinamidine hydrochloride (1 g, 6.35 mmol) in anhydrous DMF (12 mL) is added sodium salt of 2-dimethoxymethyl-3-hydroxy-acrylicacid methyl ester (1.46 g, 7.36 mmol) and the reaction mixture is heated at 1000C under N2 for 3 hours. After this time the reaction is cooled to room temperature and water (48 mL) is added. The precipitate is collected by filtration, washed with water and vacuum dried to afford 2-pyridin-3-yl- pyrimidine-5-carboxylic acid methyl ester (0.7 g, 51%). MS: 216 (M+H).
Step 4: A solution of 2-pyridin-3-yl-pyrimidine-5-carboxylic acid methyl ester (0.73 g, 3.32 mmol) and IM aqueous LiOH (3.32 mL) in MeOH (5 mL) is stirred at rt overnight. The MeOH is removed in vacuo, and the aqueous solution is treated with 3 N aqueous HCl to adjust the pH ~ 2-3. The solid is filtered off and washed with water and dried in vacuum to yield 2-pyridin-3 -yl-pyrimidine-5 -carboxy lie acid (0.2 g, 30%) as a solid. MS: 202 (M+H).
Step 5: A solution of 2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (506 mg, 2.13 mmol), HCTU (970 mg, 2.34 mmol), and DIPEA (1 mL, 5.72 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-2-methyl-indol-l-ylamine (311 mg, 1.89 mmol) is added. The resulting mixture is stirred at 75°C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 45% EtOAc in heptane to afford 2-pyridin-3-yl- pyrimidine-5 -carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide (300 mg, 46%) as a solid. MS: 348 (M+H). 1H NMR (300MHz, DMSO-d6): δ 12.02 (s, IH), 9.60 (d, IH), 9.49 (s, 2H), 8.82-8.76 (m, 2H), 7.64 (dd, IH), 7.39 (dd, IH), 7.29 (dd, IH), 6.94 (dt, IH), 6.35 (s, IH), 2.33 (s, 3H).
Example 2
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-2-methyl-indol- 1 - vDamide
Figure imgf000057_0001
Step 1 : Na0 (0.66 g, 28.6 mmol) is added to anhydrous EtOH (100 rnL) and stirred at rt for 15 min. 3-Fluorobenzamidine hydrochloride (4.87 g, 27.8 mmol) is added and the solution is stirred for 15 min. 2-Dimethylaminomethylene-3-oxo-butyric acid ethyl ester (5.3 g, 28.6 mmol,) is added and the reaction mixture is heated at reflux under N2 for 1 hours. The reaction is cooled to rt and concentrated in vacuo. The residue is dissolved in EtOAc (300 mL), washed with brine (2x100 mL), dried (Na2SO4), filtered, and concentrated to afford 2-(3- fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid ethyl ester (6.8 g, 99%). MS: 261 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.43 (t, J= 7.0 Hz, 3H), 2.92 (s, 3H), 4.42 (q, J= 7.0 Hz, 2H), 7.24 (m, IH), 7.45 (m, IH), 8.27 (m, IH), 8.37 (m, IH), 9.21 (s, IH).
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid ethyl ester (6.7 g, 27.2 mmol) and NaOH (2.1 g, 54.4 mmol) in a 1 :1 :1 solution of THF, MeOH and water (300 mL) is heated at reflux for 45 min. The THF/MeOH is evaporated, and the aqueous solution is treated with 3 N HCl to adjust the pH to between 2 and 3. The solid is filtered off, washed with water and dried in vacuo to yield 2-(3-fluoro-phenyl)-4-methyl- pyrimidine-5-carboxylic acid (5.4 g, 91%) as a solid. MS: 233 (M+H); 1U NMR (300 MHz, CD3OD): δ 2.85 (s, 3H), 7.24 (m, IH), 7.50 (m, IH), 8.17 (m, IH), 8.32 (m, IH), 9.20 (s, IH).
Step 3: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (340 mg, 1.46 mmol, prepared according to the general procedure described in Example 1, steps 3 and 4), HOAt (248 mg, 1.82 mmol), and HATU (645 mg, 1.70 mmol) in DMF (15 mL) is stirred at rt under N2 for 20 min. 5-Fluoro-2-methyl-indol-l-ylamine (237 mg, 1.44 mmol) and DIPEA (380 μL, 2.18 mmol) are added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fJuoro-2-methyl-indol- 1 -vQamide (300 mg, 55%) as a solid. MS: 379 (M+H). 1U NMR (300MHz, CD3OD): δ 9.14 (s, IH), 8.38-8.20 (m, 3H), 7.56-7.52 (m, IH), 7.30-7.27 (m, 2H), 7.19-7.16 (m, IH), 6.96-6.90 (m, IH), 6.32 (s, IH), 2.83 (s, 3H), 2.42 (s, 3H).
Example 3
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)amide
Figure imgf000058_0001
Step 1 : A suspension of NaH (2.01 g, 50.3 mmol, 60% in mineral oil) in DMF (45 mL) at 00C is treated with 5-fluoro-3-methyl-lH-indole (500 mg, 3.55 mmol), and the mixture is stirred at 00C for 1 h. NH2OSO3H (1.9 g, 16.75 mmol) is added portion wise, and the mixture is then warmed to rt and stirred for 2 h. The mixture is quenched with MeOH, diluted with water, extracted with EtOAc, dried (Na2SO4), filtered and concentrated to afford 5 -fluoro-3 -methyl- indol-1-ylamine. MS: 165 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.22 (s, 3H), 6.86 (m, IH), 6.99 (s, IH), 7.08 (m, IH), 7.36 (m, IH).
Step 2: Na0 (31.7 mmol) is added to anhydrous EtOH (100 mL) and stirred at rt for 15 min. Pyridine -2-carboxamidine hydrochloride (31.7 mmol) is added and the solution is stirred for 15 min. 2-Dimethylaminomethylene-3-oxo-butyric acid ethyl ester (31.7mmol) is added and the reaction mixture is heated at reflux under N2 for 1 h. The reaction is cooled to rt and concentrated in vacuo. The residue is dissolved in EtOAc (200 mL), washed with brine (2x100 mL), dried (Na2SO4), filtered, and concentrated to afford 4-methyl-2-pyridin-2-yl- Pyrimidine-5-carboxylic acid ethyl ester (6.77 g, 88%). MS: 261 (M+H); 1H 1H NMR (300 MHz, CDCl3): δ 1.44 (t, 3H), 2.97 (s, 3H), 4.44 (q, 2H), 7.44 (m, IH), 7.91 (m, IH), 8.60 (m, IH), 8.90 (m, IH), 9.31 (s, IH).
Step 3: A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid ethyl ester (26.7 mmol) and LiOH (53.4 mmol) in a 1 :1 :1 solution of THF, MeOH and water (200 mL) is stirre at rt overnight. The THF/MeOH is evaporated, and the aqueous solution is treated with 10% aqueous HCl to adjust the pH to between 1.5 and 2.5. The solid is filtered off, washed with water and dried in vacuo to yield 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5.50 g, 96%) as a solid. MS: 233 (M+H); 1H 1H NMR (300 MHz, CD3OD): δ = 2.93(s, 3H), 7.59 (m, IH), 8.05 (t, IH), 8.62 (d, IH), 8.76 (d, IH), 9.28 (s, IH).
Step 4, Method A: A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (335 mg, 1.56 mmol), HOTT (638 mg, 1.72 mmol), and DIPEA) (700 μL, 4.01 mmol in DMF (6 mL) is stirred stirred at rt under N2 for 20 min. 5-Fluoro-3-methyl-indol-l-ylamine (241 mg, 1.47 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 60% EtOAc in heptane to afford 4-methyl-2-pyridin-2- yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yDamide (193 mg, 36%) as a solid. MS: 362 (M+H). 1H NMR (300MHz, CDCl3): δ 10.41 (s, IH), 8.84 (s, IH), 8.55 (s, IH), 8.48-8.45 (m, IH), 7.86 (t, IH), 7.40-7.36 (m, IH), 7.24-7.20 (m, 2H), 7.05-7.01 (m, 2H), 2.82 (s, 3H), 2.32 (s, 3H).
Step 4, Method B:
5-Fluoro-3-methyl-indol-l-ylamine (10.6 mmol) is treated with 4-methyl-2-pyridin-2- ylpyrimidine-5-carboxylic acid (2.75 g, 12.8 mmol) in DMF (75 mL) and the mixture is stirred at rt for 10 min. The mixture is then treated with 2,4-dimethoxy-6-(4- methylmorpholin-4-yl)-[l,3,5]triazine chloride (3.82 g, 13.85 mmol) and stirred at 600C for 1 h. The mixture is concentrated in vacuo. The residue is diluted with Et2O (50 mL) and 10% NaHCO3 (50 mL), and the mixture is stirred at rt for 20 min. The resulting solid is filtered, washed, and dried to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3- methyl-indol- 1 -yDamide (3.2 g, 83%). The solid is crystallized with MeOH:water (4:1) to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 - vQamide as a crystal. MS: 362 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.27 (s, 3H), 2.78 (s, 3H), 7.06 (m, IH), 7.34 (m, IH), 7.37 (s, IH), 7.44 (m, IH), 7.59 (m, IH), 8.05 (m, IH), 8.45 (m, IH), 8.80 (m, IH), 9.25 (s, IH). IC50 = 7 nM.
Example 4
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -vD-amide
Figure imgf000060_0001
Step 1 : Following the procedures similar to those of Example 1, step 3, but substituting pyridine-2-carboxamidine hydrochloride nicotinamidine hydrochloride, there is prepared I1 pyridin-2-yl-pyrimidine-5-carboxylic acid methyl ester.
Step 2: Following the procedures similar to those of Example 2, step 1, but substituting 2- pyridin-2-yl-pyrimidine-5-carboxylic acid methyl ester for 2-pyridin-3-yl-pyrimidine-5- carboxylic acid methyl ester, there is prepared 2-pyridin-2-yl-pyrimidine-5-carboxylic acid.
Step 3: A solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (209 mg, 0.88 mmol),
HOTT (435 mg, 1.17 mmol), and DIPEA (400 μL, 2.29 mmol) in DMF (10 mL) is stirred at rt under N2 for 20 min. 5-Fluoro-3-methyl-indol-l-ylamine (125 mg, 0.76 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCθ3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 70% EtOAc in heptane to afford 2-pyridin-2-yl-pyrimidine-5 - carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide (180 mg, 68%) as a solid. MS: 348 (M+H). 1H NMR (300MHz, DMSO-d6): δ 12.12 (s, IH), 9.47 (s, 2H), 8.82 (d, IH), 8.51 (d, IH), 8.05 (td, IH), 7.62 (dd, IH), 7.42 (dd, IH), 7.35 (dd, IH), 7.33 (s, IH), 7.03 (td, IH), 2.27 (s, 3H).
Example 5
4-Methyl-2-pyridin-3-yl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide
Figure imgf000060_0002
Step 1 : Following the procedures similar to those of Example 2, step 1, but substituting nicotinamidine hydrochloride for 3-fluorobenzamidine hydrochloride, there is prepared 2=. pyridin-3-yl-4-methyl-pyrimidine-5-carboxylic acid ethyl ester.
Step 2: Following the procedures similar to those of Example 2, step 1, but substituting 2- pyridin-3-yl-4-methyl-pyrimidine-5-carboxylic acid ethyl ester for 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid ethyl ester, there is prepared 4-methyl-2-pyridin-3-yl- pyrimidine-5-carboxylic acid.
Step 3: A solution of 4-methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (502 mg, 2.33 mmol), HCTU (1.054 g, 2.55 mmol), and DIPEA (1.10 mL, 6.30 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3-methyl-indol-l-ylamine (341 mg, 2.08 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCθ3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is triturated in ether (4 times) to afford 4-methyl-2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 - methyl-indol- 1 -ylV amide (160 mg, 21%) as a solid. MS: 362 (M+H). 1U NMR (300MHz, DMSO-de): δ 11.86 (s, IH), 9.58 (s, IH), 9.24 (s, IH), 8.79-8.78 (m, IH), 8.74 (td, IH), 7.62 (dd, IH), 7.44 (dd, IH), 7.37-7.36 (m, 2H), 7.06 (td, IH), 2.78 (s, 3H), 2.27 (s, 3H).
Example 6
2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5 -fluoro-3 -methyl-indol- 1 -yl)-amide
Figure imgf000061_0001
A solution of 2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (664 mg, 2.79 mmol), HCTU (1.27 g, 3.07 mmol), and DIPEA (1.4 mL, 8.02 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-fluoro-3-methyl-indol-l-ylamine (491 mg, 2.55 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is triturated in ether (3 times) and methanol to afford 2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol- 1 - vQ-amide (375 mg, 42%) as a solid. MS: 348 (M+H). 1U NMR (300MHz, DMSO-d6): δ 12.10 (s, IH), 9.61-9.60 (m, IH), 9.45 (s, 2H), 8.81-8.80 (m, IH), 8.77 (dt, IH), 7.64 (dd, IH), 7.41 (dd, IH), 7.35 (dd, IH), 7.32 (s, IH), 7.03 (td, IH), 2.27 (s, 3H). IC50 = 10 nM.
Example 7
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide
Figure imgf000062_0001
A solution of 2-pyridin-2 -yl-pyrimidine-5 -carboxylic acid (485 mg, 2.04 mmol), HCTU (909 mg, 2.2 mmol), and DIPEA (1 niL, 5.72 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-2-methyl-indol-l-ylamine (299 mg, 1.82 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 70% EtOAc in heptane to afford 2-pyridin-2-yl-pyrimidine-5 - carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide (112 mg, 18%) as a solid. MS: 348 (M+H). 1H NMR (300MHz, DMSO-d6): δ 12.03 (s, IH), 9.51 (s, 2H), 8.83 (d, IH), 8.50 (d, IH), 8.05 (dt, IH), 7.62 (dd, IH), 7.39 (dd, IH), 7.28 (dd, IH), 6.94 (dt, IH), 6.35 (s, IH), 2.33 (s, 3H).
Example 8
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5 -fluoro-3 -methyl-indol-l-vO-amide
Figure imgf000062_0002
Step 1 : To a solution of 3-fluoro-benzamidine hydrochloride (4 g, 22.6mmol) in anhydrous DMF (35 mL) is added sodium 3,3-dimethoxy-2-carbomethoxyprop-l -en- 1 -oxide (4.99g, 25.2mmol). The reaction mixture is heated at 1000C under N2 for 3 h and then cooled to rt. Water (150 mL) is added and the mixture is extracted with EtOAc. The organic layer is washed with brine, dried (MgSO4) filtered and concentrated in vacuo to afford 2-(3-fluoro- phenvD-pyrimidine-5-carboxylic acid methyl ester (1.76 g, 34%). MS: 233 (M+H).
Step 2: To a solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid methyl ester (1.76 g, 7.58 mmol) in anhydrous MeOH (35 mL) is added LiOH (0.38g, 15.9mmol) and the reaction mixture is stirred at rt overnight. The mixture is concentrated in vacuo and the residue is partitionned between EtOAc and 3 N aqueous HCl (7.6 mL). The mixture is extracted with EtOAc and the organic layer is washed with brine, dried (MgSO4), filtered and concentrated in vacuo to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (1.62 g, 98%) as a solid. MS: 219 (M+H).
Step 3: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (372 mg, 1.7 mmol), HCTU (757 mg, 1.83 mmol), and DIPEA (780 μL, 4.47 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3-methyl-indol-l-ylamine (250 mg, 1.52 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is triturated in ether to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide (332 mg, 60%) as a solid. MS: 365 (M+H). 1H NMR (300MHz, DMSO-d6): δ 12.08 (s, IH), 9.43 (s, 2H), 8.36 (d, IH), 8.20 (dt, IH), 7.70-7.62 (m, IH), 7.48 (dt, IH), 7.40 (dd, IH), 7.35 (dd, IH), 7.32 (s, IH), 7.03 (dt, IH), 2.27 (s, 3H).
Example 9
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide
Figure imgf000063_0001
A solution of 4-methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (504 mg, 2.34 mmol), HCTU (1.06 g, 2.55 mmol), and DIPEA (1.1 mL, 6.30 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-2-methyl-indol-l-ylamine (346 mg, 2.11 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCCh, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 70% EtOAc in heptane to afford 4-methyl-2-pyridin-3 -yl- pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide (82 mg, 11%) as a solid. MS: 362 (M+H). 1H NMR (300MHz, DMSO-d6): δ 11.80 (s, IH), 9.59 (d, IH), 9.29 (s, IH), 8.80-8.73 (m, 2H), 7.63 (dd, IH), 7.22 (dd, IH), 7.28 (dd, IH), 6.97 (dt, IH), 6.35 (s, IH), 2.79 (s, 3H), 2.37 (s, 3H).
Example 10
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yD- amide
Figure imgf000064_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (645 mg, 2.78 mmol), HCTU (1.25 g, 3.02 mmol), and DIPEA (1.35 mL, 7.73 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3-methyl-indol-l-ylamine (380 mg, 2.31 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is triturated in ether to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3- methyl-indol- 1 -ylV amide (533 mg, 61%) as a solid. MS: 379 (M+H). 1H NMR (300MHz, DMSO-de): δ 11.84 (s, IH), 9.21 (s, IH), 8.32 (d, IH), 8.17-8.15 (m, IH), 7.66-7.61 (m, IH), 7.47-41 (m, 2H), 7.36-7.34 (m, 2H), 7.05 (dt, IH), 2.76 (s, 3H), 2.26 (s, 3H). IC50 = 6 nM.
Example 11 2-(3-Fluoro-phenv0-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -vQamide
Figure imgf000065_0001
A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (389 mg, 1.78 mmol), HOAt (290 mg, 2.13 mmol), and HATU (811 mg, 2.13 mmol) in DMF (20 mL) is stirred at rt under N2 for 20 min. 5-Fluoro-2-methyl-indol-l-ylamine (290 mg, 1.77 mmol) and DIPEA (450 μL, 2.58 mmol) are added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 25% DCM in heptane to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 vDamide (300 mg, 47%) as a solid. MS: 365 (M+H). 1H NMR (300MHz, CDCl3): δ 9.23 (s, IH), 8.76 (s, IH), 8.35-8.22 (m, 2H), 7.54-7.45 (m, IH), 7.19-6.86 (m, 5H), 6.25 (s, IH), 2.29 (s, 3H).
Example 12
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide
Figure imgf000065_0002
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (810 mg, 3.76 mmol), PyBrOP (1.76 g, 3.78 mmol), and DIPEA (1.9 mL, 10.89 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-2-methyl-indol-l-ylamine (560 mg, 3.41 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 3% MeOH in DCM to afford 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide (174 mg, 14%) as a solid. MS: 362 (M+H). 1H NMR (300MHz, DMSO-d6): δ 11.82 (s, IH), 9.30 (d, IH), 8.81 (d, IH), 8.46 (d, IH), 8.03 (dt, IH), 7.59 (dd, IH), 7.43 (dd, IH), 7.29 (dd, IH), 6.98 (dt, IH), 6.35 (s, IH), 2.79 (s, 3H), 2.38 (s, 3H). IC50 = 8 nM.
Example 13 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3- dihydro-indol- 1 -yl)-amide
Figure imgf000066_0001
Step 1 : Isoamyl nitrite (3.4 mL, 25.42 mmol) is added to a solution of 5-fluoro-3,3-dimethyl- 2,3-dihydro-lH-indole (3.75 g, 22.69 mmol) in DCM. The mixture is refluxed overnight. The mixture is cooled and portioned between DCM and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo to afford 5-fluoro-3,3-dimethyl-l-nitroso-2,3-dihydro-lH-indole (4.23 g, 96%) as a solid. MS: 195 (M+H). 1H NMR (300MHz, CD3Cl)): δ 7.77 (dd, IH), 7.08- 6.98 (m, 2H), 3.94 (s, 2H), 1.39 (s, 6H).
Step 2: To a solution of 5-fluoro-3,3-dimethyl-l-nitroso-2,3-dihydro-lH-indole (4.03 g, 20.75 mmol) in THF (70 mL) at 00C is added a solution OfLiAlH4 (40 mL, 40 mmol) in THF dropwise. The mixture is allowed to warm to rt and stirred overnight. The mixture is quenched with a saturated aqueous solution of Rochelle's Salt. The resulting mixture is stirred until a slurry is obtained. The organic phase is separated, washed with 10% aqueous HCl, saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 25% EtOAc in heptane to afford 5-fluoro-3,3-dimethyl-2,3-dihydro-indol-l-ylamine (3.51 g, 94%) as an oil. MS: 181 (M+H). 1H NMR (300MHz, CD3Cl)): δ 6.85-6.78 (m, IH), 6.75-6.68 (m, 2H), 3.44 (br s, 2H), 3.14 (s, 2H), 1.28 (s, 6H).
Step 3: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (348 mg, 1.5 mmol), HOTT (618 mg, 1.66 mmol), and DIPEA (700 μL, 4.01 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3,3-dimethyl-2,3-dihydro-indol-l-ylamine (239 mg, 1.33 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCCh, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 15% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3,3- dimethyl-2.3-dihvdro-indol-l-yl)-amide (416 mg, 80%) as a solid. MS: 395 (M+H). 1H NMR (300MHz, DMSO-de): δ 10.43 (s, IH), 8.99 (s, IH), 8.28 (d, IH), 8.15-8.11 (m, IH), 7.66- 7.58 (m, IH), 7.46-7.39 (m, IH), 7.06 (dd, IH), 6.95-6.88 (m, IH), 6.75-6.71 (m, IH), 3.51 (s, 2H), 2.68 (s, 3H), 1.33 (s, 6H).
Example 14
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-acetyl)-indol-
1-vH-amide
Figure imgf000067_0001
Step 1 : Following procedures similar to those of Example 1, step 1, but substituting 3-(2,2,2- trifluoro-acetyl)indole for 5-fluoro-2-methylindole, l-(l-amino-lH-indol-3-yl)-2,2,2- trifluoro-ethanone is prepared.
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (360 mg, 1.55 mmol), HOTT (628 mg, 1.69 mmol), and DIPEA (740 μL, 4.24 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. l-(l-Amino-lH-indol-3-yl)-2,2,2-trifluoro-ethanone (322 mg, 1.4 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by HPLC reverse phase column chromatography eluting with a mobile phase of 0.1% TF A/water through 100% MeCN in a 30 min. ramp to afford 2-(3- fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-acetyl)-indol-l-yl"|- amide (71 mg, 11%) as a solid. MS: 443 (M+H). 1H NMR (300MHz, DMSO-d6): δ 12.56 (s, IH), 9.32 (s, IH), 8.90 (d, IH), 8.35 (d, IH), 8.30-8.27 (m, IH), 8.22-8.17 (m, IH), 7.75-72 (m, IH), 7.69-7.62 (m, IH), 7.52-7.44 (m, 3H), 2.81 (s, 3H). Example 15
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihvdro- indol- 1 -vD-amide
Figure imgf000068_0001
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (685 mg, 3.18 mmol), HOTT (1.29 g, 3.48 mmol), and DIPEA (1.6 mL, 9.16 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3,3-dimethyl-2,3-dihydro-indol-l-ylamine (542 mg, 3.01 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 2% MeOH in DCM to afford 4; methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihydro-indol- l-ylVamide (585 mg, 52%) as a solid. MS: 378 (M+H). 1H NMR (300MHz, DMSO-d6): δ 10.46 (s, IH), 9.02 (s, IH), 8.78 (d, IH), 8.42 (d, IH), 8.00 (dt, IH), 7.56 (dd, IH), 7.06 (dd, IH), 6.92 (dt, IH), 6.76-6.72 (m, IH), 3.32 (s, 2H), 2.70 (s, 3H), 1.33 (s, 6H).
Example 16
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihvdro- indol- 1 -yl)-amide
Figure imgf000068_0002
A solution of 4-methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (706 mg, 3.28 mmol), HOTT (1.34 g, 3.6 mmol), and DIPEA (1.65 mL, 9.45 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 5-Fluoro-3,3-dimethyl-2,3-dihydro-indol-l-ylamine (560 mg, 3.11 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCCh, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 35% EtOAc in heptane to afford 4-methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihvdro- indol-l-vD-amide (617 mg, 53%) as a solid. MS: 378 (M+H). 1U NMR (300MHz, DMSO-d6): δ 10.44 (s, IH), 9.55-9.54 (m, IH), 9.01 (s, IH), 8.77-8.75 (m, IH), 8.72-8.68 (m, IH), 7.60 (dd, IH), 7.06 (dd, IH), 6.96-6.88 (m, IH), 6.76-6.72 (m, IH), 3.51 (s, 2H), 2.70 (s, 3H), 1.33 (s, 6H).
Example 17 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3-dimethyl-indol-l-vD-amide
Figure imgf000069_0001
Step 1 : Following procedures similar to those of Example 1, step 1, but substituting 2,3- dimethylindole for 5-fluoro-2-methylindole, there is prepared 2,3-dimethyl-indol- 1 -ylamine as a solid. MS: 161 (M+H). 1H NMR (300MHz, CDCl3): δ 7.48-7.45 (m, IH), 7.33-7.30 (m, IH), 7.19-7.13 (m, IH), 7.10-7.05 (m, 1 H), 4.40 (br s, 2H), 2.37 (s, 3H), 2.23 (s, 3H).
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (764 mg, 3.29 mmol), HOTT (1.33 g, 3.58 mmol), and DIPEA (1.65 mL, 9.45 mmol) in DMF (15 mL) is stirred at rt under N2 for 10 min. 2,3-Dimethyl-indol-l-ylamine (497 mg, 3.1 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3-dimethyl-indol- 1 -yl)-amide (568 mg, 49%) as a solid. MS: 375 (M+H). 1H NMR (300MHz, DMSO-d6): δ 11.68 (s, IH), 9.24 (s, IH), 8.33 (d, IH), 8.20-8.15 (m, IH), 7.69-7.61 (m, IH), 7.50-7.43 (m, 2H), 7.37 (d, IH), 7.17-7.05 (m, 2H), 2.78 (s, 3H), 2.30 (s, 3H), 2.24 (s, 3H). Example 18
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (S-chloro^-methyl-indol- 1 -yl)- amide
Figure imgf000070_0001
Step 1 : Following procedures similar to those of Example 1, step 1, but substituting 5-chloro- 2-methylindole for 5-fluoro-2-methylindole, there is prepared 5-chloro-2-methyl-indol-l- ylamine as a solid. MS: 181 (M+H). 1H NMR (300MHz, CDCl3): δ 7.46-7.43 (m, IH), 7.27- 7.24 (m, IH), 7.12-7.09 (m, IH), 6.10 (s, 1 H), 4.44 (br s, 2H), 2.44-2.43 (m, 3H).
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (379 mg, 1.63 mmol), HOTT (662 mg, 1.78 mmol), and DIPEA (800 μL, 4.58 mmol) in DMF (10 mL) is stirred at rt under N2 for 10 min. 5-Chloro-2-methyl-indol-l-ylamine (274 mg, 1.52 mmol) is added. The resulting mixture is stirred at 800C overnight. The mixture is cooled and portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is triturated in ether to afford 2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-chloro-2-methyl-indol- 1 -vQ-amide (93 mg, 16%) as a solid. MS: 395 (M+H). 1H NMR (300MHz, DMSO-d6): δ 11.83 (s, IH), 9.27 (s, IH), 8.33 (d, IH), 8.20-8.15 (m, IH), 7.69- 7.61 (m, IH), 7.56 (d, IH), 7.50-7.43 (m, 2H), 6.36 (s, IH), 2.78 (s, 3H), 2.37 (s, 3H).
Example 19
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-bromo-indol- 1 -yl)-amide
Figure imgf000070_0002
Step 1 : Following procedures similar to those of Example 1, step 1, but substituting 5- bromoindole for 5-fluoro-2-methylindole, there is prepared 5 -bromoindol- 1 -ylamine as a solid. MS: 211 (M+H). 1H NMR (300MHz, CDCl3): δ 7.71-7.70 (m, IH), 7.29-7.28 (m, 2H), 7.13 (d, IH), 6.32-6.31 (m, 1 H), 4.73 (br s, 2H).
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (596 mg, 2.57 mmol), PyAOP (2.63 mmol), and DIPEA (830 μL, 4.75 mmol) in DCM (20 niL) is stirred at rt under N2 for 10 min. 5-Bromoindol-l-ylamine (500 mg, 2.37 mmol) is added. The resulting mixture is stirred at rt overnight. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 2% MeOH in DCM to afford 2-(3-fluoro-phenvD-4-methyl- pyrimidine-5-carboxylic acid (5-bromo-indol-l-yl)-amide (246 mg, 24%) as a solid. MS: 425 (M) & 427 (M+2). 1H NMR (300MHz, DMSO-d6): δ 12.02 (s, IH), 9.24 (s, IH), 8.34 (d, IH), 8.20-8.15 (m, IH), 7.84 (d, IH), 7.68-7.61 (m, IH), 7.59 (d, IH), 7.50-7.43 (m, 2H), 7.35 (dd, IH), 6.57 (dd, IH), 2.78 (s, 3H).
Example 20
3-Oxo-4-r(2-phenyl-pyrimidine-5-carbonyl)-aminol-piperazine-l-carboxylic acid benzyl ester
Figure imgf000071_0001
Step 1 : Following the procedures described in M. A. Brook, T. H. Chan Synthesis 1983, (3), 201-204, there is prepared benzyloxycarbonylamino-acetic acid ethyl ester (95%). MS: 238 (M+H); 1H NMR (300 MHz, CDCl3) δ 7.24-7.41 (m, 5H), 5.20-5.37 (br s, IH), 5.13 (s, 2H), 4.21 (q, J=7.0 Hz, 2H), 3.96 (br d, J=5.3 Hz, 2H), 1.27 (t, J=7.1 Hz, 3H).
Step 2: Following the procedures described in P. Shenbagamurthi, H. A. Smith, J. M. Becker, F. Naider J. Med Chem. 1986, 29 (5), 802-809; R. K. Olsen J. Org. Chem. 1970, 55 (6), 1912-1915, there is prepared (allyl-benzyloxycarbonyl-amino)-acetic acid ethyl ester as a liquid (92%): MS: 278 (M+H); 1H NMR (300 MHz, CDCl3) δ 7.17-7.41 (m, 5H), 5.70-5.88 (m, IH), 5.06-5.25 (m, 4H), 4.02-4.23 (m, 2H), 3.81-4.02 (m, 4H), 1.10-1.30 (m, 3H). Step 3: To a O0C solution of AD-mix-β (2.54 g) in a mixture of t-butanol (10 rnL) and water (12 rnL) is added a solution of (allyl-benzyloxycarbonyl-amino)-acetic acid ethyl ester (0.52 g, 1.91 mmol) in t-butanol (2.00 rnL). The reaction mixture is allowed to gradually warm to ambient temperature over 2 h, and stirred at rt for 20 h. Excess oxidant is quenched by the addition OfNa2SOs (2.58 g, 20.44 mmol) and the mixture is stirred vigorously for 4 h. The mixture is extracted with EtOAc (50 mL) and the organic phase is washed with satuated aqueous NaCl (2 x 30 mL). The organic solution is dried (MgSO4), filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography (1 :1 :1 of EtOAc:DCM : heptane to 50:50 D CM: EtOAc gradient elution) to afford [benzyloxycarbonyl-(2,3- dihydroxy-propyD-amino] -acetic acid ethyl ester as an oil (0.276 g, 46%). MS: 312 (M+H); 1H NMR (300 MHz, CDCl3) δ 7.20-7.40 (m, 5H), 5.05-5.18 (m, 2H), 3.95-4.25 (m, 4H), 3.80- 3.95 (m, IH), 3.20-3.80 (m, HH), 1.11-1.35 (m, 3H). (See H. Takahata, H. Ouchi, M. Ichinose, H. Nemoto Org. Lett. 2002, 4 (20), 3459-3462 and supplementary material; J. Gonzalez, C. Aurigemma, L. Truesdale Org. Synth. 2002, 79, 93-102).
Step 4: To a solution of [benzyloxycarbonyl-(2,3-dihydroxy-propyl)-amino]-acetic acid ethyl ester (1.98 g, 6.37 mmol) in DCM (30 mL) is added NaIO4-impregnated silica (13.04 g). The slurry is stirred rapidly for 4.5 h, and then filtered through a coarse porosity sintered glass funnel. The filtrate is concentrated to afford [benzyloxycarbonyl-(2-oxo-ethyl)-amino"|-acetic acid ethyl ester (1.65 g, 92%). MS: 280 (M+H); 1H NMR (300 MHz, CDCl3) δ 9.60-9.68 (m, IH), 7.26-7.40 (m, 5H), 510-5.19 (m, 2H), 4.00-4.22 (m, 6H), 1.18-1.30 (m, 3H). (see Y.-L. Zhong, T. K. M. Shing J. Org. Chem. 1997, 62 (8), 2622-2624).
Step 5: N-Aminophthalimide (0.55 g, 3.4 mmol) is added to a solution of benzyloxycarbonyl- (2 -oxo-ethyl)-amino] -acetic acid ethyl ester (0.72, 2.6 mmol) in 1,4-dioxane (10 mL), and the mixture is heated to reflux under N2 for 15 h. The reaction mixture is cooled to rt and filtered through diatomaceous earth. The filtrate is concentrated. The residue is re-dissolved in CHCl3 (30 mL) and filtered again through diatomaceous earth. This filtrate is concentrated to afford (benzyloxycarbonyl- (2-[(E)- 1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-ylimino"|ethyl| -amino)- acetic acid ethyl ester (~ 100%). MS: 424 (M+H); 1U NMR (300 MHz, CDCl3) δ 8.77-8.88 (n, IH), 7.80-7.93 (m, 2H), 7.67-7.80 (m, 2H), 7.23-7.40 (m, 5H), 5.09-5.21 (m, 2H), 4.25- 4.45 (m, 2H), 3.97-4.25 (m, 4H), 1.12-1.32 (m, 3H). Step 6: A solution of (benzyloxycarbonyl-{2-[(E)-l,3-dioxo-l,3-dihydro-isoindol-2- ylimino]ethyl}-amino)-acetic acid ethyl ester (7.7 mmol) in CH3CN (65 rnL) is treated with sodium cyanoborohydride (1.92 g, 30.5 mmol), and acetic acid (6.8 mL, 118.8 mmol) is added with stirring under N2. After 5.5 h, the reaction solution is diluted with EtOAc (150 mL) and washed with saturated aqueous KHCO3 (3 x 50 mL) and saturated aqueous NaCl (50 mL). The organic phase is dried (MgSθ4), filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography (75:25 to 50:50 heptane:ethyl acetate gradient elution) to afford {benzyloxycarbonyl-[2-(l,3-dioxo-l,3-dihydro-isoindol-2-ylamino)-ethyl1-amino}- acetic acid ethyl ester as an oil (2.66 g, 81%). MS: 426 (M+H); 1U NMR (300 MHz, CDCl3) δ 7.79-7.91 (m, 2H), 7.69-7.79 (m, 2H), 7.17-7.39 (m, 5H), 5.04-5.21 (m, 2H), 4.87-5.04 (m, IH), 4.04-4.23 (m, 4H), 3.48-3.59 (m, 2H), 3.18-3.38 (m, 2H), 1.10-1.30 (m, 3H).
Step 7: A solution of (benzyloxycarbonyl-[2-(l,3-dioxo-l,3-dihydro-isoindol-2-ylamino)- ethyl] -amino} -acetic acid ethyl ester (0.22 g, 0.52 mmol) in diphenyl ether (3 mL) is heated to reflux for 2 h. Diphenyl ether is removed by vacuum distillation and the residue is purified by flash silica gel chromatography (2:1 :1 to 1 :1 :1 heptane:DCM:EtOAc gradient elution) to afford 4-(l ,3-dioxo- 1 ,3-dihydro-isoindol-2-yl)-3-oxo-piperazine- 1 -carboxylic acid benzyl ester as a solid (0.126 g, 64%). MS: 380 (M+H); 1H NMR (300 MHz, CDCl3) δ 7.86-7.95 (m, 2H), 7.75-7.86 (m, 2H), 7.24-7.42 (m, 5H), 5.20 (s, 2H), 4.42 (s, 2H), 3.90-4.05 (m, 2H), 3.65-3.87 (m, 2H).
Step 8: To a solution of benzamidine hydrochloride hydrate (2 mmol) in anhydrous DMF (4 mL) is added sodium salt of 2-dimethoxymethyl-3-hydroxy-acrylicacid methyl ester (0.46 g, 2.32 mmol) and the reaction mixture heated at 1000C under N2 for 1 hour. The reaction is cooled to rt and water (15 mL) is added. After addition of water, immediate precipitation of the product is observed. The solids are collected by filtration, washed with water (2.5 mL) and vacuum dried to yield 2 -phenyl-pyrimidine-5 -carboxylic acid methyl ester (0.32 g, 74%). (see: P. Zhichkin, D.J. Fairfax, S.A. Eisenbeis, Synthesis, 2002, 720-722.)
Step 9: A solution of 2-phenyl-pyrimidine-5 -carboxylic acid methyl ester (3.15 g) and LiOH (0.71 g) in a mixture of MeOH, THF and water (1 :1 :1 in volume, 120 mL) is stirred at rt overnight. MeOH and THF are evaporated off to give an aqueous solution. The aqueous solution is acidified with 5% hydrochloric acid to adjust pH to between 2.5 and 3. The precipitate is filtered off and washed with water, dried in vacuo to yield 2.94 g (-100%) of 2z phenyl-pyrimidine-5 -carboxylic acid as a solid. MS: 201 (M+H).
Step 10: A solution of 4-(l,3-dioxo-l,3-dihydro-isoindol-2-yl)-3-oxo-piperazine-l-carboxylic acid benzyl ester (53 mg, 0.14 mmol) in MeOH (10 rnL) is treated with anhydrous hydrazine (0.3 mL, 9.56 mmol). The reaction mixture is stirred at reflux under N2 for 3.5 h. The reaction mixture is concentrated. The residue is dissolved in a mixture of DMF (2 mL) and DCM (2 mL), and treated with 2-phenyl-pyrimidine-5-carbonyl chloride (32 mg, 0.15 mmol). The mixture is stirred under N2 for 16 h, and then diluted with EtOAc (35 mL). The mixture is washed successively with saturated aqueous KHCO3, (15 mL), water (2 x 15 mL), and saturated aqueous NaCl (15 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue is purified by flash silica gel chromatography (80:20 to 0:100 heptane:EtOAc gradient elution) to afford 3-oxo-4-r(2-phenyl-pyrimidine-5-carbonyl)-aminol-piperazine-l-carboxylic acid benzyl ester as an oil (111 mg, 18%). MS: 432 (M+H); 1H NMR (300 MHz, CDCl3) δ 9.70-10.10 (br, IH), 9.06 (s, 2H), 8.46 (dd, J=7.8, 1.7 Hz, 2H), 7.44-7.60 (m, 3H), 7.25-7.40 (m, 5H), 5.18 (s, 2H), 4.36 (s, 2H), 3.93 (t, J=5.1 Hz, 2H), 3.69-3.81 (br s, 2H). IC50 = 103.5 nM.
Example 21 2-(3 -Fluorophenyl)pyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 -fluoro-indol- 1 - vDamide
Figure imgf000074_0001
Step 1 : A solution of 5-fluoroindole (5.4 g) and toluene-4sulponyl chloride (9.12 g) in toluene (300 mL) is treated with a cooled solution of sodium hydroxide pellets (23.2 g) in water (200 mL) followed by the tetrabutylammonium hydrogen sulfate catalyst (400 mg). The mixture is stirred at rt for 24 h. The organic phase is separated, washed with water and brine, dried (MgSO4) and concentrated in vacuo to afford 5 -fluoro- 1 -(toluene-4-sulfonvD- 1 H-indole (10.7 g, 78%). MS: 290 (M+H) Step 2: A solution of 5-fluoro-l-(toluene-4-sulfonyl)indole (5.2 g) in dry CH3CN (80 niL) is cooled in an ice-bath and treated drop wise with chlorosulfonic acid (12 mL). The reaction mixture is allowed to warm to rt and stirred for 24 h. The reaction mixture is carefully poured onto ice/water (300 mL). The precipitate is collected by filtration and washed with water to afford 5-fluoro-3-chlorosulfonyl-l-(toluene-4-sulfonyl)-lH-indole (6.8 g, 98%) as a solid. MS: 386 (M-H).
Step 3: A solution of 5-fluoro-3-chlorosulfonyl-l-(toluene-4-sulfonyl)indole (2.52 g) in DCM (75 mL) is added to an aqueous solution of dimethylamine (40%, 20 mL) in water (50 mL) and stirred at rt for 20 h. The organic phase is separated, washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo to afford 5 -fluoro- 1 -(toluene-4-sulfonvD- 1 H- indole-3-sulpfonic acid dimethylamide (2.55 g, 99%) as a solid. MS: 397 (M+H).
Step 4: A mixture of 5 -fluoro- l-(touene-4-sulfonyl)indole-3 -sulfonic acid dimethylamide (2.55 g) in MeOH (100 mL) and 5 N KOH (15mL) is heated to reflux for 1.5 hours. The reaction mixture is concentrated in vacuo. The residue is diluted with water (50 mL) and acidified to pH ~ 3 with IO N aqueous HCl. The mixture is extracted with EtOAc. The organic layer is separated, washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo to afford 5 -fluoro- lH-indole-3 -sulfonic acid dimethylamide (1.35 g, 87%) as a solid. MS: 241 (M-H).
Step 5: A solution of 5 -fluoro- lH-indole-3 -sulfonic acid dimethylamide (1.24 g) in dry DMF (50 mL) is cooled to 00C and treated portion wise with 60% MaH oil dispersion (3.07 g). The mixtire is stirred at 00C for 30 min. Hydroxylamine-O-sulfonic acid (2.9 g) is added portion wise and the mixture is warmed to rt and stirred for 5 h. The reaction mixture is poured onto ice/water and extracted with EtOAc. The organic layer is separated, washed water and brine, dried (MgSO4) filtered and concentrated in vacuo. The residue is triturated with ether. The solid is collected by filteration to afford l-amino-5 -fluoro- lH-indole-3 -sulfonic acid dimethylamide (0.53 g, 41%). MS: 258 (M+H).
Step 6: A suspension of 2-(3-fluorophenyl)-pyrimidine-5-carboxylic acid (76 mg) in dry DCM (25mL)/dry DMF (2 drops) is treated with oxalyl chloride (0.15mL) and stirred at rt for 3.5 hours. The reaction mixture is concentrated in vacuo. The residue is dissolved in toluene (15 niL) and then concentrated in vacuo. The residue is dried on high vacuum pump, and then dissolved in EtOAc (7 mL). The solution is added to a mixture of l-amino-5-fluoro-lH- indole-3 -sulfonic acid dimethylamide (100 mg) and Na2CO3 (106 mg) in EtOAc (5mL)/water (5mL). The mixture is stirred at rt for 24 h. The organic phase is separated, washed water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 50% EtOAc in heptane to afford 2-(3 -fluorophenyOpyrimidine- 5 -carboxylic acid-(3 -dimethylsulfamoyl-5 -fluoroindol- 1 -vDamide (100 mg, 62%) as a solid. MS: 458 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.67 (s, 6H), 7.20-7.3 (m, IH), 7.45-7.55 (m, IH), 7.57-7.6 (dd, IH), 7.65-7.75 (m, 2H), 8.2 (d, IH), 8.38-8.4 (d, 2H), 9.45 (s, 2H), 12.6 (s, IH).
Example 22
2-(3 -Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 - fluoroindol- 1 -vDamide
Figure imgf000076_0001
A solution of 2-(3-fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid (116 mg) and HATU
(190 mg) in dry DMF is treated with DIPEA (0.09 mL) and stirred at rt for 40 min. 1-Amino- 5 -fluoro-lH-indole-3 -sulfonic acid dimethylamide (192 mg) is added and the mixture is stirred at rt for 24 h. The mixture is concentrated in vacuo. The residue is dissolved in EtOAc, washed with 2 N aqueous NaOH, water and brine, dried (MgSO4) and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% EtO Ac/heptane to afford 2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 - fluoroindol- l-vOamide (85 mg, 40%) as a solid. MS: 472 (M+H); 1U NMR (300 MHz, DMSO-de): δ 2.68 (s, 6H), 2.79 (s, 3H), 7.25-7.35 (m, IH), 7.45-7.55 (m, IH), 7.57-7.80 (m, 3H), 8.20 (d, IH), 8.35 (s, IH), 8.47 (s, 2H), 9.28 (s, IH), 12.40 (s, IH).
Example 23
2-(3-Fluorophenyl)pyrimidine-5-carboxylicacid-[5-fluoro-3-(morpholine-4-sulfonyl)indol-l- yll amide
Figure imgf000077_0001
Step 1 : A solution of 5-fluoro-3-chlorosulfonyl-l-(toluene-4-sulfonyl)-lH-indole (1 g) in DCM is added to a solution of morpholine (2.26 niL) in water (50 mL) and stirred at rt for 5 h. The organic phase is separated and washed water, brine and dried (MgSO4), filtered and concentrated in vacuo to afford 5-fluoro-3-(morpholine-4-sulfonyl)-l-(toluene-4-sulfonyl)- lH-indole q.3 g, ~ 100%). MS: 439 (M+H).
Step 2: A solution of 5-fluoro-3-(morpholine-4-sulfonyl)-l-(toluene-4-sulfonyl)-lH-indole (1.3 g) in MeOH (50 mL)/5 N KOH (3mL) is heated to reflux for 1 h. The reaction mixture is concentrated in vacuo. The residue is diluted with water (30 mL) and acidified with IO N aqueous HCl to pH ~ 4. The mixture is extracted with EtOAc. The organic layer washed with water, brine and dried (MgSO4), filtered and concentrated in vacuo to afford 5-fluoro-3- (morpholine-4-sulfonviy 1 H-indole (0.8 g, 95%) as a solid. MS: 285 (M+H).
Step 3: Following procedures similar to those of Example 21, step 5, but substituting 5-fluoro- 3 -(morpholine-4-sulfonyl)-l H-indole for 5 -fluoro-lH-indole-3 -sulfonic acid dimethylamide, and the product is purified by silica gel chromatography eluting with 20% EtOAc, there is prepared l-amino-5-fluoro-3-(morpholine-4-sulfonyl)-l H-indole (16%) as a solid. MS: 300 (M+H).
Step 4: Following procedures similar to those of Example 21, step 6, but substituting 1-amino- 5 -fluoro-3-(morpholine-4-sulfonyl)-l H-indole for l-amino-5-fluoro-lH-indole-3 -sulfonic acid dimethylamide, there is prepared 2-(3-fluorophenyl)pyrimidine-5-carboxylicacid-r5-fluoro-3- (morpholine-4-sulfonvnindol- 1 -yll amide (27%) as a solid. MS: 500 (M+H). 1H NMR (300 MHz, DMSO-de): δ 2.95 (m, 4H), 3.67 (m, 4H), 7.25-7.35 (m, IH), 7.45-7.55 (m, IH), 7.57- 7.60 (dd, IH), 7.62-7.72 (q, IH), 7.75-7.80 (q, IH), 8.20 (d, IH), 8.35-8.40 (d, IH), 8.41 (s, IH), 9.45 (s, 2H), 12.6 (s, IH).
Example 24 2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3- (morpholine-4- sulfonyl) indol-1-vH amide
Figure imgf000078_0001
Following procedures similar to those of Example 22, but substituting l-amino-5-fluoro-3- (morpholine-4-sulfonyl)-lH-indole for l-amino-5-fluoro-lH-indole-3 -sulfonic acid dimethylamide, there is prepared 2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid- r5-fluoro-3-(morpholine-4-sulfonyl)indol-l-yll amide (48%) as a solid. MS: 512 (M-H). 1H NMR (300 MHz, DMSO-d6): δ 2.80 (s, 3H), 2.95 (m, 4H), 3.67 (m, 4H), 7.25-7.35 (m, IH), 7.45-7.55 (m, IH), 7.57-7.60 (m, IH), 7.62-7.72 (m, IH), 7.75-7.80 (m, IH), 8.15-8.20 (d, IH), 8.30-8.35 (d, IH), 8.45 (s, IH), 9.30 (s, IH), 12.4 (s, IH).
Example 25
2-(3 -Fluorophenyl)pyrimidine-5 -carboxylic acid-[5 -fluoro-3 -sulfamoylindol- 1 -vDamide
Figure imgf000078_0002
Step 1 : A solution of 2-(3-fluorophenyl)pyrimidine-5 -carboxylic acid-(5-fluoroindol-l- yl)amide (0.35 g,) in dry CH3CN (20 mL) is treated with chlorosulfonic acid (0.5 mL) and stirred at rt for 24 h. Thereaction mixture is poured onto ice/water (150 mL) and extracted with EtOAc. The organic layer is washed with water, brine and dried (MgSO4), filtered and concentrated in vacuo to afford 5 -fluoro- 1 - { [2-(3 -fluorophenyl)pyrimidine-5 - carbonyll amino I - 1 H-indole-3 -sulfonyl chloride (0.43 g, 95%). MS: 449 (M+H).
Step 2: A solution of 5-fluoro-l-{[2-(3-fluorophenyl)pyrimidine-5-carbonyl]amino}-lH- indole-3 -sulfonyl chloride (0.14 g) in DCM (20 mL) is treated with a solution of aqueous ammonia solution (28%-5 mL) in water (15 mL) and stirred at rt for 24 h. The reaction mixture is acidified with IO N aqueous HCl to pH ~ 3 and extracted with DCM. The organic layer is washed with water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 50% EtOAc in heptane to afford 2-(3 -fluorophenyl)pyrimidine-5 -carboxylic acid- [5 -fluoro-3 -sulfamoylindol- 1 -yDamide (10 mg, 8%) as a solid. MS: 430 (M+H). 1H NMR (300 MHz, DMSO-d6): δ 7.20-7.30 (m, IH), 7.40-7.50 (m, 2H), 7.60-7.72 (m, 2H), 8.10 (s, IH), 8.19-8.22 (d, IH), 8.33-8.37 (d, IH), 9.44 (s, IH), 12.45 (s, IH).
Example 26
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-methylsulfamoyl)indol- 1 - yDamide
Figure imgf000079_0001
Following procedures similar to those of Example 25, but substituting 40% aqueous methylamine for aqueous ammonia solution, there is prepared 2-(3 -fluorophenyDpyrimidine- 5-carboxylic acid-r5-fluoro-3-methylsulfamoyl)indol- 1 -vDamide (60%) as a solid. MS: 444 (M+H). 1H NMR (300 MHz, DMSO-d6): δ 2.45 (d, 3H), 7.20-7.30 (m, IH), 7.40-7.50 (m, 2H), 7.60-7.70 (m, 3H), 8.19-8.22 (d, IH), 8.24 (s, IH), 8.34-8.37 (d, IH), 9.44 (s, IH), 12.50 (s, IH).
Example 27
2-(3-Fluorophenyl)pyrimidine-5-carboxylic acid-r5-fluoro-3-(2-morpholin-4- ylethylsulfamoyDindol- 1 -yDamide
20
Following procedures similar to those of Example 25, but substituting an aqueous
Figure imgf000079_0002
solution of 2-(morpholin-4-yl) ethylamine for the aqueous ammonia solution, there is prepared 2-(3 -fluorophenyl)pyrimidine-5 - carboxylic acid- [5 -fluoro-3 -(2 -morp ho lin-4-ylethylsulfamoyl)indol-l-yl)amide (35%). MS: 543 (M+H). 1H NMR (300 MHz, DMSO-d6): δ 2.20-2.38 (m, 6H), 2.89-2.95 (q, 2H), 3.40- 3.50 (s, 4H), 7.20-7.30 (m, IH), 7.42-7.55 (m, 2H), 7.63-7.70(m, 3H), 8.19-8.22 (d, IH), 8.26 (s, IH), 8.34-8.37 (d, IH), 9.44 (s, 2H), 12.40-12.60 (s, IH). Example 28
2-(3-Fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-[5-fluoro-3- methylsulfamoyl)indol- 1 -vDamide
Figure imgf000080_0001
Step 1 : A solution 2-(3-fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-(5-fluoroindol-l- yl)amide (1 g, 2.75 mmol) in dry CH3CN is cooled to 00C and treated drop wise with chlorosulfonic acid (0.55 mL) and stirred for 2hours.The precipitated solid is filtered off and washed with ether to afford 5 -fluoro- 1 - { [2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carbonyll amino 1-1 H-indole-3 -sulfonic acid (1.06 g, 87%) as an off-white solid. MS: 443 (MH-).
Step 2: To a suspension of 5 -fluoro- 1-{[2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carbonyl]amino}-lH-indole-3-sulfonic acid (1.06 g) in DCM (60 mL) at 00C is added dry DMF (10 drops). Oxalyl chloride (1.05 mL) is added drop wise and the mixture is stirred at 00C for 3 h. The mixture is filtered and the collected solid is washed with ether to afford 5^ fluoro- 1 - { [2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carbonyl] amino 1-1 H-indole-3 -sulfonyl chloride (0.94 g). MS: 461 (M-H)
Step 3: Following procedures similar to those of Example 25, step 2, but substituting 40% aqueous methylamine for the aqueous ammonia solution, and substituting 5 -fluoro- 1-{[2-(3- fluorophenyl)-4-methylpyrimidine-5 -carbonyl] amino} -1 H-indole-3 -sulfonyl chloride for 5- fluoro- 1 - { [2-(3 -fluorophenyl)pyrimidine-5 -carbonyl] amino } - 1 H-indole-3 -sulfonyl chloride, there is prepared 2-(3-fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-[5-fluoro-3- methylsulfamovOindol- 1 -vQamide (40 mg, 35%) as a solid. MS: 456 (M-H); 1U NMR (300 MHz, DMSO-de): δ 2.45 (d, 3H), 2.80 (s, 3H), 7.20-7.30 (m, IH), 7.40-7.50 (m, 2H), 7.60- 7.70 (m, 3H), 8.17-8.20 (d, IH), 8.30-8.35 (d, 2H), 9.28 (s, IH), 12.30 (s, IH).
Example 29
2-(3-Fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-{5-fluoro-|Y3-tetrahydropyran-4- ylmethvDsulfamoyliindol- 1 -yl| amide
Figure imgf000081_0001
Following procedures similar to those of Example 25, step 2, but substituting an aqueous solution of 4-aminomethyltetrahydropyran for the aqueous ammonia solution, and substituting 5 -fluoro- 1 - { [2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carbonyl] amino } - 1 H-indole-3 - sulfonyl chloride for 5-fluoro-l -{[2-(3 -fluorophenyl)pyrimidine-5 -carbonyl] amino} -IH- indole-3-sulfonyl chloride, there is prepared 2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carboxylic acid- {5-fluoro-r(3-tetrahvdropyran-4-ylmethyl)sulfamoyllindol- 1 -yl| amide as a solid. MS: 542 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 1.00-1.15, (m, 2H), 1.50-1.70, (m, 3H), 2.60-2.70, (t, 2H), 2.80, (s, IH), 3.1-3.2, (t, 2H), 3.70-3.80, (dd, 2H), 7.20-7.30, (m, IH), 7.40-7.50, (m, IH), 7.60-7.70, (m, 4H), 8.16-8.20, (d, IH), 8.28-8.34 (d, 2H), 9.28, (s, IH), 12.25, (s, IH).
Example 30
2-(3-Fluorophenyl)-4-methylpyrimidine-5-carboxylic acid-r5-fluoro-3-(2-morpholin-4- ylethylsulfamovDindol- 1 -vDamide
Figure imgf000081_0002
Following procedures similar to those of Example 25, step 2, but substituting an aqueous solution of 2-(morpholin-4-yl) ethylamine for the aqueous ammonia solution, and substituting 5 -fluoro- 1 - { [2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carbonyl] amino } - 1 H-indole-3 - sulfonyl chloride for 5-fluoro-l -{[2-(3 -fluorophenyl)pyrimidine-5 -carbonyl] amino} -IH- indole-3 -sulfonyl chloride, there is prepared 2-(3 -fluorophenyl)-4-methylpyrimidine-5 - carboxylic acid-r5-fluoro-3-(2-morpholin-4-ylethylsulfamoyl)indol-l-yl)amide ( 58%) MS: 557 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.20-2.30 (s, 4H), 2.30-2.40 (t, 2H), 2.80 (s, 3H), 2.89-2.95 (q, 2H), 3.40-3.50 (s, 4H), 7.20-7.30 (m, IH), 7.42-7.55 (m, 2H), 7.63-7.70(m, 3H), 8.17-8.20 (d, IH), 8.32-8.35 (d, 2H), 9.28 (s, 2H), 12.25-12.30 (s, IH). Example 31
2-(3-Fluorophenyl)pyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -vDamide
Figure imgf000082_0001
Step 1 : The crude product of l-amino-4-fluoroindole is prepared according to the procedures described in J.Hymes et al., J.O.C., (2004), 69, 1368-1371. The crude product is then purified by silica gel chromatography eluting with 30% DCM in heptane to afford l-amino-4- fluoroindole (43%). MS: 151 (M+H).
Step 2: A solution of 2-(3-fluorophenyl)-pyrimidine-5-carboxylic acid (0.33 g), HATU (0.67 g) and hydroxy azabenzotriazole (0.26 g) in dry DMF (15 rnL) is stirred at rt for 30 min under N2. A solution of l-amino-4-fluoroindole (0.24 g) in dry DMF (5 mL) is added followed by the addition of DIPEA (0.39 mL). The mixture is stirred at 800C for 24 h, cooled to rt, and then concentrated in vacuo. The residue is dissolved in EtOAc and washed with water, brine and dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 60% DCM/heptane to afford 2-(3 -fluorophenv0pyrimidine-5 - carboxylic acid-(4-fluoroindol- 1 -vQamide (0.24 g, 53%) as a solid. MS: 351 (M+H); 1H NMR (300 MHz, DMSO-de): δ 6.64 (d, IH), 6.89-6.92 (q, IH), 7.15-7.22 (m, IH), 7.31-7.33 (d, IH), 7.46-7.52 (m, IH), 7.56 (d, IH), 7.63-7.70 (q, IH), 8.18-8.23 (d, IH), 8.34-8.37 (d, IH), 9.45 (s, 2H), 12.30 (s, IH). IC50 = 11 nM.
Example 32
2-(3 -Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(4-fluoroindol- 1 -vDamide
Figure imgf000082_0002
Following procedures similar to those of Example 31, step 2, but substituting 2-(3- fluorophenyl)-4-methylpyrimidine-5-carboxylic acid for 2-(3-fluorophenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(3 -fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid- (4-fluoroindol- 1 -vQamide (63%) as a solid. MS: 365 (M-H); 1U NMR (300 MHz, DMSO-d6): δ 2.75 (σ, 3H), 6.61 (d, IH), 6.86-6.92 (q, IH), 7.15-7.22 (m, IH), 7.30-7.32 (d, IH), 7.40- 7.46 (m, IH), 7.56-7.65 (m, 2H), 8.13-8.16 (d, IH), 8.28-8.31 (d, IH), 9.21 (s, IH), 12.05 (s, IH).
Example 33 2-(Pyridin-2-yl)-pyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -vDamide
Figure imgf000083_0001
A suspension of 2-(pyridine-2-yl)-pyrimidine-5-carbonyl chloride (0.44 g) in EtOAc (20 mL) is added portion wise to a mixture of l-amino-4-fluoroindole (0.30 g) and K2CO3 (0.276 g) in EtOAc (10 mL) / water (20 mL) and the resulting mixture is stirred at rt for 24 h. The aqueous phase is separated and extracted twice with EtOAc. The combined organic layer is washed with water and brine, dried (MgSO4), filtered and concentration in vacuo. The residue is purified by silica gel chromatography eluting with EtOAc to afford 2-(pyridin-2- vDpyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -vDamide (0.115 g, 17%) as a solid. MS: 334 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 6.65 (d, IH), 6.89-6.95 (q, IH), 7.16-7.23 (m, IH), 7.32-7.35 (d, IH), 7.57 (d, IH), 7.57-7.64 (m, IH), 8.02-8.08 (t, IH), 8.50-8.52 (d, IH), 8.82- 8.83 (d, IH), 9.49 (s, 2H), 12.30 (s, IH).
Example 34
2-(Pyridin-2-yl)-4-methylpyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -vDamide
Figure imgf000083_0002
A solution of 2-(pyridine-2-yl)-4-methylpyrimidine-5 -carboxylic acid (0.11 g) and HATU (0.19 g) in dry DMF (7mL) is treated with DIPEA (0.09 mL) and stirred at rt under N2 for 30 min. l-Amino-4-fluoroindole (0.112 g) is added and the mixture is stirred at rt for 24 h. The mixture is concentrated in vacuo. The residue is dissolved in EtOAc, washed with water and brine and dried (MgSO4), filtered, and concentration in vacuo. The residue is purified by silica gel chromatography eluting with 75% EtOAc to afford 2-(pyridin-2-yl)-4- methylpyrimidine-5-carboxylic acid-(4-fluoroindol-l-yl)amide (0.085gms, 50%). MS: 348 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.82 (s, 3H), 6.65 (d, IH), 6.93-6.97 (q, IH), 7.19- 7.26 (m, IH), 7.35-7.38 (d, IH), 7.62 (d, IH), 7.74-7.78 (m, IH), 8.20-8.25 (t, IH), 8.58-8.61 (d, IH), 8.85-8.86 (d, IH), 9.33 (s, IH), 12.15 (s, IH).
Example 35
2-Phenyl-pyrimidine-5-carboxylic acid [6-(4-fluoro-phenyl)-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazin-4-yl] -amide
Figure imgf000084_0001
Step 1 : Following procedures described in F. Chau, J.-C. Malanda, and R. Milcent J. Heterocyclic Chem. 1997, 34, 1603-1606, there is prepared 5-methyl-3H-l,3,4-oxadiazol-2- one (24%). MS: 101 (M+H); 1H NMR (300 MHz, CDCl3) δ 9.76 (br s, IH), 2.28 (s, 3H).
Step 2: To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (2.77 g, 27.7 mmol) in MeOH (25 mL) is added 25 wt % NaOMe solution in methanol (6.4 mL, 27.9 mmol) and the mixture is stirred at rt for 10 min. The mixture is concentrated in vacuo and the residue is added to a solution of 2-chloro-4'-fluoroacetophenone (4.71 g, 27.3 mmol) and tetrabutylammonium bromide (0.174 g, 0.54 mmol) in CHCl3 (16 mL). The mixture is heated to reflux for 2.5 h under N2. The reaction mixture is then allowed to cool and stirred overnight at ambient temperature. The resultant slurry is filtered through qualitative filter paper and the filtrate is concentrated to obtain a liquid. This liquid is further filtered through a pad of silica gel, eluting with 1 : 1 EtOAc/DCM. The filtrate is concentrated in vacuo to afford 3-[2-(4-fluoro- phenylV2-oxo-ethvH-5-methyl-3H-l,3.4-oxadiazol-2-one (~ 100%). MS: 237 (M+H); 1H NMR (300 MHz, CDCl3) δ 7.90-8.10 (m, 2H), 7.10-7.22 (m, 2H), 5.08 (s, 2H), 2.29 (s, 3H). Step 3: To a solution of 3-[2-(4-fluoro-phenyl)-2-oxo-ethyl]-5-methyl-3H-l,3,4-oxadiazol-2- one (2.3 g, 9.7 mmol) in a mixture of 2-propanol (12 mL) and water (0.3 rnL) is added hydrzazine monohydrate (0.71 mL, 14.6 mmol). The reaction mixture is heated to reflux under N2 for 14.5 h, and then a solution of oxalic acid (0.3 g, 3.3 mmol) in 2-propanol (6 mL) is added. The resulting precipitate is removed by filtration. The filtrate is concentrated to ~ 35 mL and then chilled to afford N-[6-(4-fluoro-phenyl)-3-oxo-2,5-dihydro-3H-l,2,4-triazin- 4-yll-acetamide as a crystal that is collected by filtration (0.83 g, 34%). MS: 251 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 10.37 (s, IH), 10.16 (s, IH), 7.65-7.79 (m, 2H), 7.16-7.27 (m, 2H), 4.57 (s, 2H), 1.90 (s, 3H).
Step 4: To a slurry of N-[6-(4-fiuoro-phenyl)-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl]- acetamide (0.48 g, 1.9 mmol) in MeOH (5 mL) is added 37% aqueous HCl. The mixture is heated to reflux for 3 h, and then cooled to rt. The mixture is basifϊed with 1 M aqueous NaOH to pH ~ 12. The resulting precipitate is collected by filtration and dried to afford 4; amino-6-(4-fluoro-phenylV4.5-dihvdro-2H- 1.2.4-triazin-3-one (0.35 g, 88%). MS: 209
(M+H); 1H NMR (300 MHz, DMSO-d6) δ 10.17 (s, IH), 7.67-7.75 (m, 2H), 7.18-7.29 (m, 2H), 4.75 (s, 2H), 4.45 (s, 2H).
Step 5: To a slurry of 4-amino-6-(4-fluoro-phenyl)-4,5-dihydro-2H-l,2,4-triazin-3-one (0.26 g, 1.23 mmol), 2-phenyl-pyrimidine-5-carboxylic acid (0.25 g, 1.23 mmol), and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.37 g, 1.94 mmol) in DMF (12 mL) is added Et3N (0.2 mL, 1.435 mmol) under N2 and the reaction mixture is stirred at rt for 49 h. The mixture is diluted with EtOAc (120 mL), and washed successively with saturated aqueous NH4Cl (2 x 50 mL), water (2 x 50 mL), and saturated aqueous NaCl (50 mL). The organic phase is dried (MgSO4), filtered, and concentrated in vacuo. The residue is triturated with EtOH (30 mL) to afford 2-phenyl-pyrimidine-5-carboxylic acid [6-(4-fluoro-phenyl)-3- oxo-2.5-dihydro-3H- 1.2.4-triazin-4-yll-amide (0.12 g, 25%). MS: 391 (M+H); 1U NMR (300 MHz, DMSO-de) δ 11.25 (s, IH), 10.58 (s, IH), 9.31 (s, 2H), 8.47 (dd, J=7.7, 1.8 Hz, 2 H), 7.70-7.86 (m, 2 H), 7.49-7.67 (m, 3H), 7.18-7.34 (m, 2H), 4.77.
Example 36
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid-r4-(2-hvdroxy-ethyl)-prperazin- 1 -yll -amide
Figure imgf000086_0001
To a solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (0.28 g, 1.4 mmol) in anhydrous DCM (10 rnL) at O0C is added the oxalyl chloride (0.18 mL, 1.4 mmol) followed by the addition of DMF (0.11 mL). The mixture is stirred at O0C for 30 min, and then allowed to warm up to rt and stirred for 30 min. The mixture is concentrated in vacuo. The residue is dissolved in anhydrous DCM (10 mL). 2-(4-Amino-piperazin-l-yl)-ethanol (0.145 g, 1 mmol) is added at rt followed by the addition of NMP (0.19 mL, 2 mmol). The mixture is stirred at rt for 2 h and the mixture is then concentrated in vacuo. The residue is triturated in Et2O and the resulting solid is collected by filtration to afford 2-(3 -fluoro-phenyO-pyrimidine- 5-carboxylic acid-[4-(2-hydroxy-ethyl)-piperazin-l-yl"|-amide (0.16 g). MS: 346 (M+H).
Example 37
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000086_0002
To a solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (0.317 g, 1.45 mmol) in anhydrous DMF (5 mL) is added 4-amino-6-methyl-4,5-dihydro-2H-[l,2,4]triazin-3-one (0.206 g, 1.45 mmol) followed by the addition of DMTMM (0.421 g, 1.52 mmol). The mixture is stirred at rt overnight. The mixture is partitioned between a saturated aqueous NaHCθ3Sθlution and EtOAc. The organic phase is separated, dried (MgSO4), filtered and concentrated in vacuo to afford 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-methyl- 3-oxo-2.5-dihvdro-3H-ri.2.41triazin-4-vn-amide (0.306 g) as a solid. MS: 329 (M+H).
Example 38 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid[5-fluoro-3-(2-hydroxy-2-methyl-propyl)- indol-1-vH -amide
Figure imgf000087_0001
Step 1 : A solution of (5-fluoro-lH-indol-3-yl)-acetic acid (1 g, 5.2 mmol) in MeOH (20 mL) is treated with sulfuric acid (20 μL) and stirred at rt for 1 h. This mixture is treated with 10% aqueous NaHCO3 (200 μL) and then concentrated in vacuo to afford (5-fluoro-lH-indol-3-yl)- acetic acid methyl ester, which is used in the next step without further purification. MS: 208 (M+H); 1H NMR (300MHz, CD3OD): δ 3.68 (s, 3H), 3.72 (s, 2H), 6.86 (m, IH), 7.16 (m, IH), 7.21 (s, IH), 7.28 (m, IH).
Step 2: The above (5-fluoro-lH-indol-3-yl)-acetic acid methyl ester is dissolved in THF (40 mL), cooled to 00C, and treated with MeMgBr (18.5 mL, 26 mmol, 1.4 M in PhMe/THF
(3:1)). The mixture is stirred at rt for 12 h. Additional MeMgBr (5 mL, 7 mmol) is added and the mixture is stirred at rt for 6 h. The mixture is poured onto ice/water, extracted with EtOAc (100 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20% - 70% EtOAc in heptane to afford l-(5-fluoro-lH- indol-3-vn-2-methyl-propan-2-ol (0.65 g, 60%). MS: 208 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.28 (s, 6H), 2.87 (s, 2H), 6.94 (m, IH), 7.14 (m, IH), 7.26-7.30 (m, 2H).
Step 3: A solution of l-(5-fluoro-lH-indol-3-yl)-2-methyl-propan-2-ol (207 mg, 1 mmol) in DMF (10 mL) is cooled to 00C, treated with NaH (600 mg, 15 mmol, 60% in mineral oil) and stirred for 30 min. H2NOSO3H (565 mg, 5 mmol) is added portion wise, and the mixture is warmed to rt over 2 h. The mixture is diluted with EtOAc (100 mL), quenched with water, extracted with EtOAc, dried (Na2SO4), filtered and concentrated in vacuo to afford 1-(1- amino-5-fluoroindol-3-yl)-2-methyl-propan-2-ol, which is used in the next step without further purification.
Step 4: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (175 mg, 0.8 mmol) in DCM (5 mL) is treated with DMF (20 μL) and ClCOCOCl (348 μL, 4 mmol), and stirred at rt for 3 h. Toluene (10 mL) is added and the mixture is concentrated in vacuo. The residue is added to a solution of the above l-(l-amino-5-fluoroindol-3-yl)-2-methyl-propan-2-ol and Na2CO3 (1 g) in EtOAc/H2O (20 mL, 1 :1). The mixture is stirred at rt for 12 h. The mixture is then diluted with saturated aqueous Na2CO3, extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% - 50% EtOAc in heptane to afford 2-(3-fluoro-phenyl)- pyrimidine-5-carboxylic acid[5 -fluoro-3 -(2-hvdroxy-2 -methyl -propyl)-indol-l-yll-amide (160 mg, 50%). MS: 423 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 1.14 (s, 6H), 2.77 (s, 2H), 7.03 (m, IH), 7.33 (s, IH), 7.35-7.55 (m, 3H), 7.65 (m, IH), 8.21 (m, IH), 8.36 (m, IH), 9.43 (s, 2H).
Example 39 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5 -fluoro-3 -(2-hydroxy-2-methyl- propyD-indol- 1 -yll -amide
Figure imgf000088_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (250 mg, 1.07 mmol) in DCM (10 mL) is cooled to 00C, treated with DMF (20 μL) and ClCOCOCl (280 μL, 3.21 mmol), and stirred for 20 min. Toluene (10 mL) is added and the mixture is concentrated in vacuo. The residue is dissolved in pyridine (10 mL) and treated with DMAP (5 mg) and 1- (l-amino-5-fluoroindol-3-yl)-2-methyl-propan-2-ol (0.72 mmol). The mixture is stirred at rt for 12 h. The mixture is diluted with saturated aqueous Na2CO3, extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20% - 60% EtOAc in heptane to afford I1 (3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(2-hvdroxy-2-methyl- propylVindol-l-yll-amide (218 mg, 70%). MS: 437 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 1.14 (s, 6H), 2.77 (s, 2H), 3.29 (s, 3H), 7.03 (m, IH), 7.37 (s, IH), 7.35-7.55 (m, 3H), 7.65 (m, IH), 8.19 (m, IH), 8.34 (m, IH), 9.22 (s, IH).
Example 40
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(2-hvdroxy-2 -methyl- propyl)-indol-l yll -amide
Figure imgf000089_0001
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (748 mg, 3.48 mmol) in DMF (30 niL) is treated with HATU (1.3 g, 3.48 mmol) and DIPEA (1.2 mL, 6.96 mmol), and the mixture is stirred at rt for 30 min. l-(l-Amino-5-fluoroindol-3-yl)-2-methyl-propan-2-ol (2.9 mmol) is added and the mixture is stirred at 800C for 12 h. The mixture is diluted with EtOAc, washed with saturated aqueous NH4Cl and saturated aqueous Na2CO3, dried (Na2SO4), filtered and concentrated in vacuo to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid [5-fluoro-3-(2-hydroxy-2-methyl-propyl)-indol-l yl] -amide (990 mg, 81%). MS: 420 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 1.13 (s, 6H), 2.75 (s, 2H), 2.85 (s, 3H), 6.84 (m, IH), 7.24 (m, IH), 7.37 (m, IH), 7.53 (m, IH), 7.95 (s, IH), 7.98 (m, IH), 8.44 (m, IH), 8.76 (m, IH), 9.15 (s, IH).
Example 41
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyano-5-fluoro-indol-l-yD- amide
Figure imgf000089_0002
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-indol-l- yl)-amide (300 mg, 0.82 mmol) in THF (8 mL) is cooled to 00C, treated with chlorosulfonyl isocyanate (86 μL, 0.99 mmol) and the mixture is stirred at rt for 1 h. The mixture is treated with Et3N (138 μL, 0.99 mmol) and stirred for 1 h. The mixture is diluted with brine, extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 25% - 35% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cvano-5-fluoro-indol-l-yr)-amide (120 mg. 38%). MS: 390 (M+H); 1H NMR (300 MHz, DMSO-de): δ 2.78 (s, 3H), 7.32 (m, IH), 7.46 (m, IH), 7.55 (m, IH), 7.66 (m, IH), 7.77 (m, IH), 8.20 (m, IH), 8.35 (m, IH), 8.65 (s, IH), 9.28 (s, IH). Example 42
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid r5-fluoro-3-(lH-tetrazol-5-yl)- indol-1-vH -amide
Figure imgf000090_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyano-5-fluoro- indol-l-yl)-amide (120 mg, 0.31 mmol), TMSN3 (62 μL, 0.465 mmol), and TBAF (0.155 μL, 0.155 mmol, 1 M in THF) in toluene (3 mL) is heated at 800C for 18 h. The mixture is cooled, diluted with EtOAc, and washed with 1 M HCl. The organic layer is extracted with Na2CO3. The aqueous layer is acidified to pH ~ 3 with 3 N aqueous HCl, extracted with
EtOAc The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3-(lH-tetrazol-5- vn-indol-1-yll-amide (100 mg, 75%). MS: 433 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.81 (s, 3H), 7.28 (m, IH), 7.47 (m, IH), 7.67 (m, IH), 7.73 (m, IH), 8.01 (m, IH), 8.21 (m, IH), 8.33 (m, IH), 8.36 (s, IH), 9.33 (s, IH). IC50 = 5 nM.
Example 43
2- Phenyl-pyrimidine-5-carboxylic acid [1,2,41 triazol-4-ylamide
Figure imgf000090_0002
To a solution of 2-phenyl-pyrimidine-5-carboxylic acid (300 mg, 1.5 mmol) in DCM (10 mL) is added l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (316mg, 1.65 mmol) and N- hydroxybenzotriazole (223 mg, 1.65 mmol) at rt and the mixture is stirred for 10 min. 4- Amino-4H-l,2,4-triazole (252 mg, 3 mmol) is added and the mixture is stirred at rt for 3 days. The resulting precipitate is filtered, washed with DCM and water, and dried in vacuum oven at 400C overnight to afford 2- phenyl-pyrimidine-5-carboxylic acid [1,2,4] triazol-4-ylamide (270 mg) as a solid. MS: 267 (M+H); 1U NMR (300 MHz, DMSO): δ = 7.59 (m, 3H), 8.50 (d, 2H), 8.84 (s, 2H), 9.36 (s, 2H). IC50 = 262.5 nM.
Example 44
2-phenyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide
Figure imgf000091_0001
Method A: To a solution of 2-phenyl-pyrimidine-5-carboxylic acid (150 mg, 075 mmol) in DCM (10 mL) is added l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (158 mg, 0.83 mmol) and N-hydroxybenzotriazole (112 mg, 0.83 mmol) at rt and the mixture is stirred for 10 min. 1-Aminopiperidine (150 mg, 1.5 mmol) is added. The mixture is stirred at rt overnight. The mixture is washed with 2 N aqueous HCl (5 mL), saturated aqueous NaHCO3, (5 mL), and water (5 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% EtOAc in heptane to afford 2-phenyl- pyrimidine-5-carboxylic acid piperidin-1-ylamide (125 mg) as a solid. MS: 290 (M+H).
Method B: Following procedures similar to those of Example 127 but substituting piperadin- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid piperadin-1-yl-amide (72%) as a solid. MS: 283 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.35-1.98 (m, 6H), 2.20-3.60 (m, 4H), 6.60-7.17 (d, N-H), 7.52 (s, 3H), 8.52 (s, 2H), 9.07-9.39 (d, 2H).
Example 45
2-Phenyl-pyrimidine-5-carboxylic acid N'-(2-fluoro-phenyl)-hvdrazide
Figure imgf000091_0002
Following procedures similar to those of Example 44, but substituting (2-fluoro-phenyl)- hydrazine for 1-aminopiperidine, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'- (2-fluoro-phenvn-hvdrazide as a solid. MS: 309 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.68 (broad, IH), 6.87 (m, IH), 7.04 (m, 3H), 7.51 (m, 3H), 8.51 (m, 2H), 9.36 (s, 2H), 10.65 (broad, IH). IC50 = 12 nM.
Example 46 2-Phenyl-pyrimidine-5 -carboxylic acid N ' -ethyl-N ' -tolyl-hydrazide
Figure imgf000092_0001
Following procedures similar to those of Example 44, but substituting N-ethyl-N-para-tolyl- hydrazine for 1-aminopiperidine, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'- ethyl-N'-toryl-hvdrazide as a solid. MS: 333 (M+H); 1H NMR (300 MHz, CDCl3): δ = 0.87 (t, IH), 1.11 (t, 2H), 1.28 (t, 3H), 2.28 (d, 3H), 3.46 (q, IH), 3.65(q, IH), 6.84 (d, IH), 6.94( d, IH), 7.10( t, 2H), 7.52 (m, 3H), 8.47 (m, 2H), 9.12 (s, IHO, 9.23 (s, IH).
Example 47 2-Phenyl-pyrimidine-5-carboxylic acid (3-oxo-morpholin-4-yl)-amide
Figure imgf000092_0002
Following procedures similar to those of Example 44, but substituting 4-amino-morpholin-3- one for 1-aminopiperidine, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (3-oxo- morpholin-4-viyamide as a solid. MS: 299 (M+H); 1H NMR (300 MHz, DMSO): δ = 3.66 (m, 2H), 4.00 (m, 2H), 4.26 (s, 2H), 7.60 (m, 3H), 8.47 (m, 2H), 9.29(s, 2H), 11.27 (s, IH). IC50 = 55 nM.
Example 48
2-(5 -Methyl- r 1 ,2,41oxadiazol-3-yl)-pyrimidine-5-carboxylic acid r4-(2-hvdroxy-ethyl)- piperazin- 1 -yl] -amide
Figure imgf000093_0001
Step 1 : To a solution of 2-methylsulfanyl-pyrimidine-5-carboxylic acid methyl ester 1 (1 g, 5.43 mmol) in DCM (60 mL) is added MCPBA (2.81 g, 16.29 mmol) portion wise at rt. The resulting solution is stirred at rt overnight. A solution OfNa2S2O3 (1.6 g) in water (60 mL) is added. The mixture is stirred at rt for 20 min. The layer is separated, and the water layer is extracted with DCM (2x20 mL). The combined DCM layer is washed with saturated NaHCO3 (3x20 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford 2=. methanesulfonyl-pyrimidine-S-carboxylic acid methyl ester as a solid (1.05 g, 90%). MS: 217 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.41 (s, 3H), 4.06 (s, 3H), 9.44 (s, 2H).
Step 2: To a solution of 2-methanesulfonyl-pyrimidine-5-carboxylic acid methyl ester 2 (2.5 g, 11.56 mmol) in DCM (30 mL) is added a solution of tetrabutylammonium cyanide (3.1 g, 11.56 mmol) in water (30 mL) slowly at rt. The mixture is stirred for 80 min. The mixture is washed with water (2x20mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by column chromatography eluting with 5-60% EtOAc in heptane to afford 2-cyano-pyrimidine-5-carboxylic acid methyl ester (1.16 g, 61%) as a solid. MS: 164 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.05 (s, 3H), 9.37 (s, 2H).
Step 3: To a solution of 2-cyano-pyrimidine-5-carboxylic acid methyl ester 3 (1 g, 6.13 mmol) in MeOH (20 mL) at rt is added hydroxylamine hydrochloride (0.64g, 9.2mmol) and sodium acetate (0.76 g, 9.2 mmol). The resulting mixture is heated to reflux for 2 hours. The mixture is cooled to rt and concentrated in vacuo. Water (30 mL) is added to the residue, and the solid is filtered, and washed with water twice. The solid is dried in vacuum oven overnight to afford 2-(N-hvdroxycarbamimidoyl)-pyrimidine-5-carboxylic acid methyl ester (1.09 g, 91%) as a solid. MS: 197 (M+H).
Step 4: To a solution of 2-(N-hydroxycarbamimidoyl)-pyrimidine-5-carboxylic acid methyl ester (900 mg, 4.59 mmol) in pyridine (15 mL) is added acetyl chloride (432 mg, 5.5 mmol) dropwise. The resulting solution is stirred at rt for 1 hour, and heated to reflux for 3h. The solution is cooled to rt and concentrated in vacuo. Water (30 mL) is added to the residue, and the mixture is extracted with EtOAc (3x20 mL). The combined organic layer is washed with saturated NaHCθ3, dried (Na2SO4), filtered and concentrated in vacuo to afford 2-(5-methyl- [l,2,31oxadiazo-3-yl)-pyrimidine-5-carboxylic acid methyl ester (900 mg, 89%) as a solid. MS: 221 (M+H).
Step 5: To a solution of 2-(5-methyl-[l,2,3]oxadiazo-3-yl)-pyrimidine-5-carboxylic acid methyl ester (900 mg) in MeOH (20 mL) is added a solution of LiOH (100 mg) in water (20 mL) at O0C. The ice-bath is removed, and the mixture is stirred for another 10 min. The solvent is evaporated, and water (20 mL) is added. The water solution is washed with ether (2x20mL), and acidified with 2 N HCl to pH ~ 3. The resulting precipitate is filtered, washed with water and dried in vacuum oven overnight to afford 2-(5-methyl-|"l,2,4"|oxadiazol-3-yl)- pyrimidine-5-carboxylic acid (350 mg, 37%) as a solid. MS: 207 (M+H); 1H NMR (300 MHz, DMSO-de): δ 2.73 (s, 3H), 9.39 (s, 2H).
Step 6: Following procedures similar to those of Example 44, but substituting 2-(5-methyl- [l,2,4]oxadiazol-3-yl)-pyrimidine-5-carboxylic acid for 2-phenyl-pyriminde-5-carboxylic acid, and substituting 2-(4-amino-piperazin-l-yl)-ethanol for 1-aminopiperidine, there is prepared 2-(5 -methyl- 1" 1 ,2,41oxadiazol-3-yl)-pyrimidine-5-carboxylic acid [4-(2-hvdroxy- ethyQ-piperazin- 1 -yll-amide as a solid. MS: 334 (M+H). IC50 = 461 nM.
Example 49
2-(5-Methyl-[ 1 ,2,41oxadiazol-3-yl)-pyrimidine-5-carboxylic acid morpholin-4-ylamide
Figure imgf000094_0001
Following procedures similar to those of Example 44, but substituting 2-(5-methyl- [l,2,4]oxadiazol-3-yl)-pyrimidine-5-carboxylic acid for 2-phenyl-pyriminde-5-carboxylic acid, and substituting morpholine-4-ylamine for 1-aminopiperidine, there is prepared 2-(5- methyl-F 1 ,2,4"|oxadiazol-3-yl)-pyrimidine-5-carboxylic acid morpholin-4-ylamide as a solid. MS: 291 (M+H).
Example 50 2-Benzoyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide
Figure imgf000095_0001
Step 1 : 5-Bromo-2-chloropyrimidine (7.51 g, 38.83 mmol) is dissolved in DMSO (20 niL) is added to a mixture of NaCN (1.9 g, 38.83 mmol) and l,4-diazabicyclo[2,2,2]octane (0.87 g, 7.77 mmol) in DMSO (10 mL) and water (20 mL). The mixture is stirred at rt overnight, and then water (100 mL) is added. The mixture is extracted with ether (3x100 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 5_; bromo-pyrimidine-2-carbonitrile (6.28 g, 88%) as a solid. MS: 184 (M+H).
Step 2: 5-Bromo-pyrimidine-2-carbonitrile(2.5 g, 13.59 mmol) is dissolved ether (30 mL), and PhMgBr (3 ether solution, 13.59 mmol, 4.53 mL) is added dropwise at rt. The mixture is heated to reflux for 3 h under N2, and then cooled to rt. THF (30 mL) is added followed by the addition of 2 N aqueous HCl (10 mL). The resulting solution is stirred at rt for 30 min, and water (30 mL) is added. The aqueous layer is extracted with EtOAc (3x20 mL). The combined organic layer is washed with saturated aqueous NaHCO3 (15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting 70% EtOAc in heptane to afford (5-bromo-pyrimidine-2-yl)-phenyl-methanone (3.01 g, 84%) as a solid. MS: 264 (M+H).
Step 3: (5-Bromo-pyrimidine-2-yl)-phenyl-methanone (1.6 g, 6.08 mmol) is dissolved in dimethylacetamide (20 mL), and potassium hexacyanoferrate(II) trihydrate (0.57 g, 1.34 mmol) is added, followed by Na2CO3 (0.64 g, 6.08 mmol), and palladium (II) acetate (68 mg, 0.3 mmol). The mixture is heated to 1500C under N2 for 3 h, and then cooled to rt. EtOAc (30 mL) is added and the mixture is filtered. The filtrate is washed with water (2 x15 mL) and 5% aqueous NH4OH (15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 70% EtOAc in heptane to afford 2-benzoyl-pyrimidine-5-carbonitrile (0.53 g, 42%) as a solid. MS: 210 (M+H).
Step 4: 2-Benzoyl-pyrimidine-5-carbonitrile (500 mg, 2.39 mmol) is suspended in MeOH (5 mL), a solution of KOH (148 mg, 2.63 mmol) in water (5 mL) is added in one portion at 00C. The mixture is stirred at 00C for 25 min, and then acidified with 2 N aqueous HCl to pH ~ 3. MeOH is evaporated in vacuo and the residue is extracted with DCM (2x 5 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 2=. benzoyl-pyrimidine-5-carboxylic acid methyl ester (500 mg, 86%) as an oil. MS: 243 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.05 (s, 3H), 7.50 (m, 2H), 7.65 (m, IH), 8.01 (m, 2H), 9.46 (s, 2H).
Step 5: 2-Benzoyl-pyrimidine-5-carboxylic acid methyl ester (420 mg, 1.73 mmol) is dissolved in THF (5 mL), and a solution of LiOH (46 mg, 1.91 mmol) in water (5 mL) is added in one portion at 00C. The mixture is stirred at 00C for 60 min. THF is evaporated in vacuo, and the residue is diluted with water (5 mL) and washed with ether (10 mL). The aqueous layer is acidified with 2 N aqueous HCl to pH ~ 3. The resulting precipitate is collected by filtration, washed with water three times, and dried in vacuum oven overnight to afford 2-benzoyl-pyrimidine-5-carboxylic acid (260 mg, 66%). MS: 229 (M+H); 1H NMR (300 MHz, DMSO): δ 7.60 (m, 3H), 7.73 (m, IH), 7.85 (m, 2H), 9.4 (s, IH).
Step 6: 2-Benzoyl-pyrimidine-5-carboxylic acid (50 mg, 0.22 mmol) is dissolved in anhydrous DCM (5 mL), and a 2 M oxalyl chloride (0.26 mmol, 0.13 mL) solution in DCM is added at rt followed by one drop of DMF. The mixture is stirred at rt for 2 h, and then concentrated in vacuo. The residue is dissolved in DCM (5 mL), and morpholine-4-ylamine (0.24 mmol, 25 mg) is added, followed by DIPEA (0.44 mmol, 57 mg). The reaction mixture is stirred at rt overnight, and then concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with 10% MeOH in DCM to afford 2-benzoyl-pyrimidine-5 - carboxylic acid morpholin-4-ylamide (42 mg) as a solid. MS: 313 (M+H). IC50 = 342 nM.
Example 51
2-Benzoyl-pyrimidine-5-carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yl"|-amide
Figure imgf000096_0001
Following procedures similar to those of Example 49, step 6, but substituting 2-(4-amino- piperazin-l-yl)-ethanol for morpholine-4-ylamine, there is prepared 2-benzoyl-pyrimidine-5 - carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yll -amide as a solid. MS: 356 (M+H). IC50 = 665 nM.
Example 52 2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - [5 -trifluoromethyl-pyridin-2-yl"|- hydrazide
Figure imgf000097_0001
To a solution of 2-phenyl-pyrimidine-5 -carboxylic acid (100 mg, 0.52 mmol), 1- hydroxybenzotriazole (77 mg, 0.57 mmol), l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (111 mg, 0.57mmol) and DIPEA (0.57 mmol) in DCM (5 mL) is added N-methyl-N-(5- trifluoromethyl-pyridin-2-yl)-hydrazine (109 mg, 0.57 mmol). The reaction mixture is stirred at rt for 18 hours and then concentrated. The residue is purified by silica gel chromatography eluting with 10-75% EtOAc in heptane to afford 2-phenyl-pyrimidine-5-carboxylic acid N'- methyl-N ' - [5 -trifluoromethyl-pyridin-2-vH -hydrazide as a solid (189mg). MS: 374 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.54 (s, 3H), 6.82 (d, IH), 7.53-7.59 (m, 3H), 7.74 (d, IH), 8.45 (d, 2H), 8.53 (d, 2H), 9.25 (s, 2H). IC50 = 100 nM.
Example 53
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - r4-trifluoromethyl-pyridin-2-yll- hydrazide
Figure imgf000097_0002
Following procedures similar to those of Example 52, but substituting N-methyl-N-(4- trifluoromethyl-pyridin-2-yl)-hydrazine (109mg, 0.57 mmol) for N-methyl-N-(5- trifluoromethyl-pyridin-2-yl)-hydrazine, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'-methyl-N'-r4-trifluoromethyl-pyridin-2-yl1-hvdrazide as a solid. MS: 374 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.54 (s, 3H), 6.95 (m, 2H), 7.50-7.68 (m, 3H), 8.35 (d, IH), 8.4 (s, IH), 8.52 (d, 2H), 9.26 (s, 2H).
Example 54 2-Phenyl-pyrimidine-5-carboxylic acid N'-pyridin-2-yl-hydrazide
Figure imgf000098_0001
Following procedures similar to those of Example 52, but substituting 2-hydrazinopyridine (54 mg, 0.52 mmol) for N-methyl-N-(5-trifluoromethyl-pyridin-2-yl)-hydrazine, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'-pyridin-2-yl-hydrazide as a solid (56 mg). MS: 292 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 6.72-6.8 (m, 2H), 7.53-7.62 (m, 4H), 8.09 (m, 2H), 8.48 (d, 2H), 8.62 (s, IH), 9.34 (s, 2H).
Example 55 2-Phenyl-pyrimidine-5-carboxylic acid N'-(2-chloro-phenyl)-hydrazide
Figure imgf000098_0002
Following procedures similar to those of Example 52, but substituting 2- chlorophenylhydrazine hydrochloride (93mg, 0.52mmol) for N-methyl-N-(5-trifluoromethyl- pyridin-2-yl)-hydrazine, and using 1.14 mmol of DIPEA, there is prepared 2-phenyl- pyrimidine-5-carboxylic acid N'-(2-chloro-phenyl)-hydrazide as a solid (65mg). MS: 325 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.65-6.75 (m, 2H), 6.90-7.05 (m, 2H), 7.25 (t, IH), 7.39 (d, IH), 7.58 (m, 3H), 8 (s, IH), 8.55 (d, 2H), 9.25 (s, 2H).
Example 56
2-Phenyl-pyrimidine-5-carboxylic acid N'-(2-oxo-prperidin-l-yl)-amide
Figure imgf000099_0001
Step 1 : A mixture of Methyl-5-bromovalerate(3 g, 15.4 mmol) and hydrazine hydrate (55%, 15.4 mmol) in MeOH (50 mL) is stirred at rt for 18 h. A solution of NaOMe (15.4 mmol) in MeOH (10 mL) is added and the reaction mixture is stirred at rt for 18 h. The reaction mixture is concentrated in vacuo. The residue is triturated with cold MeOH and then filtered. The filtrate is concentrated in vacuo. The residue is placed on a SCX column (10 g) and the column is washed with MeOH (3x20 mL. The product is eluted with 7 M ammonia in MeOH to afford 1 -amino-piperidin-2-one as an oil. MS: 137 (M+Na).
Step 2: To a solution of 2-phenyl-pyrimidine-5-carboxylic acid (100 mg, 0.52 mmol), 1- hydroxybenzotriazole (77 mg, 0.57 mmol), l-[3-(dimethylamino)propyl-3-ethylcarbodiimide (111 mg, 0.57 mmol) and DIPEA (0.57 mmol) in DCM (5 mL) is added l-amino-piperidin-2- one (64 mg, 0.57 mmol), and the mixture is stirred at rt for 18 h. DCM (15 mL) is added and the mixture is washed with 0.5 N aqueous HCl (25 mL) and brine, and dried (Na2SO4.), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography through eluting with 50-100% EtOAc in heptane to afford 2-phenyl-pyrimidine-5 -carboxylic acid N'-(2-oxo-piperidin-l-yl)-amide (20 mg) as a solid. MS: 297 (M+H); 1U NMR (300 MHz, CDCl3): δ 1.96-2.10 (m, 4H), 2.60 (t, 2H), 3.77 (t, 2H), 7.51-7.56 (m, 3H), 8.51 (d, 2H), 9.02 (bs, IH), 9.16 (s, 2H). IC50 = 55 nM.
Example 57
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -cyclohexyl-N ' -methyl-hydrazide
Figure imgf000099_0002
Following procedures similar to those of Example 52, but substituting N-methyl-N- cyclohexyl-hydrazine hydrochloride (72 mg, 0.44 mmol) for N-methyl-N-(5-trifluoromethyl- pyridin-2-yl)-hydrazine, and using 0.88 mmol of DIPEA, there is prepared 2-phenyl- pyrimidine-5-carboxylic acid N'-cyclohexyl-N'-methyl-hydrazide as a solid (40 mg). MS: 311 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 0.9-1.35 (m, 5H), 1.60-1.95 (m, 6H), 3.25 (s, 3H) 7.53-7.62 (m, 3H), 8.09 (m, 2H), 9.09 (s, 2H). IC50 = 146.5 nM.
Example 58
2-Phenvoxy-pyrimidine-5 -carboxylic acid N'-morpholin-4-yl-amide
Figure imgf000100_0001
Step 1 : To a solution of 2-methylsulfanyl-pyrimidine-5-carboxylic acid methyl ester (I g, 5.43 mmol) in DCM (60 mL) is added MCPBA (2.81 g, 16.29 mmol) portion wise at rt. The resulting solution is stirred at rt overnight. A solution OfNa2S2O3 (1.6 g) in water (60 mL) is added. The mixture is stirred at rt for 20 min. The organic layer and aqueous layer are separated, and the aqueous layer is extracted with DCM (2x20 mL). The combined organic layer is washed with saturated aqueous NaHCO3 (3x20 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford 2-methanesulfonyl-pyrimidine-5-carboxylic acid methyl ester (1.05 g, 90%) as a solid. MS: 217 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.41 (s, 3H), 4.06 (s, 3H), 9.44 (s, 2H).
Step 2: To a solution of 2-methanesulfonyl-pyrimidine-5-carboxylic acid methyl ester (0.8 g, 3.7 mmol) in NMP (3 mL) is added sodium phenoxide trihydrate (0.68 g, 4 mmol). The mixture is heated at 1000C in Biotage Microwave for 60 sec. The reaction is poured into water and the precipitate is collted by filtration and dried to afford 2-phenoxy-pyrimidine-5 - carboxylic acid methyl ester (0.56g, 66%) as a solid. MS: 231 (M+H); 1U NMR (300 MHz, CDCl3): δ 4.75 (s, 3H), 7.19-7.33 (m, 3H), 7.46 (t, 2H) 9.10 (s, 2H).
Step 3: To a solution of 2-phenoxy-pyrimidine-5-carboxylic acid methyl ester (0.5 g, 2.17 mmol) in THF (10 mL) and water (5 mL) is added LiOH (105 mg, 4.35 mmol). The reaction is stirred at O0C for 1 h. The THF is evaporated and the aqueous reissue is washed with ether, acidified with 2 M aqueous HCl. The resulting precipitate is filtered and dried to afford I1 phenoxy-pyrimidine-5 -carboxylic acid (0.34g, 73%) as a solid. MS: 217 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.20-7.35 (m, 3H), 7.47 (t, 2H) 9.16 (s, 2H). Step 4: To a solution of 2-phenoxy-pyrimidine-5-carboxylic acid (60 mg, 0.28 mmol) in DCM (5 niL) is added oxalyl chloride (2M in DCM, 0.15 rnL, 0.29 mmol) and 1 drop of DMF. The reaction is stirred at rt for 1 h and concentrated in vacuo. The residue is dissolved in DCM (3 mL), and DIPEA (53 μL, 0.3 mmol) and 4-amino-morpholine (30 μL, 0.3 mmol) is added. The reaction is stirred at rt for 18 h and then water and DCM are added. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20-100% EtOAc in heptane to afford 2-phenvoxy- pyrimidine-5-carboxylic acid N'-morpholin-4-yl-amide (20 mg) as a solid. MS: 301 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.85-3.05 (m, 4H), 3.75-3.95 (m, 4H), 7.18-7.35 (m, 3H), 7.45 (t, 2H), 8.95 (s, 2H). IC50 = 227 nM.
Example 59
2-(3-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000101_0001
Step 1 : 2-Methylsulfanyl-pyrimidine-5-carboxylicacid methyl ester (323 mg, 1.75 mmol), Copper(I)thiophene-2-carboxylate (501 mg, 2.63 mmol), tetrakis(triphenylphosphine) palladium(O) (202 mg, 0.175 mmol) and 3-methoxyphenylboronic acid (400 mg, 2.63 mmol) are taken in a glass tube, evacuated, refilled with N2, added anhydrous THF (6 mL) and is heated overnight at 85°C after closing with a cap. The reaction is cooled to rt, diluted with EtOAc and ammonium hydroxide is added. The organic layer is seperated, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by flash silica gel chromatography to afford 2-(3-methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester (152 mg) as a powder. MS: 245 (M+H); 1H NMR (CDCl3): δ 4.00 (s, 3H), 4.82 (d, 2H), 7.55 (m, 2H), 8.46 (m, IH), 8.53 (s, IH), 9.33 (s, 2H).
Step 2: A mixture of 2-(3-methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester (145 mg, 0.59 mmol), lithium hydroxide monohydrate (49.5 mg, 1.18 mmol), MeOH (1.5 mL), water (1.5 mL) and THF (1.5 ml) is stirred at rt for 3.5 hrs. Ther eaction mixture is concentrated, and water (1 rnL) and 1 N aqueous HCl (1.2 rnL) are added. The precipitated product is filtered and dried to afford 2-(3 -methoxy-phenyl)-pyrimidine-5 -carboxylic acid (140 mg). MS: 231 (M+H); 1H NMR (DMSO-d6): δ 4.62 (s, 3H), 7.54 (m, 2H), 8.14 (s, IH), 8.34 (m, IH), 8.46 (s, IH), 9.30 (s, 2H).
Step 3: A mixture of 2-(3-methoxy-phenyl)-pyrimidine-5 -carboxylic acid (135 mg, 0.58 mmol), 4-amino-6-methyl-4,5-dihydro-2H-[l,2,4]triazin-3-one (76 mg, 0.58 mmol), DMTMM (171 mg, 0.6 mmol) and DMF (3 mL) is stirred at rt for 2 days. Water (3 ml) is added, and the precipitated product is filtered, washed with water and dried to afford 2-(3- methoxy-phenvO-pyrimidme-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1.2.41triazin-4-yl)-amide (127 mg). MS: 341 (M+H); 1H NMR (DMSO-d6): δ 1.91 (s, 3H), 4.23 (s, 3H), 4.62 (s, 2H), 7.53 (m, 2H), 8.34 (m, IH), 8.46 (s, IH), 9.27 (s, 2H), 9.97 (s, IH), 11.08 (s, IH). IC50 = 174.5 nM.
Example 60
2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-3-oxo-2,5-dihydro-3H-l ,2,4-triazine-4- vD-amide
Figure imgf000102_0001
Step 1 : To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (5.509 g, 55.0 mmol) in MeOH (40 mL) is added 25wt % NaOMe solution in methanol (12.7 mL, 58.8 mmol). The mixture is stirred at rt for 15 min and then concentrated in vacuo. The residue is added to a solution of tetrabutylammonium bromide (0.358 g, 1.08 mmol) and chloro-acetone (4.6 ml, 54.9 mmol) in CHCI3 (33 mL), and the mixture is heated to reflux for 5 h under N2. The mixture is cooled to rt and stirred overnight. The resulting slurry is filtered, and the filtrate is concentrated in vacuo. The residue is purified on a pad of silica gel, eluting with 2:1 :1 / heptane:EtOAc:DCM to afford 5-methyl-3-(2-oxo-propyl)-3H-l,3,4-oxadiazol-2-one (7.32 g, 86%) as a crystalline solid. MS: 157 (M+H); 1H NMR (300 MHz, CDCl3) δ 4.46 (s, 2H), 2.27 (s, 3H), 2.21 (s, 3H).
Step 2: To a solution of 5-methyl-3-(2-oxo-propyl)-3H-l,3,4-oxadiazol-2-one (1.518 g, 9.72 mmol) in a mixture of 2-propanol (8.8 rnL) and water (0.22 rnL) is added methyl hydrazine (0.79 mL, 14.6 mmol). The reaction mixture is heated to reflux under N2 for 4 h, and then a solution of oxalic acid (0.273 g, 2.92 mmol) in 2-propanol (4 mL) is added. The resulting precipitate is removed by filtration. The filtrate is concentrated in vacuo and the residue dissolved in 2-propanol (25 mL). The solution is chilled and Et2O is added. The precipitate is collected by filtration and dried to afford N-(2,6-dimethyl-3-oxo-2,5-dihydro-3H-l,2,4-triazin- 4-ylVacetamide (0.96 g, 54%) as a crystalline solid. MS: 185 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 8.28 (s, IH), 4.18 (s, 2H), 3.28 (s, 3H), 2.02 (s, 3H), 1.95 (s, 2H).
Step 3: To a slurry of N-(2,6-dimethyl-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl)-acetamide (0.34 g, 1.846 mmol) in MeOH (3 mL) is added concentrated HCl (0.25 mL, 2.9 mmol). The mixture is heated to reflux for 3 h. The mixture is then chilled to O0C, adjusted to pH ~ 12 with 1 M aqueous NaOH (2.9 mL) and concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo to afford 4-amino-2.6-dimethyl-4.5-dihvdro-2H- 1.2.4-triazin-3-one (-100%)). MS: 143 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 4.6-3.6 (broad peak, 2H), 4.02 (s, 2H), 3.29 (s, 3H), 1.95 (s, 3H).
Step 4: To a solution of 4-amino-2,6-dimethyl-4,5-dihydro-2H-l,2,4-triazin-3-one (0.219g, 1.58 mmol) and 2-phenyl-pyrimidine-5-carboxylic acid (0.317 g, 1.58 mmol) in dry DMF (10 mL) under N2 is added DMTMM (0.46 g, 1.66 mmol). The mixture is stirred at rt for 22 h, then diluted with EtOAc (70 mL), and washed successively with saturated aqueous NaHCθ3 solution (2x10 mL) and brine (10 mL). The organic phase is dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with heptane :EtO Ac gradient to afford 2-phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-3- oxo-2.5-dihydro-3H- 1.2.4-triazin-4-yl)-amide as a solid (0.28 g, 55%). MS: 325 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 9.24 (s, 2H), 8.45 (dd, J=7.7, 2.0 Hz, 2 H), 7.52-7.62 (m, 3H), 4.25 (s, 2H), 3.18 (s, 3H), 1.95 (s, 3H).
Example 61
2-Phenyl-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazine-4- vD-amide
Figure imgf000104_0001
Step 1 : To a solution of 5-methyl-3H-l,3,4-oxadiazol-2-one (1.01 g, 10.09 mmol) in MeOH (8 niL) is added 25 wt % NaOMe solution in methanol (2.32 niL, 10.8 mmol). The mixture is stirred at rt forl5 min and then concentrated in vacuo. The residue is added to a solution of tetrabutylammonium bromide (0.07 g, 0.22 mmol) and 1-chloropinacolone (1.35 mL, 10.07 mmol). in CHCI3 (7 mL), and the mixture is heated to reflux for 5 h under N2. The mixture is cooled to rt and stirred over the weekend at rt. The resulting slurry is filtered, and the filtrate is concentrated in vacuo to afford 3-(3,3-dimethyl-2-oxo-butyl)-3H-l,3,4-oxadiazol-2-one (1.876 g, 94%) as an oil. MS: 199 (M+H); 1H NMR (300 MHz, CDCl3) δ 4.62 (s, 2H), 2.26 (s, 3H), 1.23 (s, 9H).
Step 2: To a solution of 3-(3,3-dimethyl-2-oxo-butyl)-3H-l,3,4-oxadiazol-2-one (0.91 g, 4.59 mmol) in a mixture of 2-propanol (4 mL) and water (0.1 mL) is added hydrazine monohydrate (0.34 mL, 6.89 mmol). The reaction mixture is heated to reflux under nitrogen for 5 h, then a solution of oxalic acid (0.13 g, 1.38 mmol) in 2-propanol (5 mL) is added to the hot solution. The resulting precipitate is removed hot by filtration. The filtrate is concentrated in vacuo and the residue is purified on a pad of silica gel, eluting with heptane :EtO Ac gradient to afford N- (6-tert-bu1yl-3-oxo-2.5-dihvdro-3H-1.2.4-triazin-4-yl)-acetamide (0.546 g, 56%) as a solid. MS: 213 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 8.29 (s, IH), 7.64 (s, IH), 4.22 (s, 2H), 2.04 (s, 3H), 1.15 (s, 9H).
Step 3: To a slurry of N-(6-tert-butyl-3-oxo-2,5-dihydro-3H-l,2,4-triazin-4-yl)-acetamide (0.51 g, 2.40 mmol) in MeOH (5 mL) is added concentrated HCl (0.33 mL, 3.84 mmol). The mixture is heated to reflux for 3 h. The mixture is then chilled to O0C and basified with 1 M aqueous NaOH (2.9 mL) to pH ~ 12, and concentrated in vacuo. EtOH is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo. CH3CN is added to the residue with stirring and the mixture is filtered. The filtrate is concentrated in vacuo to afford 4-amino-6-tert-butyl-4,5-dihvdro-2H- 1 ,2,4-triazin-3-one (0.354 g, 84%) as a solid. MS: 171 (M+H); 1H NMR (300 MHz, DMSO-d6) δ 7.49 (br s, IH), 4.22 (br s, 2H), 4.06 (s, 2H), 1.15 (s, 9H).
Step 4: Following the procedure similar to those of Example 60, step 4, but substituting A- amino-6-tert-butyl-4,5-dihydro-2H-l ,2,4-triazin-3-one for 4-amino-2,6-dimethyl-4,5-dihydro- 2H- 1 ,2,4-triazin-3-one, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (6-tert-butyl- 3-oxo-2.5-dihvdro-3H-1.2.4-triazin-4-yl)-amide (74%) as a solid. MS: 353 (M+H); 1H NMR (300 MHz, DMSO-de) δ 11.09 (s, IH), 10.03 (s, IH), 9.27 (s, 2H), 8.45 (dd, J=7.7, 2.0 Hz, 2 H), 7.52-7.60 (m, 3H), 4.29 (s, 2H), 1.13 (s, 9H).
Example 62
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- 1 ,2,4-triazine- 4-vD-amide
Figure imgf000105_0001
Step 1 : To a solution of 5-methyl-3-(2-oxo-propyl)-3H-l,3,4-oxadiazol-2-one (2.052 g, 13.14 mmol) in a mixture of 2-propanol (12 mL) and water (0.3 mL) is added hydrazine monohydrate (0.96 mL, 19.8 mmol). The mixture is stirred at rt under N2 for 15 h, and then heated to reflux for 7 h. A solution of oxalic acid (0.363 g, 4.032 mmol) in 2-propanol (6 mL) is added to the warm reaction solution. The resulting precipitate is removed by filtration through a coarse porosity sintered glass funnel, and the filtrate is concentrated in vacuo to approximately 10 mL in total volume. The concentrated solution is chilled to -12°C , and the resulting crystals are collected by filtration and dried to afford N-(6-methyl-3-oxo-2,5- dihvdro-3H- 1.2.4-triazin-4-ylV acetamide (1.562 g, 70%). MS: 171 (M+H); 1H NMR (300 MHz, CDCl3) δ 8.10 (br s, IH), 7.57 (br s, IH), 4.20 (s, 2H), 2.04 (s, 3H), 1.95 (s, 3H); 1H NMR (300 MHz, DMSO-d6) δ 9.98 (s, 1), 9.74 (s, 1), 4.04 (s, 2), 1.84 (s, 6).
Step 2: Following the procedure similar to those of Example 35, step 4, but substituting N-(6- methyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazin-4-yl)-acetamide for N-[6-(4-fluoro-phenyl)-3-oxo- 2,5-dihydro-3H-l,2,4-triazin-4-yl]-acetamide, there is prepared 4-amino-6-methyl-4,5- dihvdro-2H- 1.2.4-triazin-3-one (92%) as a solid. MS: 129 (M+H); 1H NMR (300 MHz, CD3CN) δ 8.25 (br s, IH), 4.26 (br s, 2H), 3.96 (s, 2H), 1.85 (s, 3H).
Step 3: To a solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (0.152 g, 0.75 mmol), in dry DCM (3 mL) and DMF (0.9 μL) in a dry flask under N2 is added oxalyl chloride (74 μL, 0.86 mmol). The reaction mixture is stirred at rt for 1 h. The solvent is evaporated and toluene is added and evaporated three times. The residue is dissolved in dry DCM (3 mL), and a solution of 4-amino-6-methyl-4,5-dihydro-2H-l,2,4-triazin-3-one (0.77 g, 0.6 mmol) in DCM (5 mL) is added followed by the addition of DIPEA (0.14 mL, 0.79 mmol). The mixture is stirred at rt overnight, and then concentrated in vacuo. The residue is diluted with water and adjusted to pH ~ 8.5 with saturated aqueous NaHCO3 solution. The resulting precipitate is filtered to afford 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo- 2,5-dihydro-3H- 1 ,2,4-triazine-4-vnamide (0.043 g, 23%). MS: 312 (M+H); 1H NMR (300 MHz, DMSO-de) δ 11.11 (s, IH), 9.95 (s, IH), 9.31 (s, 2H), 8.78 (d, IH), 8.45 (d, IH), 8.01 (tr, IH), 7.58 (dd, IH), 4.22 (2, 2H), 1.91 (s, 3H).
Example 63
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazine-4-vD-amide
Figure imgf000106_0001
Following the procedure similar to those of Example 62, step 3, but substituting 2-(3-Fluoro- phenyl)-pyrimidine-5-carbonyl chloride for 2-pyridin-2-yl-pyrimidine-5-carbonyl chloride, substituting 4-amino-6-tert-butyl-4,5-dihydro-2H-l,2,4-triazin-3-one for 4-amino-6-methyl- 4,5-dihydro-2H-l,2,4-triazin-3-one, and substituting Et3N for DIPEA, there is prepared 2-(3- fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazine-4-vn-amide (0.067 g, 61%). MS: 371 (M+H); 1H NMR (300 MHz, CD3OD) δ 9.26 (s, 2H), 8.35 (d, J=8.1 Hz, IH), 8.21 (d, J=10.3 Hz), 7.55 (q, J=10.3 Hz, 1 H), 7.30 (tr, J=8.2 Hz, IH), 4.37 (s, 2H), 1.19 (s, 9H).
Example 64 S-llΛ-Dioxo-S-ffl-pheyl-pyrimidine-S-carbonyπ-aminol-LlJΛ-tetrahydro-pyrimidin-S-yU- propionic acid methyl ester
Figure imgf000107_0001
A mixture of 2-phenyl-pyrimidine-5-carboxylic acid (1.17 mmol), 1-hydroxybenzotriazole (1.99 mmol), and PS-DCC (1.21 mmol/g, 2.34 mmol in DMF (8 mL) is shaken at rt for 60 min. 3-{3-Amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester (1.17 mmol) is added and the mixture is shaken at rt for 2-4 days. Polymer supported-trisamine (PS-trisamine) (4.08 mmol/g, 3.51 mmol) is added and the mixture is continually shaken at rt for 18 hours. The solid is filtered and washed with MeOH. The filtrate is concentrated. The residue is purified by silica gel chromatography eluting with 10-60% EtOAc in hexanes to afford 3-{2,4-dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-aminol-l,2,3,4-tetrahydro-pyrimidin- 5-yl-propionic acid methyl ester (115 mg, 25%) as a solid. MS: 397 (M+H) 397; 1U NMR (300 MHz, CDCl3): δ 2.57-2.76 (m, 2H), 2.80-3.00 (m, 2H), 3.64 (s, 3H), 5.30 (br. N-H), 7.37-7.55 (m, 3H), 8.35 (d, 2H), 9.26 (s, 2H).
Example 65
3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-aminol-l,2,3,4-tetrahydro-pyrimidin-5-yl|- propionic acid
Figure imgf000107_0002
3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-amino]-l,2,3,4-tetrahydro-pyrimidin-5-yl}- propionic acid methyl ester (0.22 mol) is hydrolyzed by LiOH (0.88 mol) in MeOH/water/THF (1 : 1 : 1) at rt overnight. MeOH and THF are evaporated in vacuo. The residue is acidified by 5% aqueous HCl. The resulting precipitate is collected and dried to afford 3-{2,4-dioxo-3-r(2-pheyl-pyrimidine-5-carbonyl)-aminol-l,2,3,4-tetrahydro-pyrimidin- 5-vU -propionic acid (40 mg, 48%). MS: 383 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.68- 2.77 (m, 2H), 2.98-2.90 (m, 2H), 5.49 (s. N-H), 7.48-7.60 (m, 3H), 8.41-8.56 (m, 2H), 9.32 (s, 2H).
Example 66 2-Phenyl-pyrimidine-5-carboxylic acid (4-methyl-piperazin- 1 -yl)-amide
Figure imgf000108_0001
Following procedures similar to those of Example 64 but substituting 4-methyl-piperazin- 1- ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5 -carboxylic acid (4-methyl-piperazin- 1 -yl)-amide .
Example 67
2-Phenyl-pyrimidine-5-carboxylic acid (4-methyl-prperazin-l-vO-amide dihydrochloride
Figure imgf000108_0002
2-Phenyl-pyrimidine-5-carboxylic acid (4-methyl-piperazin- l-yl)-amide is dissolved in HCl methanol solution and evaporated methanol to dryness to afford 2-phenyl-pyrimidine-5 - carboxylic acid (4-methyl-piperazin- l-yl)-amide dihydrochloride as a solid. MS: 298 (M+H).
Example 68
2-Phenyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide
Figure imgf000108_0003
Following procedures similar to those of Example 64 but substituting 4-aminomorpholine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide (71%) as a solid. MS: 285 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.90-3.00 (m, 2H), 3.80-3.85 (m, 2H), 7.44-7.58 (m, 3H), 8.45-8.53 (m, 2H), 9.18 (s, 2H).
Example 69 2-Phenyl-pyrimidine-5 -carboxylic acid r4-(2-hvdroxy-ethyl)-prperazin- 1 -yll -amide
Figure imgf000109_0001
Following procedures similar to those of Example 64 but substituting 2-(4-amino-piperazin-l- yl)-ethanol for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5 -carboxylic r4-(2-hvdroxy-ethyl)-piperazin- 1 - yl-amide (25%) as a solid. MS: 328 (M+H); 1U NMR (300 MHz, CD3OD): δ 2.65 (t, 2H), 2.80 (br, 2H), 3.04 (br, 2H), 3.73 (t, 2H), 7.24-7.34 (m, H), 7.47-7.57 (m, 3H), 7.62-7.73 (m, H), 8.43-8.52 (m, 2H), 9.18 (s, 2H).
Example 70 2-Phenyl-pyrimidine-5-carboxylic acid ((s)-2-methoxymethyl)-pyrrolidin- 1 -yll-amide
Figure imgf000109_0002
Following procedures similar to those of Example 64 but substituting (S)-2-methoxymethyl- pyrrolidin-1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2 -phenyl-pyrimidine-5 -carboxylic acid ((s)-2-methoxymethyl)- pyrrolidin-1-yll-amide (63%) as a solid. MS: 313 (M+H); 1U NMR (300 MHz, CDCl3): δ 1.57-2.15 (m, 4H), 2.70-3.70 (m, 8H), 6.93 (br, 0.4N-H), 7.81 (br, 0.6N-H), 7.50 (m, 3H), 8.48 (m, 2H), 9.10-9.38 (d, 2H).
Example 71
2-Phenyl-pyrimidine-5-carboxylic acid ((R)-2-methoxymethyl)-pyrrolidin- 1 -yll -amide
Figure imgf000110_0001
Following procedures similar to those of Example 64 but substituting (R)-2-methoxymethyl- pyrrolidin-1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (YR)-2- methoxymethvO-pyrrolidin- 1 -yll-amide ( 66%) as a solid. MS: 313 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.57-2.15 (m, 4H), 2.71-3.63 (m, 8H), 6.93 (br, 0.4N-H), 7.71 (br, 0.6N-H), 7.50 (m, 3H), 8.50 (m, 2H), 9.10-9.38 (d, 2H).
Example 72 2-Phenyl-pyrimidine-5-carboxylic acid (5-bromo-2, 4-dioxo-3,4-dihvdro-2H-pyrimidin-l-vD- amide
Figure imgf000110_0002
Following procedures similar to those of Example 64 but substituting 5-bromo-2, 4-dioxo-3,4- dihydro-2H-pyrimidin- 1 -ylamine for 3- {3-amino-2,4-dioxo- 1 ,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (5- bromo-2.4-dioxo-3 Λ-dihvdro^H-pyrimidin- 1 -vD-amide (34%) as a solid. MS: 389 (M+H); 1H NMR (300 MHz, CD3OD): δ 7.49-7.62 (m, 3H), 7.98 (br, 3H), 8.23 (s, H), 8.54 (d, 2H), 9.29 (s, 2H). IC50 = 107.5 nM.
Example 73
2-Phenyl-pyrimidine-5-carboxylic acid (3-isopropyl-5-oxo- 1 ,5-dihydro-[ 1 ,2,4"|triazol-4-vD- amide
Figure imgf000111_0001
Following procedures similar to those of Example 64 but substituting 3-isopropyl-5-oxo-l,5- dihydro(l ,2,4)-triazol-4-ylamine for 3- {3-amino-2,4-dioxo-l ,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (3- isopropyl-5-oxo- 1 ,5-dihydro-r 1.2.41triazol-4-yl)-amide (25%) as a solid. MS: 325 (M+H).
Example 74
2-Phenyl-pyrimidine-5-carboxylic acid pyrrol- 1-ylamide
Figure imgf000111_0002
Following procedures similar to those of Example 64 but substituting pyrrol- 1-ylamine for 3- {3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid pyrrol- 1-ylamide (62%) as a solid. MS: 265 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.25 (d, 2H), 6.76 (d, 2H), 7.48-7.63 (m, 3H), 8.52 (d, 2H), 8.95-9.60 (br, 2H).
Example 75
2-Phenyl-pyrimidine-5-carboxylic acid (5-morpholin-4-ylmethyl-2-oxo-oxazolidin-3-yl)- amide
Figure imgf000111_0003
Following procedures similar to those of Example 64 but substituting 5-morpholin-4- ylmethyl-2-oxo-oxazolidin-3-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin- 5 -propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (5- morpholin-4-ylmethyl-2-oxo-oxazolidin-3-ylVamide (51%) as a solid. MS: 384 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.50-2.95 (m, 6H), 3.64-3.85 (m, 5H), 3.98 (t, H), 4.88 (m, H), 7.48-7.60 (m, 3H), 8.49 (d, 2H), 9.16 (s, 2H), 9.37 (br. N-H). IC50 = 20 nM.
Example 76
2-Phenyl-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin- 1 -yll -amide
Figure imgf000112_0001
Following procedures similar to those of Example 64 but substituting 4-cyclopentyl-piperazin- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin-l-yl]- amide (67%) as a solid. MS: 352 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.25-2.00 (m, 8H), 2.00-3.35 (m, 9H), 6.70-7.40 (m, N-H), 7.40-7.60 (m, 3H), 8.50 (s, 2H), 8.86-9.38 (m,2H).
Example 77 2-Phenyl-pyrimidine-5-carboxylic acid (2-oxo-oxazolidin-3-yl)-amide
Figure imgf000112_0002
Following procedures similar to those of Example 64 but substituting 2-oxo-oxazolidin-3- ylamine hydrochloride for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (2-oxo-oxazolidin- 3-vO-amide (18%) as a solid. MS: 285 (M+H); 1U NMR (300 MHz, CD3OD): δ 3.94 (t, 2H), 4.55 (t, 2H), 7.46-7.62 (m, 3H), 8.53 (d, 2H), 9.30 (d, 2H). IC50 = 49 nM.
Example 78
4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- r 1 ,2,41triazin-4-yll-amide
Figure imgf000113_0001
Following procedures similar to those of Example 64 but substituting 6-methyl-3-oxo-2,5- dihydro-3H-[ 1 ,2,4]triazin-4-ylamine for 3- {3-amino-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidin- 5 -propionic acid methyl ester, there is prepared 4-methyl-2-phenyl-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2.5-dihvdro-3H-π.2.41triazin-4-yll-amide (87%) as a solid. MS: 325 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.95 (s, 3H), 3.72 (s, 3H), 4.30 (s, 2H), 7.34-7.58 (m, 4H), 7.72 (br, H), 8.92 (br, H), 8.43 (d, 2H), 8.87 (s, H), 9.46 (br, H).
Example 79 rN'-(2-Phenyl-pyrimidine-5-carbonyl)-hydrazinol-acetic acid ethyl ester
Figure imgf000113_0002
Et3N (13.15 mmol) is added to a stirred solution of 2-phenyl-pyrimidine-5 -carboxylic acid chloride (5.26 mmol) and hydrazine-acetic acid ethyl ester hydrochloride (5 mmol) in DCM (30 mL) at rt, and the mixture is stirred at rt for 5 h. The mixture is quenched with water and extracted with EtOAc (60 mL). The organic layer is washed with water (20 mL) and brine(15 mL), dried, filtered and concentrated in vacuo. The residue is purified by silical gel chromatography eluting with 5-50% EtOAc in heptane to afford [N ' -(2-phenyl-pyrimidine-5 - carbonyD-hydrazino] -acetic acid ethyl ester (256 mg, 16%) as a solid. MS: 301 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.35 (s, 3H), 4.20-4.40 (m, 4H), 4.56 (s, 2H), 7.54 (m, 3H), 8.53 (m, 2H), 9.24 (s, 2H).
Example 80
2- [N ' -(2-Phenyl-pyrimidine-5 -carbonvD-hydrazinol -acetamide
Figure imgf000114_0001
A mixture of [N '-(2-phenyl-pyrimidine-5-carbonyl)-hydrazino] -acetic acid ethyl ester (0.37 mmol) in 25% ammonia solution (25 mL) is stirred at rt over night. The solid is collected by filtration and dried to afford 2-[N ' -(2-phenyl-pyrimidine-5 -carbonyD-hydrazino] -acetamide (46%). MS: 272 (M+H); 1H NMR (300 MHz, CD3OD): δ 4.45 (s, 2H), 7.45-7.56 (m, 3H), 8.40-8.50 (m, 2H), 9.18 (s, 2H).
Example 81 4-[3-(4-Morpholino)propyll-l-(2-phenyl-pyrimidine-5-carbonyl)-3-thiosemicarbazide
Figure imgf000114_0002
Following procedures similar to those of Example 64 but substituting 4-[3-(4-morpholino)- propyl]-3-thiosemicarbazide for 3- {3-amino-2,4-dioxo-l ,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 4-[3-(4-morpholino)propyH- 1 -(2-phenyl- pyrimidine-5 -carbonvO- 3 -thiosemicarbazide (32%) as a solid. MS: 401 (M+H); 1H NMR (300 MHz, CD3OD): δ 1.67-1.97 (m, 2H), 2.27-2.84 (m, 6H), 3.40-3.86 (m, 6H), 7.34-7.59 (m, 3H), 8.33-8.57 (m, 2H), 9.24 (s, 2H).
Example 82 2-Phenyl-pyrimidine-5-carboxylic acid (2,3-dihvdro-indol- 1 -yl)-amide
Figure imgf000114_0003
Oxalyl chloride in DCM (2 M, 1.5 mL) is added to a solution of 2-phenyl-pyrimidine-5- carboxylic acid (200 mg, 2 mmol) in DCM (20 mL) and stirred at rt for 2 h. The reaction solution is concentrated in vacuo. The residue is dissolved in DCM (20 rnL). N-amino- indoline (268 mg, 2 mmol) and triethylamine (404 mg, 4 mmol) are added and stirred at rt overnight. The mixture is concentrated in vacuo and the residue is purified by silica gel column chromatography eluting with 0-40% EtOAc in heptane to afford 2-phenyl-pyrimidine- 5-carboxylic acid (2.3-dihvdro-indol-l-yl)-amide ( 195 mg, 31 %) as a solid. MS : 317 (M+H); 1H NMR (300 MHz, CD3OD): δ 3.07 (t, 2H), 3.77 (t, 2H), 6.76 (m, H), 6.82-6.95 (m, H) 7.09- 7.24 (m, 2H), 7.54-7.63 (m, 3H), 8.52 (d, 2H), 9.28 (s, 2H) and 2-phenyl-pyrimidine-5- carboxylic acid (indol-l-vD-amide (10 mg, 2%). MS: 315 (M+H). IC50 = 2 nM.
Example 83
(4- r2-Phenyl-pyrimidine-5 -carbon yl)-aminol-piperazin-l-vU -acetic acid methyl ester
Figure imgf000115_0001
Step 1 : Following procedures similar to those of Example 64 but substituting piperazin-1- ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid piperazin-1-yl-amide.
Step 2: Phenyl-pyrimidine-5-carboxylic acid piperazin-1-yl-amide is dissolved in HCl methanol solution and evaporated methanol to dryness to afford 2-phenyl-pyrimidine-5 - carboxylic acid piperazin-1-vD-amide dihydrochloride as a solid.
Step 3: A suspended solution of 2-phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide dihydrochloride (0.5 mmol), methyl bromoacetate (0.5 mmol) and Na2CO3 (2.5 mmol) in wet THF (20 mL) is stirred at rt for 20 h. The mixture is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 1-5% methanol in DCM to afford (4-[2- phenyl-pyrimidine-5-carbonyl)-amino"|-piperazin-l-yl| -acetic acid methyl ester (135 mg, 76%) as a solid. MS: 356 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.60-3.18 (m, 8H), 3.18- 3.35 (d, 2H), 3.74 (s, 3H), 6.67 (br, 0.5 N-H) 7.03 (br, 0.5 N-H), 7.46-7.60 (m, 3H), 8.50 (d, 2H), 9.21 (d, 2H). Example 84
2-Phenyl-pyrimidine-5-carboxylic acid (4-cyanomethyl-piperazin- 1 -yl)-amide
Figure imgf000116_0001
A solution of 2-phenyl-pyrimidine-5-carboxylic acid piperazin-1-ylamide dihydrochloride (0.29 mmol), bromoacetonitrile (0.29 mmol) and Na2CO3 (1.46 mmol) in wet THF (8 mL) is stirred at rt overnight. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 1-2% methanol in DCM to afford 2-phenyl-pyrimidine-5-carboxylic acid (4-cyanomethyl-piperazin- 1 -yl)-amide (38 mg, 40%) as a solid. MS: 323 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.60-3.30 (m, 8H), 3.55 (s, 2H), 6.63 (br, 0.5 N-H), 7.14 (br, 0.5 N-H), 7.52 (s, 3H), 8.53 (d, 2H), 9.06-9.38 (m, 2H).
Example 85
Acetic acid 2-{4-r(2-phenyl-pyrimidine-5-carbonyl)-aminol-piperazin-l-yl|-ethvl ester
Figure imgf000116_0002
A solution of 2-phenyl-pyrimidine-5-carboxylic [4-(2-hydroxy-ethyl)-piperazin-l-y]-amide
(0.21 mmol), acetyl chloride(1.06 mmol) in pyridine (4 mL) is stirred at 8O0C overnight. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is dissolved in EtOAc (10 mL), washed with water (10 mL), 10% Na2CO3 (10 mL) and brine (1OmL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-5% methanol in DCM to afford 2- {4-r(2-phenyl-pyrimidine-5- carbonyP-amino] -piperazin- 1 -yl)-ethyl ester (12 mg, 15%) as a solid. MS: 370 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.08 (s, 3H), 2.42-3.20 (m, 8H), 3.20-3.80 (m, 3H), 4.10-4.52 (m, 2H) 7.42-7.65 (m, 3H), 8.52 (m, 2H), 9.07-9.38 (d, 2H).
Example 86 2-Phenyl-pyrimidine-5-carboxylic acid (4-acetyl-piperazin- 1 -yl)-amide
Figure imgf000117_0001
A solution of 2-phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide dihydrochloride (0.43 mmol), acetyl chloride (1.28 mmol) and Et3N (1.72 mmol) in DMF (8 rnL) is stirred at rt overnight, mixture is concentrated in vacuo. The residue is dissolved in EtOAc (15 mL), washed with water and brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with ether to afford 2-phenyl-pyrimidine-5-carboxylic acid (4-acetyl-piperazin-l- vQ-amide (98 mg, 71%) as a solid. MS: 326 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.12 (s, 3H), 2.92-3.10 (m, 4H), 3.40-4.10 (m, 4H), 7.43-7.60 (m, 3H), 7.75 (br, N-H), 8.52 (m, 2H), 9.11-9.38 (br, 2H).
Example 87
2-Phenyl-pyrimidine-5 -carboxylic acid r4-(2-oxo-tetrahydro-furan-3 -yl)-piperazin- 1 -yll - amide
Figure imgf000117_0002
A solution of 2-phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide dihydrochloride (0.45 mmol) and bromo-dihydro-furan-2-one (1.8 mmol) in DMF (10 mL) is stirred under N2 at O0C for 15 min, then NaH (60%, 1.8 mmol) is added and the mixture is warmed to rt and stirred overnight. The mixture is quenched with water, and extracted with EtOAC. The organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-2% methanol in DCM to afford give 2-phenyl- pyrimidine-5 -carboxylic acid [4-(2-oxo-tetrahydro-furan-3-yl)-piperazin- 1 -yl]-amide (120 mg, 73%) as a solid. MS: 368 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.34 (s, 2H), 2.50-3.30 (m, 8H), 3.42-3.70 (m, H), 4.17-4.50 (m, 2H), 7.34-7.68 (m, 3H), 8.50 (d, 2H), 9.06-9.38 (d, 2H). IC50 = 26 nM. Example 88
2-Phenyl-pyrimidine-5-carboxylic acid r4-(2,2,2-trifluoro-acetyl)-piperazin- 1 -yll-amide
Figure imgf000118_0001
A solution of 2-phenyl-pyrimidine-5-carboxylic acid piperazin-1-ylamide dihydrochloride (0.36 mmol), trifluoroacetic anhydride (1.08 mmol) and Et3N (1.44 mmol) in DMF (8 rnL) is stirred under N2 at rt overnight. The reaction mixture is concentrated in vauo. The residue is dissolved in EtOAc (15 mL), washed with water (10 ml) and brine (15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with ether to give 2-phenyl- pyrimidine-5-carboxylic acid [4-(2,2,2-trifluoro-acetyl)-piperazin-l-yl"|-amide (136 mg, ~ 100%) as a solid. MS: 380 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.95-3.40 (s, 4H), 3.60- 4.10 (m, 4H), 7.41-7.68 (m, 3H), 8.52 (d, 2H), 9.03-9.40 (br, 2H). IC50 = 57 nM.
Example 89
2-Phenyl-pyrimidine-5-carboxylic acid r4-(2-methoxy-ethyl)-prperazin- 1 -yll -amide
Figure imgf000118_0002
Step 1 : To a suspended solution of 2-phenyl-pyrimidine-5-carboxylic acid [4-(2-hydroxy- ethyl)-piperazin-l-yl]-amide (0.83 mmol) in DCM (8 mL) under N2 are added a solution of Et3N (2.67 mmol) in DCM (1 mL), a solution of N,N-dimethyl-4-aminopyridine (0.2 mmol) in DCM (1 mL) and a solution of di-tert-butyl dicarbonate (1.48 mmol) in DCM (1 mL) at rt. The resulting mixture is stirred at rt for 3 h, and then concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 6% ethanol in EtOAc to afford [4-(2- methoxy-ethyD-piperazin- 1 -yll-(2-phenyl-pyrimidine-5-carbonyl)-carbamic acid tert-butyl ester (70 mg, 20%) as a solid. MS: 428 (M+H). Step 2: A solution of [4-(2-methoxy-ethyl)-piperazin-l-yl]-(2-phenyl-pyrimidine-5-carbonyl)- carbamic acid tert-butyl ester (0.21 mmol), NaH (60%, 0.66 mmol) and iodomethane (0.63 mmol) in DMF (8 rnL) is stirred under N2 at rt overnight. The reaction mixture is quenched with water, and extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-2% methanol in DCM to afford 2-phenyl-pyrimidine-5-carboxylic acid [4-(2-methoxy- ethvQ-piperazin- 1 -yli-amide (32 mg, 44%) as a solid. MS: 342 (M+H).
Example 90 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazin-l-yl"|- amide
Figure imgf000119_0001
A solution of 2-phenyl-pyrimidine-5-carboxylic acid piperazin-1-ylamide dihydrochloride (0.43 mmol) and NaH (60%, 2.15 mmol) in DMF (10 mL) is stirred under N2 at rt for 20 min. 2-Chloro-l-morpholin-4-yl-ethanone (0.65 mmol)) is added and the reaction mixture is stirred at rt overnight. The reaction mixture is quenched with water, and extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-4% methanol in DCM to afford 2-phenyl- pyrimidine-5-carboxylic acid r4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazin- 1 -yll -amide (24 mg, 14%) as a solid. MS: 411 (M+H); 1U NMR (300 MHz, CDCl3): δ 2.85-3.10 (m, 2H), 3.60-4.00 (m, 12H), 4.46 (d, 2H), 4.84 (s, 2H), 7.44-7.62 (m, 3H), 8.34-8.58 (m, 2H), 9.20- 9.38 (d, 2H). IC50 = 831.5 nM.
Example 91 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (2,3-dihvdro-indol-l-vD-amide
Figure imgf000120_0001
Following procedures similar to those of Example 64 but substituting 2-(3-fluoro-phenyl)- pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2,3-dihydro-indol-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (2.3-dihvdro-indol- 1 -vQ-amide (83%) as a solid. MS: 335 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.00 (s, 2H), 3.70 (s, 2H), 6.53-7.34 (m, 5H), 7.45 (s, H), 8.00-8.38 (m, 2H), 9.20 (s, 2H). IC50 = 3 nM.
Example 92
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid prperadin-1-yl-amide
Figure imgf000120_0002
Following procedures similar to those of Example 64 but substituting 2-(3-fluoro-phenyl)- pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting piperadin-1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid piperadin-1- yl-amide (71%) as a solid. MS: 301 (M+H); 1U NMR (300 MHz, CDCl3): δ 1.20-2.00 (m, 6H), 2.20-3.60 (m, 4H), 6.97-7.30 (m, H), 7.34-7.56 (m, H), 8.06-8.38 (m, 2H), 9.00-9.38 (d, 2H). IC50 = 19.5 nM.
Example 93
2-(4-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- r 1 ,2,4"|triazin-4-yl)-amide.
Figure imgf000121_0001
Step 1 : Following the procedures similar to those of Example 59, step 1, but substituting 4- methoxyphenylboronic acid for 3-methoxyphenylboronic acid, there is prepared 2-(4- methoxy-phenvD-pyrimidine-5-carboxylic acid methyl ester.
Step 2: Following the procedures similar to those of Example 59, step 2, but substituting 2-(4- methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester for 2-(3-methoxy-phenyl)- pyrimidine-5-carboxylic acid methyl ester, there is prepared 2-(4-methoxy-phenvD- pyrimidine-5-carboxylic acid.
Step 3: Following the procedures similar to those of Example 59, step 3, but substituting 2-(4- methoxy-phenyl)-pyrimidine-5-carboxylic acid for 2-(3-methoxy-phenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(4-methoxy-phenyl)-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H-π.2.41triazin-4-yl)-amide. MS: 341 (M+H); 1U NMR (DMSO- d6): δ 1.91 (s, 3H), 3.86 (s, 3H), 4.22 (s, 2H), 7.12 (d, J= 8.5 Hz, IH), 7.95 (s, IH), 8.42 (d, J = 8.6 Hz, IH), 9.21 (s, 2H), 9.95 (s, IH), 11.02 (s, IH).
Example 94
2-Phenyl-pyrimidine-5-carboxylic acid (hexahvdro-cvclopentarclpyrrol-2-yl)-amide
Figure imgf000121_0002
Following procedures similar to those of Example 64 but substituting hexahydro- cyclopenta[c]pyrrol-2-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (hexahvdro-cvclopenta|clpyrrol-2-yiyamide (39%) as a solid. MS: 309 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.20-1.90 (m, 6H), 2.40-3.50 (m, 6H), 6.94 (s, N-H), 7.52 (s, 3H), 8.50 (s, 2H), 9.08-9.38 (d, 2H).
Example 95 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -vD-amide
Figure imgf000122_0001
Following procedures similar to those of Example 64 but substituting 4-methyl-2-phenyl- pyrimidine-5-carboxylic acid chloride for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2,3-dihydro-indol- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro- pyrimidin-5 -propionic acid methyl ester, there is prepared there is prepared 4-methyl-2- phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-vD-amide (80%) as a solid. MS: 331 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.69 (s, 3H), 2.74-3.10 (m, 2H), 3.64 (t, 2H), 6.58-6.97 (m, 2H), 7.03-7.30 (m, 2H), 7.49 (s, 3H), 7.96 (s, N-H), 8.44 (s, 2H), 8.72 (d, 2H). IC50 = 5.5 nM.
Example 96
2-Phenyl-pyrimidine-5-carboxylic acid pyrrolidin-1-yl-amide
Figure imgf000122_0002
Following procedures similar to those of Example 64 but substituting pyrrolidin- 1-ylamine hydrochloride for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolidin-1-yl- amide (67%) as a solid. MS: 269 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.70-2.20 (m, 4H), 2.70-3.46 (m, 4H), 7.55 (s, 3H), 8.42-8.67(m, 2H), 9.14-9.49(t, 2H).
Example 97
2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-prperadin-l-vD-amide
Figure imgf000123_0001
Following procedures similar to those of Example 64 but substituting 2,6-dimethyl-piperadin- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-piperadin-l-yD- amide (69%) as a solid. MS: 311 (M+H); 1U NMR (300 MHz, CDCl3): δ 0.95-1.24 (m, 6H), 1.24-1.87 (m, 6H), 1.88-3.60 (m, 2H), 6.35 (br, N-H), 7.53 (s, 3H), 8.52 (s, 2H), 9.10-9.73 (m, 2H).
Example 98
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin- 1 -yl)-amide
Figure imgf000123_0002
Following procedures similar to those of Example 64 but using substituting 2-(3-fluoro- phenyl)-pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 4-cyclopentyl-piperazin-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro- pyrimidin-5 -propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5- carboxylic acid (4-cvclopentyl-piperazin-l-yl-amide (64%) as a solid. MS: 370 (M+H).
Example 99
2-Phenyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihvdro-indol- 1 -vD-amide
Figure imgf000123_0003
Following procedures similar to those of Example 64 but substituting 2-methyl-2,3-dihydro- indol-1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihydro- indol-l-vO-amide (32%) as a solid. MS: 331 (M+H); 1U NMR (300 MHz, CDCl3): δ 1.05 (m, 3H), 2.50-2.79 (m, H), 3.03-3.24 (m, H), 3.40-3.58 (m, 0.5H), 3.92 (br, 0.5H), 6.67 (d, 0.5N- H), 6.77-7.33 (m, 4H), 7.51 (m, 3H), 7.98 (s, 0.5N-H), 8.52 (m, 2H), 9.23 (d, 2H). IC50 = 4 nM.
Example 100
2-(3-Fluoro-phenvD-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihvdro-indol-l-yl)-amide
Figure imgf000124_0001
Following procedures similar to those of Example 64 but substituting 2-(3-fluoro-phenyl)- pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2-methyl-2,3-dihydro-indol-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro- pyrimidin-5 -propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-pyrimidine-5- carboxylic acid (2-methyl-2.3-dihvdro-indol-l-vO-amide (31%) as a solid. MS: 349 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.00-1.48 (m, 3H), 2.43-2.78 (m, 2H), 3.32-4.06 (m, H), 6.50- 6.93 (m, 1.5H), 6.93-7.34 (m, 4H), 7.34-7.54 (d, H), 8.05-8.32 (m, 2H), 8.56 (s, 0.5N-H), 9.17 (d, 2H). IC50 = 4 nM.
Example 101
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -pyridin-2-yl-hydrazide
Figure imgf000124_0002
Following procedures similar to those of Example 64 but substituting N' -methyl-N '-pyridin- 2-yl-hydrazine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N '-methyl-N '-pyridin- 2-yl-hvdrazide (31%) as a solid. MS: 306 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.48 (s, 3H), 6.88 (m, 2H), 7.40-7.70 (m, 4H), 8.23 (s, H), 8.52 (m, 2H), 9.13 (br, N-H), 9.28 (s, 2H).
Example 102 2-Phenyl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide
Figure imgf000125_0001
Step 1 : A solution of 5-fluoro-lH-indole (16.9 mmol) and potassium tert-butoxide (33.8 mmol) in DMF (76 niL) is stirred at rt under N2 for 2 h. 0.15 M NH2CLm ether (169.2 mL) is added drop-wise for 15 minutes at rt. The reaction mixture is stirred at rt for 2 h, then quenched with 10 % Na2S2O3 aqueous solution and extracted with ether. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 60-80% EtOAc in heptane to afford 5-fluoro-indole-l- ylamine (751 mg, 30%) as a solid. 1H NMR (300 MHz, CDCl3): δ 4.80 (br, 2N-H), 6.38 (d, H), 7.00 (m, H), 7.19-7.43 (m, 3H).
Step 2: Diethyl-iso-propylamine (2.30 mmol) is added to a stirred solution of 2-phenyl- pyrimidine-5-carboxylic acid chloride (1.15 mmol) and 5-fluor-indol-l-ylamine (1.15 mmol) in DCM (20 mL) at rt. The reaction mixture is stirred at rt overnight and concentrated in vacuo. The residue is dissolved in EtOAc (30 mL), then washed with 5% HCl (10 mL), water (10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10-40% EtOAc in heptane to afford I1 phenyl-pyrimidine-5-carboxylic acid (5-fluoro-indol-l-yl)-amide (185 mg, 49%) as a solid. MS: 333 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.56 (s, H) 7.02 (m, H), 7.10-7.38 (m, 4H), 7.55 (s, 3H), 8.53 (s, 2H), 8.70-9.40 (br, 2H). IC50 = 3 nM.
Example 103
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -vD-amide
Figure imgf000125_0002
Following procedures similar to those of Example 64 but substituting 2-pyridin-2-yl- pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2,3-dihydro-indol-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5- propionic acid methyl ester, there is prepared 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2.3-dihvdro-indol-l-vn-amide (98%) as a solid. MS: 318 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.85-3.20 (m, 2H), 3.77 (t, 2H), 6.76 (d, 0.5N-H), 6.82-7.49 (m, 4H), 7.46 (d, H), 7.89 (d, H), 8.07 (br, 0.5N-H), 8.57 (m, H), 8.84 (d, H), 9.30 (s, 2H). IC50 = 3 nM.
Example 104
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid indol-1-yl-amide
Figure imgf000126_0001
A suspended solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-yl)- amide (0.28 mmol) and MnO2 (1.42 mmol) in DCM (8 mL) is stirred at rt for 2 h. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-5% methanol in DCM to afford 2-pyridin-2-yl- pyrimidine-5-carboxylic acid indol-1-yl-amide (45 mg, 50%) as a solid. MS: 316 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.48 (s, H), 6.72-7.48 (m, 5H), 7.56 (s, H), 7.88 (s, H), 8.52 (br, 2H), 9.08 (br, 2H), 11.56 (br, N-H). IC50 = 4.5 nM.
Example 105
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid indol- 1 -yl-amide
Figure imgf000126_0002
A suspended solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- l-yl)-amide (0.39 mmol) and MnO2 (1.95 mmol) in DCM (10 mL) is stirred at rt for 40 min. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-40% EtOAc in heptane to afford 2-(3- fluoro-phenvD-pyrimidine-5-carboxylic indol- 1-yl-amide (70 mg, 54%) as a solid. MS: 333 (M+H); 1U NMR (300 MHz, CDCl3): δ 6.60 (s, H), 7.10 (d, H), 7.14-7.46 (m, 4H), 7.50 (br, H), 7.64 (d, H), 8.37 (d, 2H), 8.60-9.40 (br, 3H). IC50 = 5 nM.
Example 106
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-vD-amide
Figure imgf000127_0001
Following procedures similar to those of Example 64 but substituting 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2,3-dihydro-indol-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro- pyrimidin-5 -propionic acid methyl ester, there is prepared 2-(3-fluoro-phenvO-4-methyl- pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-vD-amide (91%) as a solid. MS: 349 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.77-3.08 (m, 2H), 3.09-3.80 (m, 2H), 6.75-7.00 (m, 2H), 7.04-7.32 (m, 3H), 7.44 (q, H), 8.06-8.31 (m, 2H), 8.51 (d, 2H). IC50 = 23 nM.
Example 107
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihvdro-indol- 1 - vD-amide
Figure imgf000127_0002
Following procedures similar to those of Example 64 but substituting 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2-methyl-2,3-dihydro-indol-l-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4- tetrahydro-pyrimidin-5 -propionic acid methyl ester, there is prepared 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihvdro-indol- 1 -vD-amide (94%) as a solid. MS: 363 (M+H); 1H NMR (300 MHz, CDCl3): δ 1.00-1.50 (d, 3H), 2.30-2.80 (m, 4H), 3.01 (m, H), 3.26-3.96 (m, H), 6.45-7.00 (m, 2H), 7.00-7.30 (m, 3H), 7.41 (q, H), 7.97-8.28 (m, 2H), 8.68 (d, H).
Example 108 2-(3-Fluoro-phenvD-pyrimidine-5-carboxylic acid (2-methyl-indol- 1 -yl)-amide
Figure imgf000128_0001
A suspended solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (2-methyl-2,3- dihydro-indol-l-yl)-amide (0.98 mmol) and MnO2 (4.88 mmol) in DCM (15 mL) is stirred at rt for 2 h. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-40% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (2 -methyl- indol-l-yl)-amide (230 mg, 97%) as a solid. MS: 347 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.08-2.40 (m, 3H), 6.27 (s, H), 6.95-7.35 (m, 4H), 7.36-7.65 (m, 2H), 8.20-8.44 (m, 2H), 8.49-9.20 (d, 2H). IC50 = 6 nM.
Example 109
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid indol- 1 -ylamide
Figure imgf000128_0002
A suspended solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3- dihydro-indol-l-yl)-amide (0.72 mmol) and MnO2 (3.60 mmol) in DCM (10 mL) is stirred at rt for 40 min. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-40% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid indol- 1 -ylamide (185 mg, 75%) as a solid. MS: 347 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.73 (s, 3H), 6.53 (s, H), 7.03 (d, H), 7.08-7.36 (m, 4H), 7.37-7.75 (m, 2H), 8.04-8.40 (m, 2H), 8.56 (br, H), 8.81 (br, H). IC50 = IO nM.
Example 110
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -vD-amide
Figure imgf000129_0001
Following procedures similar to those of Example 64 but substituting 4-methyl-2-pyridin-2- yl-pyrimidine-5-carboxylic acid for 2-phenyl-4-yl-pyrimidine-5-carboxylic acid, and substituting 2,3-dihydro-indol- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro- pyrimidin-5 -propionic acid methyl ester, there is prepared 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (2,3-dihydro-indol- l-yl)-amide (96%) as a solid. MS: 332 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.78 (s, 3H), 3.09 (t, 2H), 3.77 (t, 2H), 6.70-7.01 (m, 2H), 7.09-7.23 (m, 2H), 7.36-7.46 (m, H), 7.85 (t, H), 8.43-8.64 (m, 2H), 8.80 (d, H). IC50 = 3 nM.
Example 111
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid indol- 1 -ylamide
Figure imgf000129_0002
A suspended solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro- indol- l-yl)-amide (1.00 mmol) and MnO2 (5.00 mmol) in DCM (10 mL) is stirred at rt for 60 min. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-5% methanol in DCM to afford 4; methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid indol- 1 -ylamide (196 mg, 60%) as a solid. MS: 330 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.77 (s, 3H), 6.58 (s, H), 7.15 (s, 2H), 7.26 (m, 3H), 7.84 (d, H), 8.44 (s, 2H), 8.73 (s, H), 10.94 (br, N-H). IC50 = 5 nM. Example 112
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol-l-yl)-amide
Figure imgf000130_0001
Step 1 : A solution of 5-methanesulfonyl-indoline (4.11 mmol) and MnO2 (20.55 mmol) in DCM (20 mL) is stirred at rt overnight. The reaction mixture is filtered and the filtrate is concentrated in vacuo to afford 5 -methanesulfonyl- 1 H-indole (782 mg, 100%) as a solid. MS: 196 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.09 (s, 3H), 6.71 (s, H), 7.39 (s, H), 7.53 (d, H), 7.74 (m, H), 8.30 (s, H), 8.66 (br, N-H).
Step 2: A solution of 5 -methanesulfonyl-1 H-indole (4.1 mmol) and potassium tert-butoxide (8.2 mmol) in DMF (20 mL) is stirred at rt under N2 for 2 h. 0.15 M NH2Cl in ether (41 mL) is added drop-wise for 15 min at rt and the reaction mixture is stirred at rt for 2 h. The reaction mixture is quenched with 10 % Na2S2O3 aqueous solution, and extracted with ether (3x40 mL). The combined orgaic layer is washed with water (2x30 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with EtOAc and heptane to afford 5 -methanesulfonyl-indole- 1 - ylamine (230 mg, 32%) as a solid. MS: 211 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.08 (s, 3H), 4.94 (br, 2N-H), 6.55 (d, H), 7.34 (m, H), 7.57 (d, H), 7.73 (m, H), 8.21 (m, H). Step 3: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid chloride (0.62 mmol) in EtOAc (10 mL) is added to a stirred solution of 5 -methanesulfonyl-indole-1 -ylamine (0.62 mmol) and K2CO3 (3.08 mmol) in EtOAc (10 mL) and H2O (10 mL) at O0C, and the reaction mixture is warmed to rt and stirred overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration. The solid is triturated with DCM to afford 2-(3-fluoro-phenyl)- pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide (85 mg, 34%) as a solid. MS: 411 (M+H); 1H NMR (300 MHz, CD3OD): δ 3.13 (s, 3H), 6.81 (m, H) 7.25-7.39 (m, H), 7.49-7.67 (m, 3H), 7.72-7.84 (m, H), 8.21-8.32 (m, 2H), 8.39 (d, H), 9.41 (s, 2H).
Example 113
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-methanesulfonyl-indol-l-vD-amide
Figure imgf000131_0001
Step 1 : A solution of 6-methanesulfonyl-lH-indole (2.66 mmol) and potassium tert-butoxide (5.32 mmol) in DMF (15 mL) is stirred at rt under N2 for 2 h. 0.15 M NH2Cl in ether (26.6 mL) is added drop-wise for 15 minutes at rt and the reaction mixture is stirred at rt for 2 h. The reaction mixture is quenched with 10 % Na2S2O3 aqueous solution, and extracted with ether (3x20 mL). The combined orgaic layer is washed with brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with EtOAc to give (> methanesulfonyl-indole- 1 -ylamine (270 mg, 51%) as a solid. MS: 211 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.09 (s, 3H), 6.49 (d, H), 7.41 (m, H), 7.61 (d, H), 7.71 (d, H), 8.12 (s, H).
Step 2: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid chloride (0.65 mmol) in EtOAc (15 mL) is added to a stirred solution of 5 -methanesulfonyl-indole-1 -ylamine (0.65 mmol) and potassium carbonate (2.60 mmol) in EtOAc (10 mL) and H2O (10 mL) at O0C, and the reaction mixture is warmed to rt and stirred overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration, and purified by silica gel chromatography eluting with 20-60% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (6- methanesulfonyl-indol- 1 -vQ-amide (85 mg, 33%) as a solid. MS: 411 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.08 (s, 3H), 6.62 (d, H) 7.33-7.44 (m, 2H), 7.46-7.59 (m, 2H), 7.75 (s, H), 8.29 (d, 2H), 8.39 (d, H), 9.42 (s, 2H), 10.80 (br, H). IC50 = 8 nM.
Example 114
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide
Figure imgf000131_0002
Diethyl-iso-propylamine (3.54 mmol) is added a solution of 2-pyridin-2-yl-pyrimidine-5- carboxylic acid HCl (1.18 mmol), 5 -methanesulfonyl-indol-1 -ylamine (1.18 mmol) and TBTU (1.77 mmol) in anhydrous DMF (16 mL) at rt. The reaction mixture is stirred at 9O0C overnight and then concentrated in vacuo. The residue is dissolved in EtOAc (50 rnL) and water (50 mL). The organic layer is separated, washed with water (2x20 mL) and brine (20 rnL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with EtOAc and DCM to affrod 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 - vQ-amide (125 mg, 27%) as a solid. MS: 394 (M+H); 1U NMR (300 MHz, CD3OD): δ 3.14 (s, 3H), 6.82 (m, H) 7.50-7.72 (m, 3H), 7.80 (m, H), 8.07 (m, H), 8.30 (m, 2H), 8.70(d, H), 8.80 (s, H), 9.51 (s, 2H).
Example 115 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 -vD-amide
Figure imgf000132_0001
Diethyl-iso-propylamine (3.84 mmol) is added a solution of 2-pyridin-2-yl-pyrimidine-5- carboxylic acid hydrochloride(1.28 mmol), 5-methanesulfonyl-indol-l-ylamine (1.28 mmol) and TBTU (1.92 mmol) in anhydrous DMF (16 mL) at rt. The reaction mixture is stirred at 9O0C overnight and then concentrated in vacuo. The residue is dissolved in EtOAc (60 mL), and washed with water (2x30 mL) and brine (20 mL), The organic layer is separated, washed with water (2x20 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-5% MeOH in DCM to afford 2-pyridin-3 -yl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-indol- 1 -yl)-amide (125 mg, 25%) as a solid. MS: 394 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.10 (s, 3H), 6.61 (m, H) 6.98 (m, H), 7.34 (s, H), 7.51 (m, H), 7.91 (s, H), 8.83 (m, 2H), 9.49 (s, H), 9.77 (s, H), 10.10 (s, N-H).
Example 116 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol-l-vD- amide
Figure imgf000133_0001
2.0 M of NaHMDS (sodium bis(trimethylsilyl)amide) in THF is added to a stirred solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid chloride (0.72 mmol) and 5- methanesulfonyl-indol-1-ylamine (0.72 mmol) and in anhydrous pyridine (10 mL) at rt. The reaction mixture is stirred at 9O0C overnight and then concentrated in vacuo. The residue is purified ny silica gel chromatography eluting with 1.5% MeOH in DCM to afford 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-indol- 1 -yl)-amide (50 mg, 8%) as a solid. MS: 425 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.86 (s, 3H), 3.02 (s, 3H), 6.55 (s, H) 6.92 (d, H), 7.17-7.38 (m, 3H), 7.53 (m, H), 7.78 (s, H), 8.27 (d, H), 8.38 (d, H), 9.16 (s, H).
Example 117
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolor2,3-b1pyridin-l-ylamide
Figure imgf000133_0002
Step 1 : A solution of pyrrolo[2,3-b]pyridine (16.9 mmol) and potassium tert-butoxide (33.8 mmol) in DMF (76 mL) is stirred at rt under N2 for 2 h. 0.15 M NH2Cl in ether (169.2 mL) is added drop-wise at rt and the reaction mixture is stirred at rt for 2 h. The reaction mixture is quenched with 5 % Na2S2O3 aqueous solution (100 mL), and extracted with ether for three times. The combined organic layer is washed with brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 60- 80% EtOAc in heptane to afford pyrrolor2,3-b1pyridin- 1 -ylamine (703 mg, 31%) as a solid. MS: 134 (M+H); 1H NMR (300 MHz, CDCl3): δ 5.04 (br, 2N-H), 6.35 (d, H), 7.09 (m, H), 7.35 (m, H), 7.91 (m, H), 8.34 (d, H). Step 2: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid chloride (1.13 mmol) in EtOAc (20 rnL) is added to a stirred solution of pyrrolo[2,3-b]pyridin-l-ylamine (1.13 mmol) and K2CO3 (1.13 mmol) in EtOAc (10 mL) and H2O (20 mL) at rt and the reaction mixture is stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolo|"2,3- blpyridin-1-ylamide (305 mg, 81%) as a solid. MS: 334 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.57 (d, H) 7.13-7.55 (m, 4H), 7.99 (m, H), 8.10-8.40 (m, 3H), 9.27 (s, 2H), 12.57 (br, N-H).
Example 118
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxyric acid pyrrolor3,2-b1pyridin-l-vlamide
Figure imgf000134_0001
Step 1 : A solution of pyrrolo[3,2-b]pyridine (1.64 mmol) and potassium tert-butoxide (3.29 mmol) in DMF (7.3 mL) is stirred at rt under N2 for 2 h. 0.15 M NH2CLm ether (16.3 mL) is added drop-wise at rt and the reaction mixture is stirred at rt for 3 h. The reaction mixture is quenched with 5 % Na2S2O3 aqueous solution (10 mL), and extracted with ether. The combined organic layer is washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with EtOAc to afford pyrrolon .2-blpyridin- 1 -ylamine (136 mg, 62%) as a solid. MS: 134 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.89 (br, 2N-H), 6.61 (d, H), 7.16 (m, H), 7.38 (d, H), 7.76 (d, H), 8.47 (d, H).
Step 2: A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid chloride (0.45 mmol) in EtOAc (8 mL) is added to a stirred solution of pyrro Io [3, 2-b]pyridin-l -ylamine (0.45 mmol) and K2CO3 (0.45 mmol) in EtOAc (4 mL) and H2O (8 mL) at rt, and the reaction mixture is stirred at rt for 30 min. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolo[3,2- blpyridin-1-ylamide (116 mg, 77%) as a solid. MS: 334 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.60 (d, H) 7.15-7.60 (m, 4H), 8.01 (m, H), 8.10-8.41 (m, 3H), 9.27 (s, 2H), 12.45 (br, N-H). IC50 = 18 nM.
Example 119 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-indol-l-vD-amide
Figure imgf000135_0001
A solution of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid chloride (1 mmol) in EtOAc (20 rnL) is added to a stirred solution of 5-fluoro-indol-l-ylamine (1 mmol) and potassium carbonate (1 mmol) in EtOAc (10 mL) and H2O (20 mL) at rt and the reaction mixture is stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-indol-l-vD- amide (148 mg, 42%) as a solid. MS: 351 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.56 (m, H) 7.02 (m, H), 7.12-7.34 (m, 3H), 7.51 (m, H), 8.24 (d, H), 8.34 (s, H), 8.92 (br, H), 9.24 (br, 2H).
Example 120
2-(2-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000135_0002
Step 1 : Following the procedures similar to those of Example 59, step 1, but substituting 2- methoxyphenylboronic acid for 3-methoxyphenylboronic acid, there is prepared 2-(2- methoxy-phenvD-pyrimidine-5-carboxylic acid methyl ester.
Step 2: Following the procedures similar to those of Example 59, step 2, but substituting 2-(2- methoxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester for 2-(3-methoxy-phenyl)- pyrimidine-5-carboxylic acid methyl ester, there is prepared 2-(2-methoxy-phenyD- pyrimidine-5-carboxylic acid.
Step 3: Following the procedures similar to those of Example 59, step 3, but substituting 2-(2- methoxy-pheny^-pyrimidine-S-carboxylic acid for 2-(3-methoxy-phenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(2-methoxy-phenyl)-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H-π.2.41triazin-4-vn-amide. MS: 341 (M+H); 1H NMR (DMSO- d6): δ 1.91 (s, 3H), 3.79 (s, 2H), 4.22 (s, 2H), 7.09 (m, IH), 7.19 (d, J= 8.2 Hz, IH), 7.52 (m, IH), 7.65 (m, IH), 9.24 (s, 2H), 9.96 (s, IH), 11.06 (s, IH). IC50 = 199 nM.
Example 121
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo|"3,2-blpyridin-l-ylamide
Figure imgf000136_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid chloride (0.45 mmol) in EtOAc (8 mL) is added to a stirred solution of pyrrolo[3,2-b]pyridin-l-ylamine
(0.45 mmol) and potassium carbonate (0.45 mmol) in EtOAc (4 mL) and H2O(8 mL) at rt and the reaction mixture is stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration. The solid is purified by silica gel chromatography eluting with 20-80% EtOAc in heptane to afford 2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid pyrrolor3.2-blpyridin-l-ylamide (38 mg, 24%) as a solid. MS: 348 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.76 (s, 3H), 6.59 (m, H) 7.07-7.64 (m, 4H), 7.96 (m, H), 8.23 (m, H), 8.32 (m, 2H), 9.12 (s, H), 10.01 (br, N-H).
Example 122 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolor2,3-b1pyridin-l-ylamide
Figure imgf000137_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid chloride (1 mmol) in EtOAc (10 rnL) is added to a stirred solution of pyrrolo[2,3-b]pyridin-l-ylamine (1 mmol) and K2CO3 (1 mmol) in EtOAc (20 mL) and H2O (20 mL) at rt, then stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration. The solid is purified by silica gel chromatography eluting with 20-80% EtOAc in heptane to afford 2-(3- fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo|"2,3-blpyridin-l-ylamide (162 mg, 47%) as a solid. MS: 348 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.78 (s, 3H), 6.59 (m, H) 7.09-7.58 (m, 4H), 7.96 (m, H), 8.22 (m, H), 8.31 (d, 2H), 9.14 (s, 2H). IC50 = 12 nM.
Example 123
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide
Figure imgf000137_0002
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid chloride (1 mmol) in EtOAc (20 mL) is added to a stirred solution of 5-fluoro-indol- 1-ylamine (1.20 mmol) and
K2CO3 (2 mmol) in EtOAc (10 mL) and H2O (20 mL) at rt, and the reaction mixture is stirred at rt overnight. The reaction mixture is extracted with EtOAc. The organic layer is washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-10% MeOH in DCM to give a solid. The solid is triturated with EtO Ac/heptane to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5-fluoro-indol- 1 -vQ-amide (122 mg, 35%) as a solid. MS: 348 (M+H); 1U NMR (300 MHz, CD3OD): δ 2.77 (s, 3H), 6.55 (m, H) 7.06 (m, H), 7.32-7.66 (m, 4H), 8.02 (m, H), 8.45 (d, H), 8.79 (s, H), 9.26 (s, H), 12.00 (s, N-H). IC50 = 17 nM.
Example 124 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide
Figure imgf000138_0001
A solution of 2-pyridin-2-yl-pyrimidine-5-carboxylic acid chloride (1 mmol) in EtOAc (20 rnL) is added to a stirred solution of 5-fluoro-indol- 1-ylamine (1 mmol) and K2CO3 (2 mmol) in EtOAc (10 mL) and H2O (20 mL) at rt, and the reaction mixture is stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration. The solid is purified by silica gel chromatography eluting withO-10% MeOH in DCM to afford 2-pyridin- 2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- l-yl)-amide (65 mg, 20%) as a solid. MS: 334 (M+H); 1H NMR (300 MHz, CD3OD): δ 6.56 (m, H) 7.04 (m, H), 7.28-7.79 (m, 3H), 8.04 (m, H), 8.49 (m, H), 8.81 (m, H), 9.48 (s, 2H), 12.22 (s, N-H). IC50 = 18 nM.
Example 125
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolor2,3-b1pyridine- 1 -ylamide
Figure imgf000138_0002
Diethyl-iso-propylamine (1.13 mmol) is added a solution of 2-pyridin-2-yl-pyrimidine-5 - carboxylic acid (0.75 mmol), pyrrolo[2,3-b]pyridine- 1-ylamine (0.75 mmol) and TBTU in anhydrous DMF (7 mL) at rt, and the reaction mixture is stirred at 8O0C overnight. The reaction mixture is concentrated in vacuo. The residue is dissolved in EtOAc, washed with water twice, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% MeOH in DCM to give a crude product. The product is crystallized from EtOAc to afford 2 -pyridin-2-yl-pyrimidine-5 -carboxylic acid pyrrolor2.3-blpyridine-l-ylamide (78 mg, 25%) as a solid. MS: 317 (M+H); 1H NMR (300 MHz, CD3OD): δ 6.56 (m, H) 7.24 (m, H), 7.53 (m, H), 7.61 (m, H), 8.01-8.17 (m, 2H), 8.27 (d, H), 8.69 (m, H), 8.78(m, H), 9.51 (s, 2H).
Example 126 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolor2,3-b1pyridin- 1 -ylamide
Figure imgf000139_0001
Diethyl-iso-propylamine (1.13 mmol) is added a solution of 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (0.75 mmol), pyrrolo[2,3-b]pyridine-l-ylamine (0.75 mmol) and TBTU (0.9 mmol) in anhydrous DMF (7 mL) at rt, and the reaction mixture is stirred at 8O0C overnight. The reaction mixture is concentrated in vacuo. The residue is dissolved in EtOAc, washed with saturated aqueous Na2CO3 and water, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% CH3CN in DCM to give a crude product. The crude product is crystallized from EtOAc to afford 4; methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrroir2,3-blpyridine- 1 -ylamide (95 mg, 38%) as a solid. MS: 331 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.89 (s, 3H), 6.65 (d, H), 7.23 (m, H), 7.48-7.66 (m, 2H), 8.01-8.15 (m, 2H), 8.29 (m, H), 8.64 (d, H), 8.77 (d, H), 9.33 (s, 2H).
Example 127
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxyric acid pyrrolor3,2-b1pyridin-l-ylamide
Figure imgf000139_0002
Diethyl-iso-propylamine (1.88 mmol) is added a solution of 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (0.75 mmol), pyrrolo[3,2-b]pyridine-l-ylamine (0.75 mmol) and TBTU (0.9 mmol) in anhydrous DMF (7 mL) at rt, and the reaction mixture is stirred at 8O0C for 8 h. The reaction mixture is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-10% MeOH in DCM to afford 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid pyrrol|"3,2-blpyridine-l -ylamide (155 mg, 63%) as a solid. MS: 331 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.89 (s, 3H), 7.01 (d, H), 7.64-7.77 (m, 2H), 8.15 (m, H), 8.25 (m, H), 8.59-8.76 (m, 3H), 8.82 (d, H), 9.31 (s, 2H). IC50 = 13 nM. Example 128
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolor2,3-clpyridin-l-ylamide
Figure imgf000140_0001
Step 1 : A solution of pyrrolo[2,3-c]pyridine (8.47 mmol) and potassium tert-butoxide (16.9 mmol) in DMF (38 mL) is stirred at rt under N2 for 2 h. 0.15 M NH2Cl in ether (84.6 mL) is added drop-wise at rt, and the reaction mixture is stirring at rt for 2 h., quenched with 5 % Na2S2O3 aqueous solution (10 mL), and extracted with ether. The organic layer is separated, washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-10% MeOH in DCM to afford pyrrolo[2,3- clpyridin-1-ylamine (226 mg, 11%) as a solid. MS: 134 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.96 (br, 2N-H), 6.43 (d, H), 7.29 (m, H), 7.50 (d, H), 8.29 (d, H), 8.89 (s, H).
Step 2: Diethyl-iso-propylamine (1.13 mmol) is added a solution of 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid (0.75 mmol), pyrrolo[2,3-c]pyridine-l-ylamine (0.75 mmol) and TBTU (0.9 mmol) in anhydrous DMF (7 mL) at rt, and the reaction mixture is stirred at 8O0C overnight. Water is added and the mixture is extracted with EtOAc. The organic layer is separated, washed with water and brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 40- 100% MeOH in DCM to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolor2.3-clpyridin- 1 -ylamide (117 mg, 45%) as a solid. MS: 348 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.84 (s, 3H), 6.72 (d, H), 7.29 (m, H), 7.55 (m, H), 7.71 (m, H), 8.14-8.29 (m, 2H), 8.36 (d, 3), 8.75 (s, H), 9.17 (s, H). IC50 = 28.5 nM.
Example 129 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolor2,3-c1pyridin- 1 -ylamide
Figure imgf000141_0001
Following procedures similar to those of Example 127 but substituting pyrrolo[2,3-c]pyridine- 1-ylamine for pyrrolo[3,2-b]pyridine-l-ylamine, there is prepared 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid pyrrol[2,3-clpyridine-l-ylamide (46%) as a solid. MS: 331 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.79 (s, 3H), 6.64 (d, H), 7.53-7.65 (m, 2H), 7.78 (d, H), 8.02 (m, H), 8.22 (m, H), 8.46 (m, H), 8.80 (d, H), 8.87 (s, H), 9.30 (s, H).
Example 130
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid pyrrolor3,2-b1pyridin-l-ylamide
Figure imgf000141_0002
Following procedures similar to those of Example 127 but substituting 4-methyl-2-pyridin-3- yl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid, there is prepared 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo|"3,2- blpyridine-1-ylamide (40%) as a solid. MS: 331 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.86 (s, 3H), 6.74 (m, H), 7.31 (m, H), 7.61 (m, H), 7.71 (d, H), 7.92 (d, H), 8.41 (d, H), 8.71 (d, H), 8.91 (d, H), 9.20 (s, H), 9.64 (s, H). IC50 = 14 nM.
Example 131
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide
Figure imgf000141_0003
Following procedures similar to those of Example 127 but substituting 4-methyl-2-pyridin-3- yl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid, and substituting 5-fluoro-indol-l-ylamine for pyrrolo[3,2-b]pyridine-l-ylamine, there is prepared 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide (34%) as a solid. MS: 348 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.85 (s, 3H), 6.57 (m, H), 7.02 (m, H), 7.23-7.46 (m, 2H), 7.62 (m, H), 8.70 (d, H), 8.91 (d, H), 9.17 (s, H), 9.63 (s, H).
Example 132
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide
Figure imgf000142_0001
Method A: Following procedures similar to those of Example 127 but substituting 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, and substituting 5-fluoro-indol-l-ylamine for pyrrolo[3,2-b]pyridine-l- ylamine, there is prepared 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5- fluoro-indol-l-yl)-amide (17%) as a solid. MS: 365 (M+H); 1H NMR (300 MHz, CD3OD): δ 6.56 (d, H), 7.02 (m, H), 7.22-7.44 (m, 4H), 7.55 (m, H), 8.22 (d, H), 8.36 (d, H), 9.13 (s, H).
Method B: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid chloride (1 mmol) in EtOAc (20 mL) is added to a stirred solution of 5-fluoro-indol-l-ylamine (1 mmol) and K2CO3 (1 mmol) in EtOAc (10 mL) and H2O (20 mL) at rt, then stirred at rt overnight. EtOAc is evaporated in vacuo, and the resulting solid is collected by filtration. The solid is crystallized from EtO Ac/heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine- 5-carboxylic acid (5-fluoro-indol- l-vD-amide (62 mg, 17%) as a solid. MS: 365 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.82 (s, H), 6.55 (s, H) 6.90-7.41 (m, 4H), 7.49 (m, H), 8.26 (d, 2H), 8.57 (br, H), 8.96 (br, H). IC50 = 19 nM.
Example 133
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-vD-amide
Figure imgf000143_0001
Step 1 : A solution of 5-methoxy-lH-indole (16.9 mmol) and potassium tert-butoxide (33.8 mmol) in DMF (76 niL) is stirred at rt under N2 for 2 h. 0.15 M NH2Cl in ether (169.2 mL) is added drop-wise for 15 minutes at rt. The reaction mixture is stirred at rt for 2 h, quenched with 5 % Na2S2O3 aqueous solution (100 mL), and stirred at rt overnight. The mixture is extracted with ether. The organic layer is separated, washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-20% EtOAc in heptane to afford 5 -methoxy-indole- 1 -ylamine (388 mg, 14%) as a solid. 1H NMR (300 MHz, CDCl3): δ 4.78 (br, 2N-H), 6.35 (d, H), 6.94 (d, H), 7.08 (d, H), 7.17 (d, H), 7.30-7.39 (d, H).
Step 2: Following procedures similar to those of Example 127 but substituting2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, and substituting 5-methoxy-indol-l-ylamine for pyrrolo[3,2-b]pyridine-l- ylamine, there is prepared 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5- methoxy-indol- 1 -ylV amide (43%) as a solid. MS: 377 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.83 (s, 3H), 3.84 (s, 3H), 6.50 (d, H), 6.90 (m, H), 7.12 (d, H), 7.22-7.36 (m, 3H), 7.55 (m, H), 8.22 (d, H), 8.36 (d, H), 9.11 (s, H). IC50 = 6 nM.
Example 134
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-cvano-indol- 1 -vP)-amide
Figure imgf000143_0002
Step 1 : NaH (60%, 60 mmol) is potion-wise added to a solution of 5-cyano-lH-indole (20 mmol) in NMP (35 mL), and the reaction mixture is O0C for 1 h. A solution of HOSA (60 mmol) in NMP (14 mL) is added drop-wise at O0C. The reaction mixture is warmed to rt and stirred overnight, then quenched with water and extracted with EtOAc. The organic layer is separated, washed with water three times and with brine, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 20- 40% EtOAc in heptane to afford 5-cvano-indole-l-ylamine (531 mg, 16%) as a solid. 1H NMR (300 MHz, CDCl3): δ 4.88 (br, 2N-H), 6.53 (d, H), 7.32 (d, H), 7.54 (q, 2H), 7.98 (d, H).
Step 2: Following procedures similar to those of Example 127 but substituting 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, and substituting 5-cyano-indol-l-ylamine for pyrrolo[3,2-b]pyridine-l- ylamine, there is prepared 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5- cvano-indol- 1 -vQ-amide (39%) as a solid. MS: 372 (M+H); 1U NMR (300 MHz, DMSO-d6): δ 2.77 (s, 3H), 6.73 (d, H), 7.45 (m, H), 7.53-7.82 (m, 4H), 8.08-8.23 (m, 2H), 8.32 (d, H), 9.27 (s, H), 12.15 (br, N-H).
Example 135
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (4-cvano-indol- 1 -vP)-amide
Figure imgf000144_0001
Step 1 : Following procedures similar to those of Example 134, step 1, but substituting A- cyano-lH-indole for 5-cyano-lH-indole, there is prepared 4-cyano-indole- 1 -ylamine (33%) as a solid. 1H NMR (300 MHz, CDCl3): δ 4.1 (br, 2N-H), 6.88 (d, H), 7.22-7.40 (m, 2H), 7.51 (d, H), 7.72 (d, H).
Step 2: Following procedures similar to those of Example 127, but substituting 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5 -carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, and substituting 4-cyano-indol-l -ylamine for pyrrolo[3,2-b]pyridine-l- ylamine, there is prepared 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (A- cvano-indol- 1 -vQ-amide (29%) as a solid. MS: 372 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.77 (s, 3H), 6.71 (s, H), 7.32-7.51 (m, 2H), 7.57-7.69 (m, 2H), 7.88 (m, 2H), 8.16 (d, H), 8.31 (d, H), 9.25 (s, H).
Example 136
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid r4-(lH-tetrazol-5-yl)-indol-l-yll- amide
Figure imgf000145_0001
A solution of (0.5 mmol), ammonia chloride (6 mmol) and sodium azide(6 mmol) in anhydrous DMF (6 mL) is heated in the microwave at 2000C for 1 h. The reaction mixture is quenched with saturated aqueous Na2CO3 solution, and washed with EtOAc. The aqueous layer is separated, acidified with concentrated aqueous HCl to adjust pH to ~ 1, and extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 3% MeOH in DCM to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid r4-(lH-tetrazol-5-vD- indol-1-yl-amide (18 mg, 9%) as a solid. MS: 415 (M+H); 1U NMR (300 MHz, CD3OD): δ 2.85 (s, 3H), 7.20-7.35 (m, 2H), 7.44 (m, H), 7.52-7.59 (m, 2H), 7.65 (m, H), 7.77 (d, H), 8.23 (d, H), 8.37 (d, H), 9.18 (s, H).
Example 137 l-{[2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyll-amino|-lH-indol-4-carboxylic acid methyl ester
Figure imgf000145_0002
Step 1 : Following procedures similar to those of Example 133, step 1, but substituting IH- indole-4-carboxylic acid methyl ester for 5-methoxy-lH-indole, there is prepared 1 -amino- lH-indole-4-carboxylic acid methyl ester (10%) as a solid. 1H NMR (300 MHz, CDCl3): δ 4.88 (br, 2N-H), 7.03 (d, H), 7.33 (m, 2H), 7.49 (d, H), 7.94 (d, H).
Step 2: Following procedures similar to those of Example 127, but substituting 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, substituting 1 -amino- lH-indole-4-carboxylic acid methyl ester for pyrrolo[3,2-b]pyridine-l-ylamine, and the reaction is stirred at 15O0C for 45 minutes, there is prepared l-{[2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyll-amino|-lH-indol-4- carboxylic acid methyl ester (33%) as a solid. MS: 405 (M+H); 1H NMR (300 MHz, DMSO- d6): δ 2.77 (s, 3H), 3.92 (s, 3H), 7.44 (m, H), 7.63 (m, H), 7.72 (m, H), 7.76-7.88 (m, 2H), 8.17 (d, H), 8.31 (d, H), 9.26(s, H), 12.06 (br, N-H).
Example 138 l-{r2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyll-amino|-lH-indol-4-carboxylic acid
Figure imgf000146_0001
A solution of l-{[2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl]-amino}-lH-indol-4- carboxylic acid methyl ester (0.48 mmol) and LiOH (1.91 mmol) in Methanol/THF/H2O (1 :1 :1, 6 mL) is stirred at rt overnight. The reaction mixture is diluted with water and washed with DCM. The aqueous layer is separated and acidified with 10% aqueous HCl to adjust pH to ~1. The mixture is extracted with ether twice. The organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford l-{[2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl]- aminol-lH-indol-4-carboxylic acid (186 mg, 99%) as a solid. MS: 391 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.85 (s, 3H), 7.20 (m, H), 7.24-7.40 (m, 2H), 7.46-7.61 (m, 2H), 7.66 (d, H), 7.92 (d, H), 8.23 (d, H), 8.37 (d, H), 9.16 (s, H).
Example 139
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyanomethyl-indol- 1 -yl)- amide
Figure imgf000147_0001
Step 1 : Following procedures similar to those of Example 133, step 1, but substituting IH- indol-3-yl-acetonitrile for 5-methoxy-lH-indole, there is prepared ( 1 -amino- lH-indol-3-y I)- acetonitrile (17%) as a solid. 1H NMR (300 MHz, CDCl3): δ 3.83 (s, 2H), 4.80 (br, 2N-H), 7.17-7.25 (m, 2H), 7.33 (t, H), 7.46 (d, H), 7.59 (d, H).
Step 2: Following procedures similar to those of Example 127, but substituting 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid for 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid, substituting 3-cyanomethyl-indol-l-ylamine for pyrrolo[3,2-b]pyridine-l- ylamine, and the reaction is stirred at 15O0C for 1 h, there is prepared 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid (3-cyanomethyl-indol- 1 -yl)-amide (42%) as a solid. MS: 386 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.84 (s, 3H), 4.03 (s, 2H), 7.15-7.48 (m, 5H), 7.55 (m, H), 7.70 (d, H), 8.23 (d, H), 8.37 (d, H), 9.14 (s, H).
Example 140
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-vD-amide
Figure imgf000147_0002
Following procedures similar to those of Example 127, but substituting 5-methoxy-indol-l- ylamine for pyrrolo[3,2-b]pyridine-l -ylamine, and the reaction is stirred at 15O0C for 1 h, there is prepared 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-indol- 1 -yl)-amide (22%) as a solid. MS: 360 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.88 (s, 3H), 3.84 (s, 3H), 6.50 (d, H) 6.90 (m, H), 7.13 (d, H), 7.25-7.34 (m, 2H), 7.60 (m, H), 8.05 (m, H), 8.65 (d, H), 8.79 (d, H), 9.20 (s, 2H).
Example 141 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(lH-tetrazol-5-ylmethyD- indol-1-vH -amide
Figure imgf000148_0001
Following procedures similar to those of Example 136, but substituting 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid (3-cyanomethyl-indol-l-yl)-amide for 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid (4-cyano-indol-l-yl)-amide, there is prepared 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(lH-tetrazol-5-ylmethyl)-indol- 1-yl-amide (12%) as a solid. MS: 429 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.85 (s, 3H), 4.52 (s, 2H), 7.15 (m, H), 7.24-7.35 (m, 2H), 7.36-7.50 (m, 2H), 7.55 (m, H), 8.23 (d, H), 8.37 (d, H), 9.15 (s, H).
Example 142
2-(2-Phenyl-pyrimidine-5-carbonyl)- 1 -hydrazinecarboxamide
Figure imgf000148_0002
Following procedures similar to those of Example 64 but substituting semicarbazide hydrochloride for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-(2-phenyl-pyrimidine-5-carbonyl)- 1 -hydrozinecarboximide (62%) as a solid. MS: 258 (M+H).
Example 143
2-(2-Phenyl-pyrimidine-5 -carbonyl)- 1 -hydrazine- 1 -carbothioamide
Figure imgf000149_0001
Following procedures similar to those of Example 64, but substituting thiosemicarbazide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-(2-phenyl-pyrimidine-5-carbonyl)-l -hydrazine- 1-carbothioamide (27%) as a solid. MS: 274 (M+H).
Example 144
2-Phenyl-pyrimidine-5-carboxylic acid (2,4-dioxo-imidazolidin-l-vD-amide
Figure imgf000149_0002
Following procedures similar to those of Example 64 but substituting 2,4-dioxo-imidazolidin- 1-ylamine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (2,4-dioxo-imidazolidin-l-vD- amide (8%) as a solid. MS: 298 (M+H).
Example 145
2-Phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H-π ,2,41triazin-4-vD- amide
Figure imgf000149_0003
Following procedures similar to those of Example 64 but substituting 6-methyl-3-oxo-2,5- dihydro-3H-[ 1 ,2,4]triazin-4-ylamine for 3- {3-amino-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidin- 5 -propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H-r 1.2.41triazin-4-yl)-amide (39%) as a solid. MS: 311 (M+H); 1H NMR (300 MHz, CD3OD): δ 1.98 (s, 3H), 4.32 (s, 2H), 7.45-7.63 (m, 3H), 8.50 (d, 2H), 9.24 (s, 2H).
Example 146
2-Phenyl-pyrimidine-5-carboxylic acid N'-phenyl-hydrazide
Figure imgf000150_0001
Following procedures similar to those of Example 64 but substituting N '-phenyl-hydrazine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'-phenyl-hydrazide (18%) as a solid. MS: 291 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.34 (s, N-H), 6.82-7.04 (m, 2H), 7.15-7.39 (m, 3H), 7.40-7.63 (m, 3H), 7.94 (s, N-H), 8.51 (d, 2H), 9.20 (s, 2H).
Example 147
Pyridine -2-carboxylic acid N ' -(2-phenyl-pyrimidine-5 -carbonvD-hydrazide
Figure imgf000150_0002
Following procedures similar to those of Example 64, but substituting 2-pyridine-2-carboxylic acid hydrazide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared pyridine-2-carboxylic acid N'-(2-phenyl-pyrimidine-5- carbonvO-hydrazide (52%) as a solid. MS: 320 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 7.75(m, 4H), 7.98-8.14 (m, 2H), 8.46 (d, 2H), 8.73 (d, H), 9.32 (s, 2H), 10.81 (s, N-H), 10.96 (br, N-H).
Example 148
4- [N ' -(2-Phenyl-pyrimidine-5 -carbonvD-hydrazinol -benzenesulfonamide
Figure imgf000151_0001
Following procedures similar to those of Example 64, but using substituting 4-hydrazino- benzebesulfonamide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 4- [N ' -(2-phenyl-pyrimidine-5 -carbonyD-hydrazino] - benzenesulfonamide (36%) as a solid. MS: 370 (M+H).
Example 149
3 -Hydroxy-benzoic acid N ' -(2-phenyl-pyrimidine-5 -carbonvD-hydrazide
Figure imgf000151_0002
Following procedures similar to those of Example 64, but substituting 3 -hydroxy-benzoic acid hydrazide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 3 -hydroxy-benzoic acid N'-(2-phenyl-pyrimidine-5-carbonv0- hvdrazide (56%) as a solid. MS: 335 (M+H).
Example 150
Benzori,31dioxo-5-carboxyric acid N'-(phenyl-pyrimidine-5-carbonyl)-hydrazide
Figure imgf000151_0003
Following procedures similar to those of Example 64, but substituting benzo[l,3]dioxo-5- carboxylic acid hydrazide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared benzori,31dioxo-5-carboxylic acid N'-fphenyl-pyrimidine- 5-carbonyl)-hvdrazide (83%) as a solid. MS: 363 (M+H).
Example 151 3 ,4-Dimethoxy-benzoic acid N ' -(phenyl-pyrimidine-5 -carbonyD-hydrazide
Figure imgf000152_0001
Following procedures similar to those of Example 64 but substituting 3,4-dimethoxy-benzoic acid hydrazide for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 3,4-dimethoxy-benzoic acid N'-(phenyl-pyrimidine-5- carbonvO-hydrazide (76%) as a solid. MS: 379 (M+H).
Example 152
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -phenyl-hvdrazide
Figure imgf000152_0002
Following procedures similar to those of Example 64, but substituting N' -methyl-N '-phenyl- hydrazine for 3-{3-amino-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidin-5-propionic acid methyl ester, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid N'-methyl-N'-phenyl- hvdrazide (80 mg, 88%) as a solid. MS: 305 (M+H).
Example 153
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-indol- 1 -vD- amide
Figure imgf000152_0003
Step 1 : A solution of potassium tert-butoxide (5.23 g, 46.62 mmol) and 5-methoxy-3- methylindole (3.41 g, 21.15 mmol) in DMF (20 mL) is stirred at rt for 45 min. A solution of monochloroamine in ether (400 mL, 60 mmol) is added via an addition funnel over 15 min. The resulting mixture is stirred for 2 h. The solvent is removed and the residue is partitioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCθ3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by column chromatography eluting with 10% EtOAc in heptane to afford 5-methoxy- 3-methyl-indol- 1 -ylamine (1.42 g, 38%) as a solid. MS: 176 (M+H); 1H NMR (300MHz, CDCl3): δ 7.26-7.23 (m, IH), 6.98-6.97 (m, IH), 6.91-6.87 (m, 2H), 4.64 (br s, 2 H), 3.86 (s, 3H), 2.26-2.25 (m, 3H).
Step 2: A microwave vial (20 mL) is charged with 2-(3-fluoro-phenyl)-4-methyl-pyrimidine- 5-carboxylic acid (657 mg, 2.83 mmol), HOTT (1.16 g, 3.11 mmol), DIPEA (1.35 mL, 7.73 mmol) and DMF (6 mL). The mixture is stirred at 23°C under N2 for 15 min. 5-Methoxy-3- methyl-indol-1 -ylamine (456 mg, 2.59 mmol) is added and the vial is capped. The resulting mixture is heated in a microwave (Biotage-Initiator) at 1500C for 6 min. The mixture is portioned between EtOAc and water. The organic phase is separated, washed with saturated aqueous NaHCO3, water and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue is purified by column chromatography eluting with 45% EtOAc in heptane to afford 2z (3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-indol- 1 -vD- amide (327 mg, 32%) as a solid. MS: 391 (M+H); 1H NMR (300MHz, d6-DMSO): δ 11.75 (s, IH), 9.19 (s, IH), 8.32 (d, IH), 8.18-8.16 (m, IH), 7.66-7.62 (m, IH), 7.45 (td, IH), 7.30 (d, IH), 7.22 (s, IH), 7.05 (d, IH), 6.85 (dd, IH), 3.81 (s, 3H), 2.76 (s, 3H), 2.27 (s, 3H).
Example 154
2-(3-Hvdroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000153_0001
Step 1 : Following the procedures similar to those of Example 59, step 1, but substituting 3- hydroxyphenylboronic acid for 3-methoxyphenylboronic acid, there is prepared 2-(3-hydroxy- phenvD-pyrimidine-5-carboxylic acid methyl ester. Step 2: Following the procedures similar to those of Example 59, step 2, but substituting 2-(3- hydroxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester for 2-(3-methoxy-phenyl)- pyrimidine-5-carboxylic acid methyl ester, there is prepared 2-(3 -hydroxy-phenyl)- pyrimidine-5-carboxylic acid.
Step 3: Following the procedures similar to those of Example 59, step 3, but substituting 2-(3- hydroxy-phenyl)-pyrimidine-5-carboxylic acid for 2-(3-methoxy-phenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(3-hvdroxy-phenyl)-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H-π.2.41triazin-4-vn-amide. MS: 327 (M+H); 1U NMR (DMSO- d6): δ 1.91 (s, 3H), 4.22(s, 2H), 5.75 (s, IH), 6.98 (m, IH), 7.36 (m, IH), 7.90 (m, IH), 9.25 (s, 2H), 9.71 (s, IH), 9.95 (s, IH), 11.05 (s, IH). IC50 = 21 nM.
Example 155
2-(2-Hvdroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000154_0001
Step 1 : Following the procedures similar to those of Example 59, step 1, but substituting 2- hydroxyphenylboronic acid for 3-methoxyphenylboronic acid, there is prepared 2-(2-hydroxy- phenyl)-pyrimidine-5-carboxylic acid methyl ester.
Step 2: Following the procedures similar to those of Example 59, step 2, but substituting 2-(2- hydroxy-phenyl)-pyrimidine-5-carboxylic acid methyl ester for 2-(3-methoxy-phenyl)- pyrimidine-5-carboxylic acid methyl ester, there is prepared 2-(2-hydroxy-phenyD- pyrimidine-5-carboxylic acid.
Step 3: Following the procedures similar to those of Example 59, step 3, but substituting 2-(2- hydroxy-phenyl)-pyrimidine-5-carboxylic acid for 2-(3-methoxy-phenyl)-pyrimidine-5- carboxylic acid, there is prepared 2-(2-hydroxy-phenyl)-pyrimidine-5-carboxylic acid (6- methyl-3-oxo-2.5-dihvdro-3H-π.2.41triazin-4-vn-amide. MS: 327 (M+H); Hl NMR (DMSO-d6): δ = 1.91 (s, 3H), 4.22(s, 2H), 7.02 (m, 2H), 7.50 (m, IH), 8.46 (m, IH), 9.32 (s, 2H), 9.97 (s, IH), 11.12 (s, IH), 12.95 (s, IH).
Example 156 2-(4-Hvdroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihvdro-3H- r 1 ,2,41triazin-4-yl)-amide
Figure imgf000155_0001
A mixture of 2-(4-methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5- dihydro-3H-[l,2,4]triazin-4-yl)-amide (100 mg, 0.29 mmol), sodium methanethiolate (206 mg, 2.9 mmol) and DMF (2 mL) is stirred at 1100C for 6 h., and then cooled to rt. The reaction mixture is concentrated in vacuo, and the residue is purified on a reverse phase HPLC chromatography to afford 2-(4-hvdroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3- oxo-2.5-dihvdro-3H-π.2.41triazin-4-vn-amide (32 mg). MS: 327 (M+H); 1H NMR (DMSO- d6): δ 1.87 (s, 3H), 4.17 (s, 2H), 6.74 (m, 2H), 8.21 (d, J= 6.9 Hz, 2H), 9.08 (s, 2H), 9.53 (s, IH).
Example 157
4-Methyl-r2,2'1bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide
Figure imgf000155_0002
Step 1 : A flask containing 2-cyanopyrimidine (16.6 g, 158 mmol), ammonium acetate (14.6 g, 189.6 mmol) and N-acetylcysteine (2.58 g, 15.8 mmol) and ethanol (160 mL) is heated to reflux. After 1.25 h, the reaction is allowed to cool slightly (to approximately 5O0C), and sodium tert-butoxide (15.18 g, 158 mmol) and ethanol (160 mL) are added. After stirring for 10 minutes, 2-dimethylaminomethylene-3-oxo-butyric acid ethyl ester (33.6 g, 181.7 mmol) is added. The reaction is then heated to reflux for an additional 2 h. The reaction is then allowed to cool to rt, and sodium hydroxide (12.6 g, 316 mmol) in water (50 mL) is added. After 2 h, the reaction is chilled in an ice water bath and the reaction pH is adjusted to ~ 3 using a solution of- 12M aqueous HCl. The reaction mixture is then reduced in vacuo to ~ 100 mL. Additional water (100 mL) is added and the suspension is chilled in an ice water bath, filtered and the solids are washed with minimal chilled water. The solids are then dried in vacuo to afford 4-methvH2,2Hbipyrimidinyl-5-carboxylic acid (85%). MS: 217 (M+H); 1H NMR (300 MHz, CDCl3): δ = 2.80 (s, 3H), 7.66 (t, IH), 9.01 (d, 2H), 9.14 (s, IH).
Step 2. 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (0.5 g, 2.31 mmol) is combined with 5-fluoro-3-methyl-indol-l-yl-ammonium chloride (464 mg, 2.31 mmol), N-methylmorpholine (233 mg, 2.31 mmol) and DMF (10 mL). The suspension is stirred for 5 minutes at rt, then 4- (4,6-dimethoxy-[l,3,5]triazin-2-yl)-4-methyl-morpholin-4-ium chloride is added (640 mg, 2.31 mmol). The reaction is heated to 5O0C for 4 h. The reaction is then poured into water (50 mL), the suspension is chilled for 2 h in the refrigerator, and then filtered. The solids are then suspended in acetonitrile at 5O0C for 4 h, cooled, then filtered to afford 4-methyl- r2,2'lbipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide (60%). MS: 363 (M+H); 1H NMR (300 MHz, CDCl3): δ = 2.27 (s, 3H), 2.77 (s, 3H), 7.07 (dt, IH), 7.36 (dd, IH), 7.38 (s, IH), 7.44-7.48 (m, IH), 7.70 (t, IH), 9.05 (d, 2H), 9.29 (s, IH), 11.9 (s, IH). IC50 = 4.5 nM.
Example 158
2-Thiazol-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide
Figure imgf000156_0001
Step 1 : A flask is charged with 2-cyanothiazole (6.7 g, 60.9 mmol), ammonium acetate (5.63 g, 73 mmol), N-acetylcysteine (993 mg, 6.09 mmol), and methanol (6OmL). The reaction is then heated to reflux overnight. The reaction is reduced in vacuo to yield a residue that is used in the next step without further modifications. Step 2: The crude residue from Step 1 is suspended in DMF (100 mL). To this is added sodium 2-ethoxycarbonyl-3-oxo-but-l-en-l-olate (13.86 g, 70 mmol). The reaction is then heated to 1000C for 1.5 h then allowed to cool to rt. The reaction is then poured into ice water (1 L). The suspension is filtered and the filtrate is successively extracted with DCM (100 mL) and EtOAc (200 mL). The organic layers are dried (Na2SO4), filtered and concentrated to yield a residue (10.31 g).
Step 3: The residue from Step 2 (6.26 g, 28.32 mmol) is combined with a solution of sodium hydroxide (2.26 g, 56.65 mmol) in water (90 mL) and methanol (90 mL) and stirred at rt overnight. The volume of solution is reduced by half under vacuo and the pH is adjusted to 3 with aqueous HCl (approximately 12 M). The solid is collected by filtration and dried in vacuo to afford 2-thiazol-2-yl-pyrimidine-5-carboxylic acid (56% over 3 steps). MS: 208 (M+H); 1H NMR (300 MHz, CDCl3): δ = 8.11 (d, IH), 8.16 (d, IH), 9.32 (s, 2H).
Step 4 : A mixture of 2-thiazol-2-yl-pyrimidine-5-carboxylic acid (50 mg, 0.244 mmol), 5- fluoro-3-methyl-indol-l-yl-ammonium chloride (49 mg, 0.244 mmol), diisopropylethylamine (31.5 mg, 0.244 mmol) in DMF (1 mL) is stirred at rt for 5 min. 4-(4,6-Dimethoxy- [l,3,5]triazin-2-yl)-4-methyl-morpholin-4-ium chloride (37 mg, 0.244 mmol) is added. The reaction is heated to 5O0C for 1.5 h and then concentrated in vacuo. The residue is taken up in DMSO- d6 then purified via reverse phase Cl 8 HPLC chromatography eluting with water and acetonitrile containing 0.1% TFA buffer to afford 2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -vQ-amide (58%). MS: 354 (M+H); 1H NMR (300 MHz, CDCl3): δ = 2.27 (s, 3H), 7.05 (dt, IH), 7.32 (s, IH), 7.32-7.44 (m, 2H), 8.11 (d, IH), 8.19 (d, IH), 9.42 (s, 2H), 12.12 (s, IH).
Example 159
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide
Figure imgf000158_0001
Step 1 : A solution of 2-cyanothiazole (1.55 g, 14.2 mmol) in MeOH (12 mL) is treated with //-acetylcysteine (234 mg, 1.42 mmol), ammonium acetate (1.5 g, 18.5 mmol) and heated in a microwave at 1200C for 15 min. The mixture is then treated with 2-dimethylaminomethylene- 3-oxo-butyric acid ethyl ester (3.2 g, 17.0 mmol) and KOt-Bu (2.2 g, 20 mmol), and heated in a microwave at 1200C for an additional 15 min. The mixture is then treated with a solution of KOH (1.2 g, 20 mmol) in H2O (5 mL) and heated at reflux for 1 h. The mixture is neutralized with concentrated aqueous HCl. The precipitate is collected by filtration and dried to afford 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (1.95 g, 62%). MS: 222 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 13.77 (s. OH, IH), 9.18 (s, IH), 8.13 (d, IH), 8.07 (d, IH), 2.81 (s, 3H).
Step 2: A mixture of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (221 mg, 1 mmol), 5-fluoro-3-methyl-indol-l-yl-ammonium chloride (200 mg, 1 mmol) and N-methylmorpho line (101 mg, 1 mmol) in DMF (5 mL) is stirred at rt for 5 min. 4-(4,6-Dimethoxy-[l,3,5]triazin- 2-yl)-4-methyl-morpholin-4-ium chloride (277 mg, 1 mmol) is added and the reaction is heated to 5O0C for 4 h. The reaction mixture is then poured into water (50 mL). The precipitate is collected via filtration and dried in vacuo to provide 4-methyl-2-thiazol-2-yl- pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide (68%). MS: 368 (M+H); 1H NMR (300 MHz, CDCl3): δ = 2.27 (s, 3H), 2.76 (s, 3H), 7.06 (dt, IH), 7.35-7.38 (m, 2H), 7.42-7.47 (m, IH), 8.07 (d, IH), 8.14 (d, IH), 9.22 (s, IH), 11.9 (s, IH).
Example 160
[2,2'lBipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide
Figure imgf000159_0001
Step 1 : A pressure vessel is charged with 2-cyanopyrimidine (7.88 g, 75 mmol), N-acetyl cysteine (1.22g, 7.5 mmol), ammonium acetate (6.93 g, 90 mmol), and MeOH (75 mL). The vessel is sealed and heated at HO0C for 1.5 h, and then cooled to rt. To the reaction mixture is added sodium 2-ethoxycarbonyl-3-oxo-but-l-en-l-olate (17 g, 86.25 mmol) and MeOH (75 mL). The mixture is heated to reflux for 1.5 h and then cooled to rt. NaOH (6 g, 150 mmol) and water (80 mL) are added. The mixture is stirred for 30 min or until LC-MS indicates complete hydrolysis of the intermediate ester. The pH of the reaction mixture is adjusted to ~ 3 with concentrated (~12 M) aqueous HCl. MeOH is evaporated in vacuo, and the resulting precipitate is collected via filtration and washed with minimal chilled water to yield r2.2'lbipyrimidinyl-5-carboxylic acid (59%). MS: 203 (M+H); 1H NMR (300 MHz, CDCl3): δ = 7.71 (t, IH), 9.06 (d, 2H), 9.40 (s, 2H).
Step 2: A mixture of [2,2']bipyrimidinyl-5-carboxylic acid (166 mg, 0.82 mmol), 5-fluoro-3- methyl-indol-1-yl-ammonium chloride (164 mg, 0.82 mmol) and DIPEA (106 mg, 0.82 mmol) in DMF (5 mL) is stirred at rt for 5 min. 4-(4,6-Dimethoxy-[l,3,5]triazin-2-yl)-4- methyl-morpholin-4-ium chloride (226 mg, 0.82 mmol) is added. The reaction mixture is heated to 5O0C for 1.5 h and then concentrated in vacuo. The residue is taken up in DMSO- d6 and then purified via reverse phase Cl 8 HPLC chromatography eluting with water and acetonitrile containing 0.1% TFA buffer to afford r2,2'lbipyrimidinyl-5-carboxylic acid (5- fluoro-3-methyl-indol- 1 -vQ-amide (56%). MS: 349 (M+H); 1U NMR (300 MHz, CDCl3): δ = 2.27 (s, 3H), 7.05 (dt, IH), 7.33 (s, IH), 7.36 (dd, IH), 7.42-7.46 (m, IH), 7.72 (t, IH), 9.07 (d, 2H), 9.51 (s, 2H), 12.17 (s, IH).
Example 161
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylicacid(3chloro-5-fluoro-indol-l-yl)- amide
Figure imgf000160_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-indol-l- yl)-amide (300 mg, 0.824 mmol) in MeCN (20 niL) is treated with NCS (185 mg, 1.42 mmol) and the mixture is stirred at 600C in a sealed flask for 2 h. The mixture is then concentrated, diluted with 10% aqueous Na2S2O8 (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 20% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylicacid(3chloro-5-fluoro-indol-l- vQ-amide (160 mg, 49%). MS: 399 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.79 (s, IH), 8.04 (d, IH), 7.92 (d, IH), 7.18 (m, IH), 7.04 (s, IH), 7.00 (m, 3), 6.76 (m, 1), 2.52 (s, 3H).
Example 162
5 -Fluoro- 1 - { [2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyll -amino 1-1 H-indole-3 - carboxylic acid amide
Figure imgf000160_0002
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-indol-l- yl)-amide (300 mg, 0.82 mmol) in 2-Me-THF (7 mL) is treated with chlorosulfonyl isocyanate (CSI) (85 uL, 2.0 mmol) at 00C, and the mixture is warmed to rt for 2 h. The mixture is then cooled to 00C, treated with 1 M NaOH (1 mL), diluted with brine (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo to afford 5 -fluoro- 1 - { [2-(3 -fluoro-pheny l)-4-methyl-pyrimidine-5 - carbonyll-aminol-lH-indole-3-carboxylic acid amide (275 mg, 83%). MS: 408 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.27 (s, IH), 8.35 (d, IH), 8.26 (s, IH), 8.20 (d, IH), 7.95 (d, IH), 7.59 (m, 3H), 7.15 (m, IH), 2.78 (s, 3H). IC50 = 8 nM. Example 163
2-{5-Fluoro-l-r(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-aminol-lH-indol-3-yl|-2- methyl-propionic acid
Figure imgf000161_0001
Step 1 : A solution of (5-fluoro-lH-indol-3-yl)-acetic acid methyl ester (3 g, 14.8 mmol) in MeCN (25 niL) is treated with BoC2O (4.3 g, 16.3 mmol) and DMAP (200 mg, 1.63 mmol), and the mixture is stirred at rt for 1 h. The mixture is diluted with saturated aqueous NH4Cl (50 mL), and extracted with DCM (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 8% EtOAc in heptane to afford 5 -fluoro-3 - methoxycarbonylmethyl-indole-l-carboxylic acid fert-butyl ester (1.6 g, 35%). MS: 371 (M+Na+ACN); 1H NMR (300 MHz, CDCl3): δ 8.09 (m, IH), 7.59 (s, IH), 7.17 (m, IH), 7.04 (m, IH), 3.72 (s, 3H), 3.67 (s, 2H), 1.55 (s, 9H).
Step 2: A solution of 5 -fluoro-3 -methoxycarbonylmethyl-indole-l-carboxylic acid tert-butyl ester (1.6 g, 5.2 mmol) in 2-Me-THF (50 mL) at -78°C is treated with LDA (5.7 mL 1.8 M in THF, 10.4 mmol) and stirred for 0.5 h. MeI (1.02 mL, 15.6 mmol) is added and the mixture is warmed to 00C over 2 h. The mixture is diluted with saturated aqueous NH4Cl (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo to afford 5 -fluoro-3 -( 1 -methoxycarbonyl- 1 -methyl-ethyl)- indole-1-carboxylic acid fert-butyl ester, which is used in the next step without further purification.
Step 3 : A solution of 5 -fluoro-3 -( 1 -methoxycarbonyl- 1 -methyl-ethyl)-indole- 1 -carboxylic acid tert-butyl ester (5.2 mmol) in MeOH (25 mL) is treated with K2CO3 (720 mg, 5.2 mmol) and heated at reflux for 2 h. The mixture is diluted with brine (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 2-(5-fluoro-lH-indol-3-yl)-2-methyl-propionic acid methyl ester (650 mg, 53%, 2 steps), which is used in the next step without further purification. MS: 236 (M+H); 1H NMR (300 MHz, DMSO- d6): δ 7.35 (m, IH), 7.30 (m, IH), 7.14 (m, IH), 6.91 (m, IH), 3.54 (s, 3H), 1.57 (s, 6H).
Step 4: A suspension of NaH (1.02 g, 25.5 mmol, 60% in mineral oil) in DMF (25 rnL) at 00C is treated with 2-(5-fluoro-lH-indol-3-yl)-2-methyl-propionic acid methyl ester (400 mg, 1.7 mmol) and stirred at 00C for 0.5 h. The mixture is treated with HOSA (960 mg, 8.5 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 100 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 2-(l-amino-5-fluoro-lH-indol-3-yl)- 2- methyl-propionic acid methyl ester, which is used in the next step without further purification.
Step 5: A solution of 2-(l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-propionic acid methyl ester (0.85 mmol) and 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (201 mg, 0.935 mmol) in DMF (8.5 mL) is stirred at 400C for 0.5 h. The mixture is treated with DMTMM (246 mg, 0.89 mmol) and stirred at 600C for 1 h. The mixture is concentrated in vacuo, diluted with saturated aqueous Na2CO3 (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 2-{5- fluoro- 1 -[(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-aminol- lH-indol-3-yl| -2-methyl- propionic acid methyl ester, which is used in the next step without further purification.
Step 6: A solution of 2-{5-fluoro-l-[(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)- amino]-lH-indol-3-yl}-2-methyl-propionic acid methyl ester (0.85 mmol) in MeOH (5 mL) is treated with 10% aqueous NaOH (2 mL) and stirred at rt overnight. The mixture is then concentrated, diluted with EtOAc (50 mL), and extracted with 10% aqueous NaOH (3 x 50 mL). The aqueous layer is acidified with 12 M aqueous HCl, extracted with DCM (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated. The residue is triturated with Et2O to afford 2- {5-fluoro- 1 -[(4-methyl-2-pyridin-2-yl-pyrimidine-5- carbonvD-aminol - 1 H-indol-3 -yl| -2-methyl-propionic acid (100 mg, 27%, 3 steps). MS: 434 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.26 (s, IH), 8.79 (m, IH), 8.44 (d, IH), 8.03 (t, IH), 7.59 (m, IH), 7.53 (s, IH), 7.49 (m, IH), 7.35 (d, IH), 7.08 (t, IH), 2.79 (s, 3H), 1.59 (s, 6H). Example 164
2-(5-Fluoro-l-{[2-(3-fluoro-phenyl) ^-methyl-pyrimidine-S-carbonyli-aminol-lH-indol-S- yl)-2-methyl-propionic acid
Figure imgf000163_0001
Step 1 : A solution of 2-(l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-propionic acid methyl ester (0.85 mmol) and 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (217 mg, 0.935 mmol) in DMF (8.5 mL) is stirred at 400C for 0.5 h. The mixture is treated with DMTMM (246 mg, 0.89 mmol) and stirred at 600C for 1 h. The mixture is concentrated in vacuo, diluted with saturated aqueous Na2CO3 (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo to afford 2-(5 -fluoro- 1 - { [2-(3 -fluoro-phenyl) -4-methyl-pyrimidine-5 -carbonyl]- amino|-lH-indol-3-yl)-2-methyl-propionic acid methyl ester, which is used in the next step without further purification.
Step 2: A solution of 2-(5-fluoro-l-{[2-(3 -fluoro-phenyl) -4-methyl-pyrimidine-5-carbonyl]- amino}-lH-indol-3-yl)-2-methyl-propionic acid methyl ester (0.85 mmol) in MeOH (5 mL) is treated with 10% aqueous NaOH (2 mL) and stirred at rt overnight. The mixture is then concentrated, diluted with EtOAc (50 mL), and extracted with 10% aqueous NaOH (3 x 50 mL). The aqueous layer is acidified with 12 M HCl, and extracted with DCM (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated. The residue is triturated with Et2O to afford 2-(5 -fluoro- 1 - {[2-(3 -fluoro-phenyl) -4-methyl-pyrimidine-5- carbonyll -amino I - 1 H-indol-3 -vO- 2-methyl-propionic acid (139 mg). MS: 451 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.22 (s, IH), 8.33 (d, IH), 8.18 (d, IH), 7.63 (m, IH), 7.50 (m, 3H), 7.33 (m, IH), 7.07 (m, IH), 2.78 (s, 3H), 1.59 (s, 6H). IC50 = 7 nM.
Example 165
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3- (3-hvdroxy-3- methyl-butvD-indol- 1 -yll -amide
Figure imgf000164_0001
Step 1 : A solution of 5-fluoroindole (10.5 g, 78 mmol) in MeCN (150 niL) at 00C is treated with methyl vinyl ketone (9.5 mL, 117 mmol) and Sc(0Tf)3 (383 mg, 0.78 mmol) and stirred for 1 h. The mixture is then stirred an additional 6 h at rt. The mixture is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 50% EtOAc in heptane to afford 4-(5-fluoro-lH-indol-3-v0-butan-2-one (11.1 g, 70%).
Step 2: A solution of 4-(5-fiuoro-lH-indol-3-yl)-butan-2-one (11.1 g, 54.1 mmol) in THF (200 mL) at 00C is treated with MeMgBr (54.1 mL, 3 M in THF, 162.3 mmol) and stirred at 00C for 2 h, and warmed to rt overnight. The mixture is then poured over ice, treated with solid NH4Cl (3 g), and extracted with EtOAc (3 x 120 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 60% EtOAc in heptane to afford 4-(5-fluoro-lH-indol-3- yl)-2-methyl-butan-2-ol (3.07 g, 26%). MS: 222 (M+H); 1U NMR (300 MHz, CDCl3): δ 7.94 (s, NH, IH), 7.22 (m, 2H), 7.03 (s, IH), 6.93 (m, IH), 2.81 (m, 2H), 1.90 (m, 2H), 1.33 (s, 6H).
Step 3: A suspension of NaH (8.1 g, 204 mmol, 60% in mineral oil) in DMF (100 mL) at 00C is treated with 4-(5-fluoro-lH-indol-3-yl)-2-methyl-butan-2-ol (3 g, 13.6 mmol) and stirred at 00C for 0.5 h. The mixture is treated with HOSA (7.7 g, 68 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 100 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by filtration through a short plug of silica gel to afford 4-(l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-butan-2-ol, which is used in the next step without further purification. MS: 237 (M+H); 1U NMR (300 MHz, CDCl3): δ 7.30 (m, IH), 7.22 (m, IH), 6.98 (m, 2H), 4.71 (s, NH2, 2H), 2.75 (m, 2H), 1.86 (m, 2H), 1.31 (s, 6H). Step 4: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (278 mg, 1.2 mmol) and 4-(l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-butan-2-ol (1.2 mmol) in DMF (10 niL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (331 mg, 1.2 mmol) and stirred at 500C for 1 h. The mixture is concentrated in vacuo, diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 50% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid [5-fluoro-3- (3-hvdroxy-3-methyl-butyl)-indol-l-vH- amide (330 mg, 61%). MS: 451 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.10 (s, IH), 8.36 (d, IH), 8.23 (d, IH), 7.55 (m, IH), 7.32 (m, 3H), 7.18 (s, IH), 7.03 (m, IH), 3.91 (s, OH, IH), 2.84 (s, 3H), 2.82 (m, 2H), 1.91 (m, 2H), 1.31 (s, 6H).
Example 166
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl- butyD-indol- 1 -y 1] -amide
Figure imgf000165_0001
A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5 -carboxylic acid (516 mg, 4 mmol) and A- (l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-butan-2-ol (566 mg, 4 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (662 mg, 4 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 4% - 10% MeOH in DCM to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5- fluoro-3-(3-hvdroxy-3-methyl-butvn-indol- 1 -yll-amide (450 mg, 44%). MS: 434 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.25 (s, IH), 8.81 (d, IH), 8.47 (d, IH), 8.02 (m, IH), 7.58 (m, IH), 7.43 (m, 3H), 7.06 (m, IH), 4.29 (s, OH, IH), 2.78 (s, 3H), 2.72 (m, 2H), 1.77 (m, 2H), 120 (s, 6H). Example 167
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3- (2-pyridin-3-yl- ethyD-indol-l-yli- amide
Figure imgf000166_0001
Step 1 : A solution of 5-fluorogramine (576 mg, 3 mmol) and pyridine-3-carboxaldehyde (531 mg, 3 mmol) in MeCN (6 mL) is treated with Bu3P (1.12 mL, 4.5 mmol) and stirred at 900C for 24 h. The mixture is concentrated, filtered through a pad of silica gel eluting with 30% EtOAc in heptane to afford 5-fluoro-3-(2-pyridin-3-yl-vinyl)-lH-indole as a mixture of olefin isomers, which is used in the next step without further purification.
Step 2: A solution of 5-fluoro-3-(2-pyridin-3-yl-vinyl)-lH-indole (3 mmol) in MeOH (10 mL) is treated with Pd/C (200 mg) and shaken in a Parr apparatus under 40 atm of H2 for 18 h. The mixture is filtered through Celite and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 10% MeOH in DCM to afford 5_; fluoro-3-(2-pyridin-3-yl-ethylVlH-indole (360 mg, 50%, 2 steps).
Step 3: A suspension of NaH (600 mg, 15 mmol, 60% in mineral oil) in DMF (10 mL) at 00C is treated with 5-fluoro-3-(2-pyridin-3-yl-ethyl)-lH-indole (240 mg, 1 mmol) and stirred at 00C for 0.5 h. The mixture is treated with HOSA (565 mg, 5 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 1050 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 5-fluoro-3-(2-pyridin-3-yl-ethyl)-indol- 1 -ylamine, which is used in the next step without further purification.
Step 4: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (232 mg, 1 mmol) and 5-fluoro-3-(2-pyridin-3-yl-ethyl)-indol-l-ylamine (255 mmol) in DMF (10 mL) is stirred at 500C for 10 min. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 0.5 h. The mixture is diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by triturating in MeOH:H2O (2:1) to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5-fluoro-3- (2-pyridin-3- yl-ethvn-indol-1-yll- amide (6 mg, 1%). MS: 470 (M+H); 1U NMR (300 MHz, DMSO-d6): δ 9.21 (s, IH), 8.51 (m, IH), 8.40 (m, IH), 8.33 (d, IH), 8.19 (d, IH), 7.74 (d, IH), 7.63 (m, IH), 7.45 (m, 4H), 7.33 (m, IH), 7.06 (m, IH), 3.29 (s, 2H), 3.01 (s, 2H), 2.77 (s, 3H).
Example 168
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-formyl-indol- 1 -yl)-amide
Figure imgf000167_0001
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol-l-yl)- amide (250 mg, 0.55 mmol) in H2O (5.5 mL) is treated with DDQ (369 mg, 1.6 mmol) in
EtOAc (0.5 mL), and stirred at rt for 2 h. The mixture is diluted with EtOAc (50 mL), washed with brine (50 mL), and extracted with saturated aqueous NaHCO3 (3 x 50 mL). The aqueous layer is acidified to pH 2 with HCl (cone.) and washed with Et2O (50 mL). The aqueous layer is neutralized with 10% aqueous NaOH and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by triturating in Et2O to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5-fJuoro-3-formyl-indol- 1 -vQ-amide (87 mg, 43%). MS: 376 (M+H); 1H NMR (300 MHz, DMSO-de): δ 12.53 (s, NH, IH), 10.00 (s, IH), 9.34 (m, IH), 8.81 (m, IH), 8.66 (s, IH), 8.48 (m, IH), 8.04 (m, IH), 7.86 (m, IH), 7.72 (m, IH), 7.61 (m, IH), 7.27 (m, IH), 2.80 (s, 3H).
Example 169
5 -Fluoro- 1 - |Y4-methyl-2-pyridin-2-y l-pyrimidine-5 -carbonyP-amino] - 1 H-indole-3 -carboxylic acid
Figure imgf000167_0002
Step 1 : A solution of 5-fluoro- lH-indole-3-carboxylic acid methyl ester (510 mg, 2.6 mmol) in NMP (6.5 rnL) at rt is treated with KOt-Bu (342 mg, 2.9 mmol) and stirred at rt for 0.5 h. A solution of O-amino-4-nitrobenzoic acid (558 mg, 3.0 mmol) in NMP (2.5 mL) is added and the mixture is stirred for 3 h. The mixture is diluted with EtOAc (50 mL) and washed with 10% aqueous NaHCO3 (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo to afford l-amino-5-fluoro-lH-indole-3-carboxylic acid methyl ester, which is used in the next step without further purification.
Step 2: A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5-carboxylic acid (559 mg, 2.6 mmol) and l-amino-5-fluoro-lH-indole-3-carboxylic acid methyl ester (540 mg, 2.6 mmol) in DMF (25 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (718 mg, 2.6 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 1 % - 10% MeOH in DCM to afford 5-fluoro- 1 -r(4-methyl-2-pyridin-2-yl- pyrimidine-S-carbonvD-aminoi-lH-indole-S-carboxylic acid methyl ester.
Step 3: A solution of 5-fluoro- 1- [(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-amino]- lH-indole-3-carboxylic acid methyl ester (2.6 mmol) in MeOH (10 mL) is treated with an aqueous solution of KOH (500 mg, 8.9 mmol) in H2O (200 mL) and heated at reflux for 2 h. The mixture is diluted with EtOAc (50 mL) and extracted with 1% aqueous KOH (3 x 50 mL). The combined aqueous layer is neutralized with HCl (cone), and the precipitate is collected by filtration and dried in vacuo to afford 5-fluoro- 1 -[(4-methyl-2-pyridin-2-yl- pyrimidine-S-carbonvD-aminoi-lH-indole-S-carboxylic acid (195 mg, 19%, 3 steps). MS: 392 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.44 (s, OH, IH), 12.31 (s, NH, IH), 9.31 (s, IH), 8.81 (d, IH), 8.48 (d, IH), 8.35 (s, IH), 8.03 (m, IH), 7.77 (m, IH), 7.62 (m, 2H), 7.19 (m, IH), 2.79 (s, 3H).
Example 170 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -hydroxymethyl-indol- 1 -vD- amide
Figure imgf000169_0001
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5 -fluoro-3 -formyl-indol- l-yl)-amide (230 mg, 0.614 mmol) in MeOH (10 niL) is treated with NaBH4 (233 mg, 6.14 mmol) and stirred at rt for 1 h. The mixture is diluted with EtOAc (50 mL) and H2O, neutralized with HCl (cone), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by preparative reverse-phase HPLC eluting with 20% - 100% MeCN in H2O to afford 4-methyl- 2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -hydroxymethyl-indol- 1 -yl)-amide (90 mg, 8%). MS: 378 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 11.92 (s, NH, IH), 9.27 (s, IH), 8.81 (d, IH), 8.47 (d, IH), 8.05 (m, IH), 7.61 (m, IH), 7.44 (m, 3H), 7.10 (m, IH), 5.00 (t, OH, IH), 4.66 (d, 2H), 2.78 (s, 3H).
Example 171
4-Methyl-r2,2'lbipyrimidinyl-5-carboxylic acid [5 -fluoro-3 -(3 -hvdroxy-3-methyl-butyl)-indol- 1-vH-amide
Figure imgf000169_0002
A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (300 mg, 1.38 mmol) and 4-(l- amino-5-fluoro-lH-indol-3-yl)- 2-methyl-butan-2-ol (325 mg, 1.38 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (380 mg, 1.38 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 7% MeOH in DCM to afford 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid [5 -fluoro-3 -(3- hvdroxy-3-methyl-butvn-indol- 1 -yll-amide (200 mg, 33%). MS: 435 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.26 (s, IH), 9.09 (d, 2H), 7.70 (t, IH), 7.29 (m, 2H), 7.22 (s, IH), 7.01 (m, IH), 2.90 (s, 3H), 2.82 (m, 2H), 1.91 (m, 2H), 1.31 (s, 6H).
Example 172 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid r5-fluoro-3-(3-hvdroxy-3-methyl- butvD-indol- 1 -yll -amide
Figure imgf000170_0001
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (300 mg, 1.36 mmol) and 4-(l-amino-5-fluoro-lH-indol-3-yl)- 2-methyl-butan-2-ol (325 mg, 1.38 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (380 mg, 1.38 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 7% MeOH in DCM to afford 4-methyl-2-thiazol-2-yl-pyrimidine-5- carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl-butyD-indol- 1 -yl] -amide (155 mg, 26%). MS: 440 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.22 (s, IH), 8.14 (d, IH), 8.08 (d, IH), 7.40 (m, 3H), 7.06 (m, IH), 4.31 (s, OH, IH), 2.76 (s, 3H), 2.71 (m, 2H), 1.77 (m, 2H), 1.20 (s, 6H). IC50 = 5 nM.
Example 173
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- 1-vD-amide
Figure imgf000170_0002
Step 1 : A solution of 2-iodo-4-trifluoromethyl-phenylamine (10 g, 34.8 mmol) in DCM (100 niL) is treated with TFAA (5.55 mL, 41.8 mmol) and pyridine (3.4 mL, 41.8 mmol), and stirred at rt for 1 h. The mixture is diluted with H2O (150 mL), and extracted with DCM (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is diluted with MeCN (100 mL), treated with trans-crotyi bromide (5.4 mL, 52.2 mmol) and K2CO3 (9.6 g, 69.6 mmol), and heated at reflux for 2 h. The mixture is cooled, filtered through a pad of Celite and concentrated. The residue is purified by silica gel chromatography eluting with 0% - 10% EtOAc in heptane to afford iV-but-2-enyl-2,2,2- trifluoro-N-(2-iodo-4-trifluoromethyl-phenylVacetamide (12.7 g, 84%). MS: 438 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.18 (s, IH), 7.67 (s, IH), 7.26 (m, IH), 5.52 (m, 2H), 4.88 (m, IH), 3.51 (m, IH), 1.68 (d, 3H).
Step 2: A solution of 7V-but-2-enyl-2,2,2-trifluoro-N-(2-iodo-4-trifluoromethyl-phenyl)- acetamide (12.7 g, 29 mmol) in DMF (60 mL) is treated with /7-Bu4NCl (8.8 g, 32 mmol), Pd(OAc)2 (131 mg, 0.58 mmol), and stirred at 1000C for 2 h. The mixture is cooled to rt, diluted with EtOAc (150 mL), filtered through a pad of silica gel, and washed with 1 M HCl (150 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 30% EtOAc in heptane to afford 3-ethyl-5-trifluoromethyl-lH-indole (2.6 g, 42%). MS: 214 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.08 (s, NH, IH), 7.89 (s, IH), 7.41 (m, 2H), 7.07 (m, IH), 2.81 (q, 2H), 1.34 (t, 3H).
Step 3: A suspension of NaH (7 g, 176 mmol, 60% in mineral oil) in DMF (50 mL) at 00C is treated with 3-ethyl-5-trifluoromethyl-lH-indole (2.4 g, 11.3 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (6.6 g, 59 mmol) portion wise and warmed to rt over 2 h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 50% EtOAc in heptane to afford 3 -ethyl-5 -trifluoromethyl-indol- 1 -ylamine (1.3 g, 50%). MS: 229 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.84 (s, IH), 7.45 (s, 2H), 7.02 (s, IH), 4.74 (s, NH2, 2H), 2.77 (q, 2H), 1.31 (t, 3H). Step 4: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (232 mg, 1.0 mmol) and 3-ethyl-5-trifluoromethyl-indol-l-ylamine (228 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)-amide (240 mg, 54%). MS: 443 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.24 (s, IH), 8.34 (d, IH), 8.26 (d, IH), 8.19 (s, IH), 7.58 (m, 2H), 7.42 (m, 3H), 2.84 (q, 2H), 2.78 (s, 3H), 1.31 (t, 3H).
Example 174
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)- amide
Figure imgf000172_0001
A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5-carboxylic acid (215 mg, 1 mmol) and 3- ethyl-5-trifluoromethyl-indol-l-ylamine (228 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)-amide (235 mg, 55%). MS: 426 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.28 (s, IH), 8.81 (d, IH), 8.48 (d, IH), 8.03 (m, IH), 7.99 (s, IH), 7.60 (m, 4H), 2.82 (q, 2H), 2.79 (s, 3H), 1.31 (t, 3H).
Example 175 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)- amide
Figure imgf000173_0001
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (221 mg, 1 mmol) and 3- ethyl-5-trifluoromethyl-indol-l-ylamine (228 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4-methyl-2-thiazol-2-yl- pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)-amide (250 mg, 58%). MS: 432 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.07 (s, NH, IH), 9.25 (s, IH), 8.15 (d, IH), 8.09 (d, IH), 7.99 (s, IH), 7.68 (d, IH), 7.51 (m, 2H), 2.77 (s, 3H), 2.74 (q, 2H), 1.29 (t, 3H).
Example 176
4-Methyl-r2,2'lbipyrimidinyl-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol-l-yl)-amide
Figure imgf000173_0002
A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (216 mg, 1 mmol) and and 3- ethyl-5-trifluoromethyl-indol-l-ylamine (228 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 2 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo. The solid is triturated in Et2O to afford 4-methyl-[2,2'lbipyrimidinyl-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol-l-yl)- amide (100 mg, 23%). MS: 427 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.11 (s, NH, IH), 9.32 (s, IH), 9.07 (d, 2H), 8.00 (s, IH), 7.69 (m, 2H), 7.53 (m, 2H), 2.80 (q, 2H), 2.79 (s, 3H), 1.31 (t, 3H). IC50 = 8 nM. Example 177
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy- indol- 1 -vD-amide
Figure imgf000174_0001
Step 1 : A solution of 2-bromo-4-trifluoromethoxy-phenylamine (7.6 g, 29.7 mmol) in DCM (60 niL) is treated with TFAA (5 rnL, 35.6 mmol) and pyridine (2.87 mL, 35.6 mmol), and stirred at rt overnight. The mixture is diluted with H2O (150 mL), and extracted with DCM (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is diluted with MeCN (60 mL), treated with trans-cxotyl bromide (4.6 mL, 44.5 mmol) and K2CO3 (8.1 g, 59 mmol), heated at reflux for 1 h, and then stirred at rt for 2 h. The mixture is filtered through a pad of Celite and the filtrate is concentrated. The residue is purified by silica gel chromatography eluting with 0% - 15% EtOAc in heptane to afford N-(2- bromo-4-trifluoromethoxy-phenyl)-Λ/-but-2-enyl-2,2,2-trifluoro-acetamide (10.5 g, 87%). MS: 406 (M+); 1H NMR (300 MHz, CDCl3): δ 7.56 (s, IH), 7.22 (m, 2H), 5.52 (m, 2H), 4.86 (m, IH), 3.57 (m, IH), 1.65 (d, 3H).
Step 2: A solution of./V-(2-bromo-4-trifluoromethoxy-phenyl)-./V-but-2-enyl-2,2,2-trifluoro- acetamide (10 g, 24.7 mmol) in DMF (50 mL) is treated with /7-Bu4NCl (7.5 g, 27.2 mmol), Pd(OAc)2 (221 mg, 0.98 mmol), and stirred at 1000C for 1 h. H2O (10 mL) is added, and the mixture is cooled to rt, filtered through a pad of silica gel. The filtrate is extracted with heptane (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 25% EtOAc in heptane to afford 3 -ethyl-5 -trifluoromethoxy- 1 H-indole (3.1 g, 55%). MS: 230 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.97 (s, NH, IH), 7.44 (s, IH), 7.29 (m, IH), 7.07 (m, 2H), 2.77 (q, 2H), 1.32 (t, 3H).
Step 3: A suspension of NaH (7.9 g, 197 mmol, 60% in mineral oil) in DMF (60 mL) at 00C is treated with 3 -ethyl-5 -trifluoromethoxy- 1 H-indole (3 g, 13.1 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (7.4 g, 65.5 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice and filtered through a pad of Celite. The filtrate is extracted with heptane (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 30% EtOAc in heptane to afford 3 -ethyl-5 -trifluoromethoxy-indol- 1 -ylamine (2.05 g, 64%). MS: 245 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.37 (m, 2H), 7.11 (m, IH), 7.00 (s, IH), 4.72 (s, NH2, 2H), 2.73 (q, 2H), 1.29 (t, 3H).
Step 4: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (250 mg, 1.1 mmol) and 3-ethyl-5-trifluoromethoxy-indol-l -ylamine (244 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethoxy-indol-l-yl)-amide (270 mg, 59%). MS: 459 (M+H); 1H NMR (300 MHz, CDCl3): δ 11.51 (s, NH, IH), 9.08 (s, IH), 8.35 (d, IH), 8.24 (d, IH), 7.48 (m, 2H), 7.22 (m, 2H), 7.11 (m, 2H), 2.85 (s, 3H), 2.80 (q, 2H), 1.35 (t, 3H).
Example 178 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1 - vD-amide
Figure imgf000175_0001
A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5-carboxylic acid (250 mg, 1.1 mmol) and 3- ethyl-5 -trifluoromethoxy-indol- 1 -ylamine (244 mg, 1.0 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1.0 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5- trifluoromethoxy-indol- 1 -vQ-amide (300 mg, 68%). MS: 442 (M+H); 1H NMR (300 MHz, DMSO-dg): δ 9.27 (s, IH), 8.81 (d, IH), 8.47 (d, IH), 8.03 (m, IH), 7.57 (m, 3H), 7.47 (s, IH), 7.21 (d, IH), 2.78 (s, 3H), 2.74 (q, 2H), 1.29 (t, 3H).
Example 179 4-Methyl-r2,2'lbipyrimidinyl-5-carboxylic acid (3-ethyl-5-trifluoromethoxy-indol-l-vO-amide
Figure imgf000176_0001
A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (250 mg, 1.1 mmol) and 3-ethyl- 5-trifluoromethoxy-indol-l-ylamine (244 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1.0 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl42,2Hbipyrimidinyl-5-carboxylic acid (3-ethyl-5- trifluoromethoxy-indol- 1 -vQ-amide (130 mg, 29%). MS: 443 (M+H); 1H NMR (300 MHz, DMSO-dg): δ 9.25 (s, IH), 9.05 (d, 2H), 7.69 (t, IH), 7.64 (s, IH), 7.54 (m, 2H), 7.14 (d, IH), 2.80 (s, 3H), 2.76 (q, 2H), 1.29 (t, 3H).
Example 180
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethoxy-indol- 1 - vD-amide
Figure imgf000176_0002
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (250 mg, 1.1 mmol) and
3-ethyl-5-trifluoromethoxy-indol-l-ylamine (244 mg, 1.0 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (276 mg, 1.0 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 rnL) and heptane (50 mL), and dried in vacuo to afford 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5- trifiuoromethoxy-indol- 1 -vO-amide (250 mg, 56%). MS: 448 (M+H); 1U NMR (300 MHz, DMSO-de): δ 9.23 (s, IH), 8.15 (m, IH), 8.09 (m, IH), 7.55 (m, 2H), 7.48 (s, IH), 7.19 (d, IH), 2.78 (s, 3H), 2.71 (m, 2H), 1.29 (t, 3H).
Example 181
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)- amide
Figure imgf000177_0001
Step 1 : A suspension of NaH (6.5 g, 162 mmol, 60% in mineral oil) in DMF (54 mL) at 00C is treated with 6-trifluoromethylindole (2.0 g, 10.8 mmol) and stirred at 00C for 0.5 h. The mixture is treated with HOSA (6.1 g, 54 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice and filtered through a pad of Celite. The filtrate is extracted with Et2O (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% - 30% EtOAc in heptane to afford 6-trifluoromethyl-indol- 1 -ylamine (1.79 g, 83%). MS: 201 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.74 (s, IH), 7.67 (d, IH), 7.35 (d, IH), 7.30 (m, IH), 6.45 (d, IH), 4.83 (s, NH2, 2H).
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (278 mg, 1.2 mmol) and 6-trifluoromethyl-indol- 1 -ylamine (200 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with Et2O/heptane overnight. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (6-trifluoromethyl-indol- l-ylVamide (180 mg, 44%). MS: 415 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.09 (s, NH, IH), 9.33 (s, IH), 8.35 (d, IH), 8.20 (d, IH), 7.90 (s, IH), 7.79 (m, 2H), 7.65 (m, IH), 7.46 (m, 2H), 6.74 (d, IH), 2.79 (s, 3H).
Example 182 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide
Figure imgf000178_0001
A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5-carboxylic acid (258 mg, 1.2 mmol) and 6- trifluoromethyl-indol-1-ylamine (200 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with Et2O/heptane overnight. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl-2- pyridin-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide (160 mg, 40%). MS: 398 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.13 (s, NH, IH), 9.36 (s, IH), 8.82 (d, IH), 8.48 (d, IH), 8.04 (m, IH), 7.83 (m, 3H), 7.60 (m, IH), 7.44 (d, IH), 6.74 (d, IH), 2.80 (s, 3H).
Example 183
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1-vO-amide
Figure imgf000178_0002
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (265 mg, 1.2 mmol) and 6-trifluoromethyl-indol- 1-ylamine (200 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with Et2θ/heptane overnight. The precipitate is collected by filtration, washed with H2O (50 rnL) and heptane (50 mL), and dried in vacuo to afford 4; methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide (160 mg, 40%). MS: 404 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.12 (s, NH, IH), 9.33 (s, IH), 8.15 (d, IH), 8.05 (d, IH), 7.91 (s, IH), 7.79 (m, 2H), 7.44 (m, IH), 6.73 (d, IH), 2.77 (s, 3H).
Example 184
4-Methyl-r2,2'1bipyrimidinyl-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide
Figure imgf000179_0001
A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (259 mg, 1.2 mmol) and 6- trifluoromethyl-indol-1-ylamine (200 mg, 1 mmol) in DMF (5 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is triturated with Et2O/heptane overnight. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl- |"2,2'"|bipyrimidinyl-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide (100 mg, 25%). MS: 399 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.16 (s, NH, IH), 9.39 (s, IH), 9.06 (d, 2H), 7.92 (s, IH), 7.81 (m, 2H), 7.70 (t, IH), 7.44 (d, IH), 6.74 (d, IH), 2.79 (s, 3H).
Example 185
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl- pyrrolor3,2-b"|pyridin-l-yl)-amide
Figure imgf000179_0002
Step 1 : A solution of 2-iodo-6-trifluoromethyl-pyridin-3-ylamine (5.09 g, 17.7 mmol) in DCM (50 mL) is treated with TFAA (3 rnL, 21.2 mmol) and pyridine (1.7 niL, 21.2 mmol), and stirred at rt for 1 h. The mixture is diluted with H2O (150 mL), and extracted with DCM (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is diluted with MeCN (50 mL), treated with trans-crotyi bromide (2.8 mL, 26.6 mmol) and K2CO3 (4.7 g, 34.4 mmol), and heated at reflux for 2 h. The mixture is filtered through a pad of Celite. The filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 25% EtOAc in heptane to afford ./V-but-2-enyl- 2.2.2-trifluoro-N-(2-iodo-6-trifluoromethyl-pyridin-3-vπ -acetamide (5.5 g, 71%). MS: 439 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.71 (d, IH), 7.53 (d, IH), 5.52 (m, 2H), 4.98 (m, IH), 3.58 (m, IH), 1.68 (d, 3H).
Step 2: A solution of Λ/-but-2-enyl-2,2,2-trifluoro-Λ/-(2-iodo-6-trifluoromethyl-pyridin-3-yl) - acetamide (5.2 g, 11.9 mmol) in DMF (24 mL) is treated with /7-Bu4NCl (3.6 g, 13.1 mmol), Pd(OAc)2 (107 mg, 0.48 mmol), and stirred at 1000C for 1 h. H2O (10 mL) is added, and the mixture is cooled to rt and filtered through a pad of silica gel. The filtrate is extracted with EtO Ac/heptane (3 x 50 mL) (1 :1). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 5% - 50% EtOAc in heptane to afford 3 -ethyl-5 -trifluoromethyl- 1 H-pyrrolo [3 ,2-blpyridine (2.2 g, 86%). MS: 215 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.24 (s, NH, IH), 7.73 (d, IH), 7.50 (d, IH), 7.34 (d, IH), 2.93 (q, 2H), 1.36 (t, 3H).
Step 3: A suspension of NaH (4.65 g, 116 mmol, 60% in mineral oil) in DMF (40 mL) at 00C is treated with 3 -ethyl-5 -trifluoromethyl- 1 H-pyrrolo [3, 2-b]pyridine (2 g, 7.75 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (4.4 g, 38.8 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice, treated with solid NH4Cl (3 g), and filtered through a pad of Celite. The filtrate is extracted with Et2O (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% - 50% EtOAc in heptane to afford 3^ ethyl-5 -trifluoromethyl-pyrrolo [3.2-blpyridin- 1 -ylamine (1.5 g, 84%). MS: 230 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 7.97 (d, IH), 7.59 (d, IH), 7.54 (s, IH), 6.12 (s, NH2, 2H), 2.78 (q, 2H), 1.28 (t, 3H). Step 4: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (278 mg, 1.1 mmol) and 3-ethyl-5-trifluoromethyl-pyrrolo[3,2-b]pyridin-l-ylamine (230 mg, 1 mmol) in DMF (5 niL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C overnight. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 2-(3-fluoro-phenyl)-4-methyl- pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrrolo [3 ,2-blpyridin- 1 -yl)-amide (195 mg, 44%). MS: 444 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.16 (s, NH, IH), 9.28 (s, IH), 8.34 (d, IH), 8.18 (m, 2H), 7.86 (s, IH), 7.65 (m, 2H), 7.45 (m, IH), 2.83 (q, 2H), 2.78 (s, 3H), 1.35 (t, 3H).
Example 186
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrrolo [3 ,2- blpyridin- 1 -yl)-amide
Figure imgf000181_0001
A solution of 2-(2-pyridyl)-4-methyl-pyrimidine-5-carboxylic acid (258 mg, 1.1 mmol) and 3- ethyl-5-trifluoromethyl-pyrrolo[3,2-b]pyridin-l-ylamine (230 mg, 1.0 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C overnight. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5- carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrrolo [3 ,2-blpyridin- 1 -yl)-amide (175 mg, 41%). MS: 427 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.18 (s, NH, IH), 9.31 (s, IH), 8.80 (d, IH), 8.45 (d, IH), 8.16 (d, IH), 8.01 (m, IH), 7.88 (s, IH), 7.72 (d, IH), 7.59 (m, IH), 2.81 (q, 2H), 2.79 (s, 3H), 1.35 (t, 3H).
Example 187
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrrolo [3 ,2- blpyridin- 1 -vD-amide
Figure imgf000182_0001
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (88 mg, 0.40 mmol) and 3-ethyl-5-trifluoromethyl-pyrrolo[3,2-b]pyridin-l-ylamine (89 mg, 0.40 mmol) in DMF (5 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (113 mg, 0.41 mmol) and stirred at 500C overnight. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 10 min. The precipitate is collected by filtration, washed with H2O (50 mL) and heptane (50 mL), and dried in vacuo to afford 4-methyl-2-thiazol-2-yl-pyrimidine-5- carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrrolo [3 ,2-blpyridin- 1 -yl)-amide (75 mg, 40%). MS: 433 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 12.19 (s, NH, IH), 9.28 (s, IH), 8.15 (m, 2H), 8.08 (d, IH), 7.87 (s, IH), 7.72 (d, IH), 2.83 (q, 2H), 2.77 (s, 3H), 1.35 (t, 3H).
Example 188
4-Methyl-r2,2'lbipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3,2- blpyridin- 1 -yl)-amide
Figure imgf000182_0002
A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (259 mg, 1.2 mmol) and 3-ethyl-
5-trifluoromethyl-pyrrolo[3,2-b]pyridin-l-ylamine (230 mg, 1.0 mmol) in DMF (5 mL) is stirred at 500C for 0.5 h. The mixture is treated with DMTMM (290 mg, 1.05 mmol) and stirred at 500C overnight. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by preparative reverse-phase HPLC eluting with 20% - 100% MeCN in H2O to afford 4-methyl-r2.2'lbipyrimidinyl-5-carboxylic acid (3- ethyl-5 -trifluoromethyl-pyrrolo [3.2-blpyridin- 1 -vQ-amide (230 mg, 54%). MS: 428 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.28 (s, IH), 9.05 (d, 2H), 8.11 (d, IH), 7.98 (s, IH), 7.69 (t, IH), 7.64 (d, IH), 2.83 (q, 2H), 2.80 (s, 3H), 1.34 (t, 3H).
Example 189 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-2-methyl-indol- 1 -vD- amide
Figure imgf000183_0001
Step 1 : A suspension of NaH (1.25 g, 51 mmol, 60% in mineral oil) in DMF (47 mL) at 00C is treated with 5-methoxy-2-methylindole (500 mg, 3.1 mmol) and stirred at 00C for 0.5 h. The mixture is treated with HOSA (1.92 g, 17.0 mmol) portion wise and warmed to rt over 2h. The mixture is then poured over ice, and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 5-methoxy-2- methyl-indol- 1 -ylamine, which is used in the next step without further purification.
Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (719 mg, 3.1 mmol) and 5-methoxy-2-methyl-indol-l -ylamine (550 mg, 3.1 mmol) in DMF (4 mL) is stirred at 500C for 15 min. The mixture is treated with DMTMM (856 mg, 3.1 mmol) and stirred at 500C for 1 h. The mixture is concentrated in vacuo, diluted with EtOAc (50 mL), and washed with saturated aqueous Na2CO3 (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl- pyrimidine-5-carboxylic acid (5-methoxy-2-methyl-indol- 1 -yl)-amide (180 mg, 15%, 2 steps). MS: 391 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.23 (s, IH), 8.34 (d, IH), 8.18 (d, IH), 7.63 (m, IH), 7.46 (m, IH), 7.31 (d, IH), 7.02 (d, IH), 6.77 (m, IH), 6.25 (s, IH), 3.76 (s, 3H), 2.77 (s, 3H), 2.34 (s, 3H).
Example 190
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid iVf, JV-diphenyl-hydrazide
Figure imgf000184_0001
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (500 mg, 2.2 mmol) and JV,iV-diphenyl-hydrazine (422 mg, 2.2 mmol) in DMF (3 mL) is stirred at 500C for 15 min. The mixture is treated with DMTMM (633 mg, 2.2 mmol) and stirred at 500C for 3 h. The mixture is diluted with EtOAc (50 mL), and washed with saturated aqueous Na2CO3 (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 75% EtOAc in heptane to afford 2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid iVf, iV-diphenyl-hydrazide (60 mg, 7%). MS: 399 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.04 (s, IH), 8.30 (d, IH), 8.15 (m, IH), 7.61 (m, IH), 7.44 (m, IH), 7.35 (m, 4H), 7.22 (m, 4H), 7.04 (m, 2H), 2.64 (s, 3H). IC50 = 16 nM.
Example 191
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (7-fluoro-3-methyl-indol-l-yl)- amide
Figure imgf000184_0002
Step 1 : A suspension of NaH (805 mg, 20.1 mmol, 60% in mineral oil) in DMF (5 mL) at 00C is treated with 7-fluoro-3-methylindole (200 mg, 1.34 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (757 mg, 6.7 mmol) portion wise and warmed to rt over 2 h. The mixture is then poured over ice, and extracted with EtOAc (3 x 100 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford Jz fluoro-3 -methyl-indol- 1 -ylamine, which is used in the next step without further purification. Step 2: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (1.34 mmol) and 7-fluoro-3-methyl-indol-l-ylamine (342 mg, 1.47 mmol) in DMF (15 mL) is stirred at 500C for 1 h. The mixture is treated with DMTMM (407 mg, 1.47 mmol) and stirred at 500C for 4 h. The mixture is concentrated in vacuo, diluted with Et2O (50 mL), and washed with saturated aqueous Na2CO3 (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% -100% DCM in EtOAc to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (7-fluoro-3-methyl-indol-l-vn-amide (241 mg, 48%). MS: 379 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.05 (s, IH), 8.32 (d, IH), 8.18 (d, IH), 7.64 (m, IH), 7.45 (m, IH), 7.40 (m, IH), 7.31 (s, IH), 7.05 (m, 2H), 2.74 (s, 3H), 2.29 (s, 3H).
Example 192
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-3 -methyl- indol- 1 -vD-amide
Figure imgf000185_0001
Step 1 : A solution of allyl-(2-iodo-4-methanesulfonyl-phenyl)-amine (1.43 g, 4.1 mmol) in
DMF (20 mL) is treated with /7-Bu4NCl (1.47 g, 5.32 mmol), Pd(OAc)2 (56.6 mg, 0.2 mmol), and stirred at 1000C for 1 h. HCl (5.3 mL, 3 M) is added, and the mixture is cooled to rt, filtered through a pad of Celite, and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 60% EtOAc in heptane to afford 5 -methanesulfonyl-3 - methyl- lH-indole (370 mg, 43%).
Step 2: A suspension of NaH (1.06 g, 26.6 mmol, 60% in mineral oil) in DMF (15 mL) at 00C is treated with 5 -methanesulfonyl-3 -methyl- lH-indole (370 mg, 1.77 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (1 g, 8.85 mmol) portion wise and warmed to rt overnight. The mixture is then poured over ice, and extracted with EtOAc (3 x 100 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo to afford 5_; methanesulfonyl-3 -methyl-indol- 1 -ylamine, which is used in the next step without further purification.
Step 3: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (1.77 mmol) and 5 -methanesulfonyl-3 -methyl-indol- 1 -ylamine (452 mg, 1.95 mmol) in DMF (15 mL) is stirred at rt for 1 h. The mixture is treated with DMTMM (538 mg, 1.95 mmol) and stirred at 600C for 1.5 h. The mixture is diluted with EtOAc (50 mL), and washed with saturated aqueous Na2CO3 (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 100% EtOAc in heptane, and then by triturating in Et2O to afford 2-(3-fluoro-phenyl)-4- methyl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-3 -methyl-indol- 1 -yl)-amide (106 mg, 14%). MS: 439 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.15 (s, IH), 8.37 (d, IH), 8.24 (m, 2H), 7.82 (m, IH), 7.59 (d, IH), 7.54 (m, IH), 7.34 (s, IH), 7.29 (m, IH), 3.13 (s, 3H), 2.83 (s, 3H), 2.42 (s, 3H).
Example 193
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolor2,3-b1pyridin- 1 -vD- amide trifluoro acetic acid salt
Figure imgf000186_0001
Step 1 : (Ref.: J. Org. Chem. 2002, 67, 6226-6227) 7-Azaindole (5 g, 42.3 mmol) is added to a stirred suspension OfAlCl3 (22.6 g, 169 mmol) in DCM (300 mL). After stirring at rt for 1 h, acetyl chloride (13.3g, 169 mmol) is added drop wise and the resulting mixture is stirred for 18 h. The mixture is cooled to O0C, quenched with MeOH (150 mL) and stirred for 1 h. Silica gel is added to the mixture, the solvents are removed under vacuum, and the residue is purified by silica gel chromatography eluting with 10% MeOH in DCM to afford 1-(1H- pyrrolo r2.3-blpyridin-3-vn-ethanone (1.6g). 1H NMR (300 MHz, CH3OD): δ 8.93(d, IH), 8.45(s, 2H), 7.50(t, IH), 3.30(s, 3H). Step 2: To a solution of l-(lH-Pyrrolo[2,3-b]pyridin-3-yl)-ethanone (1.34 g, 8.38 mmol) in TFA (25 niL) is added triethylsilane (6.09 g, 52.4 mmol) and stirred at rt for 18 h. The mixture is concentrated, diluted with 2 N aqueous KOH solution and extracted three times with DCM. The combined organic layer is dried (Na2SO4), filtered and evaporated. The resulting residue is chromatographed through silica gel eluting with 10% MeOH in DCM to afford 3-ethyl-lH-pyrrolor2.3-blpyridine (0.91 g). MS: 147 (M+H); 1H NMR (300 MHz, CDCl3): δ 9.23 (broad s, IH), 8.32 (d, IH), 7.94 (s,lH), 7.05-7.14 (m, 2H), 2.80 (q, 2H), 1.35 (t,3H).
Step 3: 3-Ethyl-lH-pyrrolo[2,3-b]pyridine (0.91 g, 6.2 mmol) and KOtBu (1.39 g, 12.4 mmol) are dissolved in DMF (28 mL) and stirred for 2 h at rt. While vigorously sparging with nitrogen, NH2Cl (92 ml 0.15 M in ether) is added in portions. The reaction mixture is stirred at rt for 2 h. The mixture is cooled O0C and then quenched with Na2S2O3 (2.7 g) in water (50 mL). After standing at rt for 18 h, the mixture is concentrated, triturated in DCM and filtered. The filtrate is concentrated and chromatographed through silica gel eluting with 10% MeOH in DCM to afford 3-ethyl-pyrrolor2.3-blpyridin-l-yl- amine (380 mg). MS: 162 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.32 (d, IH), 7.90 (d, IH), 7.04-7.13(m, 2H), 4.96 (broad s, 2H), 2.76 (q, 2H), 1.33 (t, 3H).
Step 4. A mixture of 3-ethyl-pyrrolo[2,3-b]pyridin-l-ylamine (126 mg, 0.78 mmol), 4-methyl- 2-pyridin-2-yl-pyrimidine-5-carboxylic acid (168 mg, 0.78 mmol), HATU (356 mg, 0.936 mmol) and DIPEA (302 mg, 2.34 mmol) in DMF (4 mL) is heated at 1500C for 1 h. The reaction is quenched with water and extracted with EtOAC. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is first chromatographed through silica gel eluting wiht 10% MeOH in DCM. The resulting product is chromatographed again using reverse phase HPLC eluting with 0.1% TFA in water and acetonitrale to afford 4-methyl-2- pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolor2,3-blpyridin-l-yl)-amide trifluoroacetic acid salt (29 mg). MS: 359 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.45 (s, IH), 9.04 (d, IH), 8.93 (d, IH), 8.67 (t, IH), 8.31 (d, IH), 8.19-8.08 (m, 2H), 7.34 (s, IH), 7.27 (dd, IH), 2.96 (s, 3H), 2.85 (q, 2H), 1.39 (t, 3H).
Example 194 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo|"2,3-b1pyridin- 1 - yl)-amide
Figure imgf000188_0001
A mixture of 3-ethyl-pyrrolo[2,3-b]pyridin-l-ylamine (126 mg, 0.78 mmol), 2-(3-Fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid (180 mg, 0.78 mmol), HATU (356 mg, 0.036 mmol) and DIPEA (302 mg, 2.34 mmol) in DMF (4 mL) is heated at 1500C for 1 h. The reaction is quenched with water and extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-100% ethyl acetate in heptane to afford 2-(3-fluoro-phenvO-4-methyl- pyrimidine-5-carboxylic acid (3-ethyl-pyrrolor2,3-blpyridin- 1 -yl)-amide (128 mg). MS: 376 (M+H); 1H NMR (300 MHz, DMSO-J6): 5 9.10 (s, IH), 8.25-8.33 (m, 2H), 8.16 (d, IH), 8.05 (d, IH), 7.62 (q, IH), 7.39-7.48 (m, 2H), 7.16 (dd, IH), 2.78 (s, 3H), 2.75 (q, 2H), 1.29(t, 3H).
Example 195
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolor2,3c1 pyridin-1- vD-amide
Figure imgf000188_0002
A mixture of 3-ethyl-pyrrolo[2,3-c]pyridin-l-ylamine (93 mg, 0.577 mmol), 2-(3-Fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid (134 mg, 0.757 mmol), HATU (263 mg, 0.692 mmol) and DIPEA (223 mg, 1.73 mmol) in DMF (3 mL) is heated at 150° C for 1 h. The reaction is quenched with water and extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by silica gel column chromatography eluting with 0-100% ethyl acetate in heptane to afford 2-(3-Fluoro-phenyl)-4- methyl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo|"2,3-c]pyridin- 1 -yl)-amide (86 mg). MS: 376 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.15 (s, IH), 8.69 (s, IH), 8.37 (d, IH), 8.15-8.26 (m, 2H), 7.70 (d, IH), 7.55 (q, IH), 7.49 (s, IH), 7.29 (t, IH), 2.80-2.90 (m, 5 H), 1.38 (t, 3H). IC50 = 7 nM.
Example 196
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo|"2,3-c]pyridin- 1 -yl)- amide trifluoroacetic acid salt
Figure imgf000189_0001
Step 1 : (Ref.: J. Org. Chem. 2002, 67, 6226-6227) 6-Azaindole (2.5 g, 21.25 mmol) is added to a stirred suspension OfAlCl3 (11.3 g, 84.5 mmol) in CH2Cl2 (150 mL). After stirring at rt for 1 h, acetyl chloride (6.65g, 84.5 mmol) is added drop wise and the resulting mixture is stirred for 18 h. The mixture is cooled to 00C, quenched with MeOH (75 mL) and stirred for 1 h. Silica gel (40 mL), MeOH and DCM are added to the mixture, the solvents are removed under vacuum and the residue is purified by silica gel chromatography eluting with 10%
MeOHl in DCM to afford l-(lH-pyrrolor2.3-c1pyridin-3-yl)-ethanone (1.52g, 45%). MS: 161 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.20 (s, IH), 8.95 (s, H), 7.82(d, IH), 8.72 (d, IH), 8.43 (d, 1-H), 2.64(s, 3H).
Step 2: To a solution of l-(lH-pyrrolo[2,3-c]pyridin-3-yl)-ethanone (1.53 g, 9.55 mmol) in TFA (29 mL) triethylsilane (6.88g, 59.21 mmol) is added and stirred at rt for 18 h. The mixture is concentrated and extracted with EtOAc. The organic layer is washed with 2 N aqueous KOH, dried (Na2SO4), filtered and evaporated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM to afford 3-ethyl-lH-pyrrolor2.3- clpyridine (1.35 g, 97%). MS: 147 (M+H); 1H NMR (300 MHz, CDCl3): δ 13.3 (broad, N-H) 9.46 (s, IH), 8.04 (s, IH), 7.71-7.88 (m, 2H), 2.88 (q, 2H), 1.39 (t, 3H).
Step 3: 3-Ethyl-lH-pyrrolo[2,3-c]pyridine (1.21 g, 8.29 mmol) and KOtBu (1.86 g, 16.57 mmol) are dissolved in DMF (47 mL) and stirred for 2 h at rt. While vigorously purging with nitrogen, NH2Cl (101 niL 0.15 M in ether) is added in portions. The reaction mixture is stirred at rt for 1 h. The mixture is then cooled to O0C and quenched with Na2S2O3 (4.3 g) in water (80 mL). After standing at rt for 2 days, the layers are separated. Brine is added to the aqueous layer and then extracted with EtOAc. The organic layers are combined and dried (Na2SO4) to give a mixture of 3-ethyl-pyrrolo[2,3-c]pyridin-l-ylamine and starting material. This mixture is purified by chromatography through silica gel eluting with 10% MeOH in DCM to afford 3-ethyl-pyrrolor2,3-c1pyridin- 1 -ylamine (93 mg). The remaining mixture of starting material and product is collected and dissolved in DCM. This solution is cooled to O0C and charged with BOC2O (164 mg, 0.75 mmol). The resulting mixture is purified by silica gel chromatography eluting with 10% MeOH in DCM to afford aaditional 3-ethyl- pyrrolor2.3-clpyridin- 1 -ylamine (145 mg). 1H NMR (300 MHz, CDCl3): δ 8.85 (s, IH), 8.25 (d, IH), 7.48 (d, IH), 7.10 (s, IH), 4.88 (s, 2H), 2.75 (q, 2H), 1.35(t, 3H).
Step 4. A mixture of 3-ethyl-pyrrolo[2,3-c]pyridin-l-ylamine (122 mg, 0.757 mmol), A- methyl^-pyridin^-yl-pyrimidine-S-carboxylic acid (163 mg, 0.757 mmol), HATU (356 mg, 0.936 mmol) and DIPEA (294 mg, 2.27 mmol) in DMF (4 mL) is heated at 150° C for 1 h. The reaction is quenched with water and the extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM. The resulting product is chromatographed again using reverse phase HPLC eluting with 0.1% TFA in water and acetonitrale to afford 4-methyl-2- pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolor2,3-c1pyridin- 1 -vD-amide trifluoroacetic acid salt (42 mg, 9.5%). MS: 359 (M+H); 1U NMR (300 MHz, DMSO- d6): δ 9.43 (s, IH), 9.37 (s, IH), 8.80 (d, IH), 8.45 (t, 2H), 8.26 (s, IH), 8.22 (d, IH), 8.03 (t, IH), 7.59 (t, IH), 2.86 (q, 2H), 2.80 (s, 3H), 1.32 (t, 3H).
Example 197
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolor3,2-b1pyridin-
1-vD-amide
Figure imgf000191_0001
A mixture of 3-methyl-pyrrolo[3,2-b]pyridin-l-yl amine (75% pure) (240 mg, <1.63 mmol), 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (379 mg, 1.63 mmol), HATU (744 mg, 1.96 mmol) and DIPEA (388 mg, 4.89 mmol) in DMF (5 mL) is heated at 1500C for I h. The reaction is quenched with water, extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM. The resulting product is recrystallized with ether to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolor3,2-blpyridin- l-ylVamide (197 mg, 44%). MS: 362 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.14 (s, IH), 8.40 (d, IH), 8.36 (d, IH), 8.22 (d, IH), 7.85(d, IH), 7.55 (q IH), 7.47 (s, IH), 7.25-7.34 (m, 2H), 2.83 (s, 3H), 2.42(s, 3H). IC50 = 2 nM.
Example 198
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-5-trifluoromethyl-indol- 1 - vD-amide
Figure imgf000191_0002
Stepl : To a mixture of 2-iodo-4-trifluoromethyl-aniline (5 g, 17.4 mmol), KOt-Bu (2.05 g, 18.3 mmol) and THF (200 mL) at -780C, is added allyl bromide (2.21 g, 18.3 mmol). The resulting mixture is warmed to rt and stirred for 18 h. Water is added, and the mixture is extracted with EtOAc. The organic layer is separated, dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-50% EtOAc in heptane to afford allyl-(2-iodo-4-trifluoromethyl-phenyl)-amine (1.9 g, 33%). MS 328 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.90 (s, IH), 7.45 (d, 1 H), 5.88-6.02 (m, IH), 5.33 (d, 1 H), 5.25 (d, IH), 4.72(broad s, IH), 3.90 (s, 2H). Step 2: A mixture of allyl-(2-iodo-4-trifluoromethyl-phenyl)-amine (1.75 g, 5.35 mmol), tetrabutylammonium chloride (1.68 g, 5.35 mmol), palladium acetate (120 mg, 0.54 mmol) and potassium carbonate (2.22 g, 16.0 mmol) in DMF (50 mL) is heated at 80° C for 1.5 h. The reaction is quenched with water and extracted three times with DCM. The combined organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-40% EtOAc in heptane to afford 3 -methyl-5 -trifluoromethyl- lH-indole (401 mg). 1H NMR (300 MHz, CDCl3): δ = 8.09 (broad s, IH), 7.90 (s, 1 H), 7.44 (s, IH), 7.10 (s, IH), 2.38 (s, 3H).
Step 3: 60% NaH (1.21 g, 30.2 mmol) is added to a stirred solution of 3-methyl-5- trifluoromethyl-lH-indole (400 mg, 2.01 mmol) in DMF (6 mL) at O0C in portions. The mixture is stirred at O0C for 1 h. HOSA (1.14g, 10.0 mmol) is added in portions at O0C and the mixture is allowed to warm to rt over 2 h. The reaction is quenched with aqueous saturated ammonium chloride, extracted with extracted three times with DCM. The combined organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-40% EtOAc in heptane to afford 3 -methyl-5 -trifluoromethyl- indol-1-ylamine (223 mg, 52%). MS: 215 (M+H); 1H NMR (300 MHz, CDCl3): δ = 7.84 (s, IH), 7.48 (s, 2H), 7.04 (s, IH), 4.77 (s, 2H), 2.34 (s, 3H).
Step 4: A mixture of 3 -methyl-5 -trifluoromethyl-indol-1-ylamine (223 mg, 1.04 mmol), 4- methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (224 g, 1.04 mmol), HATU (475 mg, 1.25 mmol), DIPEA (404 mg 3.13 mmol) is stirred in DMF at 150° C for Ih. The reaction is quenched with water, extracted with extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-5-trifluoromethyl-indol-l-yl)-amide (122 mg, 28%). MS: 412 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.22 (s, IH), 8.79 (d, IH), 8.66 (d, IH), 8.06 (t, IH), 7.91 (s, IH), 7.60 (dd, IH), 7.51 (s, 2H), 7.29 (s, 3H), 2.88 (s, 3H), 2.40 (s, 3H).
Example 199
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo|"3,2-blpyridin-l-yD- amide
Figure imgf000193_0001
Step 1 : To a solution of 3-amino-2-chloropyridine (5 g 38.9 mmol) in THF (35 mL) is added 2 M NaHMDS in THF (38.9 mL, 77.8 mmol). After stirring at rt for 15 min, BOC2O (7.7g, 35.6 mmol) in THF (20 mL) is added in one portion and then stirred for 5 h at rt. 0.1% aqueous HCl is added. The mixture is extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-50% EtOAc in heptane to afford (2-chloro-pyridin-3-yl)-carbamic acid tert- butyl ester (7.18g, 89%). MS: 229 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.52 (d, IH), 8.05 (dd, IH), 7.23 (dd, IH), 7.02 (broad s, IH), 1.55 (s, 9H)).
Step 2: A mixture of (2-chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (7 g, 30.7 mmol), allyl bromide (5.26g, 40.8 mmol) and cesium carbonate (20.8g, 63.8 mmol) in DMF (280 mL) is heated at 60° C for 1 h. The reaction is quenched with water, extracted with EtOAC. The organic layer is dried (Na2SO4), filtered and concentrated to afford allyl-(2-chloro-pyridin-3- yl)-carbamic acid tert-butyl ester (8.03g, 98%), which is sued in the next step with no further purification.
Step 3: A mixture of allyl-(2-chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (8.03 g, 30 mmol), tetrabutylammonium chloride (9.4 g, 30 mmol), palladium acetate (673 mg, 3 mmol) and potassium carbonate (12.4 g, 3 mmol) in DMF (300 mL) is heated at 80° C for 1.5 h. The reaction is quenched with DCM and washed with water. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0- 40% EtOAc in heptane to afford 3-methyl-pyrrolo|"3,2-blpyridine-l-carboxylic acid tert-butyl ester and 3-methylene-2,3-dihvdro-pyrrolor3,2-blpyridine-l-carboxylic acid tert-butyl ester (1.58 g).
Step 4: The above mixture is then stirred in DCM (10 mL) and TFA (10 mL) at rt for 3 h. The reaction is concentrated, and 2 M KOH aqueous solution and DCM are added. The precipitate is collected by filtration to afford 3-methyl-lH-pyrrolor3,2-b1pyridine potassium salt (I g, 20%). MS: 133 (M+H); 1H NMR (300 MHz, CD3OD): δ 8.26(d, IH), 7.75(d, IH), 7.33(s, IH), 7.12(dd, IH), 2.36 (s, 3H).
Step 5: A mixture of 3-methyl-lH-pyrrolo[3,2-b]pyridine potassium salt (1 g, 5.88 mmol), KOtBu (660mg, 5.88 mmol) in DMF (26 mL) is purged with N2 and stirred at rt for 2 h. Chloramine in ether (0.15 M, 29 mL) is added and the mixture is stirred for 45 min. The reaction is cooled to O0C, Na2S2O3 (3.4 g) in water (70 mL) is added and the mixture is stirred for 15 min. The mixture is concentrated in vacuo. The residue is triturated with DCM and then filtered. The filtrate is washed with 2 M aqueous KOH, dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM to afford a mixture of starting material and 3 -methyl-pyrrolo [3 ,2-blpyridin- 1 -yl amine (839 mg,~ 64%, -66 mol% pure), which is used in the next step without further purification.
Step 6: A mixture of 3 -methyl-pyrrolo [3, 2-b]pyridin-l-yl amine (839 mg, < 5.71 mmol), A- methyl^-pyridin^-yl-pyrimidine-S-carboxylic acid (1.32 g, 6.13 mmol), HATU (2.6 g, 6.85 mmol), DIPEA (2.21 g 17.1 mmol) in DMF (17 mL) is stirred at 1500C for Ih. The reaction is quenched with water and ether. The water layer is concentrated in vacuo. The residue is chromatographed through silica gel eluting with a mixture of DCM, MeOH and triethylamine (9.5: 0.5: 0.05) to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl- pyrrolor3.2-b1pyridin-l-yl)-amide (134 mg). MS: 345 345 (M+H); 1U NMR (300 MHz, CD3OD): δ 9.22 (s, IH), 8.79 (d, IH), 8.64 (d, IH), 8.40(d, IH), 8.05 (t, IH), 7.87 (d, IH), 7.60 (t, IH), 7.49 (s, IH) 7.30 (dd, IH), 2.87 (s, 3H), 2.42 (s, 3H).
Example 200 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo|"2,3clpyridin- 1 - vD-amide
Figure imgf000194_0001
Step 1 : 60% Sodium hydride (6.69 g, 167 mmol) is added to a stirred solution of 3-methyl- lH-pyrrolo[2,3-c]pyridine (1.47 g, 11.2 mmol) in DMF (33 mL) portion wise at 0° C for 1 h. Hydroxylamine-O-sulfonic acid (6.3 g, 55.8 mmol) is added in potions at O0C and stirred for 2 h at O0C. The reaction mixture is quenched at O0C with water, concentrated in vacuo to remove DMF. The residue is triturated in DCM. The solid is filtered off and the filtrate is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% MeOH in DCM to afford 3-methyl-pyrrolor2.3-clpyridin- 1 -ylamine (1 g, 61%). MS: 148 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.85 (s, IH), 8.27 (d, IH), 7.46 (d, IH), 7.09 (s, IH), 2.30 (s, 3H).
Step 2: A mixture of 3-methyl-pyrrolo[2,3-c]pyridin-l -ylamine (224 mg, 1.53 mmol), 2-(3- fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (354 mg, 1.53 mmol), HATU (693 mg, 1.82 mmol) and DIPEA (593 mg, 4.59 mmol) in DMF (8 mL) is stirred at 1500C for 1 h. The reaction is quenched with water, extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-100% EtOAc in heptane to afford 2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 - carboxylic acid (3-methyl-pyrrolor2,3-clpyridin-l-yl)-amide (55 mg). MS: 362 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.15 (s, IH), 8.69 (s, IH), 8.37 (d, IH), 8.24 (s, IH), 8.20 (d, IH), 7.68 (d, IH), 7.55 (q, IH), 7.47 (s, IH), 7.29 (t, IH), 2.84(s, 3H), 2.39 (s, 3H).
Example 201
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolor2,3-clpyridin- 1 -vD- amide
Figure imgf000195_0001
Step 1 : To a solution of 3-amino-4-chloropyridine (6.56 g, 51 mmol) in THF (46 mL) is added 2 M NaHMDS in THF (50 mL, 100 mmol). After stirring at rt for 15 min BOC2O (10.1 g, 46.4 mmol) in THF (26 mL) is added in one portion and the mixture is stirred for 3 h at rt. 0.1% aqueous HCl (590 mL) is added. The mixture is extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by silica gel chromatography eluting with 0-50% EtOAc in heptane to afford (4-chloro-pyridin-3-yD- carbamic acid tert-butyl ester (6.78g, 76 %). MS: 229 (M+H); 1H NMR (300 MHz, CDCl3): δ 9.38 (ms IH), 8.23 (d, IH), 7.30 (dd, IH), 6.85 (broad s, IH), 1.57 (s, 9H).
Step 2: A mixture of (4-chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (6.78 g, 29.7 mmol), allyl bromide (5.1 g, 40.8 mmol) and cesium carbonate (20.1 g, 61.8 mmol) in DMF (200 mL) is heated at 600C for 1 h. The reaction is quenched with water, extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by silica gel column chromatography eluting with 0-40% EtOAc in heptane to afford allyl-(4-chloro-pyridin-3-vπ-carbamic acid tert-butyl ester (5.66 g, 71%). MS: 269 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.42(d, IH), 7.40 (d, IH), 5.80-5.98 (m, IH), 4.35-4.51 (m, IH), 3.90-4.07 (m, IH).
Step 3: A mixture of allyl-(4-chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (7.68 g, 28.7 mmol), tetrabutylammonium chloride (9.Og, 28.7 mmol), palladium acetate (643 mg, 2.87 mmol) and potassium carbonate (11.9 g, 86.0 mmol) in DMF (200 mL) is heated at 800C for 1.5 h. The reaction mixture is diluted with DCM and washed three times with water. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by silica gel column chromatography eluting with 0-40% EtOAc in heptane to afford a mixture of 3^ methyl-pyrrolo|"2,3-clpyridine-l-carboxylic acid tert-butyl ester and 3 -methylene-2 ,3 -dihydro- pyrrolo|"2,3-c"|pyridine-l-carboxyric acid tert-butyl ester (3.1 g total).
Step 4: The above mixture is stirred in DCM (10 mL) and TFA (10 mL) at rt for 18 h and then concentrated in vacuo. 2 M aqueous KOH is added. The mixture is extracted with EtOAC. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by silica gel column chromatography eluting with 10% MeOH in DCM to afford 3 -methyl- IH- pyrrolor2.3-clpyridine (1.98 g, 69%). MS: 133 (M+H); 1H NMR (300 MHz, CDCl3): δ 9.10 (broad s, IH), 8.79 (s, IH), 8.28 (d, IH), 7.52 (d, IH), 7.20 (s, IH) 2.36 (s, 2H).
Step 5: A mixture of 3-methyl-lH-pyrrolo[2,3-c]pyridine (1.21 g, 9.16 mmol), KOtBu (2.05 g, 18.3 mmol) in DMF (41 mL) is purged with N2 and stirred at rt for 2 h. Chloramine in ether (0.15 M, 92 mL) is added and the mixture is stirred for 20 min. The reaction is cooled to O0C and a solution OfNa2S2O3 (5 g) in water (80 mL) is added. The mixture is stirred for 10 min, and then concentrated in vacuo. The residue is triturated in DCM and filtered. DCM is added, cooled to O0C and charged with BOC2O (541 mg, 2.48 mmol). The resulting mixture is separated by silica gel chromatography eluting with 10% MeOH in DCM to afford 3-methyl- pyrrolor2.3-clpyridin-l-yl amine (468 mg, 35 %). MS: 148 (M+H); 1U NMR (300 MHz, CDCl3): δ 8.85 ( s, IH), 8.27 (d, IH), 7.46 (d, IH), 7.09 (s, IH), 2.30 (s, 3H).
Step 6: A mixture of 3-methyl-pyrrolo[2,3-c]pyridin-l-yl amine (467 mg, 3.18 mmol), 4- methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (683 g, 3.18 mmol), HATU (1.45 g, 3.81 mmol), DIPEA (1.23 g 9.54 mmol) in DMF (10 mL) is stirred at 150° C for Ih. The reaction is quenched with water, and NaHCO3 (320 mg, 3.81 mmol) and EtOAC are added. The resulting solid is collected by filtration and then triturated with hot water. The mixture is filtered again and the solid is dried under vacuum to afford 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (3-methyl-pyrrolor2,3-clpyridin-l-yl)-amide (484 mg). MS: 345 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.24 (s, IH), 8.79 (d, 2H), 8.65 (d, IH), 8.21 (d, IH), 8.05 (t, IH), 7.72 (d, IH), 7.60 (s, IH), 7.57 (s, IH), 2.88 (s, 3H), 2.40 (s, 3H).
Example 202
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolor3,2-clpyridin-l-vD- amide
Figure imgf000197_0001
Step 1 : To a solution of 4-amino-3-chloropyridine (15 g, 116.7 mmol) in THF (60 mL) is added NaHMDS in THF (1 M, 233. mL, 233 mmol). After stirring at rt for 30 min, BOC2O (23.2 g, 106 mmol) in THF (45 mL) is added in one portion and the mixture is stirred for 3 h at rt. Additional BOC2O (2 g, 9.0 mmol) in THF (40 mL) is added and the reaction is stirred for 18 h at rt. 0.1% aqueous HCl (1.35 L) is added. The mixture is extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is recrystalized from ether to afford (3-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester (4 g). The mother liquor is purified by silica gel column chromatography eluting with 0-50% EtOAc in heptane. The collected product is crystallized from ether to afford additional 4.5 g of (3-chloro-pyridin- 4-yl)-carbamic acid tert-butyl ester (total yield 8.5 g). MS: 229 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.48 (s, IH), 8.38 (d, IH), 8.17 (d, IH), 7.18 (broad s, IH) 1.57 (s, 9H).
Step 2: A mixture of (3-chloro-pyridin-3-yl)-carbamic acid tert-butyl ester (8.4 g, 36.8 mmol), allyl bromide (7.46 g, 39.1 mmol) and cesium carbonate (24.9 g, 76.4 mmol) in DMF (100 mL) is heated at 600C for 1 h. The reaction is quenched with water, extracted with EtOAc. The organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-40% EtOAc in heptane to afford allyl- (3-cMoro-pyridm-3-yl>carbamic acid tert-butyl ester (8.4 g, 85%). MS: 269 (M+H); 1H NMR (300 MHz, CDCl3): δ = 8.66 (s, IH), 8.49 (d, IH), 7.18 (d, IH), 5.80-5.96 (m, IH) 5.15 (s, IH), 5.10(d, IH), 4.2 (broad s, IH), 1.43 (s, 9H).
Step 3: A mixture of allyl-(3-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester (8.25 g, 30.8 mmol), tetrabutylammonium chloride (9.67g, 30.8 mmol), palladium acetate (691 mg, 3.08 mmol) and potassium carbonate (12.8 g, 92.3 mmol) in DMF (100 mL) is heated at 800C for 1.5 h. The reaction is diluted with DCM and washed three times with water. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 0-40% EtOAc in heptane to afford a mixture 3 -methyl-pyrrolo [3 ,2- clpyridine-1-carboxylic acid tert-butyl ester and 3 -methylene-2,3 -dihydro-pyrrolo [3 ,2- clpyridine-l-carboxylic acid tert-butyl ester (4.21 g, total).
Step 4: The mixture from step 3 is stirred in DCM (10 mL) and TFA (10 mL) at rt for 18 h. The reaction is concentrated. 2 M aqueous KOH solution is added, and the mixture is extracted with EtOAc. The organic layer is dried (Na2SO4), filtered and concentrated. The residue is chromatographed through silica gel eluting with 10% MeOH in DCM to afford of 3^ methyl- 1 H-pyrrolo [3.2-clpyridine (1.91g, 47%). MS: 133 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.89 (s, IH), 8.24 (d, IH), 7.37 (d, IH), 7.11 (s, IH) 2.40 (s, 3H).
Step 5: A mixture of 3-methyl-lH-pyrrolo[3,2-c]pyridine (1.91 g, 14.47 mmol) and KOtBu (3.25 g, 28.9 mmol) in DMF (65 mL) is purged with N2 and stirred at rt for 2 h. Chloramine in ether (0.15 M, 145 mL) is added and the mixture is stirred for 20 min. The reaction is cooled to O0C and a solution OfNa2S2O3 (800 mg) in water (130 mL) is added. The mixture is stirred for 10 min at O0C, and then concentrated in vacuo. The residue is triturated in DCM and filtered. DCM is added to the filtrate, cooled to O0C and treated with BOC2O (793 mg, 3.6 mmol). The mixture is concentrated in vacuo, and the residue is purified by silica gel chromatography eluting with 10% MeOH in DCM to afford 3 -methyl-pyrrolo [3 ,2-clpyridin- 1 ■ yl amine (842 mg, 35 %). MS: 148 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.85 (s, IH), 8.36 (d, IH), 7.32 (d, IH), 6.95 (s, IH) 4.77 (s, 2H), 2.37 (s, 3H).
Step 6: A mixture of 3 -methyl-pyrrolo [3, 2-c]pyridin-l-yl amine (223 mg, 1.52 mmol), 4- methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (329 mg, 1.52 mmol), HATU (693 mg, 1.82 mmol) and DIPEA (593 mg, 4.59 mmol) in DMF (8 mL)is stirred at 1500C for 1 h. The reaction is quenched with water and NaHCO3 (168 mg, 2 mmol). The mixture is concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10% meOH in DCM to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -methyl-pyrrolo [3 ,2- clpyridin-l-vO-amide (91 mg, 17%). MS: 345 (M+H); 1H NMR (300 MHz, DMSO-J6): δ = 9.34 (s, 2H), 8.79 (d, IH), 8.53 (d, IH), 8.45 (d, IH), 8.13 (d, IH), 8.02 (t, IH), 7.86 (s, IH), 7.59 (t, IH), 2.77 (s, 3H), 2.43 (s, 3H).
Example 203
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolor3,2-c1pyridin- l-yl)-amide
Figure imgf000199_0001
A mixture of 3 -methyl-pyrrolo [3, 2-c]pyridin-l-ylamine (224 mg, 1.52 mmol), 2-(3-fluoro- phenyl)-4-methyl-pyrimidine-5-carboxylic acid (354 mg, 1.52 mmol), HATU (693 mg, 1.82 mmol) and DIPEA (593 mg, 4.59 mmol) in DMF (8 mL) is heated at 1500C for 1 h. The reaction is quenched with water, NaHCO3 (168 mg, 2 mmol) is added and the mixture is extracted with EtOAc. The oganic layer is separated, dried (Na2SO4), filtered and concentrated. The residue is first purified by silica gel column chromatography eluting with 10% MeOH in DCM and then recrystallized from EtOAc to afford 2-(3-fluoro-phenylV4- methyl-pyrimidine-5 -carboxylic acid (3 -methyl-pyrrolo [3 ,2-c]pyridin- 1 -yl)-amide (198 mg). MS: 362 (M+H); 1H NMR (300 MHz, CD3OD): δ 9.12 (s, IH), 8.86 (s, IH), 8.35 (d, IH), 8.15-8.31 (m, 2H), 7.47-7.60 (m, 2H), 7.35 (s, IH), 7.29 (t, IH), 2.84 (s, 3H), 2.44 (s, 3H).
Example 204
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-nitro-indol- 1 -yl)-amide
Figure imgf000200_0001
Step 1 : NaH (60%, 421.5 mmol) is added portion-wise to a solution of 5-nitro-lH-indole (28.1 mmol) in anhydrous DMF (80 rnL) at O0C and the mixture is stirred at O0C under N2 for 10 min. HOSA (140.5 mmol) is added portion-wise for 30 minutes and the mixture is stirred at O0C for 2 h. The reaction is quenched with water. Additional water (250 mL) is added and the mixture is extracted with EtOAc (3x 100 mL). The combined organic layer is washed with water (2x30 mL), brine (30 mL), dried (Na2SO4), filtered and concentrated. The residue is washed with heptane (2x20 mL) and recrystallized from EtOAc to afford 5-nitro-indole-l- ylamine (4.84 g, 97%) as a solid. MS: 178 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.93(br, 2N-H), 6.62(d, H), 7.30(d, H), 7.52(d, H), 8.17(d, H), 8.58 (s, H).
Step 2: DIPEA (12.65 mmol) is added a solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine- 5-carboxylic acid (4.22 mmol), 5-nitro-indole-l -ylamine (4.22 mmol) and HOTT (S-(I -oxido- 2-pyridyl)-thio-N,N,N',N'-tetramethyluronium hexafluorophosphate) (7.6 mmol) in anhydrous DMF (15 mL) and the mixture is heated at 80-900C overnight. After evaporation of solvent, the residue is dissolved in EtOAc (150 mL), washed with water (20 mL), 5% sodium sulfate (20 mL), water (mL) and brine (20 mL). The organic layer is dried (Na2SO4), filtered and concentrated. The residue is kept at rt overnight to yield 4-methyl-2-(3 -fluoro- phenyl)-pyrimidine-5 -carboxylic acid (5-nitro-indol-l-yl)-amide (730 mg, 44%) as a solid.
MS: 392 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.78(s, 3H), 6.88(d, H), 7.38-7.53(m, H), 7.57-7.76(m, 2H), 7.81(d, H), 8.06-8.32(m, 2H), 8.34(d, H), 8.65(d, H), 9.27(s, 2H).
Example 205 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-amino-indol-l-vD-amide
Figure imgf000201_0001
A solution of 4-methyl-2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-nitro-indol-l-yl)- amide (1.64 mmol) in MeOH (45 niL) and 10% Pd/C (0.16 mmol) is hydrogenated in a 500 niL Paar bottle under 50 psi at rt overnight. Pd/C is filtered off. The filtrate is concentrated to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-amino-indol-l-yl)-amide (545 mg, 92%) as a solid. MS: 362 (M+H); 1H NMR (300 MHz, CD3OD): δ 3.84(s, H), 6.37(d, H), 6.81(dd, H), 7.01(d, H), 7.16-7.36(m, 3H), 7.55(m, H), 8.23(d, H), 8.36(d, H), 9.50 (s, H).
Example 206
2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -(dimethanesulfonyl)-amino-
Figure imgf000201_0002
A mixture of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-amino-indol-l- yl)-amide (0.43 mmol) and methanesulfonyl chloride (0.52 mmol) in anhydrous DCM (10 mL) is stirred at O0C and triethylamine (1.29 mmol) is added. The reaction mixture is stirred at O0C for 1 h, and then warmed to rt and stirred for 30 minutes. DCM is added (20 mL), and the mixture is washed with 4% HCl (15 mL), water (10 mL) and brine (15 mL). The organic layer is dried (Na2SO4), filtered and concentrated. The residue is purified by chromatography using silica gel eluting with 0-60% EtOAC in DCM to afford 2-(3-fluoro-phenvD-4-methyl- pyrimidine-5 -carboxylic acid [5 -(dimethanesulfonyl)-amino-indol- 1 -yl] -amide (85 mg, 38%) as a solid. MS: 518 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.75(s, 3H), 2.90(s, 3H), 3.66(s, 3H), 6.51(s, H), 7.04-7.53(m, 6H), 8.03(d, H), 8.12(d, H), 8.60(s, H).
Example 207
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-benzoylamino-indol- 1 -vD- amide
Figure imgf000202_0001
A solution of benzoyl chloride (0.85 mmol) in anhydrous DCM (2 mL) is added drop-wise to a solution of 4-methyl-2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-amino-indol-l- yl)-amide (0.47 mmol) and triethylamine (1.41 mmol) in anhydrous DCM (16 mL) and the mixture is stirred at rt overnight. The reaction mixture is concentrated in vacuo. The residue is dissolved in EtOAc (25 mL), and washed with water (2X20 mL) and brine (10 mL). The organic layer is dried (Na2SO4), filtered and concentrated. The residue is triturated with EtOAc to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5- benzoylamino-indol- 1 -vQ-amide (95 mg, 43%) as a solid. MS: 466 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 2.99(s, 3H), 6.72(d, H), 7.38-7.48(m, H), 7.48-7.80(m, 6H), 7.83- 8.016(m, 3H), 8.07-8.20(m, H), 8.23-8.35(m, 2H), 9.24(s, H), 10.25(br, H).
Example 208 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5-fluoro-3-(l ,2,3,6-tetrahydro-pyridin- 4-vD-indol- 1 -yll -amide dichlorochloride
Figure imgf000202_0002
Step 1 : A mixture of 5-fluoroindole (6.65 g, 49.2 mmol) and 4-piperidone hydrate hydrochloride (18.9 g, 123 mmol) in methanol solution of 2 N KOH (90 mL) is refluxed for 6 h. After cooling to rt, water (150 mL) is added and stirred at rt for 30 minutes. The resulting precipitate is filtered, washed with water (10 mL) and ether (15 mL), and dried in vacuo to afford 5-fluoro-3-(1.2.3.6-tetrahvdropyridin-4-vn-indole (6.34 g, 60%). MS: 217 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.40 (br, H), 7.57 (dd, H), 7.24-7.37 (m, H), 7.23 (s, H), 6.98 (t, H), 6.20 (s, H), 3.62 (m, 2H), 3.16 (m, 2H), 2.50 (s, 2H).
Step 2: A solution of di-tert-butyl dicarbonate (504 mg, 2.31 mmol) in DCM (10 mL) is added to a stirred solution of 5-fluoro-3-(l,2,3,6-tetrahydropyridin-4-yl)-indole (500 mg, 2.31 mmol) in DCM (20 mL) at rt and stirred at rt overnight. The reaction mixture is concentrated in vacuo to afford 4-(5-Fluoro-lH-indol-3-yl)-3,6-dihvdro-2H-pyridine-l-carboxyric acid tert- butyl ester (730 mg). MS: 317 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.17 (br, H), 7.56 (d, H), 7.31 (m, H), 7.26 (s, H), 6.99 (t, H), 6.13 (s, H), 4.17(m, 2H), 3.70 (m, 2H), 2.57 (s, 2H), 1.54 (s, 9H).
Step 3: A solution of 4-(5-fluoro-lH-indol-3-yl)-3,6-dihydro-2H-pyridine-l-carboxylic acid tert-butyl ester (730 mg, 2.31 mmol) in anhydrous DMF is added slowly to a stirred solution of 60 % NaH (1108 mg, 27.72 mmol) in anhydrous DMF (20 mL) at O0C under N2 and stirred at rt for an hour. HOSA (1305 mg, 11.55 mmol) is added portion-wise at O0C, stirred at O0C for 5 hours, poured into ice/water (350 mL) and extracted with ether (3 x 35 mL). The combined organic extract is washed with water (2 x 20 mL) and brine (20 mL), dried
(Na2SO4), filtered and concentrated in vacuo. The residue is washed with heptane (3 x 5 mL) to afford 4-(l-Amino-5-fluoro-lH-indol-3-yl)-3,6-dihvdro-2H-pyridine-l-carboxylic acid tert- butyl ester (715 mg, 94%) as a solid. MS: 332 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.52 (d, H), 7.36 (m, H), 7.20 (s, H), 7.04 (t, H), 6.06 (s, H), 4.78 (s, 2H), 4.15(m, 2H), 3.69 (t, 2H), 2.54 (s, 2H), 1.55 (s, 9H).
Step 4: Triethylamine (2.6 mmol) is added to a stirred solution of 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (1.30 mmol) and iso-butyl chloroformate (1.95 mmol) in anhydrous DCM (20 mL) at rt under N2 and stirred at rt for 2 h. The reaction mixture is concentrated in vacuo. The residue is dried in vacuo and THF (30 mL) is added. The mixture is filtered and the filtrate is concentrated to afford iso-butyl-[ 1 -(4-methyl-2-pyridin-2-yl- pyrimidin-5 -yll 1 -carbonate (350mg, 85%). Step 5: Sodium bis(trimethylsilyl)amide (2 N) in THF (0.83 mL) is added to a stirred solution of 4-( 1 -amino-5 -fluoro- 1 H-indol-3 -yl)-3 ,6-dihydro-2H-pyridine- 1 -carboxylic acid tert-butyl ester (367 mg,l .11 mmol) in anhydrous DMF (20 mL) at rt under N2, then stirred at rt for 15 min. A solution of iso-butyl-[l-(4-methyl-2-pyridin-2-yl-pyrimidin-5-yl]]-carbonate (350mg, 1.11 mmol) in anhydrous DMF (5 mL) is added slowly at rt and stirred at 6O0C for 18 hours under N2. DMF is evaporated off. The residue is dissolved in EtOAc (60 mL), washed with water (3x20 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0-20% MeOH in DCM to afford 4-{5-fluoro-l-[(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-aminol-lH-indol-3-yl|-3,6- dihydro-2H-pyridine-l -carboxylic acid tert-butyl ester (158 mg, 28%).
Step 6: A solution of 4-{5-fluoro-l-[(4-methyl-2-pyridin-2-yl-pyrimidine-5-carbonyl)-amino]- lH-indol-3-yl}-3,6-dihydro-2H-pyridine-l-carboxylic acid tert-butyl ester (158 mg) in DCM (15 ml) is bubbled with HCl gas for 10 min at rt, then stirred at rt for 18 h. DCM is evaporated off and the residue is triturated with MeOH (2 mL). The solide is collected by filtration and dried to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxyric acid r5-fluoro-3-(l ,2,3,6- tetrahvdro-pyridin-4-vO-indol- 1 -yll -amide dichlorochloride (81 mg, 54%). MS: 429 (M+H); 1H NMR (300 MHz, CD3OD): δ =2.89(m, 2H), 2.96(s, 3H), 3.53(t, 2H), 3.94(m, H), 6.27(s, H), 7.12(t, H), 7.46(q, H), 7.59-7.71(m, H), 8.28 (t, H), 8.85 (t, H), 8.99(d, H), 9.15(d, H), 9.41(s, H).
Example 209
2-Pyridin-2-yl-4-trifluoromethyl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol- 1 -yl)- amide
Figure imgf000204_0001
A solution of 2-pyridin-2-yl-4-trifluoromethyl-pyrimidine-5 -carboxylic acid (219 mg, 0.81 mmol), 5-fluoro-3-methyl-indol-l-ylamine (0.98 mmol), DIPEA (158 mg, 1.23 mmol) and HATU (1.06 mmol) in anhydrousDMF (8 mL) is stirred at 8O0C overnight. The reaction mixture is diluted with EtOAc (40 mL) and washed with water (4x20 mL) and brine (20 mL). The organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with l%-50% EtOAc in DCM. The collected product is recrystallized from DCM to afford 2-pyridin-2-yl-4-trifluoromethyl-pyrimidine-5- carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide (105 mg, 31%) as a solid. MS: 416 (M+H); 1H NMR (300 MHz, CD3OD): δ =2.32(s, 3H), 7.04(t, H), 7.16(s, H), 7.25(dd, H), 7.34(q, H), 7.67(dd, H), 8.11 (t, H), 8.70 (d, H), 8.82(d, H), 9.57(s, H). IC50 = 8 nM.
Example 210
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-indol- 1 -yl)-amide
Figure imgf000205_0001
A mixture of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-2,3- dihydro-indol-l-yl)-amide (246 mg, 0.68 mmol) and MnO2 (296 mg, 3.4 mmol) in DCM (10 mL) is stirred at rt for 1.5 h. The reaction mixture is filtered and the filtrate is concentrated in vacuo. The residue is triturated with ether to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine- 5-carboxylic acid (2-methyl-indol- 1-ylVamide (158. 65%). MS: 361 (M+H); 1U NMR (300 MHz, CDCl3): δ 2.39 (s, 3H), 2.83 (s, 3H), 6.36 (s, H), 7.10-7.29 (m, 3H), 7.44-7.62 (m, H), 8.17 (s, H), 8.25 (d, H), 8.35 (d, H), 8.97 (s, H).
Example 211 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4- vD-amide
Figure imgf000205_0002
Step 1 : LiAlH4 (14.7 mmol, 1 M solution in THF) is added to a solution of 6-fluoro-4H- benzo[l,4]oxazin-3-one (1.23 g, 7.35 mmol) in THF at rt and heated to reflux for 2 hrs. The reaction mixture is quenched with a few drops of water followed by slow addition of ethyl acetate (10 mL). The solid is filtered off, and washed with EtOAc. The filtrate is concentrated in vacuo to afford 6-fluoro-3,4-dihydro-2H-benzo[l,41oxazine (1 g). MS: 154 (M+H).
Step 2: Isoamyl nitrite is added to a solution of 6-fluoro-3,4-dihydro-2H-benzo[l,4] oxazine (Ig) in DCM (15 mL) and heated to reflux overnight. The reaction mixture is concentrated in vacuo and the residue is purified by silica gel chromatography eluting with 10% EtOAc in heptane to give 6-Fluoro-4-nitroso-3,4-dihydro-2H-benzo[l,41oxazine (Q.83 g).
Step 3: LiAlH4 in THF (1 M, 6.58 mL) is added to a solution of 6-fluoro-4-nitroso-3,4- dihydro-2H-benzo[l,4]oxazine (0.8 g) in THF (10 mL) at 0° C and then stirred at rt overnight. The reaction mixture is quenched with a few drops of water followed by addition of EtOAc (10 mL). The solid is filtered off, and washed with EtOAc (15 mL). The filtrate is concentrated in vacuo and the residue is purified by silica gel column chromatography eluting with 15% EtOAc in heptane to afford 6-fluoro-2,3-dihydro-benzo[l,41oxazin-4-ylamine (0.44 mg).
Step 4: DIPEA (174 μL) is added to a mixture of 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (218 mg), HATU (380 mg) and 6-fluoro-2,3-dihydro-benzo[l,4]oxazin-4-ylamine (220 mg) in DMF (15 mL) and then heated at 80 0C overnight. The reaction mixture is concentrated in vacuo and the residue is purified by silica gel column chromatography eluting with 30% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid (6- fluoro-2.3-dihvdro-1.4-benzoxazin-4-vn-amide (81 mg). MS: 369 (M+H); 1H NMR (300 MHz, DMSO-D6): δ 11.05 (s, IH), 9.35 (s, 2H), 8.32 (dd, IH), 8.18 (dd, IH), 7.65 (m, IH), 7.5 (m, IH), 6.8-6.7 (m, 2H), 6.52-6.45 (m, IH), 4.36 - 4.33 (m, 2H), 3.65 (m, 2H). IC50 = 12 nM.
Example 212
2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4-yl)-amide
Figure imgf000207_0001
Following procedures similar to those of step 4 in Example 211, but substituting 2-phenyl- pyrimidine-5-carboxylic acid for 2-(3-fluoro-phenyl)-pyrimidine-5-carboxylic acid, there is prepared 2-phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4-yl)- amide as solid. MS: 351 (M+H); 1H NMR (300 MHz, DMSO-D6): δ 11.03 (s, IH), 9.33 (s, 2H), 8.49-8.46 (m, 2H), 7.61-7.55 (m, 3H), 6.8-6.7 (m, 2H), 6.52-6.45 (m, IH), 4.36 - 4.33 (m, 2H), 3.65-3.25 (m, 2H). IC50 = 21 nM.
Example 213
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolor2,3- blpyridin- 1 -yl)-amide
Figure imgf000207_0002
Step 1 : A solution of 5-fluoro-3-iodo-pyridin-2-ylamine (3 g, 12.6 mmol) in DCM (40 mL) is treated with TFAA (2.1 mL, 15.1 mmol) and pyridine (1.2 mL, 15.1 mmol), and stirred at rt for 2 h. The mixture is diluted with H2O (150 mL), and extracted with DCM (3 x 150 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is diluted with MeCN (40 mL), treated with trans-crotyi bromide (2 mL, 18.9 mmol) and K2CO3 (3.5 g, 25.2 mmol), and heated at reflux for 2 h. The mixture is cooled, filtered through a pad of Celite and concentrated. The residue is purified by silica gel chromatography eluting with 5% - 30% EtOAc in heptane to afford iV-but-2-enyl-2,2,2- trifluoro-JV-(5-fluon)-3-iodo-pyridin-2-yl)-acetamide (2.5 g, 51%). MS: 389 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.36 (m, IH), 7.98 (s, IH), 5.55 (m, 2H), 4.62 (m, IH), 3.96 (m, IH), 1.61 (m, 3H).
Step 2: A solution of Λ/-but-2-enyl-2,2,2-trifluoro-Λ/-(5-fluoro-3-iodo-pyridin-2-yl)-acetamide (2.57 g, 6.5 mmol) in DMF (10 mL) is treated with /7-Bu4NCl (2 g, 7.15 mmol), Pd(OAc)2 (59 mg, 0.26 mmol), and stirred at 1000C for 2 h. The mixture is cooled to rt, diluted with EtOAc (50 mL), filtered through a pad of silica gel, and washed with 1 M HCl (50 mL). The organic layer is separated, dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 25% - 70% EtOAc in heptane to afford 3-ethyl-5- fluoro-lH-pyrrolor2.3-blpyridine (0.75 g, 70%). MS: 165 (M+H); 1H NMR (300 MHz,
CDCl3): δ 9.62 (s, NH, IH), 8.17 (m, IH), 7.60 (m, IH), 7.16 (s, IH), 2.74 (q, 2H), 1.31 (t, 3H).
Step 3: A suspension of NaH (2.7 g, 68 mmol, 60% in mineral oil) in DMF (20 mL) at 00C is treated with 3-ethyl-5-fluoro-lH-pyrrolo[2,3-b]pyridine (745 mg, 4.5 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (2.5 g, 22.5 mmol) portion wise and warmed to rt over 2 h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% - 50% EtOAc in heptane to afford 3-ethyl-5-fluoropyrrolo|"2,3-blpyridin- 1 -ylamine (685 mg, 84%). MS: 180 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.16 (s, IH), 7.56 (m, IH), 7.14 (s, IH), 4.93 (s, NH2, 2H), 2.697 (q, 2H), 1.28 (t, 3H).
Step 4: A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (490 mg, 2.28 mmol) and 3-ethyl-5-fluoropyrrolo[2,3-b]pyridin-l -ylamine (340 mg, 1.9 mmol) in DMF (6 mL) is stirred at 400C for 1 h. The mixture is treated with DMTMM (524 mg, 1.9 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4; methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolor2,3-blpyridin- 1 - vQ-amide (427 mg, 60%). MS: 377 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 11.94 (s, NH,
IH), 9.14 (s, IH), 8.81 (d, IH), 8.47 (d, IH), 8.30 (s, IH), 8.03 (m, 2H), 7.61 (m, 2H), 2.81 (s,
3H), 2.75 (q, 2H), 1.29 (t, 3H). Example 214
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3-blpyridin- l-yl)-amide
Figure imgf000209_0001
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (509 mg, 2.28 mmol) and 3-ethyl-5-fluoropyrrolo[2,3-b]pyridin-l-ylamine (340 mg, 1.9 mmol) in DMF (6 mL) is stirred at 400C for 1 h. The mixture is treated with DMTMM (524 mg, 1.9 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4-methyl-2-thiazol-2-yl- pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3-blpyridin-l-yl)-amide (481 mg, 66%). MS: 383 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 11.95 (s, NH, IH), 9.10 (s, IH), 8.29 (s, IH), 8.14 (d, IH), 8.08 (d, IH), 8.00 (m, IH), 7.57 (s, IH), 2.79 (s, 3H), 2.75 (q, 2H), 1.29 (t, 3H).
Example 215
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-pyrrolor2,3-b1pvridin-
Figure imgf000209_0002
Step 1 : A solution of 5-fluoro-3-iodo-pyridin-2-ylamine (4 g, 16.8 mmol) in THF (50 mL) and trimethylsilylacetylene (4.7 mL, 33.6 mmol) is treated with PdCl2(PPh3)4 (353 mg, 0.5 mmol), CuI (96 mg, 0.5 mmol) and triethylamine (7 mL, 50.4 mmol) and stirred at rt for 2 h. The mixture is filtered through Celite and concentrated. The residue is purified by silica gel chromatography eluting with 10% - 35% EtOAc in heptane to afford 5-fluoro-3- trimethylsilanylethvnyl-pyridin-2-ylamine (3.3 g, 94%). MS: 209 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.90 (d, IH), 7.30 (m, IH), 4.89 (s, NH2, 2H), 0.25 (s, 9H). Step 2: A solution of 5-fluoro-3-trimethylsilanylethynyl-pyridin-2-ylamine (3.2 g, 15.4 mmol) in MeOH (77 mL) and K2CO3 (1.1 g, 7.7 mmol) is stirred at rt for 0.5 h. The mixture is filtered through Celite and concentrated. The residue is purified by silica gel chromatography eluting with 15% - 55% EtOAc in heptane to afford 3 -ethynyl-5 -fluoro- pyridin-2-ylamine (1.55 g, 74%). MS: 137 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.94 (d, IH), 7.35 (m, IH), 4.91 (s, NH2, 2H), 3.44 (s, IH).
Step 3: A solution of 3 -ethynyl-5 -fluoro-pyridin-2-ylamine (1.25 g, 9.2 mmol) in DMF (20 mL) is treated with (Rh(COd)2Cl)2 (23 mg, 0.023 mmol) and tris-(4-fluoro-phenyl)-phosphane (115 mg, 0.368 mmol) and stirred at 85°C for 0.5 h. The mixture is then poured over brine (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 35% - 75% EtOAc in heptane to afford 5-fluoro-lH-pyrrolor2,3- blpyridine (1.05 g, 84%). MS: 137 (M+H); 1H NMR (300 MHz, CDCl3): δ 9.15 (s, NH, IH), 7.99 (s, IH), 7.44 (d, IH), 7.18 (s, IH), 6.28 (s, IH).
Step 4: A suspension of NaH (4.4 g, 110 mmol, 60% in mineral oil) in DMF (37 mL) at 00C is treated with 5-fluoro-lH-pyrrolo[2,3-b]pyridine (1.0 g, 7.4 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (4.2 g, 37 mmol) portion wise and warmed to rt over 2 h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 30% - 70% EtOAc in heptane to afford 5-fluoro-pyrrolor2.3-blpyridin- 1 -ylamine (980 mg, 88%). MS: 152 (M+H); 1H NMR (300 MHz, CDCl3): δ 8.20 (s, IH), 7.60 (m, IH), 7.42 (m, IH), 6.36 (s, IH), 5.01 (s, NH2, 2H).
Step 5: A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (529 mg, 2.28 mmol) and 5-fluoro-pyrrolo[2,3-b]pyridin-l -ylamine (288 mg, 1.9 mmol) in DMF (6 mL) is stirred at 400C for 1 h. The mixture is treated with DMTMM (524 mg, 1.9 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 2-(3- fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-pyrrolor2,3-b1pyridin- 1 -vD- amide (475 mg, 68%). MS: 366 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.12 (s, IH), 8.30 (m, 2H), 8.18 (d, IH), 7.97 (d, IH), 7.82 (d, IH), 7.59 (m, IH), 7.44 (m, IH), 6.59 (d, IH), 2.80 (s, 3H).
Example 216
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-pyrrolor2,3-b1pyridin- 1 -vD- amide
Figure imgf000211_0001
A solution of 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (440 mg, 2.28 mmol) and 5-fluoro-pyrrolo[2,3-b]pyridin-l-ylamine (288 mg, 1.9 mmol) in DMF (6 mL) is stirred at
400C for 1 h. The mixture is treated with DMTMM (524 mg, 1.9 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min.
The precipitate is collected by filtration and dried in vacuo to afford 4-methyl-2-pyridin-2-yl- pyrimidine-5-carboxylic acid (5-fluoro-pyrrolor2,3-blpyridin- 1 -vD-amide (343 mg, 52%). MS: 349 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.17 (s, IH), 8.81 (d, IH), 8.53 (d, IH),
8.27 (s, IH), 8.01 (m, IH), 7.90 (m, IH), 7.77 (d, IH), 7.57 (m, IH), 6.60 (d. IH), 2.84 (s,
3H).
Example 217 4-Methyl-r2,2'lbipyrimidinyl-5-carboxylic acid (2-cvclopropyl-5-fluoro-indol- 1 -yl)-amide
Figure imgf000211_0002
Step 1 : A solution of 4-fluoro-2-iodoaniline (2 g, 8.4 mmol) in THF (15 mL) and cyclopropylacetylene (1.4 mL, 16.9 mmol) is treated with PdCl2(PPh3 )4 (177 mg, 0.25 mmol), CuI (48 mg, 0.25 mmol) and triethylamine (3.5 mL, 25.2 mmol) and stirred at rt for 2 h. The mixture is filtered through Celite and concentrated. The residue is purified by silica gel chromatography eluting with 0% - 35% EtOAc in heptane to afford 2-cyclopropylethvnyl-4- fluoro-phenylamine (1.1 g, 74%). MS: 176 (M+H); 1H NMR (300 MHz, CDCl3): δ 6.93 (m, IH), 6.81 (m, IH), 6.59 (m, IH), 4.00 (s, NH2, 2H), 1.49 (m, IH), 0.82 (m, 4H).
Step 2: A solution of 2-cyclopropylethynyl-4-fluoro-phenylamine (0.80 g, 4.5 mmol) in PhMe (16 niL) is treated with InBr3 (80 mg, 0.23 mmol) and stirred at 1100C for 0.5 h. The mixture is then poured over brine (20 mL), and extracted with EtOAc (3 x 20 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 0% - 25% EtOAc in heptane to afford 2z cvclopropyl-5 -fluoro- 1 H-indole (610 mg, 78%). MS: 176 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.88 (s, NH, IH), 7.12 (m, 2H), 6.83 (m, IH), 6.09 (s, IH), 1.90 (m, IH), 0.95 (m, 2H), 0.77 (m, 2H).
Step 3: A suspension of NaH (1.9 g, 47 mmol, 60% in mineral oil) in DMF (20 mL) at 00C is treated with 2-cyclopropyl-5 -fluoro- 1 H-indole (550 mg, 3.14 mmol) and stirred at 00C for 1 h. The mixture is treated with HOSA (1.8 g, 15.7 mmol) portion wise and warmed to rt over 2 h. The mixture is then poured over ice, filtered through a pad of Celite, and extracted with EtOAc (3 x 50 mL). The combined organic layer is dried (Na2SO4), filtered and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 5% - 35% EtOAc in heptane to afford 2-cvclopropyl-5-fluoro-indol- 1 -ylamine (420 mg, 70%). MS: 191 (M+H); 1H NMR (300 MHz, CDCl3): δ 7.30 (m, IH), 7.11 (m, IH), 6.92 (m, IH), 5.90 (s, IH), 4.57 (s, NH2, 2H), 2.07 (m, IH), 1.02 (m, 2H), 0.75 (m, 2H).
Step 4: A solution of 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (184 mg, 0.85 mmol) and 2-cyclopropyl-5-fluoro-indol-l -ylamine (135 mg, 0.71 mmol) in DMF (3 mL) is stirred at 400C for 1 h. The mixture is treated with DMTMM (235 mg, 0.71 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4-methyl- r2,2'lbipyrimidinyl-5-carboxylic acid (2-cvclopropyl-5-fluoro-indol-l-yl)-amide (35 mg, 13%). MS: 389 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 11.93 (s, NH, IH), 9.31 (s, IH), 9.06 (d, 2H), 7.70 (m, IH), 7.42 (m, IH), 7.26 (m, IH), 6.97 (m, IH), 6.16 (s, IH), 2.79 (s, 3H), 1.97 (m, IH), 1.01 (m, 2H), 0.74 (m, 2H).
Example 218 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (2-cyclopropyl-5-fluoro-indol-l-yl)- amide
Figure imgf000213_0001
A solution of 4-methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (188 mg, 0.85 mmol) and 2-cyclopropyl-5-fluoro-indol-l-ylamine (135 mg, 0.71 mmol) in DMF (3 mL) is stirred at 400C for 1 h. The mixture is treated with DMTMM (235 mg, 0.71 mmol) and stirred at 400C for 1 h. The mixture is diluted with saturated aqueous Na2CO3 (5 mL) and stirred for 5 min. The precipitate is collected by filtration and dried in vacuo to afford 4-methyl-2-thiazol-2-yl- pyrimidine-5-carboxylic acid (2-cvclopropyl-5-fluoro-indol-l-yl)-amide (60 mg). MS: 394 (M+H); 1H NMR (300 MHz, DMSO-d6): δ 9.26 (s, IH), 8.15 (d, IH), 8.08 (d, IH), 7.43 (m, IH), 7.24 (m, IH), 6.97 (m, IH), 6.18 (s, IH), 2.77 (s, 3H), 1.95 (m, IH), 1.01 (m, 2H), 0.73 (m, 2H).
Example 219 2-Pyrimidin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (5-meτhoxyl-indol-l-vD-amide
Figure imgf000213_0002
A solution of 2-pyrimidin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (496 mg, 2.30 mmol) and 5-methoxy-indol-l-ylamine (0.98 mmol) in anhydrous DMF (10 mL) is stirred at 5O0C for 30 min. DMTMM (555 mg, 2.01 mmol) is added and stirred at 5O0C for an hour. DMF is evaporated off. The residue is mixed with water (40 mL) and stirred at rt for 20 minutes. The solid is collected by filtration, washed with water (3x 5 mL) and dried in vacuum to afford I1 pyrimidin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (5-meτhoxyl-indol-l-vD-amide (410 mg) as a solid. MS: 361 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.93(s, 3H), 4.84(s, 3H), 7.04(t, H), 6.50(d, H), 6.92(d, H), 7.14(s, H), 7.26-7.37(m, 2H), 7.72 (t, H), 9.09 (d, 2H), 9.27(s, H). Example 220
4-Methyl42,2Hbipyrimidinyl-5-carboxyric acid (5-fluoro-3-methyl-pyrrolor3,2-b1pyridin-l- vD-amide
Figure imgf000214_0001
Step 1 : Bromine (1.96 g, 12.2 mmol) is added to a mixture of 2-fluoro-5-aminopyridine (1.37 g, 12.2 mmol) and sodium acetate (2 mg, 24.4 mmol) in acetic acid (30 mL) and stirred at rt for 4 hours. Acetic acid is evaporated off in vacuo. The residue is dissolved in EtOAc (50 mL), washed with saturated aqueous Na2CO3 (10 mL), water (20 mL) and brine (10 mL), dried (Na2SO4), filtered, and concentrated in vauo to afford 2-bromo-3-amino-6- fluoropyridine (2.1 g) as a solid. MS: 190 (M+H); 1H NMR (300 MHz, CDCl3): δ 4.04 (br, 2H), 6.77(dd, H), 7.17(dd, H).
Step 2: TFAA (8.31 g, 39.57 mmol) is added drop-wise to a stirred solution of 2-bromo-3- amino-6-fluoropyridine (6.30 g, 33.0 mmol) and pyridine (3.91 g, 49.46 mmol) in DCM (80 mL) at rt, and stirred at rt for an hour. Water (40 mL) is added. The organic layer is separated, dried (Na2SO4), filtered, and concentrated in vacuo to afford N-(2-bromo-6-fluoropyridin-3- yl>2.2.2-trifluoro-acetamide (9.37 g, >99%) as a solid. 1H NMR (300 MHz, CDCl3): δ 7.06(m, H), 8.40 (br, N-H), 9.75(dd, H).
Step 3: A solution of N-(2-bromo-6-fluoropyridin-3-yl)-2,2,2-trifluoro-acetamide (9.16 g, 31.9 mmol), allyl bromide (6.18 g, 47.9 mmol) and sodium carbonate (8.82 g, 63.8 mmol) in CH3CN (80 mL) is stirred at 8O0C for 2 h. The reaction mixture is concentrated in vacuo and the residue is purified by silica gel chromatography eluting with 0-60% DCM in heptane to afford N-allyl-N-(2-bromo-6-fluoro-pyridin-3-yl)-2,2,2-trifluoro-acetamide (9.05 g) as an oil. 1H NMR (300 MHz, CDCl3) δ 3.68 (q, H), 5.01 (q, H), 5.17 (d, H), 5.29 (d, H), 6.85(m, H), 7.00 (dd, H), 7.64(t, H). Step 4: A solution of N-allyl-N-(2-bromo-6-fluoro-pyridin-3-yl)-2,2,2-trifluoro-acetamide (3.41 g, 10.43 mmol), palladium acetate (94 mg, 0.42 mmol), tetra(n-butylammonium) chloride (3.19 g, 11.47 mmol) and triethylamine (2.37 g, 23.4 mmol) in anhydrous DMF (20 mL) is stirred at 1000C under N2 for an hour. DMF is evaporated off and the residue is mixed with water (12 mL) and stirred at rt for an hour. EtOAc (15 mL) is added and stirred at rt overnight. The organic layer is separated and the aqueous layer is extracted with EtOAc (35 mL). The combined organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 10-60% EtOAc in heptane to afford 5-fluoro-3-methyl-lH-pyrrolor3.2-blpyridine (1.5 g) as a solid. MS: 151 (M+ H); 1U NMR (300 MHz, CDCl3) δ 2.38(s, 3H), 6.77(d, H), 7.28(s, H), 7.74(dd, H).
Step 5: A solution of 5-fluoro-3-methyl-lH-pyrrolo[3,2-b]pyridine (10.7 mmol) in anhydrous DMF (15 mL) is added drop-wise to a stirred solution of NaH (60%, 160 mmol) in anhydrous DMF (25 mL) under N2 at O0C for 20 min and stirred at O0C under N2 for 30 minutes. HOSA (53.5 mmol) is added portion-wise for 30 minutes at O0C, and stirred at O0C for 1.5 hours.
After quenching with ice-water (400 mL), the mixture is extracted with ether (3x 60 mL). The combined organic layer is washed with water (2x30 mL) and brine (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with 0-60% EtOAc in heptane to afford 5 -fluoro-3 -methyl- pyrrolon .2-blpyridin- 1 -ylamine (570 mg). MS: 166 (M+H); 1U NMR (300 MHz, CDCl3) δ 2.32 (s, 3H), 4.82 (br, 2N-H), 6.76 (d, H), 7.17 (s, H), 7.77 (dd, H).
Step 6: A solution of 2-pyrimidin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (1.41 mmol), 5- fluoro-3-methyl-pyrro Io [3, 2-b]pyridin-l -ylamine (1.41 mmol), DIPEA (158 mg, 4.22 mmol) and HATU (1.69 mmol) in anhydrous DMF (8 mL) is stirred at 9O0C for 16 hours. DMF is evaporated off in vacuo. The residue is dissolved in EtOAc (40 mL), washed with water (3x10 mL) and brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel chromatography eluting with 1-20% MeOH in DCM to afford 4-methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo|"3,2-blpyridin-l- vQ-amide (125 mg) as a solid. MS: 364 (M+H); 1U NMR (300 MHz, CD3OD): δ 2.31 (s, 3H), 2.87 (s, 3H), 6.87 (d, H), 7.50 (s, H), 7.66 (t, H), 7.96 (t, H), 9.04 (d, 2H), 9.27 (s, H).
Example 221 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2- blpyridin- 1 -yl)-amide
Figure imgf000216_0001
A solution of 2-pyridin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (1.36 mmol), 5-fluoro-3- methyl-pyrrolo[3,2-b]pyridin-l-ylamine (1.36 mmol), DIPEA (158 mg, 4.07 mmol) and HATU (1.63 mmol) in anhydrous DMF (8 mL) is stirred at 9O0C for 15 hours. DMF is evaporated in vacuo. The residue is dissolved in EtOAc (40 mL), washed with water (3x15 mL) and brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo. The residue is recrystallized from EtOAc to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5- fluoro-3 -methyl-pyrrolo [3.2-blpyridin- 1 -ylV amide (285 mg) as a solid. MS: 363 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.35 (s, 3H), 2.87 (s, 3H), 6.92 (d, H), 7.51 (s, H), 7.60 (t, H), 7.97 (t, H), 8.05 (t, H), 8.65 (d, H), 8.78 (d, H), 9.23 (s, H).
Example 222
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolor3,2- blpyridin- 1 -yl)-amide
Figure imgf000216_0002
A solution of 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (1.34 mmol), 5- fluoro-3-methyl-pyrrolo[3,2-b]pyridin-l-ylamine (1.34 mmol), DIPEA (158 mg, 4.02 mmol) and HATU (1.60 mmol) in anhydrous DMF (8 mL) is stirred at 9O0C for 16 h. DMF is evaporated off in vacuo. The residue is dissolved in EtOAc (40 mL), and washed with water (3x20 mL) and brine (10 mL). The organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is is purified by silica gel chromatography eluting with 0-60% EtOAc in heptane to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3- methyl-pyrrolo [3.2-blpyridin- 1 -yl)-amide (340 mg) as a solid. MS: 380 (M+H); 1H NMR (300 MHz, CDCl3): δ 2.36 (s, 3H), 2.86 (s, 3H), 6.84 (d, H), 7.12-7.35 (m, 2H), 7.52 (q, H), 7.63 (t, H), 8.10-8.43 (m, 2H), 8.98 (br, N-H).
Example 223
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-pyrrolo|"3,2- blpyridin- 1 -yl)-amide
Figure imgf000217_0001
Step 1 : Bromine (4.72 g, 29.5 mmol) is added to a mixture of 2-methoxy-5-aminopyridine
(3.66 g, 29.5 mmol) and sodium acetate (4.84 g, 7.32 mmol) in acetic acid (50 mL) and stirred at rt for 20 minutes. Acetic acid is evaporated off in vacuo. The residue is dissolved in EtOAc (40 mL), and washed with water (40 mL), saturated sodium carbonate aqueous solution (20 mL), water (20 mL) and brine (20 mL). The organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is is purified by silica gel chromatography eluting with 0- 40% EtOAc in heptane to afford 2-bromo-3-amino-6-methoxypyridine (4.35 g) as an oil. MS: 202 (M+H); 1H NMR (300 MHz, CDCl3): δ 3.89 (s, 3H), 6.60(d, H), 7.07(d, H).
Step 2: TFAA (5.15 g, 24.5 mmol) is added drop-wise to a stirred solution of 2-bromo-3- amino-6-methoxypyridine (4.15 g, 20.5 mmol) and pyridine (1.94 g, 24.5 mmol) in DCM (60 mL) at rt and stirred at rt for 2.5 h. Water (40 mL) is added. The organic layer is separated, dried (Na2SO4), filtered, and concentrated in vacuo to afford N-(2-bromo-6-methoxy-pyridin- 3-yl)-2.2.2-trifluoro-acetamide (5.68 g) as a solid. 1H NMR (300 MHz, CDCl3): δ 3.96 (s,H), 6.80(s, H), 8.23 (br, N-H), 8.42(d, H).
Step 3: A mixture of N-(2-bromo-6-methoxy-pyridin-3-yl)-2,2,2-trifluoro-acetamide (5.52 g, 18.5 mmol), allyl bromide (3.57 g, 27.7 mmol) and sodium carbonate (5.1 g, 11 mmol) in CH3CN (60 mL) is stirred at 8O0C for 3 h. The mixture is filtered and the filtrate is concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with 0-60% DCM in heptane to afford N-allyl-N-(2-bromo-6-methoxy-pyridin-3-v0-2.2.2- trifiuoro-acetamide (5.55 g) as an oil. 1H NMR (300 MHz, CDCl3): δ 3.66 (q, H), 4.00 (s, H), 5.95 (q, H), 5.08-5.30 (q, 2H), 5.75-5.94 (m, H), 6.74 (d, H), 7.38 (d, H).
Step 4: A solution of N-allyl-N-(2-bromo-6-methoxy-pyridin-3-yl)-2,2,2-trifluoro-acetamide (5.54 g, 16.3 mmol), palladium acetate (147 mg, 0.65 mmol), tetra(n-butylammonium) chloride (4.99 g, 17.9 mmol) and triethylamine (3.72 g, 26.8 mmol) in anhydrous DMF (35 mL) is stirred at 1000C under N2 for an hour. DMF is evaporated off, and the residue is mixed with water (20 mL) and stirred at rt overnight. EtOAc (50 mL) is added. The organic layer is separated, dried (Na2SO4), filtered, and concentrated in vacuo. The residue is is purified by silica gel column chromatography eluting with 30-70% EtOAc in heptane to afford 5^ methoxy-3 -methyl- 1 H-pyrrolo [3.2-blpyridine (2.62 g) as a solid. 1H NMR (300 MHz, CDCl3): δ 2.38 (s, 3H), 4.05 (s, 3H), 6.62 (s, H), 7.12 (s, H), 7.54 (d, H), 7.94 (br, N-H).
Step 5: A solution of 5 -methoxy-3 -methyl- 1 H-pyrrolo [3, 2-b]pyridine (17.3 mmol) in anhydrous DMF (20 mL) is added drop-wise to a stirred solution of NaH (60%, 260 mmol) in anhydrous DMF (35 mL) under N2 at O0C for 40 min and then stirred at O0C under nitrogen for 30 minutes. HOSA is added portion-wise for 45 minutes at O0C and then stirred at O0C for 2 hours. After quenching with ice-water (500 mL), the reaction mixture is extracted with ether (3 x 40 mL). The combined organic layer is washed with water (20 mL) and brine (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with 5-60% EtOAc in heptane to afford 5 -methoxy-3 -methyl- pyrrolor3.2-blpyridin-l-ylamine (1.73 g) as a solid. MS: 178 (M+H); 1U NMR (300 MHz, CDCl3): δ 2.34 (s, 3H), 4.04(s, 3H), 4.75(br, 2N-H), 6.63(d, H), 7.04(s, H), 7.60(d, H).
Step 6: A solution of 2-pyridin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (1.69 mmol), 5- methoxy-3-methyl-pyrrolo[3,2-b]pyridin-l-ylamine (1.69 mmol), DIPEA (5.01 mmol) and HATU (2.03 mmol) in anhydrous DMF (8 mL) is stirred at 9O0C for 16 h. DMF is evaporated in vacuo. The residue is dissolved in EtOAc (40 mL), and washed with water (3x10 mL) and brine (10 mL). The organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is purified by silica gel column chromatography eluting with 0-15% MeOH in DCM to afford 4-methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -methoxy-3 -methyl- pyrrolor3.2-blpyridin- 1 -ylV amide (295 mg) as a solid. MS: 375 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.40 (s, 3H), 2.84 (s, 3H), 4.02 (s, 3H), 6.70 (d, H), 7.13 (s, H), 7.41 (m, H), 7.50 (d, H), 7.85 (t, H), 8.51 (m, 2H), 8.78 (s,2H), 10.57 (br, N-H).
Example 224
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methoxy-3 -methyl- pyrrolor3,2-b1pyridin-l-vD-amide
Figure imgf000219_0001
A solution of 2-(3-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (1.13mmol), 5-methoxy-3- methyl-pyrrolo[3,2-b]pyridin-l-ylamine (1.13 mmol), DIPEA (3.39mmol) and HATU (1.36 mmol) in anhydrous DMF (8 rnL) is stirred at 9O0C for 16 h. DMF is evaporated off in vacuo. The residue is dissolved in EtOAc (45 mL), and washed with water (3x20 mL) and brine (10 rnL). The organic layer is dried (Na2SO4), filtered, and concentrated in vacuo. The residue is is triturated with DCM to afford 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methoxy-3 -methyl-pyrro Io [3 ,2-blpyridin- 1 -yl)-amide (265 mg) as a solid. MS: 392 (M+H); 1H NMR (300 MHz, CD3OD): δ 2.33 (s, 3H), 2.79 (s, 3H), 3.97 (s, 3H), 6.67 (d, H), 7.20-7.60 (m, 2H), 7.53 (m, H), 7.64 (d, H), 8.17 (t, H), 8.34 (t, 2H), 9.05-9.20 (d, H).
Example 225 4-Methyl-2-(l-oxy-pyridin-2-yl)-pyrimidin-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yD- amide
Figure imgf000219_0002
Step 1 : A solution of 2-cyanopyridine (1.67 g, 16 mmol), 30% H2O2 (3.2 niL) and methyltrioxorhenium (0.2 g, 0.8 mmol) in DCM (6.4 mL) is stirred at rt overnight. The reaction mixture is concentrated in vacuo and the residue is purified by silica gel chromatography eluting with 3-10% MeOH in DCM to afford 1 -oxy-pyridine-2-carbonitrile (0.69 g) as a solid. 1H NMR (300 MHz, CDCl3): δ 7.34 (t, H), 7.49(t, H), 7.67(d, H), 8.30 (d, H).
Step 2: A solution of l-oxy-pyridine-2-carbonitrile (532 mg, 4.43 mmol) and sodium methoxide (0.5 M in MeOH, 0.88 mL) in MeOH (1.8 mL) is stirred at rt overnight. Ammonium chloride (261 mg. 4.87 mmol) is added and stirred at 560C for an hour, and then 7 N ammonia in MeOH (1.5 mL) is added. The reaction mixture is sealed in a tube and stirred at 4O0C for an hour, and then cooled to O0C. Sodium methoxide is added (0.5 M in MeOH, 8.86 mL). The mixture is filtered and the filtrate is concentrated in vacuo. The residue is recrystallized from ethanol to afford 1 -oxy-pyridine-2-carboxamidine (370 mg) as a solid. 1H NMR (300 MHz, CD3OD): δ 7.52-7.68(m, 2H), 7.96(dd, H), 8.35 (d, H).
Step 3: A solution of l-oxy-pyridine-2-carboxamidine (366 mg, 2.67 mmol) and N ,N- dimethylaminomethylene acetoacetate (495 mg, 2.76 mmol) in ethanol (3 mL) and DMF (3 ml) is stirred at 9O0C for 16 hours. The reaction mixture is concentrated in vacuo and the residue is purified by silica gel column chromatography eluting with 2.5 % MeOH in DCM to afford 4-methyl-2-(l-oxy-pyridin-2-yl)-pyrimidine-5-carboxylic acid ethyl ester (127 mg) as a solid. 1H NMR (300 MHz, CDCl3): δ 1.47 (t, 3H), 2.95 (s, 3H), 4.50 (q, 2H), 7.39 (m, H), 7.70(q, H), 8.36(q, H), 9.37 (s, H).
Step 4: A solution of 4-methyl-2-(-loxy-pyridin-2-yl)-pyrimidine-5-carboxylic acid ethyl ester (123 mg, 0.48 mmol) and sodium hydroxide (123 mg, 3.07 mmol) in a mixture of MeOH/THF/H2O (3 mL, 1 : 1 : 1) is stirred at 650C for 5 minutes, and then stirred at rt overnight (16 hours). 1 N HCl aqueous solution (3.07 mL) is added. The resulting solution is concentrated to afford 4-methyl-2-(l -oxy-pyridin-2-yl)-pyrimidine-5-carboxylic acid and sodium chloride (313 mg), which is used in the next step without further purification.
Step 5: A solution of 4-methyl-2-(l-oxy-pyridin-2-yl)-pyrimidine-5-carboxylic acid and sodium chloride (313 mg), 3-methyl-5-fluoro-indol-l-ylamine (78 mg, 0.48 mmol), DIEA (92 mg, 0.71 mmol) and HATU (217 mg, 0.57 mmol) in anhydrous DMF (2.4 mL) is stirred at 15O0C for 1 hour. DMF is vaporated off. The residue is purified by silica gel column chromatography eluting with 2.5-10% MeOH in DCM to afford 4-methyl-2-(l -oxy-pyridin-2- vD-pyrimidine-5-carboxyric acid (5-fluoro-3-methyl-indol-l-yl)-amide (169 mg) as a solid. MS: 378 (M+H); 1H NMR (300 MHz, CD3OD): δ =1.52(s, 3H), 2.84(s, 3H), 7.02(t, H), 7.18(s, H), 7.25 (d, H), 7.35(q, H), 7.62-7.80 (m, 2H), 7.85 (dd, H), 8.48 (d, H), 9.21(s, H). IC50 = 851.5 nM.
Example 226
2-(3-Difluoromethyl-phenvD-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -vD- amide
Figure imgf000221_0001
Following procedures similar to those of Example 158, step 4, but substituting 2-(3- difluromethyl-phenyl)-2-yl-pyrimidine-5-carboxylic acid for 2-thiazol-2-yl-pyrimidine-5- carboxylic acid, there is prepared 2-(3 -difluoromethyl-phenvD-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 -vO-amide. MS: 397 (M+H); 1U NMR (300 MHz, DMSO-d6): δ 2.27 (s, 3H), 7.04 (dt, IH), 7.13 (d, IH), 7.32 (s, IH), 7.34-7.44 (m, 2H), 7.73-7.85 (m, 2H), 8.66 (d, IH), 8.69 (s, IH), 9.45 (s, 2H). IC50 = 17 nM.
Example 227
2-(3-Trifluoromethyl-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -vD- amide
Figure imgf000221_0002
Following procedures similar to those of Example 158, step 4, but substituting 2-(3- trifluromethyl-phenyl)-2-yl-pyrimidine-5-carboxylic acid for 2-thiazol-2-yl-pyrimidine-5- carboxylic acid, there is prepared 2-(3 -trifluoromethyl-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 -vO-amide. MS: 415 (M+H). 1U NMR (300 MHz, DMSO-d6): δ 2.27 (s, 3H), 7.04 (dt, IH), 7.33 (s, IH), 7.34-7.44 (m, 2H), 7.86 (t, IH), 8.00-8.02 (m, IH), 8.75-8.79 (m, 2H), 9.47 (s, 2H). IC50 = 262 nM.
Following procedures similar to those described in the above examples, the following compounds are made: 2-Phenyl-pyrimidine-5 -carboxylic acid (4-benzyl-piperazin-l-yl)-amide,
2-Phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide,
2-Phenyl-pyrimidine-5 -carboxylic acid (4-methanesulfonyl-piperazin- 1 -yl)-amide,
2-(2-Methyl-thiazol-4-yl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide,
2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-2-carbonyl)-piperazin- 1 - yl] -amide,
2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-4-carbonyl)-piperazin- 1 - yl] -amide,
4- [(2-Phenyl-pyrimidine-5-carbonyl)-amino]-piperazine-l -carboxylic acid tert-butyl ester,
2-Phenyl-pyrimidine-5-carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- 1 -yl]-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- l-yl]-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid indol-1-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid (4-methoxy-piperidin- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2-methyl-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-fluoro-2,3-dihydro-benzo[l ,4]oxazin-4- yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-benzo[ 1 ,4]oxazin-4-yl)-amide,
1 - { [2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyl] -amino } -3 -(2-morpholin-4-yl- ethyl)- lH-indole-6-carboxylic acid methyl ester,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahydro-pyran-4- yl)-indol- 1 -yl]-amide, N-methyl-N-(5 -fluoro)-indol-3 -ylsulfonyl N ' - [2-(3 -fluoro)-phenyl-pyrimidine-5 -carbonyl] - hydrazide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahydro-pyran-4-yl)- indol-1-yl] -amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol-l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin-l-yl)- amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -methyl-pyrro Io [2,3 - c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l- ylamide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -methyl-pyrro Io [3, 2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difiuoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifiuoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-b]pyridin- 1 -yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-b]pyridin-l- yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difiuoromethyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [2,3 - b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l-ylamide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-c]pyridin-l-yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-c]pyridin- 1 - yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethy l-pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin-l-yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid pyrrolo[3,2-c]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-isopropyl-pyrrolo[3,2-c]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-pyrrolo[3,2- c]pyridin-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [3 ,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[2,3-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin- 1 - ylamide, 4-Methyl-2-(4-chloro -thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l- yl)-amide, 2-(4-Methyl-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 ■ yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-3-oxo-2,3-dihydro- indazol- 1 -yl)amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid(5-fluoro-indol- 1 - yl)amide)amide,
6-(4-Chloro-thiazol-2-yl)-2-methyl-N-pyrrolo[2,3-c]pyridin-l-yl-nicotinamide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid(5-methyl-4-oxo-4,5-dihydro- pyrrolo[3,2-c]pyridin-l-yl)amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (5 -difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo [3 ,2-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (5 -trifluoromethyl-pyrrolo [3 ,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (5-difiuoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo[3,2- b]pyridin-l-yl] -amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[3,2-c]pyridin-l-yl]-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo [3 ,2-c]pyridin- 1 -yl] -amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[2,3-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -trifluoromethyl- pyrrolo [3, 2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -trifluoromethyl- pyrrolo [3, 2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (3-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo [3 ,2-c]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-difluoromethyl-pyrrolo[3,2-b] pyridin- l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-c] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro
Io [3 ,2-c]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-2,2-diuoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-c] pyridin-l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro lo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[2,3-c]pyridin- 1 -yl]-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3-b] pyridin- l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[2,3-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[2,3-b]pyridin- 1 -yl] -amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-trifluoro methyl-pyrrolo [3 ,2-b]pyridin- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -difluorom ethyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo [3, 2-c]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[2,3-c]pyridin-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-trifluoromethyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl) -pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-indol-l-yl)-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (3-difluoromethyl-indol- 1 - yl)-amide, and 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-indol- l-yl)-amide.
IN VITRO ASSAY PROTOCOLS TO IDENTIFY INHIBITORS OF HEMATOPOIETIC PGD2 SYNTHASE
The compounds of the present invention can be tested for enzymatic inhibiting activity against PGD2 Synthase according to either one of the following assays.
Assay 1 : Fluorescence Polarization Assay
As described in PCT publication WO 2004/016223, Example II.
Assay 2: Enzyme Immunoassay (EIA) method I. Assay solutions a. Preparation of 0.1M K2HPO4ZKH2PO4 buffer (pH 7.4) Prepare 0.1 M KH2PO4 from IM KH2PO4 (Sigma, Cat# P-8709)
Prepare 0.1 M K2HPO4 from powder Of K2HPO4 (Fisher, BP363-500) Mix 0.1 M K2HPO4 with 0.1 M KH2PO4 to adjust pH to 7.4. b. Preparation of 0.5% γ-globulin
Add 0.1 g of γ-globulin (Sigma, Cat# G-5009) to 20 mL O.l M K2HPO4/KH2PO4 buffer (pH 7.4) and make 1-mL/vial aliquots and store in -8O0C. c. Preparation of 100 mM GSH
Add 307 mg of GSH (Sigma, Cat# G-6529) to 10 mL 0.1 M K2HPO4/ KH2PO4 buffer (pH 7.4) and store at - 8O0C. d. Preparation of Reaction buffer:
198 mL of 0.1M K2HPO4ZKH2PO4 buffer (pH 7.4) 2 mM GSH - Prepared from 100 mM GSH 0.4 g Glycerol 2 mL of 0.5 % γ-globulin
Add 0.4 g of glycerol and 2 mL of 0.5% γ-globulin to 198 mL of 0.1 M K2HPO4/ KH2PO4 buffer (pH7.4).
Add 0.4 mL of 100 mM GSH to 19.6 mL reaction buffer before the assay (enough for two 96- well plates). e. Preparation of FeCl2/citric acid stopping solution: (8 mg/mL FeCl2, 0.1 M citric acid)
Add 40 mg fresh FeCl2 (IGN, Cat# 158046) to 5 mL 0.1 M citric acid (Sigma, Cat# C0759). f. Preparation of MOX reagent:
10% EtOH - Add 1 mL of EtOH to 9 mL of ultra pure H2O
Dissolve 0.1 g of methoxylamine (Cayman, Cat# 400036/) in 10% EtOH (10 mL). Add 0.82 g of sodium acetate (Cayman, Cat#400037) to MOX solution and dissolve.
II. Materials and Method
Dimethylsulfoxide (DMSO; Sigma; Cat# D2650)
Prostaglandin D2-M0X express EIA kit (Caymen Chemical, Catalog No.500151)
Before the assay, cool down 10 mL of acetone in polypropylene tubes and empty 96 well plates in ice. All the procedures except compound dilution are performed on ice.
III. Compound dilution 1. Dilute compound in DMSO
Figure imgf000232_0001
2. Dilute 2 μL of each above concentration of compound to 38 μL of reaction buffer in 96- well plates and mix.
IV. Enzyme and substrate solution preparation
1. Preparation of 0.39 ng/μL enzyme solution (0.35 ng/μL at final after compound addition).
Mix 4 μL of 4 mg/mL human h-PGDS with 396 μL of reaction buffer (to give enzyme concentration 40 μg/mL). Add 46.8 μL of 40 μg/mL h-PGDS to 4.753 mL of reaction buffer to give a total volume of 4.8 mL
2. Preparation of Substrate Solution (PGH2) : Add 0.375 mL of O. l mg/mL of PGH2 to 1.625mL acetone.
V. Enzyme reaction:
1. Add 60 μL of enzyme solution to compound well and positive control (without compound) in U-bottom polypropylene plate on ice. 2. Add 60 μL of reaction buffer and 6.6 μL of 5% DMSO in reaction buffer into negative control wells in the plate.
3. Add 6.6 μL of diluted compound in reaction buffer to the compound wells and mix.
4. Add 6.6 μL of 5% DMSO in reaction buffer to the positive control well.
5. Incubate the plate in ice for at least 30 min. 6. Add 20 μL of substrate (PGH2) solution to compound, negative and positive control wells in the U-bottom 96 well plate on ice.
7. Dry the plate in cold room for about 25-28 min.
8. Pipette 45 μL of enzyme solution (above) into 96-wells with dried PGH2 and mix 3 times. Incubate on the ice for 1 min.
9. Add 45 μL of FeCl2 solution into each wells and mix.
10. Add 90 μL of MOX solution and mix.
11. Incubate for 30 min at 600C.
12. Dilute the samples 2500X with EIA buffer.
VI. EIA assay
Perform the assay according to the procedure in EIA kit provided by Cayman. Total PGD2 levels (pg/mL) were determined in the samples by EIA kits (Caymen Chemical, Catalog No. 500151)
Calculate amount of PGD2 as below
Calculated % Positive control according to the equation below;
%Positive control= (Compound value-Negative control)/(Positive value-Negative control value) x lOO.
%Positive contra 1= (Compound value-Negative control) X 100 (Positive value -Negative control value)
Compound value = PGD2 levels (pg/mL) obtained from the standard curve in EIA assay for the samples with compound
Negative control value = PGD2 levels (pg/mL) obtained from the standard curve in EIA assay for the samples without enzyme
Positive control value = PGD2 levels (pg/mL) obtained from the standard curve in EIA assay for the samples with enzyme but without compound IC50S are determined by excel fit to get the x value when y=l/2Ymax using 4 parameter logistic model for the IC50 curves.
Results Compounds within the scope of the invention produce 50% inhibition in the
Fluorescence Polarization Assay or the EIA assay at concentrations within the range of about 1 nanomolar to about 30 micromolar, particularly about 1 nanomolar to about 1 micromolar, and more particularly about 1 nanomolar to about 100 nanomolar. IC50S obtained by EIA assay for some of the examples are shown at the end of each of those examples.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof.

Claims

We claim:
1. A compound of formula (I):
Figure imgf000235_0001
(I) wherein: R1 is (Ci-C6)-alkyl optionally substituted one or more times independently by halo, hydroxy,
(Ci-Ce)-alkoxy, or (Ci-C4)-haloalkoxy, or
(C3-C6)-cycloalkyl, aryl or heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, (Ci-Ce)-alkoxy, (C1-C4)- haloalkyl or (Ci-C4)-haloalkoxy; R2 is hydrogen or (Ci-C4)-alkyl optionally substituted one or more times by halogen; R3 is hydrogen, alkyl, aryl or heteroaryl,
R4 is hydrogen, cycloalkyl, aryl, heterocyclyl, heteroaryl, arylsulfonyl, heteroarylsulfonyl, - C(=O)-NY1Y2, -C(=S)-NY1Y2, R5, -C(=O)-R5 or -C(=S)-R5, wherein the aryl, heteroaryl or heterocyclyl moiety is optionally substituted one or more times independently by R6, or
R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl, heterocyclenyl, heteroaryl, arylheterocyclyl, arylheterocylenyl, heteroarylheterocyclyl, heteroarylhetercyclenyl, heterocyclylheteroaryl or heterocyclenylheteroaryl, each of which is optionally substituted one or more times independently by R6; R5 is cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, heterocyclenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by R6; L1 is a bond, -O-, -C(=O)-, -NH-C(=O)-, or (d-C2)-alkylene optionally substituted one or more times by halo;
R6 is cyano, nitro, halo, hydroxy, carboxy, Y1Y2N-, Y1Y2N-Q=O)-, Y1Y2N-SO2-, acyl, acyloxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfmyl, or alkylsulfonyl, each of which is optionally substituted one or more times independently by: acyloxy, halo, alkoxy, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, Y1Y2N-, Y1Y2N-Q=O)-, Y1Y2N-SO2-, aryl, aryloxy, aroyl, heteroaryl, heteroaryloxy, heteroaroyl, heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by alkyl, halo, haloalkyl, alkoxy, haloalkoxy, hydroxy, amino, alkylamino, dialkylamino, carboxy, or alkoxycarbonyl, or aryl, heteroaryl, aroyl, heteroaroyl, aryloxy, heteroaryloxy, heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl, each of which is optionally substituted one or more times independently by alkyl, haloalkyl, halo, alkoxy, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, Y1Y2N-, or
Y1Y2N-SO2-, wherein the heterocyclyl, heterocyclenyl, cycloalkyl, cycloalkenyl, or multicyclic alkaryl moiety of R6 is also optionally substituted one or more times independently by oxo; Y1 and Y2 are each independently: hydrogen, alkylsulfonyl, aroyl, heteroaroyl, or alkyl optionally substituted one or more times independently by hydroxy, carboxy, halo, amino, alkylamino, dialkylamino, alkoxy, heterocyclyl, aryl or heteroaryl, or Y1 and Y2 together with the nitrogen atom to which they are attached form heterocyclyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein R1 is aryl or heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, (C1- Ce)-alkoxy, (Ci-C4)-haloalkyl or (Ci-C4)-haloalkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1, wherein R1 is phenyl or five or six membered heteroaryl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1, wherein R1 is phenyl, pyridyl, pyrimidinyl, thiazolyl, or oxodiazolyl, each of which is optionally substituted one or more times independently by halo, (Ci-Ce)-alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1, wherein R1 is phenyl, pyridyl or pyrimidnyl, each of which is optionally substituted independently at the ortho or meta position by halo, (Ci-C6)- alkyl, hydroxy, or (Ci-Ce)-alkoxy, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1, wherein R1 is phenyl optionally substituted independently at the ortho or meta position by halo, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1, wherein R1 is pyridyl, or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1, wherein R2 is hydrogen, methyl or trifluoromethyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1, wherein R2 is hydrogen, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1, wherein R2 is methyl, or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1, wherein L1 is a bond, -O-, -C(=O)-, or -NH- C(=O)-, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 1, wherein L1 is a bond, or a hydrate, solvate or N- oxide thereof, or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 1, wherein:
R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl, heterocyclenyl, arylheterocyclyl, or heteroaryl, each of which is optionally substituted one or more times independently by R6; R6 is alkoxy, hydroxyl, cycloalkyl, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by acyloxy, hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, alkylsulfonyl, cyano, Y1Y2N-, or Y1Y2N-CC=O)-, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and
Y1 and Y2 are each independently hydrogen, alkylsulfonyl, aroyl, or alkyl optionally substituted by morpholinyl, or
Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
14. The compound according to claim 1, wherein:
R3 and R4 together with the nitrogen atom to which they are attached form [l,2,4]triazolyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[3,2-b]pyridyl, or pyrrolo[2,3- c]pyridyl, each of which is optionally substituted one or more times independently by R6;
R6 is alkoxy, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by Y1Y2N-Q=O)-, hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, heterocyclyl, cycloalkyl, alkylsulfonyl, cyano, heterocyclylcarbonyl, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and Y1 and Y2 are each independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
15. The compound according to claim 1, wherein:
R3 and R4 together with the nitrogen atom to which they are attached form imidazolidinyl,
[l,2,4]triazinanyl, piperazinyl, morpholinyl, pyrrolidinyl, 1,2,3,4-tetrahydro- pyrimidinyl, piperidinyl, oxazolidinyl, 2,3-dihydro-indolyl, octahydro- cyclopenta[c]pyrrolyl, or 3,4-dihydro-benzo[l,4]oxazine, each of which is optionally substituted one or more times independently by R6; R6 is oxo, alkoxy, carboxy, cycloalkyl, halo, cyano, alkylsulfonyl, Y1Y2N-SO2-, alkyl optionally substituted one or more times independently by hydorxy, alkoxycarbonyl, alkoxy, carboxy, aryl, halo, heterocyclyl, cycloalkyl, alkylsulfonyl, cyano, heterocyclylcarbonyl, acyl or aryl, each of which is optionally substituted one or more times independently by halo, alkoxycarbonyl optionally substituted one or more times independently by aryl, heteroaroyl optionally substituted one or more times independently by alkyl, heterocyclyl optionally substituted one or more times by oxo, or aryloxy optionally substituted one or more times independently by haloalkyl; and Y1 and Y2 are each independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 1, wherein:
R3 and R4 together with the nitrogen atom to which they are attached form indolyl, optionally substituted one or more times independently by R6; R6 is Y1Y2N-SO2-, alkoxtcarbonyl, carboxyalkyl, cyano, halo, alkylsulfonyl, alkoxy, or acyl optionally substituted one or more times independently by halo; and Y1 and Y2 are each independently independently hydrogen, or alkyl optionally substituted by morpholinyl, or Y1 and Y2 together with the nitrogen atom to which they are attached form morpholinyl; or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 1, wherein: R5 is phenyl, pyridyl, or benzo[l,3]dioxolyl, each of which is optionally substituted one or more times independently by R6;
R6 is Y1Y2N-SO2-, hydroxy, alkoxy, halo, alkyl, or haloalkyl; and Y1 and Y2 are each independently hydrogen or alkyl, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 1, which is
2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 - yl)amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, 2-Pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide,
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)- amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol- 1 -yl)amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-2-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3- dihydro-indol- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-acetyl)-indol- l-yl]-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihydro- indol- 1 -yl)-amide,
4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-3,3-dimethyl-2,3-dihydro- indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2,3-dimethyl-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (S-chloro^-methyl-indol- 1 -yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-bromo-indol- 1 -yl)-amide, 3-Oxo-4-[(2-phenyl-pyrimidine-5-carbonyl)-amino]-piperazine-l-carboxylic acid benzyl ester,
2-(3 -Fluorophenyl)pyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 -fluoro-indol- 1 - yl)amide,
2-(3 -Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(3 -dimethylsulfamoyl-5 - fluoroindol-l-yl)amide,
2-(3-Fluorophenyl)pyrimidine-5-carboxylicacid-[5-fluoro-3-(morpholine-4-sulfonyl)indol-l- yl] amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3- (morpholine-4- sulfonyl) indol-1-yl] amide, 2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-sulfamoylindol-l-yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-methylsulfamoyl)indol- 1 - yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-[5-fluoro-3-(2-morpholin-4- ylethylsulfamoyl)indol- 1 -yl)amide, 2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3- methylsulfamoyl)indol- 1 -yl)amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-{5-fluoro-[(3-tetrahydropyran-4- ylmethyl)sulfamoyl]indol- 1 -yl} amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-[5-fluoro-3-(2-morpholin-4- ylethylsulfamoyl)indol- 1 -yl)amide,
2-(3-Fluorophenyl)pyrimidine-5 -carboxylic acid-(4-fluoroindol-l-yl)amide,
2-(3-Fluorophenyl)-4-methylpyrimidine-5 -carboxylic acid-(4-fluoroindol- 1 -yl)amide,
2-(Pyridin-2-yl)-pyrimidine-5-carboxylic acid-(4-fluoroindol- 1 -yl)amide,
2-(Pyridin-2-yl)-4-methylpyrimidine-5 -carboxylic acid-(4-fluoroindol- 1 -yl)amide, 2-Phenyl-pyrimidine-5-carboxylic acid [6-(4-fluoro-phenyl)-3-oxo-2,5-dihydro-3H- 1,2,4- triazin-4-yl]-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid-[4-(2-hydroxy-ethyl)-piperazin- 1 -yl]- amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-
[ 1 ,2,4]triazin-4-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid[5-fluoro-3-(2-hydroxy-2-methyl-propyl)- indol-1-yl] -amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3-(2-hydroxy-2-methyl- propyl)-indol- 1 -yl] -amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5-fluoro-3-(2-hydroxy-2-methyl- propyl)-indol-l yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyano-5-fluoro-indol-l-yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3-(lH-tetrazol-5-yl)- indol-1-yl] -amide,
2- Phenyl-pyrimidine-5-carboxylic acid [1,2,4] triazol-4-ylamide,
2-phenyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide, 2-Phenyl-pyrimidine-5-carboxylic acid N'-(2-fluoro-phenyl)-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -ethyl-N ' -tolyl-hydrazide,
2-Phenyl-pyrimidine-5-carboxylic acid (3-oxo-morpholin-4-yl)-amide,
2-(5 -Methyl- [ 1 ,2,4]oxadiazol-3-yl)-pyrimidine-5-carboxylic acid morpholin-4-ylamide,
2-Benzoyl-pyrimidine-5 -carboxylic acid morpholin-4-ylamide, 2-Benzoyl-pyrimidine-5 -carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yl] -amide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - [5 -trifluoromethyl-pyridin-2-yl]- hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' - [4-trifluoromethyl-pyridin-2-yl]- hydrazide, 2-Phenyl-pyrimidine-5 -carboxylic acid N'-pyridin-2-yl-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N'-(2-chloro-phenyl)-hydrazide,
2-Phenyl-pyrimidine-5 -carboxylic acid N'-(2-oxo-piperidin- 1 -yl)-amide,
2-Phenyl-pyrimidine-5 -carboxylic acid N ' -cyclohexyl-N ' -methyl-hydrazide,
2-Phenyoxy-pyrimidine-5 -carboxylic acid N'-morpholin-4-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-3-oxo-2,5-dihydro-3H-l,2,4-triazine-4- yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazine-4- yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- 1 ,2,4-triazine- 4-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-tert-butyl-3-oxo-2,5-dihydro-3H- 1 ,2,4- triazine-4-yl)-amide, 3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-amino]-l,2,3,4-tetrahydro-pyrimidin-5-yl}- propionic acid methyl ester,
3-{2,4-Dioxo-3-[(2-pheyl-pyrimidine-5-carbonyl)-amino]-l,2,3,4-tetrahydro-pyrimidin-5-yl}- propionic acid, 2-Phenyl-pyrimidine-5-carboxylic acid (4-methyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-hydroxy-ethyl)-piperazin-l-yl] -amide, 2-Phenyl-pyrimidine-5-carboxylic acid ((s)-2-methoxymethyl)-pyrrolidin- 1 -yl] -amide, 2-Phenyl-pyrimidine-5-carboxylic acid ((R)-2-methoxymethyl)-pyrrolidin- 1 -yl] -amide, 2-Phenyl-pyrimidine-5-carboxylic acid (5-bromo-2, 4-dioxo-3,4-dihydro-2H-pyrimidin-l-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid (3-isopropyl-5-oxo- 1 ,5-dihydro-[ 1 ,2,4]triazol-4-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid pyrrol- 1-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid (5-morpholin-4-ylmethyl-2-oxo-oxazolidin-3-yl)- amide,
2-Phenyl-pyrimidine-5-carboxylic acid (4-cyclopentyl-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2-oxo-oxazolidin-3-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [ 1 ,2,4]triazin-4-yl]-amide, [N'-(2-Phenyl-pyrimidine-5-carbonyl)-hydrazino]-acetic acid ethyl ester, 2- [N ' -(2-Phenyl-pyrimidine-5 -carbonyl)-hydrazino] -acetamide, 4-[3-(4-Morpholino)propyl]-l-(2-phenyl-pyrimidine-5-carbonyl)-3-thiosemicarbazide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, {4-[2-Phenyl-pyrimidine-5-carbonyl)-amino]-piperazin-l-yl}-acetic acid methyl ester, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-cyanomethyl-piperazin- 1 -yl)-amide,
Acetic acid 2-{4-[(2-phenyl-pyrimidine-5-carbonyl)-amino]-piperazin-l-yl}-ethyl ester, 2-Phenyl-pyrimidine-5-carboxylic acid (4-acetyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-(2-oxo-tetrahydro-furan-3 -yl)-piperazin- 1 -yl] - amide,
2-Phenyl-pyrimidine-5-carboxylic acid [4-(2,2,2-trifluoro-acetyl)-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5-carboxylic acid [4-(2-methoxy-ethyl)-piperazin- 1 -yl]-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazin-l-yl]- amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid piperadin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid piperadin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (hexahydro-cyclopenta[c]pyrrol-2-yl)-amide, 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid pyrrolidin-1-yl-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,6-dimethyl-piperadin-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (4-cyclopentyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (2-methyl-2,3-dihydro-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (2-methyl-2,3-dihydro-indol-l-yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -pyridin-2-yl-hydrazide, 2-Phenyl-pyrimidine-5 -carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid indol-1-yl-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid indol- 1 -yl-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2-methyl-2,3-dihydro-indol- 1 - yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (2-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid indol- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (2,3-dihydro-indol-l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid indol- 1 -ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (5-methanesulfonyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-methanesulfonyl-indol-l-yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide, 2-Pyridin-3-yl-pyrimidine-5 -carboxylic acid (5-methanesulfonyl-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methanesulfbnyl-indol-l-yl)- amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l-ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid pyrrolo[3,2-b]pyridin-l-ylamide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (5-fluoro-indol-l-yl)-amide,
2-(3-Fluoro-phenyl-4-methyl)-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[3,2-b]pyridin-l-ylamide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l-ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-Pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- l-yl)-amide,
2-Pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridine- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrro Io [3, 2-b]pyridin-l -ylamide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l -ylamide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid pyrro Io [3, 2-b]pyridin-l -ylamide, 4-Methyl-2-pyridin-3-yl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-cyano-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (4-cyano-indol- 1 -yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [4-(lH-tetrazol-5-yl)-indol-l -ylamide, l-{[2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl] -amino }-lH-indol-4-carboxylic acid methyl ester, l-{[2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carbonyl] -amino }-lH-indol-4-carboxylic acid,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-cyanomethyl-indol- 1 -yl)- amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-indol-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [3-(lH-tetrazol-5-ylmethyl)- indol-1-yl] -amide,
2-(2-Phenyl-pyrimidine-5-carbonyl)- 1 -hydrazinecarboxamide, 2-(2-Phenyl-pyrimidine-5 -carbonyl)- 1 -hydrazine- 1 -carbothioamide, 2-Phenyl-pyrimidine-5-carboxylic acid (2,4-dioxo-imidazolidin-l-yl)-amide, 2-Phenyl-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H-[l ,2,4]triazin-4-yl)- amide, 2-Phenyl-pyrimidine-5-carboxylic acid N'-phenyl-hydrazide,
Pyridine -2-carboxylic acid N'-(2-phenyl-pyrimidine-5-carbonyl)-hydrazide, 4- [N ' -(2-Phenyl-pyrimidine-5 -carbonyl)-hydrazino] -benzenesulfonamide, 3 -Hydroxy-benzoic acid N ' -(2-phenyl-pyrimidine-5 -carbonyl)-hydrazide, Benzo[l,3]dioxo-5-carboxylic acid N'-(phenyl-pyrimidine-5-carbonyl)-hydrazide, 3 ,4-Dimethoxy-benzoic acid N ' -(phenyl-pyrimidine-5 -carbonyl)-hydrazide, 2-Phenyl-pyrimidine-5 -carboxylic acid N ' -methyl-N ' -phenyl-hydrazide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-indol- 1 -yl)- amide, 2-(3-Methoxy-phenyl)-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl)-amide,
2-(2-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [ 1 ,2,4]triazin-4-yl)-amide,
2-(4-Methoxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [ 1 ,2,4]triazin-4-yl)-amide, 2-(3 -Hy droxy-phenyl)-pyrimidine-5 -carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [ 1 ,2,4]triazin-4-yl)-amide,
2-(2-Hydroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [ 1 ,2,4]triazin-4-yl)-amide, 2-(4-Hydroxy-phenyl)-pyrimidine-5-carboxylic acid (6-methyl-3-oxo-2,5-dihydro-3H- [l,2,4]triazin-4-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)-amide, 2-Thiazol-2-yl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, [2,2']Bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-indol-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylicacid(3chloro-5-fluoro-indol- 1 -yl)- amide,
5 -Fluoro- 1 - { [2-(3 -fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyl] -amino } - 1 H-indole-3 - carboxylic acid amide, 2- {5 -Fluoro- 1 - [(4-methyl-2-pyridin-2-yl-pyrimidine-5 -carbonyl)-amino] - 1 H-indol-3 -yl} -2- methyl-propionic acid,
2-(5-Fluoro-l-{[2-(3-fluoro-phenyl) -4-methyl-pyrimidine-5-carbonyl]-amino}-lH-indol-3- yl)-2-methyl-propionic acid, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-fluoro-3- (3 -hydroxy-3 - methyl-butyl)-indol- 1 -yl]-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl- butyl)-indol- 1 -yl] -amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3- (2-pyridin-3-yl- ethyl)-indol-l-yl]- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5 -fluoro-3 -formyl-indol- 1 -yl)-amide,
5 -Fluoro- 1 -[(4-methyl-2-pyridin-2-yl-pyrimidine-5 -carbonyl)-amino] - 1 H-indole-3 -carboxylic acid,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -hydroxymethyl-indol- 1 -yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl-butyl)-indol- l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(3 -hydroxy-3 -methyl- butyl)-indol- 1 -yl] -amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-indol- l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-ethyl-5-trifluoromethyl-indol- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy- indol- 1 -yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1 - yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1-yl)- amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3 -ethyl-5 -trifluoromethoxy-indol- 1 - yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)- amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (6-trifluoromethyl-indol- l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (6-trifluoromethyl-indol- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3, 2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3 ,2- b]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3 -ethyl-5 -trifluoromethyl-pyrro Io [3,2- b]pyridin-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-methoxy-2-methyl-indol- 1 -yl)- amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid TV, N'-diphenyl-hydrazide
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (7-fluoro-3-methyl-indol-l-yl)- amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methanesulfonyl-3 -methyl- indol- 1 -yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo[2,3-b]pyridin- 1 -yl)- amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-ethyl-pyrrolo[2,3-b]pyridin-l- yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-ethyl-pyrrolo[2,3c] pyridin-1- yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-pyrrolo[2,3-c]pyridin- 1 -yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin- l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid β-methyl-S-trifluoromethyl-indol- 1 - yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin-l-yl)- amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3c]pyridin-l- yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-c]pyridin- 1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin-l-yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin- l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-nitro-indol- 1 -yl)-amide,
2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-amino-indol-l-yl)-amide, 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid [5-(dimethanesulfonyl)-amino- indol-1-yl] -amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-benzoylamino-indol- 1 -yl)- amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid [5-fluoro-3-(l ,2,3,6-tetrahydro-pyridin- 4-yl)-indol-l-yl] -amide,
2-Pyridin-2-yl-4-trifluoromethyl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol- 1 -yl)- amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2 -methyl-indol- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5 -carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4- yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro- 1 ,4-benzoxazin-4-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-ethyl-5-fluoro-pyrrolo[2,3-b]pyridin- l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-pyrrolo[2,3-b]pyridin- l-yl)-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-pyrrolo[2,3-b]pyridin- 1 -yl)- amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (2-cyclopropyl-5-fluoro-indol- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (2-cyclopropyl-5-fluoro-indol-l-yl)- amide,
2-Pyrimidin-2-yl-4-methyl-pyrimidine-5-carboxylic acid (5-methoxyl-indol-l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2-b]pyridin-l- yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2- b]pyridin-l-yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (5-fluoro-3-methyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5-carboxylic acid (5-methoxy-3-methyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide, 2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -methoxy-3 -methyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(l-oxy-pyridin-2-yl)-pyrimidin-5 -carboxylic acid (5-fluoro-3-methyl-indol-l-yl)- amide,
2-(3-Difluoromethyl-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)- amide, or
2-(3-Trifluoromethyl-phenyl)-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol- 1 -yl)- amide, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
19. The compound accordin to claim 1, which is:
2-Phenyl-pyrimidine-5 -carboxylic acid (4-benzyl-piperazin- 1 -yl)-amide, 2-Phenyl-pyrimidine-5 -carboxylic acid piperazin-1-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid (4-methanesulfonyl-piperazin- 1 -yl)-amide, 2-(2-Methyl-thiazol-4-yl)-pyrimidine-5 -carboxylic acid morpholin-4-ylamide, 2-Phenyl-pyrimidine-5 -carboxylic acid [4-(l -methyl- 1 H-imidazole-2-carbonyl)-piperazin- 1- yl] -amide,
2-Phenyl-pyrimidine-5 -carboxylic acid [4-( 1 -methyl- 1 H-imidazole-4-carbonyl)-piperazin- 1 - yl] -amide, 4-[(2-Phenyl-pyrimidine-5-carbonyl)-amino]-piperazine-l-carboxylic acid tert-butyl ester,
2-Phenyl-pyrimidine-5-carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- 1 -yl]-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid [4-(4-trifluoromethyl-phenoxy)-piperidin- l-yl]-amide, 2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid morpholin-4-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid indol-1-ylamide,
2-Phenyl-pyrimidine-5-carboxylic acid (4-methoxy-piperidin- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (2-methyl-indol- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-benzo[l ,4]oxazin-4- yl)-amide,
2-Phenyl-pyrimidine-5-carboxylic acid (6-fluoro-2,3-dihydro-benzo[ 1 ,4]oxazin-4-yl)-amide,
1 - { [2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carbonyl] -amino } -3 -(2-morpholin-4-yl- ethyl)- lH-indole-6-carboxylic acid methyl ester,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahydro-pyran-4- yl)-indol-l-yl]-amide,
N-methyl-N-(5 -fluoro)-indol-3 -ylsulfonyl N ' - [2-(3 -fluoro)-phenyl-pyrimidine-5 -carbonyl] - hydrazide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid [5 -fluoro-3 -(tetrahy dro-pyran-4-yl)- indol-1-yl] -amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (5 -fluoro-3 -methyl-indol-l-yl)-amide,
4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2-b]pyridin-l-yl)- amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l- ylamide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[2,3-c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-methyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-b]pyridin- 1 -yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-b]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [2,3 - b]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l-ylamide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3-c]pyridin- 1 -yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin-l-ylamide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3-c]pyridin- 1 - yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-trifluoromethy l-pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2-c]pyridin-l-yl)- amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid pyrrolo[3,2-c]pyridin-l-ylamide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[3,2-c]pyridin-l- yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [3 ,2- c]pyridin-l-yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-b]pyridin- 1 - ylamide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-trifluoromethyl- pyrrolo[2,3-b]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[2,3-c]pyridin- 1 - ylamide, 4-Methyl-2-(4-chloro -thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[2,3- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[2,3-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-methyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide, 4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid pyrrolo[3,2-c]pyridin-l- ylamide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-isopropyl-pyrrolo[3,2- c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-chloro-thiazol-2-yl)-pyrimidine-5-carboxylic acid (3-difluoromethyl- pyrrolo [3 ,2-c]pyridin- 1 -yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-c]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l- yl)-amide, 2-(4-Methyl-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (5-fluoro-3-methyl-indol-l- yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (2-methyl-3-oxo-2,3-dihydro- indazol- 1 -yl)amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid(5-fluoro-indol- 1 - yl)amide)amide,
6-(4-Chloro-thiazol-2-yl)-2-methyl-N-pyrrolo[2,3-c]pyridin-l-yl-nicotinamide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid(5-methyl-4-oxo-4,5-dihydro- pyrrolo[3,2-c]pyridin-l-yl)amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (5 -trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (5-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3-difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide, 4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-trifluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (5-difluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3 -trifluoromethyl-pyrrolo [3 ,2- b]pyridin-l-yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-pyrrolo[3,2- b]pyridin- 1 -yl)-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo[3,2- b]pyridin- 1 -yl] -amide, 4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluo ro-ethyl)-pyrro Io [2,3 -b]pyridin- 1 -yl] -amide,
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (5-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid (3-trifluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
4-Methyl-2-(4-methyl-thiazol-2-yl)-pyrimidine-5 -carboxylic acid (3 -difluoromethyl- pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo [3 ,2-b]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide, 2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo [3 ,2-c]pyridin- 1 -yl] -amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-c]pyridin-l-yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-b]pyridin- 1 -yl]-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5-carboxylic acid [3-(2,2-difluoro- ethyl)-pyrrolo[2,3-b]pyridin- 1 -yl]-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (5-difluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[3,2-b] pyridin- 1 -yl)-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[3 ,2-b]pyridin- 1 -yl] -amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[3,2-c] pyridin- l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro
Io [3 ,2-c]pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-2,2-diuoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-c] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrro lo[2,3-c]pyridin-l-yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo
[2,3-c]pyridin- 1 -yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[2,3-c]pyridin- 1 -yl]-amide, 4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-trifluoromethyl-pyrrolo[2,3-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid (3-difluoromethyl-pyrrolo[2,3-b] pyridin- 1 -yl)-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2,2-trifluoro-ethyl)-pyrrolo [2,3-b]pyridin-l-yl]-amide,
4-Methyl-[2,2']bipyrimidinyl-5-carboxylic acid [3-(2,2-difluoro-ethyl)-pyrrolo
[2,3-b]pyridin- 1 -yl] -amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -trifluoro methyl-pyrrolo [3 ,2-b]pyridin- 1 -yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (5 -difluorom ethyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[3,2-b]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[3,2-c]pyridin-l-yl)-amide,
2-(3 -Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3 -trifluoro methyl-pyrrolo[2,3-c]pyridin-l-yl)-amide, 2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid (3-trifluoromethyl-pyrrolo[2,3- b]pyridin- 1 -yl)-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2-difluoro-ethyl)- pyrrolo[3,2-b]pyridin-l-yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl) -pyrrolo[3,2-b]pyridin-l-yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[3,2-c]pyridin-l-yl]-amide,
2-(3-Fluoro-phenyl)-4-methyl-pyrimidine-5 -carboxylic acid [3-(2,2,2-trifluoro-ethyl)- pyrrolo[2,3-c]pyridin- 1 -yl]-amide, 4-Methyl-2-pyridin-2-yl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-indol-l-yl)-amide,
2-(4-Chloro-thiazol-2-yl)-4-methyl-pyrimidine-5 -carboxylic acid (3-difluoromethyl-indol- 1 - yl)-amide, or
4-Methyl-2-thiazol-2-yl-pyrimidine-5-carboxylic acid (3-difluoromethyl-indol- 1 -yl)-amide, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising the compound according to claim 1, or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. A method for treating an allergic or inflammatory disorder in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 , or a hydrate, solvate or N-oxide thereof, or a pharmaceutically acceptable salt thereof.
22. The method according to claim 21, wherein the allergic or inflammatory disorder is allergic rhinitis.
23. The method according to claim 21, wherein the allergic or inflammatory disorder is asthma.
24. The method according to claim 21, wherein the allergic or inflammatory disorder is chronic obstructive pulmonary disease.
PCT/US2008/058347 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as pgds inhibitors WO2008121670A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2008232771A AU2008232771B2 (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as PGDS inhibitors
JP2010501206A JP5427769B2 (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as PGDS inhibitors
ES08744426T ES2400622T3 (en) 2007-03-30 2008-03-27 Hydrazide pyrimidine compounds as PGDS inhibitors
BRPI0809974-0A2A BRPI0809974A2 (en) 2007-03-30 2008-03-27 HYDRAYED PYRIMIDINE COMPOUNDS AS PGDS INHIBITORS
CA2682629A CA2682629C (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as pgds inhibitors
CN2008800100835A CN101646656B (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as PGDS inhibitors
MX2009009443A MX2009009443A (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as pgds inhibitors.
DK08744426.1T DK2142516T3 (en) 2007-03-30 2008-03-27 PYRIMIDINE HYDRAZIDE COMPOUNDS IN THEIR CHARACTERISTICS OF PGDS INHIBITORS
EP08744426A EP2142516B1 (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as pgds inhibitors
NZ579892A NZ579892A (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
IL200898A IL200898A (en) 2007-03-30 2009-09-13 Pyrimidine hydrazide compounds as pgds inhibitors
US12/570,355 US8258130B2 (en) 2007-03-30 2009-09-30 Pyrimidine hydrazide compounds as PGDS inhibitors
MA32299A MA31326B1 (en) 2007-03-30 2009-10-22 Pyrimidine-Hydrazide as a PGds inhibitor.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90917107P 2007-03-30 2007-03-30
US60/909,171 2007-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/570,355 Continuation US8258130B2 (en) 2007-03-30 2009-09-30 Pyrimidine hydrazide compounds as PGDS inhibitors

Publications (1)

Publication Number Publication Date
WO2008121670A1 true WO2008121670A1 (en) 2008-10-09

Family

ID=39494539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/058347 WO2008121670A1 (en) 2007-03-30 2008-03-27 Pyrimidine hydrazide compounds as pgds inhibitors

Country Status (25)

Country Link
US (1) US8258130B2 (en)
EP (1) EP2142516B1 (en)
JP (1) JP5427769B2 (en)
KR (1) KR20090125852A (en)
CN (1) CN101646656B (en)
AR (1) AR065874A1 (en)
AU (1) AU2008232771B2 (en)
BR (1) BRPI0809974A2 (en)
CA (1) CA2682629C (en)
CL (1) CL2008000911A1 (en)
DK (1) DK2142516T3 (en)
ES (1) ES2400622T3 (en)
IL (1) IL200898A (en)
MA (1) MA31326B1 (en)
MX (1) MX2009009443A (en)
MY (1) MY154895A (en)
NZ (1) NZ579892A (en)
PA (1) PA8774101A1 (en)
PE (1) PE20090552A1 (en)
PT (1) PT2142516E (en)
RU (1) RU2464262C2 (en)
SG (1) SG179437A1 (en)
TW (1) TWI430994B (en)
WO (1) WO2008121670A1 (en)
ZA (1) ZA200906082B (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068292A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
WO2011091461A1 (en) 2010-01-29 2011-08-04 Planta Naturstoffe Vertriebsges.M.B.H. Compounds for use in the treatment of diseases
WO2010150211A3 (en) * 2009-06-23 2011-08-25 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
WO2011150457A3 (en) * 2010-06-01 2012-01-26 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
US8258130B2 (en) 2007-03-30 2012-09-04 Sanofi Pyrimidine hydrazide compounds as PGDS inhibitors
WO2013079350A1 (en) 2011-11-29 2013-06-06 Syngenta Participations Ag Insecticidal triazinone derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
WO2015022546A1 (en) * 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9469627B2 (en) 2009-10-08 2016-10-18 Sanofi Phenyloxadiazole derivatives as PGDS inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3165093A1 (en) 2015-11-05 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US9650349B2 (en) 2007-08-27 2017-05-16 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2018069863A1 (en) 2016-10-13 2018-04-19 Glaxosmithkline Intellectual Property Development Limited 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
WO2018229629A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
WO2019116256A1 (en) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
US10611758B2 (en) 2014-11-27 2020-04-07 Kalvista Pharmaceuticals Limited N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
WO2020095215A1 (en) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US10752607B2 (en) 2016-06-01 2020-08-25 Kalvista Pharmaceuticals Limited Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
US10781181B2 (en) 2014-11-27 2020-09-22 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
WO2021256569A1 (en) 2020-06-19 2021-12-23 佐藤製薬株式会社 Condensed ring compounds that inhibit h-pgds
US11230537B2 (en) 2016-06-01 2022-01-25 Kalvista Pharmaceuticals Limited Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
US11242333B2 (en) 2013-08-14 2022-02-08 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US11584735B2 (en) 2017-11-29 2023-02-21 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
US11613527B2 (en) 2019-08-09 2023-03-28 Kalvista Pharmaceuticals Limited Enzyme inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375027B (en) * 2020-12-07 2023-03-31 中国药科大学 Indolesulfonamide derivative and medical application thereof
WO2023113023A1 (en) * 2021-12-17 2023-06-22 佐藤製薬株式会社 Azaindole derivative inhibiting h-pgds
CN116514769B (en) * 2022-01-21 2024-02-27 中国药科大学 4-hydroxy pyrimidine-5-formylhydrazone derivative, preparation method, pharmaceutical composition and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
WO2004016223A2 (en) 2002-08-16 2004-02-26 Aventis Pharmaceuticals Inc. Assaying compounds or agents for microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase activity
WO2004026380A2 (en) 2002-09-21 2004-04-01 Aventis Pharma Limited Inhaler
JP2007051121A (en) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk Pyrimidine compound inhibiting prostaglandin d synthetase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143173A (en) * 1984-08-06 1986-03-01 Mitsui Petrochem Ind Ltd Novel pyrimidine drivative and preparation thereof
JPS61140568A (en) * 1984-12-14 1986-06-27 Mitsui Petrochem Ind Ltd Quinazoline derivative, and hypotensor containing said derivative as active component
RU2343148C2 (en) * 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Compounds of 2,4-pyrimidindiamines and their application
HN2005000795A (en) * 2004-10-15 2010-08-19 Aventis Pharma Inc PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
BRPI0718874A2 (en) * 2006-12-22 2015-06-23 Novartis Ag Organic compounds
RU2464262C2 (en) 2007-03-30 2012-10-20 Санофи-Авентис Pyrimidine hydrazide compounds as pgds inhibitors
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
WO2004016223A2 (en) 2002-08-16 2004-02-26 Aventis Pharmaceuticals Inc. Assaying compounds or agents for microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase activity
WO2004026380A2 (en) 2002-09-21 2004-04-01 Aventis Pharma Limited Inhaler
JP2007051121A (en) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk Pyrimidine compound inhibiting prostaglandin d synthetase

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
BRIGHTLING CE; BRADDING P; PAVORD ID; WARDLAW AJ: "New Insights into the role of the mast cell in asthma", CLIN. EXP. ALLERGY, vol. 33, 2003, pages 550 - 556
BROWN, DESMOND J.; COWDEN, WILLIAM B.: "Unfused heterobicycles as amplifiers of phleomycin. VII. Some triazolyl-, thiadiazolyl- and oxadiazolylpyridines and related pyrimidines", AUST. J. CHEM., vol. 36, no. 7, 1983, pages 1469 - 1475 *
C. L. JOHNSON: "Quantitative structure-activity studies on monoamine oxidase inhibitors", J. MED. CHEM., vol. 19, no. 5, 1976, pages 600 - 605, XP002484508 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002484509, accession no. 6388585 *
DATABASE WPI Week 200724, Derwent World Patents Index; AN 2007-235635, XP002484510 *
F. CHAU, J.-C.; MALANDA; R. MILCENT, J HETEROCYCLIC CHEM., vol. 34, 1997, pages 1603 - 1606
H. TAKAHATA; H. OUCHI; M. ICHINOSE; H. NEMOTO, ORG. LETT., vol. 4, no. 20, 2002, pages 3459 - 3462
J. GONZALEZ; C. AURIGEMMA; L. TRUESDALE, ORG. SYNTH., vol. 79, 2002, pages 93 - 102
J. J. MURRAY, N ENGL. J MED., vol. 315, no. 13, 25 September 1986 (1986-09-25), pages 800
J. ORG. CHEM, vol. 67, 2002, pages 6226 - 6227
J. ORG. CHEM., vol. 67, 2002, pages 6226 - 6227
J.HYMES ET AL., J.O.C., vol. 69, 2004, pages 1368 - 1371
K. IKAI; M. JIHARA; K. FUJII; Y. URADE, BIOCHEMICAL PHARMACOLOGY, vol. 28, 1989, pages 2773 - 2676
LEWIS, RA; SOTER NA; DIAMOND PT; AUSTEN KF; OATES JA; ROBERTS LJ II: "Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE", J IMMUNOL., vol. 129, 1982, pages 1627 - 1631
M. A. BROOK; T. H. CHAN, SYNTHESIS, 1983, pages 201 - 204
MATSUSSHITA ET AL., JPN. J. PHARAMCOL., vol. 78, 1998, pages 11
OUELLET M ET AL: "Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, vol. 431, no. 1, 1 November 2004 (2004-11-01), pages 107 - 118, XP004581263, ISSN: 0003-9861 *
P. SHENBAGAMURTHI; H. A. SMITH; J. M. BECKER; F. NAIDER, J MED CHEM., vol. 29, no. 5, 1986, pages 802 - 809
P. ZHICHKIN; D.J. FAIRFAX; S.A. EISENBEIS, SYNTHESIS, 2002, pages 720 - 722
R. K. OLSEN, J ORG. CHEM., vol. 35, no. 6, 1970, pages 1912 - 1915
S.M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
T. URADE; O. HAYAISHI, VITAMIN AND HORMONES, vol. 58, 2000, pages 89 - 120
T.W. GREENE; P. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
URADE, J IMMUNOLOGY, vol. 168, 2002, pages 443 - 449
Y.-L. ZHONG; T. K. M. SHING, J ORG. CHEM., vol. 62, no. 8, 1997, pages 2622 - 2624

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258130B2 (en) 2007-03-30 2012-09-04 Sanofi Pyrimidine hydrazide compounds as PGDS inhibitors
US9650349B2 (en) 2007-08-27 2017-05-16 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US10053467B2 (en) 2007-08-27 2018-08-21 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9126973B2 (en) 2008-09-22 2015-09-08 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
WO2010068292A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
JP2012511575A (en) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド Azaindole derivatives as kinase inhibitors
US8912330B2 (en) 2008-12-12 2014-12-16 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
CN102481285B (en) * 2009-06-23 2013-11-13 国家科学研究中心 Use of derivatives of indoles for the treatment of cancer
CN102481285A (en) * 2009-06-23 2012-05-30 国家科学研究中心 Use of derivatives of indoles for the treatment of cancer
US9212138B2 (en) 2009-06-23 2015-12-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of derivatives of indoles for the treatment of cancer
WO2010150211A3 (en) * 2009-06-23 2011-08-25 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
US9937175B2 (en) 2009-10-08 2018-04-10 Sanofi Phenyloxadiazole derivatives as PGDS inhibitors
US9469627B2 (en) 2009-10-08 2016-10-18 Sanofi Phenyloxadiazole derivatives as PGDS inhibitors
EP2965755A1 (en) 2010-01-29 2016-01-13 Inoxia Lifesciences GmbH Compounds for use in the treatment of diseases
WO2011091461A1 (en) 2010-01-29 2011-08-04 Planta Naturstoffe Vertriebsges.M.B.H. Compounds for use in the treatment of diseases
WO2011150457A3 (en) * 2010-06-01 2012-01-26 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013079350A1 (en) 2011-11-29 2013-06-06 Syngenta Participations Ag Insecticidal triazinone derivatives
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105683179B (en) * 2013-08-14 2018-10-26 卡尔维斯塔制药有限公司 The inhibitor of plasma kallikrein
CN105683179A (en) * 2013-08-14 2016-06-15 卡尔维斯塔制药有限公司 Inhibitors of plasma kallikrein
US11242333B2 (en) 2013-08-14 2022-02-08 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
WO2015022546A1 (en) * 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US10221161B2 (en) 2013-08-14 2019-03-05 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US11001578B2 (en) 2014-11-27 2021-05-11 Kalvista Pharmaceuticals Limited N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
US11198691B2 (en) 2014-11-27 2021-12-14 Kalvista Pharmaceuticals Limited N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
US10611758B2 (en) 2014-11-27 2020-04-07 Kalvista Pharmaceuticals Limited N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
US11084809B2 (en) 2014-11-27 2021-08-10 Kalvista Pharmaceuticals Limited N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
US10781181B2 (en) 2014-11-27 2020-09-22 Kalvista Pharmaceuticals Limited N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
EP3165093A1 (en) 2015-11-05 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
US10752607B2 (en) 2016-06-01 2020-08-25 Kalvista Pharmaceuticals Limited Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
US11230537B2 (en) 2016-06-01 2022-01-25 Kalvista Pharmaceuticals Limited Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
US11739068B2 (en) 2016-06-01 2023-08-29 Kalvista Pharmaceuticals Limited Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
WO2018069863A1 (en) 2016-10-13 2018-04-19 Glaxosmithkline Intellectual Property Development Limited 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
WO2018229629A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
US11584735B2 (en) 2017-11-29 2023-02-21 Kalvista Pharmaceuticals Limited Solid forms of a plasma kallikrein inhibitor and salts thereof
WO2019116256A1 (en) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
WO2020095215A1 (en) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US11613527B2 (en) 2019-08-09 2023-03-28 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2021256569A1 (en) 2020-06-19 2021-12-23 佐藤製薬株式会社 Condensed ring compounds that inhibit h-pgds
KR20230027059A (en) 2020-06-19 2023-02-27 사토 세이야쿠 가부시키가이샤 Condensed ring compounds that inhibit H-PGDS

Also Published As

Publication number Publication date
MY154895A (en) 2015-08-14
IL200898A (en) 2013-12-31
RU2009140149A (en) 2011-05-10
IL200898A0 (en) 2010-05-17
PE20090552A1 (en) 2009-06-01
AU2008232771B2 (en) 2012-12-20
MA31326B1 (en) 2010-04-01
ZA200906082B (en) 2010-06-30
AR065874A1 (en) 2009-07-08
EP2142516A1 (en) 2010-01-13
PT2142516E (en) 2013-03-07
CA2682629A1 (en) 2008-10-09
PA8774101A1 (en) 2008-11-19
US8258130B2 (en) 2012-09-04
KR20090125852A (en) 2009-12-07
EP2142516B1 (en) 2012-12-26
BRPI0809974A2 (en) 2014-10-07
ES2400622T3 (en) 2013-04-11
TW200906802A (en) 2009-02-16
CL2008000911A1 (en) 2008-10-03
CN101646656B (en) 2013-08-14
RU2464262C2 (en) 2012-10-20
JP2010523494A (en) 2010-07-15
CN101646656A (en) 2010-02-10
NZ579892A (en) 2012-03-30
CA2682629C (en) 2013-03-19
JP5427769B2 (en) 2014-02-26
DK2142516T3 (en) 2013-04-15
TWI430994B (en) 2014-03-21
MX2009009443A (en) 2009-09-14
AU2008232771A1 (en) 2008-10-09
US20100048568A1 (en) 2010-02-25
SG179437A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CA2682629C (en) Pyrimidine hydrazide compounds as pgds inhibitors
AU2006299428B2 (en) Pyrimidine amide compounds as PGDS inhibitors
US8614229B2 (en) Substituted indole derivatives and methods of use thereof
US8143305B2 (en) 2,3-substituted indole derivatives for treating viral infections
US20130109661A1 (en) Imidazopyridazine compounds
JP5575799B2 (en) 7-phenoxycyclomancarboxylic acid derivative
WO2006129100A1 (en) Novel compounds
EP1844011A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
AU2005295502A1 (en) 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
JP6224832B2 (en) RORC2 inhibitor and method of use thereof
JP2023520759A (en) Substituted oxoisoindoline compounds for cancer therapy
JP2009532333A (en) Heterobicyclic carboxamides as inhibitors of kinases
JP5580814B2 (en) Tricyclic indole derivatives and methods of use thereof
TW201536773A (en) Inhibitors of BRUTON&#39;S tyrosine kinase
AU2006281242A1 (en) Pyrazolone derivatives for the treatment of tuberculosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010083.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08744426

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009443

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: DZP2009000530

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200898

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PI20093870

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 579892

Country of ref document: NZ

Ref document number: 12009501822

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008744426

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010501206

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008232771

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2682629

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09107316

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008232771

Country of ref document: AU

Date of ref document: 20080327

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6319/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20097022868

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009140149

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0809974

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090930